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Abstract 
 
While the rate of AIDS-related death has declined, as a consequence of the effectiveness 
of antiviral treatment for HIV, HIV/HCV coinfection and in particular liver-related death 
(LRD) has assumed increasing importance. This thesis aims to analyse important 
epidemiological areas of HIV/HCV coinfection to improve the knowledge base of the 
subject and provide guidance to clinicians in a fast moving area of research. 
 
Data for this thesis are from the EuroSIDA study, which is a large multi-centre pan-
European prospective observational cohort study with over 18,000 HIV-positive individuals 
including approaching 5,000 HIV/HCV coinfected individuals. The study was initiated in 
1994 and continues to expand and diversify to meet current research needs. 
 
Results from the studies included in this thesis have shown that treatment for HIV in 
coinfected individuals can also have a beneficial effect on the natural course of HCV, with 
HCV viral load remaining stable over time in those treated for HIV compared with 
increasing HCV viral load in those not yet treated. The incidence of treatment for HCV has 
steadily increased in Europe to 4.7 per 100 PYFU in 2010, but remains low with just 25% of 
eligible patients receiving treatment. LRD accounts for more than a fifth of deaths in this 
population, with significant liver fibrosis and those triple infected with HBV at increased risk. 
The 5-year probability of LRD is low for those with F0/F1 fibrosis (2.2%), but increases 
substantially for those with F2/F3 (10.3%) and F4 (14.0%) fibrosis. 
 
With potent new treatments for HCV coming to market, it is clear that while they remain 
prohibitively expensive they should be targeted at those at the greatest risk of LRD. The 
prognostic LRD score derived here will help clinicians to make difficult decisions on who 
should be prioritised for HCV treatment. 
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Chapter 1 
 
Thesis aims and analysis outline 
 
1.1 Aims 
 
The aims of this thesis were to describe epidemiological characteristics of HIV and hepatitis 
C (HCV) coinfected individuals from across Europe and to provide guidance on their 
optimal clinical management. Using data from the EuroSIDA study, five epidemiological 
studies are presented describing clinically important facets of HIV/HCV coinfection. Each 
study is outlined briefly below, in order of appearance, while the clinical importance and 
limitations of the findings are discussed in detail in each chapter. Chapter 9 draws on the 
whole body of work to discuss the overall significance and implications for the management 
of HIV/HCV coinfected individuals in Europe. 
 
1.2 Outline of thesis 
1.2.1 Chapter 2 
Introduction to HIV and HCV coinfection 
This chapter provides a thorough introduction to both HIV and HCV as independent viruses 
and HIV/HCV in coinfection. Details of the discovery and nature of the viruses, the 
changing epidemiology of infection over time, modes of infection, the clinical manifestation 
of infection and the history of treatment are discussed in depth. 
 
1.2.2 Chapter 3 
Data and statistical methodology 
This chapter introduces the EuroSIDA study, which is where the data analysed in this 
thesis are taken from, describing the origin of the study along with the spectrum of data 
collected and monitoring efforts to ensure data integrity. Also discussed are the statistical 
methods used throughout the analysis in this thesis, detailing statistical models used along 
with exploratory analysis and model building strategies. 
 
1.2.3 Chapter 4 
The natural history of HCV RNA during chronic HCV infection among HIV/HCV 
coinfected individuals 
18 
 
This chapter focuses on HCV viral load and how it changes over time in chronically infected 
HIV/HCV coinfected individuals. The aim of this chapter was to describe the natural history 
of HCV RNA in coinfected individuals and to identify factors associated with baseline HCV 
RNA and changes over time. The main statistical method used in this analysis was a 
random effects mixed model to model each individual’s HCV RNA profile accounting for 
within subject variability. 
 
The data presented in this chapter were originally presented as an oral abstract at the 
European AIDS Clinical Society (EACS) conference in Belgrade, October 2011. The 
analysis was then finalised and published in-part in HIV Medicine in February 2013. The 
published paper can be seen in Appendix III. 
 
1.2.4 Chapter 5 
Temporal changes and regional differences in the uptake of treatment for HCV 
among HIV/HCV coinfected individuals in EuroSIDA 
This chapter documents the rate of uptake of treatment for HCV among HIV/HCV 
coinfected individuals between the years 1998 and 2010. As mentioned in Chapter 2 
Section 2.2.6, gold standard HCV therapy over the follow-up period for this chapter 
consisted of pegylated-interferon plus ribavirin
1
. The aims of this chapter were to describe 
the rate of HCV treatment uptake among coinfected individuals and to highlight regional 
differences in Europe. Further, this study aimed to identify whether individuals with 
significant liver fibrosis, in the greatest need of HCV therapy, were being selected for 
treatment. Poisson regression was used to model the incidence of HCV treatment uptake 
over time. 
 
The data presented in this chapter were originally presented as an oral abstract at the 11
th
 
International Conference on Drug Therapy in HIV in Glasgow, November 2012. The 
analysis was then finalised and published in-part in HIV Medicine in May 2013. The 
published paper can be seen in Appendix IV. 
 
1.2.5 Chapter 6 
The incidence of antiretroviral drug discontinuation among HIV/HCV coinfected 
individuals and those with significant liver fibrosis 
This chapter focuses on the relationship between antiretroviral (ARV) drug discontinuation 
and HIV/HCV coinfection. The aims of this study were to describe the incidence of ARV 
drug discontinuation in HIV monoinfected and HIV/HCV coinfected individuals to see if drug 
discontinuation was more common among coinfected individuals. A further aim of this study 
19 
 
was to describe the association between significant liver fibrosis and the rate of ARV drug 
discontinuation, while identifying the drug classes and individual drugs most likely to be 
discontinued. The main statistical method used in this study was a Poisson regression 
model using generalised estimating equations to model the rate of ARV drug 
discontinuation accounting for within subject variability. 
 
The data presented in this chapter were originally presented as a poster abstract at the 20
th
 
Conference on Retroviruses and Opportunistic Infections (CROI) in Atlanta, March 2013. 
The analysis was then finalised and published in-part in AIDS in September 2013. The 
published paper can be seen in Appendix V. 
 
1.2.6 Chapter 7 
Liver-related death among HIV/HCV coinfected individuals, what are the implications 
for treatment with direct-acting antivirals? 
This chapter focuses on causes of death among HIV/HCV coinfected individuals. The aims 
of this study were to document causes of death among coinfected individuals in Europe 
and to describe changes in the rate of liver-related death (LRD) over time. Further, as it has 
become clear that new direct-acting antiviral treatments for HCV will be prohibitively 
expensive
2
, this study aimed to identify factors associated with progression to LRD so that 
those at the highest risk could be prioritised for treatment. In this study Poisson regression 
is used to model the incidence rate of LRD over time. Cox proportional hazards regression, 
using the Fine and Gray methodology for handling competing risks, was used to identify 
factors associated with LRD. 
 
The data presented in this chapter were originally presented as a poster abstract at the 21
st
 
Conference on Retroviruses and Opportunistic Infections (CROI) in Boston, March 2014. 
The analysis was then finalised and published in-part in AIDS in February 2015. The 
published paper can be seen in Appendix VI. 
 
1.2.7 Chapter 8 
A validated prognostic score for estimating the risk of liver-related death among 
HIV/HCV coinfected individuals 
This chapter builds on the work of the previous chapter by creating a prognostic score for 
progression to LRD among HIV/HCV coinfected individuals. The aims of this analysis were 
to identify factors associated with progression to LRD among HIV/HCV coinfected 
individuals and to create a simple, easily applicable prognostic score to identify those at the 
greatest risk of LRD. The prognostic score was developed using data from the EuroSIDA 
20 
 
study and then validated using data from the Swiss HIV Cohort Study. The main statistical 
method used in this analysis was a Cox proportional hazards regression model, using the 
Fine and Gray methodology for handling competing risks, to identify factors associated with 
LRD using stepwise variable selection. The prognostic score was derived from the 
coefficients of the variables retained in the model. 
 
The data presented in this chapter were originally presented as a poster abstract at the 
22
nd
 Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle, February 
2015. The analysis has been subsequently finalised with the aim of submitting for 
publication at CID in the summer of 2015. 
 
1.2.8 Chapter 9 
Overall significance and conclusions 
This chapter draws on the whole body of work in this thesis to underline the key 
conclusions and implications for the clinical management of HIV/HCV coinfection. Key 
limitations of the EuroSIDA data and analysis presented in this thesis and are discussed in 
detail along with opportunities for further work. 
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Chapter 2 
 
Introduction 
 
2.1 Human Immunodeficiency Virus (HIV) 
 
The human immunodeficiency virus (HIV) epidemic has changed markedly over its 30-year 
history. It was discovered when young gay men started dying of obscure conditions in the 
United States and has grown from a few small studies of a few infections to a well-
documented worldwide pandemic
3-5
. Scientific advancements mean that today HIV is seen 
as a chronic disease which can be controlled with appropriate treatment
6;7
. As such HIV-
positive people in resource rich settings now have life expectancy approaching that of 
those without the condition
8;9
. However, when HIV first appeared in the early 1980s little 
was known about the virus and infection would lead to death within a short time of 
developing an AIDS-defining condition
10
. 
 
Although potent treatment for HIV infection now exists there are large discrepancies in the 
availability and uptake of treatment and HIV remains one of the leading causes of death 
worldwide
11;12
. Further, the number of cases continues to increase in many regions and 
wealth settings
13
. Consequently, although gains have been made over the past decade, 
mortality rates remain comparatively high in resource-limited settings life expectancy is 
estimated to be reduced by 10-20 years
14;15
.  
 
Whereas the development of successful on-going treatment for HIV has proved fruitful, the 
search for an effective vaccine and a cure has been less successful
16-18
. Although research 
continues in these areas the reality is that HIV-positive people face a lifetime of treatment 
which places a substantial burden on their lives
16
. Further, treatment is not without 
complications with many of the available drugs associated with toxicities and adverse 
events
19-21
, although toxicity profiles are better with newer drugs
22
. More recently it has also 
emerged that HIV infection may be associated with an increased risk of death from causes 
not directly related to HIV
23-26
, while there may also be an inflammatory effect of having the 
HIV virus circulating in the body
27
. Consequently, research continues with the aim of 
improving the lives of those living with HIV. 
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2.1.1 The Beginning of the Epidemic 
Although the cause was unknown at the time, the first cases of HIV and AIDS have been 
identified from samples dating back to the 1950s
28
. A sample taken from a male from the 
Democratic Republic of the Congo in 1959 is the first identifiable evidence of HIV
28
. The 
AIDS epidemic was formally recognised by health professionals in 1981 when previously 
healthy young gay men in the United States started to die with alarming regularity from 
conditions that had rarely been seen before
3;29-31, such as the rare cancer Kaposi’s 
sarcoma and pneumocystis carinii pneumonia (PCP)
6;29-36
. Initially there was a lot of 
homophobic stigma associated with these symptoms but soon injecting drug users (IDU), 
haemophiliacs and others who had received blood transfusions started to present with 
similar symptoms
37-40;40-45
. Around the same time similar cases started to appear in Europe, 
also in gay men and in those to have received blood products or injected drugs
46-51
. 
Further, it soon became apparent that children to parents from these risk groups were also 
presenting with these rare conditions
52;53
. 
 
Africans also began to report similar cases with a large increase in the number of Kaposi’s 
sarcoma cases
54-56
. However, in Africa cases were not restricted to gay men and injecting 
drug users, giving rise to the idea of a secondary epidemic not restricted to any particular 
risk groups
56;57
. 
 
The cause of these rare diseases was soon discovered to be severe 
immunodeficiency
3;32;33
. Immunodeficiency was a rare condition but not unheard of at the 
time, however, in these new cases recovery never occurred and the mortality rate was 
100%, which was both shocking and worrying
3
. In 1982, the Centers for Disease Control 
and Prevention (CDC) named the condition Acquired Immunodeficiency Syndrome 
(AIDS)
40
. 
 
2.1.2 Discovery of the HIV Virus 
The HIV virus was discovered in 1983 along with the knowledge that it was responsible for 
the development of AIDS. A French team at the Pasteur institute and the American Robert 
Gallo and collaborators both discovered the virus at around the same time in separate 
locations. The Pasteur Institute published a paper in 1983 stating that they had isolated a 
new virus from a person at risk of AIDS which the authors called Lymphadenopathy 
Associated Virus (LAV)
58;59
. The next year Robert Gallo published a series of papers 
describing a new retrovirus which he named Human T-cell Lymphotropic Virus 3 (HTLV-III) 
and demonstrated that it was the cause of AIDS
60-62
. It was soon discovered that these two 
viruses were in fact the same and due to the effect of the virus on the human immune 
system it was renamed Human Immunodeficiency Virus (HIV)
3;63;64
. Further advances 
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continued throughout the 1980s with the discovery that HIV actually took two distinct forms, 
HIV-1 and HIV-2, which were not closely related
3
. Both viruses were also found to exhibit 
extensive genetic diversity with a number of distinct subtypes and clades identified
65
. 
 
2.1.2.1 HIV in Humans 
How HIV came to infect humans was a topic of much speculation to begin with. Many wild 
and accusatory theories were discussed ranging from a contaminated polio vaccine in 
Africa to a biological weapon of mass destruction developed in the United States
66;67
. 
These theories were dismissed when a virus very similar in nature to HIV was discovered in 
chimpanzees prior to the turn of the millennium
68
. It is now known that HIV-1 passed from 
chimpanzees to humans many times
68-70
, most likely during the preparation of food and in 
unintended blood-to-blood contact
71
, which has resulted in the wide-ranging genetic 
diversity of the virus
65;72;73
. Similarly, HIV-2 is almost identical to Simian Immunodeficiency 
Virus (SIV) which is found in sooty mangabey monkeys
65;74
. 
 
HIV has existed as a human virus for a little more than 100 years and almost certainly 
originated in Africa, with retrospective studies identifying the virus as early as the late 
1950s
75;76
. The diversity of these early strains of HIV, in comparison to the strains that 
initially crossed over into humans, leads us to believe that HIV had been present in the 
human population for many years before even these early studies have identified it
28
. It is 
thought that the first human HIV infection probably occurred in Central Africa around 1930, 
when the first townships were developing in the area
69;75;77
. AIDS can first be identified in 
Africa from medical records in the 1950s, however, as the existence of the HIV virus was 
unknown at that time it is highly likely that AIDS-related deaths occurred earlier but were 
undiagnosed
76;78;79
. 
 
HIV-1 is more infectious than HIV-2 and is responsible for the majority of prevalent cases 
and new infections worldwide
3;77;80
. In the developed world, HIV-1 predominates in high risk 
groups such as men who have sex with men, injecting drug users and sex workers
81
. In the 
United States it is estimated that the HIV-1 epidemic began sometime in the late 1960s
79;82
. 
AIDS-defining conditions were prevalent in approximately 4.5% of gay men in San 
Francisco and 6.6% of gay men in New York in 1978
83;84
, which due to the long interval 
between initial HIV infection and the development of AIDS-defining conditions, suggests 
that HIV-1 had been present in the population for some time
79
. In Europe, the first record of 
AIDS occurred as early as 1959 when a sailor was reported to die from an AIDS-related 
condition, considered to be one of the earliest records of AIDS in the developed world
85
. 
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As HIV-2 is less infectious than HIV-1 it has spread at a slower rate and as such it is easier 
to determine the origin
3
. HIV-2 accounts for a fraction of the worldwide burden of HIV 
infection and is predominantly found in West Africa, originating in Guinea Bissau
3;81
. These 
regions are also home to sooty mangabey monkeys, who are known to have been infected 
with SIV
65;74
. Transmission of HIV-2 from monkey to human is thought to have occurred in 
the home in West Africa where they are commonly kept as pets or food
65
. 
 
The existence of networks of gay men and injecting drug users meant that HIV was able to 
spread rapidly through North America and Europe during the 1980s
79
. Meanwhile, in Africa 
a massive increase in antibiotic injections was taking place
86
, which coupled with 
exponential growth in worldwide travel led to the development of a worldwide epidemic and 
a dramatic increase in the number of AIDS-related deaths
3;87
. 
 
2.1.3 The HIV Virus 
HIV is a retrovirus that belongs to a group of viruses called lentiviruses
65;88
. Retroviruses 
require help from the cells of a host to replicate and are known for long latent periods 
between infection and the development of symptoms and eventually death
12
. HIV targets 
CD4 lymphocyte cells to act as a host for viral replication
89
. These cells are a vital 
component of the human immune system and their depletion leads to the onset of 
AIDS
90;91
. The HIV lifecycle inside the body is shown in Figure 2.1.1
87
. 
 
After HIV has made its way into the blood stream of a host it begins to search for CD4 
lymphocyte cells. When it encounters a CD4 cell it binds to the surface using the CCR5 or 
CXCR4 receptors, in a process known as fusion, and releases HIV RNA
92
. In the host CD4 
cell, with the help of the HIV reverse transcription enzyme, HIV RNA is converted to DNA 
compatible with the host’s human DNA93. Through a process known as integration, the HIV 
DNA is then combined with the host DNA
3
. Once the HIV DNA has integrated with the host 
it is treated just as any other human gene
87
. Using human enzymes and a process named 
transcription, long strands of HIV RNA containing full copies of HIV’s genetic material are 
produced in the cell nucleus
94;95
. These new long HIV RNA strands are then carried outside 
the nucleus and the human protease enzyme translates them into small pieces of protein 
essential for building new HIV virons
94;95
. Once these small building blocks come together 
to form new HIV virons they bud off the host cell and re-enter the blood stream in search of 
new CD4 cells to repeat the process over again
94;95
. 
 
Once infected with HIV, a single CD4 cell can produce many thousand new HIV virons
12
. 
Further, the host cell does not survive the process as it is significantly weakened by the 
integration of HIV DNA
94
. This exponential build-up of HIV virons in the blood stream and 
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Figure 2.1.1 The HIV life cycle
87
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
subsequent depletion of CD4 cells results in the eradication of the human immune system 
and leads to AIDS and death if left untreated
91. It’s also possible for CD4 cells infected with 
HIV to lie dormant for many years and begin to produce HIV virons when activated at a 
later time
96
. These latent HIV infected particles, known as HIV reservoirs, mean that 
attempting to cure HIV is a very complicated process and as a result treatment remains a 
lifelong commitment
97
. 
 
2.1.4 HIV and the Immune System 
HIV infection leads to the death of CD4 cells while circulating HIV in the blood stream 
inhibits the body’s ability to replace them89. CD4 cells counts vary considerably due to a 
number of natural factors including exercise and stress, but in healthy individuals they are 
usually within the range 500-1600cells/mm
3 98-101
. Among HIV-positive individuals CD4 cell 
counts are often much lower and in the absence of treatment CD4 cell counts will continue 
to decrease as a consequence of HIV viral replication taking place in the body
99;102
. Figure 
2.1.2 shows the decline in CD4 cell count associated with prolonged untreated HIV 
infection. After a sharp decline in CD4 cell count during the first few weeks of infection, the 
CD4 cell count stabilizes as the immune system manages to check the rapid replication of 
HIV RNA
103
. However, the CD4 cell count will continue to decrease slowly over time to very 
low levels by 10 years after initial infection
103
. Once CD4 cell counts drop below  
 
 
 
 
 
 
 
 
Image not available due to copyright restrictions 
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Figure 2.1.2 The natural history of HIV infection, HIV viral load and CD4 cell count
103
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
200cells/mm
3
 there is a very high risk of developing an AIDS-defining condition, which will 
eventually lead to death
104-107
. 
 
Difficulties in studying the immune system in living people have proved a major stumbling 
block in understanding and explaining how the HIV virus directly impacts human CD4 
immune cells
89
. However, technology for measuring CD4 cell counts has been readily 
available for some time and remains relatively cheap, costing approximately $5 in the 
developing world and $60 in the developed world
108
. Methods to measure the amount of 
HIV RNA circulating in the blood stream became available in 1996 and have since been 
used alongside CD4 cell counts to classify each individual’s HIV infection status109-111. 
During the first few weeks of HIV infection viral loads can reach levels in the tens of millions 
per ml of blood, coinciding with a steep decline in CD4 cell count, before falling to more 
stable levels
103
. Similar to low CD4 cell count, many studies have documented an 
association between high HIV viral load and faster progression to AIDS and 
death
109;110;112;113
. 
 
HIV RNA tests are more expensive than CD4 cell counts, costing approximately $25 in the 
developing world and $120 in the developed world
108
. While both measures are important 
predictive markers of disease progression, CD4 cell count is thought to be a better short 
term marker of AIDS progression or death
114-118
, while HIV viral loads are considered good 
long term markers of disease progression
110;114;119;120
. However, in the modern era where 
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the costs of treatment and monitoring are constantly being re-evaluated, many studies have 
attempted to assess the impact of a reduction in the frequency of viral load and CD4 
monitoring, often concluding that less frequent testing is unlikely to lead to a significant 
increase in mortality or drug resistance
121;122
. 
 
2.1.5 The Clinical Stages of HIV Disease Progression 
Classification systems for the stages of HIV disease and the progression to an AIDS-
defining condition have been developed by the world health organisation (WHO) and the 
centres for disease and control (CDC). The CDC system relies on CD4 cell count 
monitoring and recognition of conditions associated with those with HIV, while the WHO 
system can be used in all resource settings, where CD4 cell count monitoring may not be 
available, and provides a description of conditions specific to the different stages of HIV 
infection
123;124
. Table 2.1.1 shows the stages of each classification system along with the 
clinical manifestations and relevant CD4 cell counts associated with each level. 
 
HIV seroconversion 
The first weeks of infection with HIV are referred to as primary or acute infection, 
seroconversion takes place in this period and is the process by which an individual’s 
 
 
Table 2.1.1 Classification of stages of HIV infection 
WHO Stage CDC Stage Clinical Monitoring
123
 CD4 Monitoring
124
 
1: Asymptomatic A: Asymptomatic No HIV-related symptoms CD4 cell count 
≥500cells/mm
3
  
2: Mild B1: Symptomatic 
High CD4 
Unexplained weight loss, 
Respiratory infections, 
Herpes zoster, 
Oral ulceration, 
Seborrhoeic dermatitis, 
Fungal nail infection 
HIV-related symptoms 
 
And 
 
CD4 cell count 
≥500cells/mm
3
 
3: Advanced B2: 
Symptomatic 
Declining CD4 
Severe weight loss, 
Chronic diarrhoea, 
Persistent fever, 
Oral candidiasis, 
Pulmonary TB, 
Severe bacterial infection 
HIV-related symptoms 
 
And 
 
CD4 cell count  
200-499cells/mm
3
 
4: Severe 
(AIDS) 
C: AIDS HIV wasting syndrome, 
Pneumonia, 
Chronic herpes simplex, 
Extrapulmonary TB, 
Kaposi sarcoma, 
HIV encephalopathy 
AIDS-defining conditions 
 
And 
 
CD4 cell count 
<200 cells/mm
3
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immune system recognises HIV and develops an immune response. Only once 
seroconversion is complete will a person test positive for HIV antibodies
125
. During primary 
infection HIV replicates rapidly infecting many CD4 cells and very high levels of HIV RNA 
are often present in the blood stream, potentially reaching millions of copies of the virus per 
millilitre of blood
12;126-128
. As shown in Figure 2.1.2 this results in a substantial, but transient, 
reduction in the number of CD4 cells and many people will experience flu-like symptoms
126-
129
. After approximately 6 weeks, primary infection will end and HIV viral load will begin to 
decline, coinciding with a rebound in the level of CD4 cells. The majority of people will then 
move to a period of clinical latency, experiencing no sign or symptoms of HIV infection for 
many years
128;129
. 
 
Clinical latency 
As shown in Figure 2.1.2, the period of clinical latency is categorised by a gradual reduction 
in the number of CD4 cell counts
12
. The immune system can cope with reducing CD4 cell 
counts for a median of 10 years following infection with HIV, with some able to survive for 
as long as 20 years without the need for treatment
130
. However, without treatment, older 
people are more likely to experience disease progression due to natural fluctuations in CD4 
cell count according to age
12
. 
 
It is estimated that the gradual reduction in CD4 cell count during the phase of clinical 
latency sees the loss of approximately 50-90 CD4 cells per ml each year, while a CD4 cell 
count of 500 represents an immune system with approximately half as many CD4 cells as a 
healthy HIV-negative person
12;131;132
. However, in the period 18-24 months before the 
development of an AIDS-defining condition, the rate of CD4 cell depletion increases 3- to 5-
fold
131;132
.  
 
It appears that the human immune system can function reasonably well with CD4 cell 
counts down to 200cells/mm
3
, as opportunistic infections are rarely seen in those with CD4 
≥200cells/mm3. However, once CD4 cell count levels drop as low as 50cells/mm3 there is a 
very high risk of opportunistic infection, complications and death
100
.  
 
AIDS 
The development of an AIDS-defining condition signals the last stage of HIV disease. Table 
2.1.2 shows the full list of AIDS-defining conditions according to the CDC
133
. The CDC also 
recognises a CD4 cell count <200cells/mm
3
 in an HIV-positive person to be an AIDS-
defining condition
124
. Life expectancy following diagnosis with an AIDS-defining condition 
will vary depending on each specific condition, however, without adequate treatment it has 
been reported that the median survival time following an AIDS diagnosis is between 3 and  
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Table 2.1.2 CDC list of AIDS-defining conditions
133
 
AIDS-defining conditions: 
Bacterial infections, multiple of recurrent 
Candidiasis of the bronchi, trachea, or lungs 
Candidiasis of esophagus 
Cervical cancer, invasive 
Coccidioiodomycosis, disseminated or extrapulmonary 
Cryptococcosis, extrapulmonary 
Cryptosporidiosis, chronic intestinal (>1 month’s duration) 
Cytomegalovirus disease (other than liver, spleen, or nodes), onset at age >1 month 
Cytomegalovirus retinitis (with loss of vision) 
Encephalopathy, HIV-related 
Herpes simplex: chronic ulcers (>1 month’s duration), or bronchitis, pneumonitis, or 
esophagitis (onset at age >1 month) 
Histoplasmosis, disseminated or extrapulmonary 
Isosporiasis, chronic intestinal (>1 month’s duration) 
Kaposi sarcoma 
Lymphoid interstitial pneumonia or pulmonary lymphoid hyperplasia complex 
Lymphoma, Burkitt (or equivalent term) 
Lymphoma, immunoblastic (or equivalent term) 
Lymphoma, primary, of brain 
Mycobacterium avium complex or Mycobacterium kansasii, disseminated or extrapulmonary 
Mycobacterium tuberculosis of any site, pulmonary, disseminated or extrapulmonary 
Mycobacterium, other species or unidentified species, disseminated or extrapulmonary 
Pneumocystis jiroveci pneumonia (PCP) 
Pneumonia, recurrent 
Progressive multifocal leukoencephalopathy 
Salmonella septicaemia, recurrent 
Toxoplasmosis of brain, onset at age >1 month 
Wasting syndrome attributed to HIV  
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50 months
134
. Further, the length of survival is thought to halve at the diagnosis of a second 
AIDS-defining condition
134
. 
 
2.1.6 The global HIV epidemic 
In 2012 UNAIDS reported on the worldwide distribution of the burden of HIV and the global 
AIDS epidemic. The report shows that there were an estimated 34.0 million (95% C.I. 31.4 
million – 35.9 million) people living with HIV at the end of 2011135. The authors estimate 
that 0.8% of adults aged 15-49 years are living with HIV worldwide, however the burden of 
the epidemic varies considerably between countries and regions
135
. 
 
The most severely affected region continues to be Sub-Saharan Africa, where approaching 
1 in 20 adults (4.9%) are living with HIV, which accounts for 69% of the total number of 
people living with HIV worldwide
135
. The second largest affected region is South-East and 
East Asia, where approaching 5 million people are living with HIV
135
. In terms of 
prevalence, following sub-Saharan Africa, the regions most heavily affected are the 
Caribbean, Eastern Europe and Central Asia, where 1.0% of adults were living with HIV in 
2011
135
. Figure 2.1.3 from the WHO shows a graphical representation of the prevalence of 
HIV infection across the world in 2010 and mirrors the estimates from UNAIDS. 
 
New infections declining 
The global peak incidence of new HIV cases was thought to have occurred in 1996, with an 
estimated 3.5 million new infections
13
. Although the number of patients infected worldwide  
 
Figure 2.1.3 Global view of the HIV epidemic in 2010
136
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Image not available due to copyright restrictions 
31 
 
with HIV is substantial, the number of people newly infected is falling per year. According to 
the UNAIDS report, the estimated number of people acquiring HIV infection in 2011 (2.5 
million (2.2 million – 2.8 million)) was 20% lower than in 2001, although here too, variation 
is considerable between countries and regions
135
. Since 2001, the fastest declines in the 
number of people acquiring HIV infection have occurred in the Caribbean (42%) and sub-
Saharan Africa (25%)
135
. However, in other parts of the world HIV trends remains a cause 
for concern. Since 2001, the number of people newly infected in the Middle East and North 
Africa has increased by more than 35% from 27,000 to 37,000 per year
135
. Data also 
indicates that the incidence of HIV infection in Eastern Europe and Central Asia began to 
rise in the late 2000’s after remaining relatively stable for several years135. Figure 2.1.4 
below from the WHO shows a graphical representation of the number of new HIV infections 
per year globally in 2010 and mirrors the estimates from UNAIDS. 
 
Many national epidemics have changed dramatically over the past decade. In 23 countries 
in sub-Saharan Africa the incidence of HIV infection has reduced by more than 25%. 
However, despite these improvements sub-Saharan Africa continues to account for 71% of 
the adults and children newly infected in 2011, which highlights the importance of efforts to 
improve HIV prevention in the region
135
. Before the HIV epidemic took hold in sub-Saharan 
Africa, progress was being made in general health with the average life expectancy 
reaching 62 years, while it was hoped further gains would see the region soon approach 
the level of life expectancy seen in the developed world. However, the HIV epidemic has 
 
 
Figure 2.1.4 Estimated number of new HIV infections worldwide in 2010
136
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had a devastating effect on the region and in 2005 the estimated life expectancy in sub-
Saharan Africa had fallen to 44 years
137
. 
 
With the exception of sub-Saharan Africa, the HIV epidemic is predominantly confined to 
IDUs, MSM and sex workers
5
. In sub-Saharan Africa the prevalence is so high and 
widespread that everyone is considered at risk of infection
5;138
. Further, as transmission in 
sub-Saharan Africa is mostly driven by heterosexual contact and mother-to-child 
transmission, it is also the only region where there is a higher prevalence among 
women
5;138
. 
 
2.1.7 The European HIV Epidemic 
HIV infection is of major public health importance in Europe. In 2011, HIV/AIDS 
surveillance in Europe reported that 53,974 HIV diagnoses were reported by 50 of the 53 
countries in the WHO European Region
139
. The surveillance results suggest that HIV 
transmission continues in many countries, with an overall rate of 7.6 diagnoses per 100,000 
population
139
. Figure 2.1.5 shows the number of new HIV infections by region of Europe 
and year of diagnosis. 
 
There are considerable regional differences in the HIV epidemic within Europe, with the 
prevalence and incidence of infection varying from country to country. The highest rates of 
infection in 2011 were seen in Eastern Europe (22.4 per 100,000 population) followed by 
the West (6.5 per 100,000 population) and Central Europe (1.6 per 100,000 population)
139
. 
The highest rates of infection reported by individual countries were Ukraine (38.0 per 
 
Figure 2.1.5 HIV infections, rates by geographical region 2004-2011
139
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100,000 population) followed by Estonia (27.3 per 100,000 population) and San Marino 
(25.6 per 100,000 population)
139
. Figure 2.1.6 shows the number of new HIV infections by 
country of Europe per 100,000 population reported in 2011. 
 
Eastern Europe 
In the UNAIDS estimates, Eastern Europe and Central Asia are grouped together because 
of their geographical location and similar population demographics
135
. The 2012 estimates 
show that this is the only region in Europe where the incidence of new HIV infections 
continues to rise (Figure 2.1.5)
135
. The 140,000 new HIV infections in this region means 
that there are now an estimated 1.4 million HIV-positive people living in Eastern Europe 
and Central Asia
135
. 
 
Since 2004, all countries that have consistently reported data have reported annual 
increases in the numbers of HIV diagnoses. A resurgence of HIV was reported by Latvia in 
2007/08 and by Lithuania in 2009
139
. Among the other countries, rates have steadily 
increased since 2004, by more than three times in Armenia, Azerbaijan, Kyrgyzstan and 
Tajikistan, and more than twice in Georgia, Kazakhstan and Moldova. In Belarus and 
Ukraine increases of 59% and 76% were observed, respectively
139
. 
 
 
Figure 2.1.6 New HIV infections in Europe per 100,000 population in 2011
139
 
   
 
 
 
 
 
 
 
Image not available due to copyright restrictions 
34 
 
Figure 2.1.7 Trends of reported HIV diagnoses by transmission mode and year of 
diagnosis in Eastern Europe
139
 
 
 
 
 
 
 
 
 
 
 
 
The overall number of HIV diagnoses among IDUs in Eastern Europe has increased by 
24.7% since 2004, however, declines were reported in Belarus, Latvia, Lithuania and 
Moldova
139
. In contrast, there have been increases in IDU infection in Georgia, Kazakhstan, 
Kyrgyzstan, Tajikistan and Ukraine
139
. However, the predominant mode of HIV 
transmission in the East has changed to heterosexual contact in recent years. The overall 
number of HIV cases acquired by heterosexual contact increased 177.8% between 2004 
and 2011, accounting for 56.7% of transmissions in 2011
139
 (Figure 2.1.7). Further, 
increases in this mode of transmission have been reported by all Eastern countries except 
for Turkmenistan
139
. Although the number of HIV transmissions among MSM is relatively 
low in the East, the number of reported cases has increased eightfold, with all countries 
except Kyrgyzstan reporting an increase
139
. 
 
Western and Central Europe 
In Western and Central Europe the total number of people living with HIV was estimated to 
be 900,000 in 2012, an increase of 41% from 2001
139
. The epidemic in the West is 
characterised by continuing increases in sexual transmission of HIV, particularly between 
men (Figure 2.1.8). Sex between men accounted for 40.1% of infections in the West in 
2011, with 37.9% attributable to heterosexual sex and just 4.2% to IDU
139
. 
 
The epidemic in Central Europe remains low and stable, although there is evidence of 
increasing sexual transmission in many countries, especially between men but also 
increasingly among heterosexuals
139
 (Figure 2.1.9). Men having sex with men accounted 
for 27.3% of HIV infections in 2011, followed by 25.7% due to heterosexual contact and 
8.2% due to IDU
139
. 
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Figure 2.1.8 Trends of reported HIV diagnoses by transmission mode and year of 
diagnosis in Western Europe
139
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1.9 Trends of reported HIV diagnoses by transmission mode and year of 
diagnosis in Central Europe
139
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The heterogeneity of transmission also characterises the Central region, with different 
transmission modes predominating in different countries. In 2011, heterosexually acquired 
cases of HIV represented more than half of all diagnoses in Albania, Bosnia and 
Herzegovina, and Romania, while at least half of all cases of HIV were due to MSM contact 
in Croatia, Cyprus, Czech Republic, Hungry, Slovakia, and Slovenia
139
.  
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2.1.8 Transmission of HIV 
HIV is transmitted via contact with contaminated bodily fluids and the risk of infection at 
each exposure is heavily dependent on the amount of HIV virus circulating in the 
body
140;141
. HIV RNA has been found in many different bodily fluids, the most prominent 
being blood and semen, but it also exists in other fluids such as the tears of an infected 
person
29
. However, the levels of HIV RNA vary greatly by the location, whereas there may 
be significant levels of virus in blood and semen, even in an individual with a very high 
plasma viral load the amount of HIV RNA in a tear would be so small that it is impossible to 
be infected following contact with it
29
. Moreover, HIV is not able to survive outside of the 
body for prolonged periods, so infection via casual contact, shaking hands and kissing, or 
via public facilities, from the toilet seat, is not possible
29
. 
 
Consequently, HIV is most frequently transmitted during unprotected sex and via blood-to-
blood contact during injecting drug use
142;143
, while historically there was a major burden of 
HIV transmission via contaminated blood transfusions
144
. In the developing world, mother-
to-child transmission is one of the major routes of infection as HIV RNA can be transmitted 
at birth and during the act of breastfeeding
145
. With the exception of mother-to-child and 
blood transfusion transmissions, the risk of infection from a one off exposure is usually low 
regardless of the transmission route, but in all cases repeated exposure will increase the 
risk of infection
146
. 
 
Sexual transmission 
Worldwide, the most frequent route of HIV transmission occurs during unprotected sex
29
. 
However, the risk of infection during sexual intercourse depends on a number of factors, 
most importantly the level of HIV RNA in the blood
128
. Recent studies have shown that in 
discordant couples, where one partner is HIV-positive, the risk of the HIV-negative partner 
contracting HIV is approaching zero when the HIV-positive partner has undetectable HIV 
RNA due to continued successful treatment
147
. When HIV RNA is present the risk of 
infection will depend on the sexual acts performed, rough sexual practises such as fisting 
are likely to cause bleeding and are associated with transmission, the presence of other 
sexually transmitted infections and whether condoms were used
12;142;148
. 
 
During sex between a man and a woman, the woman is at greater risk of infection and 
worldwide approaching half of the entire HIV-positive population consists of women who 
were infected during sexual contact
12;149
. However, condoms have been shown to be a very 
effective method of preventing sexual transmission. In couples where one individual is HIV-
positive, the risk of transmission of HIV when condoms are used correctly with no slipping 
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or splitting is negligible
12
. Unfortunately, in many settings gender inequality and financial 
constraints mean that women are unable to practise safe sex
149
.  
 
One intervention that has been found to reduce the risk of HIV transmission to men during 
sexual contact is circumcision, with risk reductions in the region of 60% reported among 
those circumcised
150-152
. Consequently, circumcision is recommended by the WHO to 
reduce HIV transmission in the developing world where access to condoms may be 
reduced or prevented by religious sentiment
153;154
. Unfortunately, circumcision infers no 
benefit for women in terms of HIV transmission, except that by reducing transmission to 
men there may be a smaller pool of HIV-positive men that could then transmit to women
155
. 
 
Sexual contact between men is the major transmission risk factor in the developed world, 
with receptive anal sex with an HIV-positive partner carrying the greatest risk
139;142
. The 
incidence of HIV infection among MSM has been rising in recent years, which is linked with 
an increase in unprotected sex evidenced by an increase in other sexually transmitted 
infections
135;156-159
. However, in some countries the rise in HIV incidence is no doubt linked 
to a better screening process and more frequent testing for HIV
160
. While sexual health and 
protecting partners from HIV infection is an important consideration for many HIV-positive 
MSM, there remains a section of the population who are either unaware of their infection 
status or ignore it and continue to take part in risky sexual practises
161-165
. 
 
Many interventions have been piloted among MSMs, with reduced transmission rates seen 
after the introduction of support groups at the individual and community level
166
. However, 
the incidence of HIV infection continues to rise in this population and it is thought that as 
treatment for HIV has become more and more successful, fear of HIV infection has 
decreased and risky sexual behaviour has increased
167
. 
 
Transmission via blood-to-blood contact 
HIV is efficiently transmitted via blood-to-blood contact and many transmissions occur 
during injecting drug use when needles and other drug paraphernalia are shared
12;143;168
. 
The chance of contracting HIV during a year of engaging in IDU has been estimated to be 
up to 50% in some populations. Consequently, the number of HIV-positive IDUs continues 
to rise worldwide
169
. Interventions among the IDU community have focused on needle 
exchange programs, community outreach and education about the dangers of sharing 
equipment which can transmit blood
169
. In the UK and Australia these programs have 
helped to keep the rate of HIV infection low among IDUs
170;171
. However, other countries do 
not support such a liberal attitude to illicit drug abuse and IDUs are criminalised and 
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refused treatment for HIV, leading to very high rates of infection and HIV-related 
mortality
172-175
. 
 
Blood-to-blood transmission can occur in circumstances other than IDU. Professionals in 
the health service are at risk of accidental needle stick injuries or splashes onto open 
wounds or the eyes
12
. However, in these cases the risk of transmission is very low and has 
been estimated to be approximately 0.3% after an accidental needle stick and 0.09% after 
a splash of blood to the eye
176
. Further, treatment is available and widely used in these 
circumstances, known as post-exposure prophylaxis which is a short course of treatment 
that stops the HIV virus from taking hold and reduces the risk of transmission by as much 
as 90%
177
. 
 
Many people were also infected with HIV due to receiving infected blood products before 
the introduction of adequate screening mechanisms. Transmission from infected blood 
products has been shown to be very efficient, as infected blood is transfused directly to the 
blood stream, with transmission rates approaching 100%
144;178
. Thankfully, since the mid-
1980s screening methods have been employed and all blood products in the United States, 
Canada and Europe have been screened for HIV
12
. The WHO also recommends 
procedures for ensuring blood safety, which are cost effective in the long term, however, 
many developing countries continue to fall short of the requirements for safe blood 
screening
179;180
. 
 
Mother-to-child transmission 
Without effective treatment for both mother and child, transmission of HIV can occur in 
labour during birth and the act of breastfeeding
145;181-184
. Studies have shown that the HIV 
viral load of the mother at the time of labour is the most important predictor of perinatal 
transmission of HIV and that without treatment the risk of transmission to the child can be 
as high as 40%
145;185;186
. It is estimated that 330,000 (95% confidence interval (CI) 
280,000-390,000) children acquired HIV in 2011, with almost all of these new infections 
due to mother-to -child transmission
135;187
. However, this represents a 43% decline since 
2003 and a 24% decline from 2009 when 430,000 (370,000-490,000) transmissions were 
estimated to have occurred
135
.  
 
Mother-to-child transmission is an area where great strides have been made, timely 
diagnosis of HIV-positive mothers and appropriate treatment should result in transmission 
rates approaching zero
188
. International plans are in place to attempt to achieve the 
elimination of new HIV infections in children by 2015, while continued reductions in the 
number of transmissions per year mean that confidence is growing in the feasibility of these 
39 
 
ambitions
135
. However, while perinatal transmission in the developed world is already at low 
levels, this is not the case in the developing world where a large proportion of new 
infections each year are due to mother-to-child transmission
145
. 
 
In the developed world, testing of all pregnant women for HIV, appropriate treatment and 
the avoidance of breastfeeding has seen the number of mother-to-child transmissions as a 
proportion of all HIV transmissions fall drastically from approximately 25% to approaching 
zero
189-192
. In Europe, most pregnant mothers with HIV will be engaged in care prior to 
falling pregnant and will have been informed of the risks associated with stopping treatment 
during pregnancy
189;190
. Current guidelines suggest that pregnant women with HIV should 
be treated in the same fashion as non-pregnant women, with just one routinely used drug, 
Efavirenz, to be avoided
193
. 
 
Mother-to-child transmission in sub-Saharan Africa is common as the majority of HIV-
positive people are women of child-bearing age
145
. Further, breastfeeding is common 
practice due to the cost of feeding infants with formula milk
145
. Consequently, it is estimated 
that 40% of mother-to-child transmissions in this region are a direct result of 
breastfeeding
191;194
.  
 
2.1.9 Treatment for HIV infection 
 
2.1.9.1 The history of treatment 
The history of drug development of ARVs for the treatment of HIV coincided with a period 
of change at regulatory bodies such as the FDA
195
. Pressure groups and activists led calls 
for change as potentially lifesaving drugs were being trialled but were not widely available 
for patients that required them
195
. Clinical trials with death as the primary study endpoint 
required too long for the benefits of treatment to become apparent
195
. In 1992 the FDA 
adopted new regulations whereby a standard was established for the approval of a drug 
based on its effect on a surrogate marker, and not a clinical outcome
196;197
. This paved the 
way for far shorter clinical trials of ARV drugs which focused on the ability to achieve an 
undetectable HIV viral load within a given timeframe (typically 24 or 48 weeks in modern 
trials)
198
. Also in 1992, the parallel track policy statement was made specifically with the 
intention of expanding the availability of investigational drugs for treatment of HIV
197
. These 
changes helped to extend treatment to a larger population and led to rapid development of 
new drugs. 
 
At the beginning of the HIV epidemic, there were no effective treatments available for HIV 
infection. The first antiretroviral drug for HIV, zidovudine a nucleoside reverse transcriptase 
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inhibitor (NRTI), was approved for use in 1987
199
. Zidovudine was originally developed in 
the 1960s to combat cancers caused by as yet unknown human retroviruses
200;201
. The first 
clinical trial in HIV-positive people showed that zidovudine, AZT for short, was effective in 
reducing mortality and opportunistic infections, compared to a control arm receiving no 
active treatment
201
. Consequently, the trial was stopped early so that those in the control 
arm could also receive treatment with zidovudine
201
. However, there were severe adverse 
events associated with treatment, which are now known to have been mostly caused by 
early overdosing of the drug
202-205
. 
 
In the remainder of the decade, the effectiveness of zidovudine waned as resistance 
mutations began to develop in those taking the drug for prolonged periods of time, which 
meant that the benefits of treatment were limited to an extended life expectancy of up to 18 
months
206-209
. Consequently, efforts were made to discover new drugs which could further 
extend the life expectancy of HIV-positive people and new drugs became available in the 
early 1990s
199;210
. 
 
In 1990, a new NRTI drug, didanosine (ddI), was evaluated in clinical trials with promising 
results documenting fewer adverse events than zidovudine, which lead to its approval by 
the FDA in 1991
211-213
. Shortly after, a similar formulation called zalcitabine (ddC) was also 
approved
199
. Switching to didanosine or zalcitabine from a failing zidovudine treatment 
often had substantial benefits to the patient
214
. This led investigators to study treatment 
regimens comprising of combinations of drugs, and it was soon found that taking either 
didanosine or zalcitabine along with zidovudine had a significant effect on progression to an 
AIDS-defining condition, compared to taking zidovudine alone
215
. However, the biggest 
strides towards effective treatment for HIV were taken when a new class of drug was 
developed in the mid-1990s, the protease inhibitor (PI)
199
. 
 
2.1.9.2 Combination antiretroviral therapy 
Combination antiretroviral therapy (cART) involves combining multiple drugs from different 
classes, targeting different functions of the HIV lifecycle, into a single treatment regimen
201
. 
Introduced in 1995, cART is the gold standard of care for HIV-positive people worldwide
201
. 
In 1996, three PIs were approved for treatment of HIV, ritonavir, indinavir and saquinavir 
and cART consisted of two NRTIs, known as the cART backbone, and a PI
199;201
. Shortly 
after, in the same year a third class of drug was approved for treatment of HIV, the non-
nucleoside reverse transcriptase inhibitor (NNRTI) nevirapine
199
, which meant there were 
different combinations of cART available. Many studies have documented improved 
efficacy of cART in comparison to dual therapy, documenting improvements in CD4 cell 
count increases and faster HIV viral load suppression
216-222
. Combination antiretroviral 
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therapy has led to dramatic declines in HIV-related mortality, meaning that today HIV is 
seen as a chronic manageable condition
6;7
. Recent studies estimate that life expectancy of 
HIV-positive people in the developed world, established in care early during the course of 
infection, have life expectancy approaching that of those without HIV infection
8;9
. 
 
Originally, the PI indinavir was the most common third drug in a cART regimen, however it 
was not well tolerated due to complicated dose scheduling and severe renal toxicity
223
. 
Ritonavir was also found to be a potent PI, but with many associated toxicities that meant it 
was rarely prescribed at the full dose
224-228
. However, ritonavir was found to be a powerful 
inhibitor of PI metabolisation, and when administered in small doses along with other PIs 
acted as a booster to increase the bioavailability of other PIs without the associated side 
effects
229
. Consequently, most PIs are now prescribed along with a small dose of ritonavir, 
and these boosted PIs have been shown to be more efficacious than their unboosted 
counterparts
230-233
. 
 
As the number of antiretroviral drugs approved for treatment of HIV has increased over 
time, studies have tried to determine the most efficacious combinations with the fewest 
adverse effects and toxicities. Studies comparing PI-based cART with NNRTI-based cART 
have shown that NNRTI-based regimens have faster viral suppression of HIV RNA, but 
CD4 cell count responses are comparable regardless of the third drug class
234-237
. 
Differences between the combinations are only apparent with regards to the toxicity and 
resistance profile of the drugs, typically patients taking an NNRTI regimen may benefit from 
fewer toxicities while those taking PI based regimens will have a higher genetic barrier to 
resistance, so which regimen to use is often a choice made dependent upon the lifestyle 
and needs of the individual
238-242
. 
 
More recently, other types of drug have become available, namely integrase inhibitors 
which prevent the integration of HIV DNA into the host genome and fusion inhibitors which 
prevent the fusion between HIV and host CD4 cells
243
. As treatment has advanced to more 
potent less toxic drugs, attention has shifted from selecting treatment regimens based on 
efficacy alone, as most commonly used drugs now have comparable efficacy
244
. 
Government needs to reduce health sector spending have in some countries, the UK and 
Europe especially, led to cost effectiveness playing an increasing role in determining 
treatment guidelines
245;246
. New drugs are typically very expensive and may only offer 
marginal gains over older drugs, which can be much cheaper, especially those which have 
gone off patent
246
. 
 
42 
 
2.1.9.3 Current treatment guidelines 
Current treatment guidelines recommend that for adults first-line therapy should consist of 
two NRTIs plus a third drug from a different class, usually an NNRTI, PI or integrase 
inhibitor
1;247
. As efavirenz is available in a fixed-dose combination pill with two NRTIs, 
lamivudine and tenofovir, it is strongly recommended as the initial drug regimen to reduce 
the pill burden
247
. PIs are recommended as first-line therapy in children under the age of 3 
and for those with anticipated poor adherence due to their higher genetic barrier to 
resistance mutations
1;247
. For children younger than 3 lopinavir boosted with ritonavir based 
regimens are recommended, while for adults the first-line PI is usually atazanavir, also 
boosted with ritonavir
1;247
.  If there are contraindications to the use of either of the NRTIs 
then a different combination of NRTIs should be used, while if there are contraindications to 
efavirenz or it is not available the NNRTI nevirapine should be used
1;247
. Due to many 
different reasons there is still some debate over which choice of first-line treatment is 
optimal, one of the most important factors being the long term durability of a regimen.  
 
Recommendations for when to start treatment are based on CD4 cell count and plasma 
HIV RNA viral loads and there is some debate over which are the optimal cut-offs in 
asymptomatic individuals. Current European guidelines recommend starting treatment once 
CD4 cell count drops below 350 cells/mm
3 1
, however, the most recent WHO 
recommendations have stated that treatment should be recommended for all patients with 
a CD4 cell count below 500 cell/mm
3 247
. Early treatment decreases the risk of early CD4 
cell depletion and lowers the viral load, which in turn, decreases the risk of infection to 
others
248
. Delaying therapy, on the other hand, avoids the risk of toxic drug effects and 
resistance mutation development and the reliance on new potent and tolerable drugs 
becoming available in the future
248
. The START (Strategic Timing of AntiRetroviral 
Therapy) study is a randomised controlled trial of ART-naïve patients with CD4 cell counts 
greater than 500 cell/mm
3
, which aims to compare patients randomised to start therapy 
immediately with those that defer treatment until CD4 cell count declines to 350 cells/mm
3 
249
. The objective of this study is to help answer the question when is the optimal time to 
start treatment. Enrolment was completed in 2013 and three years of follow-up are 
expected
249
. 
 
2.1.9.4 Currently licensed antiretrovirals 
 
Nucleoside reverse transcriptase inhibitors (NRTI) 
NRTIs were the first class of drugs licensed for treatment of HIV
199
. NRTIs are nucleotide or 
nucleoside analogues needed for HIV replication, but with flaws inserted to interrupt the 
process. They attach to the HIV reverse transcriptase and stop HIV RNA from becoming 
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HIV DNA
250. Therefore, when HIV’s reverse transcriptase uses the faulty nucleoside 
analogue, rather than the natural nucleoside, the virus is unable to replicate
250
. Tables 
2.1.3 and 2.1.4 summarise the NRTIs and NRTI fixed dose combinations currently licensed 
for the treatment of HIV in the U.S. and Europe. The currently recommended dual NRTI 
backbone of cART is the fixed-dose combination of emtricitabine and tenofovir
1;247
. 
 
Protease inhibitors (PI) 
PIs were the second class of drug to become available and were the first used in 
combination with NRTIs to create combination therapy
199;251
. PIs interrupt the protease 
enzyme, which means that after HIV has replicated its genetic material the assembly of 
new HIV virons is inhibited, so that it may not go on to infect other cells
250
. Table 2.1.6 
summarises the PIs currently licensed for HIV treatment in the U.S. and Europe. 
Atazanavir, darunavir and lopinavir, all boosted with ritonavir, are the currently 
recommended first-line PIs
1;247
. 
 
 
Table 2.1.3 NRTIs currently licensed for treatment of HIV 
Generic drug name Trade name EMA approved
252
 FDA approved
199
 
Abacavir (ABC) Ziagen 08-Jul-99 17-Dec-98 
Didanosine (ddI) Videx * 09-Oct-91 
Emtricitabine (FTC) Emtriva 24-Oct-03 02-Jul-03 
Lamivudine (3TC) Epivir 08-Aug-96 17-Nov-95 
Stavudine (D4T) Zerit 08-May-96 24-Jun-94 
Tenofovir (TDF) Viread 05-Feb-02 26-Oct-01 
Zidovudine (AZT) Retrovir * 19-Mar-87 
*Not licensed 
 
 
Table 2.1.4 Fixed dose NRTI combinations licensed for treatment of HIV 
Generic drug name Trade name EMA 
approved
252
 
FDA approved
199
 
Emtricitabine/Tenofovir (FTC/TDF) Truvada 21-Feb-05 02-Aug-04 
Lamivudine/Abacavir (3TC/ABC) Kivexa 17-Dec-04 02-Aug-04 
Lamivudine/Abacavir/Zidovudine 
(3TC/ABC/AZT) 
Trizivir 28-Dec-00 14-Nov-00 
Lamivudine/Zidovudine (3TC/AZT) Combivir 18-Mar-98 27-Sep-97 
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Table 2.1.5 PIs currently licensed for treatment of HIV 
Generic drug name Trade name EMA approved
252
 FDA approved
199
 
Atazanavir/r (ATV/r)
1
 Reyataz 02-Mar-04 20-Jun-03 
Darunavir (DRV/r) Prezista 16-Dec-08 23-Jun-06 
Fosamprenavir/r (FPV/r) Telzir 12-Jul-04 20-Oct-03 
Indinavir (IND) Crixivan 04-Oct-96 13-Mar-96 
Lopinavir/r (LPV/r) Kaletra 20-Mar-01 15-Sep-00 
Nelfinavir (NFV/r) Viracept * 14-Mar-97 
Ritonavir Norvir 26-Aug-96 01-Mar-96 
Saquinavir/r (SQV/r) Invirase 04-Oct-96 06-Dec-95 
Tipranavir (TPV/r) Aptivus 25-Oct-05 22-Jun-05 
/r: boosted with ritonavir; 
1
Can also be taken without ritonavir; *Not licensed 
 
 
Non-nucleoside reverse transcriptase inhibitors (NNRTI) 
Like NRTIs, NNRTIs prevent the conversion of HIV RNA into DNA. NNRTIs connect to the 
HIV reverse transcriptase and change its shape, meaning that it no longer fits to the HIV 
RNA
250
. As a result the RNA cannot be converted into DNA. Table 2.1.5 summarises the 
NNRTIs currently licensed for treatment of HIV in the U.S and Europe. Efavirenz, 
nevirapine and rilpivirine are the recommended first-line NNRTIs
1;247
. NNRTIs also form 
part of single pill regimens which are fixed-dose combinations of two NRTIs and an NNRTI. 
Atripla, which combines efavirenz with truvada, is currently the recommended first line 
regimen according the WHO
247
. Table 2.1.7 summarises the fixed-dose single pill regimens 
currently licensed for HIV treatment. 
 
 
Table 2.1.6 NNRTIs currently licensed for treatment of HIV 
Generic drug name Trade name EMA approved
252
 FDA approved
199
 
Efavirenz (EFV) Sustiva 28-May-99 17-Sep-98 
Etravirine (ETV) Intelence 28-Aug-08 18-Jan-08 
Delavirdine (DLV) Rescriptor * 04-Apr-97 
Nevirapine (NVP) Viramune 05-Feb-98 21-Jun-96 
Rilpivirine (RPV) Edurant 28-Nov-11 20-May-11 
*Not licensed 
 
Integrase/fusion/entry inhibitors 
Table 2.1.8 summarises the other antiretrovirals currently licensed for HIV treatment. 
Maraviroc is an entry inhibitor which blocks the chemokine co-receptor 5 (CCR5) which HIV 
uses to bind to and enter CD4 cells
250
. It is the first example of an anti-HIV drug that blocks 
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Table 2.1.7 Single pill regimens currently licensed for treatment of HIV 
Generic drug name Trade name EMA approved
252
 FDA approved
199
 
Efavirenz/Emtricitabine/Tenofovir 
(EFV/FTC/TDF) 
Atripla 13-Dec-07 12-Jul-06 
Rilpivirine/Emtricitabine/Tenofovir 
(RPV/FTC/TDF) 
Eviplera 28-Nov-11 10-Aug-11 
 
 
cellular function rather than viral function, but its use is limited to HIV virus types that use 
the CCR5 receptor. Enfurvitide is a fusion inhibitor that prevents HIV from joining with and 
infecting healthy CD4 cells
250
, however, it is expensive and has to be injected twice daily, 
so often it is reserved for patients who have exhausted all other treatment options
247
. 
Raltegravir and dolutegravir are integrase inhibitors which interfere with the integrase 
enzyme responsible for integrating HIV DNA with the host DNA. Without this process HIV 
cannot use the host cells natural process to replicate its genetic material
250
. 
 
 
Table 2.1.8 Integrase/fusion/entry inhibitors licensed for treatment of HIV 
Generic drug name Trade name EMA approved
252
 FDA approved
199
 
Maraviroc Celsentri 18-Sep-07 06-Aug-07 
Enfuvirtide Fuzeon 27-May-03 13-Mar-03 
Raltegravir Isentress 20-Dec-07 12-Oct-07 
Dolutegravir Tivicay 16-Jan-14 12-Aug-13 
 
 
2.1.9.5 Limitations of cART 
Although cART has transformed HIV from a deadly disease to a chronic manageable 
infection, cART cannot cure HIV
6
. It works by inhibiting HIV while it attempts to integrate 
with the host’s CD4 cells and reproduce. However, HIV remains in reservoirs in the body 
that cART cannot reach
97
. Once cART is stopped HIV will begin to reproduce again and 
without treatment will lead to death
97
. Therefore, treatment for HIV remains a life-long 
commitment. Further, some patients will fail treatment due to the development of 
resistance, poor adherence to treatment will lead to lower levels of drug in the body and the 
chance for HIV to develop resistance
253;254
, while others will stop treatment due to 
unmanageable side effects and toxicities. 
 
ARV resistance mutations in HIV can be acquired during transmission, where a mutated 
HIV virus is directly transferred to another, or they may develop during the course of ARV 
treatment
255
. If an individual taking ART has suboptimal adherence then complete 
suppression of the virus may not occur. When this is the case the remaining unsuppressed 
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HIV virus will adapt to tolerate the presence of ART, meaning that those drugs can no 
longer suppress the virus
255
. Consequently, use of those drugs, even with optimal 
adherence, may not be enough to control HIV infection and will lead to treatment failure 
and the need to switch to a different ARV drug or drug class
255
. 
 
Toxicities and adverse events associated with ARVs 
As with all medications, patients taking ARVs often experience adverse events. Although 
ARV-related drug toxicity has decreased as newer drugs have become available, there 
remains a significant burden of drug-related toxicity associated with treatment with ART
256
. 
Some NRTIs, particularly the older drugs, are known to inhibit mitochondrial activity within 
cells, which in the long term can lead to serious side effects
256-258
. These include myopathy 
(zidovudine), neuropathy (stavudine, didanosine, zalcitabine), hepatic steatosis and lactic 
acidosis (didanosine, zidovudine, stavudine) and lipoatrophy and lipohypertrophy (all NRTIs 
but particularly stavudine), some of which can be fatal if treatment is not discontinued
256-258
. 
 
NNRTIs are commonly associated with rash and lipid disorders
257
. The rash can be so 
severe that it will require treatment discontinuation and use of different ARV drug classes, 
whereas lipid disorders can often be managed with the use of statins and other 
supplements
257;258
. Nevirapine and efavirenz are both first generation NNRTIs that 
commonly prescribed, however, nevirapine is associated with severe hepatotoxicity while 
up to 50% of patients taking efavirenz can suffer from central nervous system adverse 
effects during the first months of treatment
257;258
. Users of the second generation NNRTI 
etravirine also experience rash (in 20% of patients) which indicates discontinuing 
treatment
257
. Further, etravirine is metabolised in the liver by similar processes to other 
drugs leading to significant drug-drug interactions
257;258
. 
 
PIs are also extensively metabolised in the liver and are associated with the most drug-
drug interactions
257
. Common adverse effects of PIs include gastrointestinal effects, 
lipohypertrophy, glucose intolerance or diabetes mellitus, and lipid disorders
256-258
. 
Approximately 60% of patients taking PIs have elevated total cholesterol levels and over 
75% have high triglyceride levels
257
. Atazanavir without ritonavir boosting is considered the 
most lipid-friendly PI, followed by boosted darunavir and boosted atazanavir
257
. A full list of 
ARV drugs and their most commonly associated toxicities are shown in Table 2.1.9. 
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Table 2.1.9 Toxicities and adverse effects associated with ARV drugs
1;256-258
 
Drug class Generic name Toxicities/adverse effects 
NRTI Lamivudine Nausea, vomiting, diarrhoea, headache, abdominal pain, 
hair loss, fever, insomnia, rash, tiredness, joint pain, lactic 
acidosis (rare), liver damage (rare) 
 Emtricitabine Nausea, diarrhoea, headache, raised creatine kinase 
levels, skin darkening, lactic acidosis (rare), liver damage 
(rare) 
 Zidovudine Nausea, vomiting, fatigue, headache, dizziness, weakness, 
muscle pain, loss of appetite, fever, dyslipidaemia, blood 
disorders (rare), lipoatrophy (rare), lactic acidosis (rare) 
 Abacavir Nausea, vomiting, diarrhoea, fever, headache, abdominal 
pain, tiredness, loss of appetite, hypersensitivity reaction 
(rare), lactic acidosis (rare) 
 Tenofovir Nausea, vomiting, diarrhoea, flatulence, dizziness, 
weakness, rash, headache, stomach pain, fatigue, bloating, 
kidney problems (rare), bone thinning (rare) 
 Stavudine Nausea, vomiting, fatigue, headache, dizziness, weakness, 
rash, itching, heartburn, steatosis, lipoatrophy, 
lipohypertrophy, peripheral neuropathy, dyslipidaemia, 
pancreatitis (rare), lactic acidosis (rare) 
 Didanosine Nausea, vomiting, diarrhoea, abdominal pain, rash 
headache, peripheral neuropathy, pancreatitis (rare), lactic 
acidosis (rare) 
NNRTI Efavirenz Rash, dizziness, sleep disturbance, abnormal dreams, 
impaired concentration, nausea, vomiting, headache, 
tiredness, diarrhoea, anxiety, depression, psychosis (rare), 
liver problems (rare) 
 Etravirine Rash, peripheral neuropathy, severe rash (rare), Steven 
Johnson syndrome (rare) 
 Nevirapine Liver toxicity, allergic reaction, rash nausea, headache, 
fatigue, stomach pain, diarrhoea, severe rash (rare), Steven 
Johnson syndrome (rare) 
 Rilpivirine Insomnia, headache, rash, raised liver enzymes, 
depression, dizziness, stomach pain, vomiting 
PI Atazanavir Nausea, diarrhoea, rash, stomach ache, headache, 
insomnia, vomiting, hyperbillirubinaemia, lipodystrophy, 
liver toxicity, diabetes, kidney stones (rare), changes in 
heart rhythm (rare)  
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Drug class Generic name Toxicities/adverse effects 
 Darunavir Diarrhoea, nausea, rash, stomach pain, vomiting, 
headache, lipodystrophy, liver toxicity, diabetes, fever, 
abnormal liver function (rare), changes to heart rhythm 
(rare) 
 Lopinavir Lipodystrophy, raised liver enzymes, nausea, vomiting, 
diarrhoea, abdominal pain, weakness, heartburn, 
headache, raised lipids, liver toxicity, diabetes 
 Ritonavir Raised lipids and liver enzymes, nausea, vomiting, 
diarrhoea, abdominal pain, headache, weakness, bad taste 
in the mouth, lipodystrophy, liver toxicity, diabetes 
 Tipranavir Nausea, diarrhoea, vomiting, abdominal pain, tiredness, 
headache, fever, liver abnormalities, rash, lipodystrophy, 
liver toxicity, diabetes, flatulence 
CCR5 
inhibitor 
Maraviroc Nausea, diarrhoea, fatigue, headache, allergic reaction 
(rare), liver problems (rare) 
Integrase 
inhibitor 
Raltegravir Headache, insomnia, severe rash (rare), hypersensitivity 
reaction (rare) extreme thirst (rare) 
 Dolutegravir Headache, insomnia, lipodystrophy (rare), ALT/AST 
elevation in hepatitis B or C coinfection individuals 
 
  
49 
 
2.2 Hepatitis 
 
Hepatitis is a medical condition that causes inflammation of the liver and is characterised 
by the presence of inflamed liver cells
259
. It can be a self-limiting condition that heals on its 
own or it can progress to scarring, fibrosis, or cirrhosis of the liver
259
. Hepatitis sufferers 
often present with symptoms of jaundice, anorexia and general malaise, although 
occasionally sufferers report limited or no symptoms
259
. Most cases of hepatitis are caused 
by a group of viruses called the hepatitis viruses, although it can be caused by other 
infections, certain medications and alcohol use
259
. 
 
In the middle of the 20
th
 century viral hepatitis was believed to consist of two major types 
only – infectious or type A hepatitis and serum or type B hepatitis260;261. Cases were 
typically recognised through symptoms such as jaundice and in the absence of diagnostic 
assays, the two types were distinguished based on the circumstances of exposure, the 
faecal-oral route and a short incubation period for hepatitis A (typically 15 – 50 days) and 
blood exposure and a long incubation period for hepatitis B (typically 30 – 180 days)260. 
The introduction of blood donor screening for hepatitis B reduced post-transfusion hepatitis 
by just 25%
261, while transfusion studies identified an ‘acute hepatitis’ that straddled the 
incubation periods of types A and B and often lacked typical hepatitis-like symptoms and 
jaundice
260
, inferring the existence of a third hepatitis virus initially referred to as non-A non-
B hepatitis. Although in 1974 non-A non-B hepatitis was briefly referred to as hepatitis C
262
, 
it wasn’t until 1989 with the development of specific serological tests that non-A non-B 
hepatitis and hepatitis C were confirmed to be one and the same
263-265
. 
 
2.2.1 Hepatitis C Virus 
Hepatitis C virus (HCV) is a small-enveloped positive-strand RNA virus that has been 
classified in the genus, Hepacivirus, within the family Flaviviridae
266-268
. HCV, as shown in 
Figure 2.2.1, consists of a core of genetic material (RNA) surrounded by a capsid shell of 
protein and further encased in a lipid envelope of cellular origin, in which two viral envelope 
glycoproteins, E1 and E2 are inserted
266
. 
 
Since it was discovered in 1989, HCV has been recognised as a major cause of chronic 
liver disease worldwide
269. The World Health Organisation’s (WHO) most recent estimate 
puts the worldwide number of people chronically infected with HCV at between 130 and 
170 million. An estimated 3 to 4 million people become newly infected each year, while 350 
thousand people are estimated to die each year from HCV liver-related diseases
270
. 
Though the HCV endemic is worldwide, the prevalence varies substantially by WHO 
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Figure 2.2.1 Structure of the hepatitis C virus
271
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
geographic region
269
. HCV is predominantly spread by contact with infected blood and the 
epidemic has thrived in areas with poor or no control over blood products as well as high 
prevalence of injecting drug use
272
. As shown in Figure 2.2.2, the highest reported 
prevalence rates are in Africa and Asia, while Western Europe and the Americas have 
lower prevalence rates. More specifically, in Europe there appear to be 3 distinct areas of 
HCV prevalence
273
. In Northern European countries the prevalence ranges from 0.1% to 
1.0%
269;273;274
, in Central European countries the prevalence is deemed intermediate 
ranging from 0.2% in the Netherlands to 1.2% in France
273;275;276
. In Southern European 
countries the overall prevalence ranges from 2.5% to 3.5%
273;276-278
. Epidemiological data 
from Eastern Europe is scarce but the prevalence of HCV is believed to be far higher, 
ranging from 1% in among blood donors up to 90% in high risk groups
273
. A breakdown of 
the prevalence of HCV in Europe can be seen in Figure 2.2.3. 
 
2.2.2 Transmission and Risk Groups 
HCV is a blood-borne infection and as such is primarily transmitted via the parenteral route 
of direct blood-to-blood contact
279;280
. As such the rapid spread and worldwide 
dissemination of HCV closely mirrors the invention and spread of blood transfusion 
methods, blood products and other invasive medical procedures that became increasingly 
available during the 20
th
 century
281
. There has, however, been much debate about potential 
modes of transmission of HCV. It was previously thought that only about half of the 
reported cases of acute HCV have a defined parenteral exposure
282
, though with evidence 
of other routes of transmission now established it’s now believed that in only 10% of cases 
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Figure 2.2.2 Geographic variability in the prevalence of HCV
269
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2.3 European HCV prevalence
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the route of HCV transmission is unknown
283, which is often described as ‘community 
acquired’ HCV280. 
 
2.2.2.1 Injecting drug use 
In resource rich countries the predominant mode of HCV transmission is needle sharing in 
IDUs, which accounts for over 50% of HCV-infected patients
284
. Studies from different 
continents have shown prevalence rates of HCV in IDUs of between 50% and 90%, while 
the strongest predictor of transmission appears to be the duration of IDU
285-287
. However, in 
recent times with focus being given to safe needle programs since the onset of the HIV 
epidemic, transmission of HCV by the sharing of drug preparation equipment may have 
become more important
288. Studies have shown that sharing ‘cookers’ (used to heat and 
mix the drugs) and cotton filters (used to strain out particles as the drug is drawn up into the 
syringe) may cause transmission
288;289
. Further, higher transmission rates have also been 
shown in those sharing straws used for snorting cocaine
284;290
. 
 
2.2.2.2 Blood transfusion 
Haemophiliacs and others requiring blood transfusions are also at risk of HCV 
transmission. Before the initiation of HCV antibody screening it’s estimated that 
approximately 5% of individuals who had received blood transfusions or other blood 
products had seroconverted to anti-HCV positive, with a relative risk of 0.45% per unit 
transfused
280;291
. Further, haemophiliacs who receive clotting factors pooled from a number 
of donors were at a far higher risk of infection, with 10%-20% seroconverting
280
. Clinicians 
in developed countries are now dealing with the long-term effects of past epidemics of 
transfusion-associated HCV. Adult cohort studies have estimated that at an average of 15 
years after contaminated blood transfusion 75% of people are HCV RNA positive and that 
the frequency of liver cirrhosis is 20%
292-294
. However, since September 1991 when 
screening of blood donors was introduced, the risk of acquiring HCV through a blood 
transfusion in resource-rich countries has been extremely low, with the risk of contracting 
HCV from a blood transfusion in the UK now estimated to be 1 in 2,000,000
295;296
. The 
residual risk is a consequence of the short window period whereby a newly infected person 
does not yet have HCV antibodies
295
. Most people that are infected with HCV will have 
HCV antibodies within 5-10 weeks and with the introduction of HCV nucleic acid testing the 
potential window period for missing an infection is down to 17 days
295;297
. 
 
The situation is, however, very different in developing countries where blood transfusion 
remains a major cause of the spread of HCV. Between 2001 and 2002 it is estimated that 6 
million blood units were not screened for major blood-borne infections, though this a 
considerable reduction from the period between 1998 and 1999, it cannot be considered 
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sufficient to limit the HCV epidemic in these areas
281
. The WHO blood safety report in 2011 
states that 39 countries still do not routinely test for transfusion-transmissible infections, 
while 47% of blood donations in low-income countries are tested in laboratories without 
quality assurance
270
. 
 
2.2.2.3 Mother to child transmission 
Transmission of HCV can also take place vertically from mother to child perinatally, and 
although comparatively rare, it is considered the most important mode of transmission in 
childhood acquisition due to the improvements in screening methods for HCV in blood 
donors and the foetal toxicity of currently available medications to treat HCV
298
. HCV viral 
load is an important factor in determining the chance of transmission from mother-to-child 
with many studies indicating that higher HCV RNA levels were related to increased risk of 
transmission
299;300
. In women with positive HCV RNA the risk of transmission has been 
reported as 4% to 7% per pregnancy
298
, but this has been shown to be far higher in those 
coinfected with HIV with 4- to 5-fold increases in transmission being reported in some 
studies
286;298;301. It’s unclear whether the method of delivery is associated with transmission 
of HCV as some studies suggest that transmission is more likely to occur with vaginal 
delivery
302;303
, while other studies do not confirm this finding
304;305
. Despite the fact that 
HCV has been found in breast milk, breastfeeding is not thought to be a significant risk of 
transmission as long as the mother’s nipples are not cracked or bleeding298. 
 
2.2.2.4 Needle stick injuries 
As HCV can be transmitted by contaminated needles transmission of HCV to or from 
health-care workers from needle stick or mucous membrane splash injuries are well 
documented
295;306;307
. However, it seems that HCV is not transmitted efficiently through 
occupational exposures to blood as it has been estimated that the risk of transmission from 
a single percutaneous exposure from an HCV-positive source is 1.8% (range 0% to 7%)
308
. 
More recently tattooing has also been considered as a potential route of HCV transmission. 
Most studies agree that tattooing is an independent risk factor for HCV
279
, while a study 
from the USA in the early 1990s found those who had tattoos acquired in commercial tattoo 
parlours to have a risk of chronic asymptomatic HCV
309
. Due to the nature of tattooing and 
the comparatively small amount of HCV entering the body sub-dermally via contaminated 
needles, it’s thought that tattooing is less likely to cause acute infection but chronic 
asymptomatic HCV
285
. However, with the impact of HIV on the use of safe needles and 
awareness of safe practises, the Center for Disease Control and Prevention (CDC) now 
believe the risk of acquiring HCV from a licensed tattoo parlour to be negligible
310
. It is also 
possible for HCV to be transmitted via household contacts. Studies have shown that 
sharing razor blades can be considered a risk factor for transmission
311, while it’s also been 
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shown that toothbrushes of HCV-positive people can harbour detectible amounts of HCV 
RNA
312
. 
 
2.2.2.5 Sexual transmission 
The frequency of HCV transmission via sexual contact is an issue of contention among 
medical professionals
313
. The potential for sexual transmission is demonstrated by the fact 
that HCV RNA has been found to be present in semen and vaginal secretions
314;315
, 
however, the likelihood of transmission appears to depend on many factors and HCV 
seems to be less efficient at transmitting sexually than other blood-borne infections such as 
hepatitis B
280
. In heterosexual couples the risk of transmission appears to be minimal. 
Several large cohort studies have failed to show an increased risk in HCV transmission 
among discordant couples
316;317
. With long follow-up periods of over 10 years in these 
studies it was estimated that the probability of transmission in heterosexual couples is as 
low as 1 in 10 million sex contacts
316
. Some studies have shown the presence of the same 
virus in couples by molecular analysis
318;319
, but these studies have been unable to rule out 
other common exposure routes. 
 
A potential confounder in studies dealing with sexual HCV transmission in heterosexual 
couples is the duration of the relationship. A few studies have shown an increased risk of 
transmission in couples in longer relationships
320;321
, but other larger studies that controlled 
for age did not confirm this finding
322-324
. One possible explanation for this is that couples 
who have been together for longer have more time in which to be exposed to other 
common routes of transmission
313
. Compared to couples in regular relationships, people 
having multiple sexual partners are at a higher risk of acquiring HCV through heterosexual 
contacts
325
. One study showed that women having sexual contacts with 2 to 4 partners 
were nearly 3 times more likely to acquire HCV than those with 1 steady partner
326
. It 
seems that data regarding sexual transmission of HCV should be treated with some degree 
of trepidation however, as Italian studies have suggested that transmissions between 
heterosexual couples could be explained by the common practise of sharing needles or 
other known transmission routes
327;328
. 
 
Another risk factor for transmission between heterosexual couples in the pre-existence of 
sexually transmitted infections (STIs), with 1 study showing a 3-fold increased risk of 
transmission to an individual with an STI than without
329
. In particular individuals with HIV 
are at a higher risk of acquiring HCV through heterosexual contact, especially among those 
partaking in high-risk sexual behaviour having unprotected sex with multiple partners
330;331
. 
In a large study of women that controlled for intravenous drug use (IDU), HIV-positive 
women were twice as likely to acquire HCV
331
. Similarly a cross-sectional study in 
55 
 
Baltimore, USA demonstrated a 4-fold increase in the risk of transmission of HCV in HIV-
positive individuals compared with those who were HIV-negative
329
. 
 
The risk of sexual transmission of HCV in HIV-negative men who have sex with men 
(MSM), although comparatively higher than heterosexuals, remains low. Infection rates 
have varied from 0 cases in 100 person-years in Amsterdam
332
 to 1.5 cases per 1,000 
person-years in the UK
333
. The situation in HIV-positive MSM is far more serious, especially 
in those who engage in high-risk and traumatic sex practises
313
. It has been estimated that 
the incidence of acute HCV infections among HIV-positive MSM in the UK has increased by 
20% per year since 2002
334;335
. In a French cohort study the incidence increased 1.2 cases 
per 1,000 person-years before 2003 to 8.3 cases per 1,000 person-years after 2003
336
. 
Many longitudinal studies have also looked at the risk of transmission by HIV serostatus 
and found that HIV-positive MSM had between 4.1- and 5.7-fold higher odds of acquiring 
HCV than HIV-negative MSM
332;333;337
. The main reasons for this increased risk in HIV-
positive MSM appear to be engaging in unsafe sexual practise and selection of sexual 
partners. Recent studies have reported on the practice of “serosorting” among HIV-positive 
MSM, whereby partners aware of their HIV-positive status engage in unprotected sex 
potentially unaware that they are coinfected with HCV
338;339
. HCV transmission has also 
been linked to sex with multiple partners
340;341
, the use of sex toys and participation in 
group sex
338
, which can potentially lead to mucosal damage
342
. Because of this 
researchers have surmised that the true risk of HCV sexual transmission in HIV-positive 
people comes down to blood to blood contact during sex
343
. 
 
2.2.3 Viral Replication 
Due to the difficultly in detecting and identifying the virus (Section 2.2.3), it was originally 
thought that HCV replicated poorly in vivo
344
. However, it has since been discovered that 
this is not the case and that HCV infection is a highly dynamic process with a viral half-life 
of approximately 3 hours and up to 10
12
 virons produced per day in an infected individual, 
which is about 100 times greater than the rate reported for HIV
344-346
. HCV only infects 
humans and chimpanzees and due to the lack of a convenient animal model, knowledge of 
the molecular mechanisms of HCV replication is based primarily on analogies to the closely 
related flavi- and pestiviruses
347;348
. The current idealised HCV life cycle can be seen in 
Figure 2.2.4. 
 
Once in the body the first step of the virus life cycle is the attachment of the infectious 
particle to a host cell. HCV predominantly targets hepatocytes but infection of B cells, 
dendritic cells and other cell types has been reported
348
. To attach to a host cell a 
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Figure 2.2.4 HCV life cycle
344
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
protein on the surface of the viron particle must interact with a receptor on the host cell. 
Recently, CD81 a tetraspanin protein that is found on the surface of many cell types has 
been identified as a receptor for HCV due to its strong interaction with the E2 
glycoprotein
349
. However, whether the virus binding to CD81 receptors is followed by 
internalisation of the virus particle is not yet understood. Apart from this route, HCV can 
enter the host cell by binding to low-density lipoprotein receptors
347
. When the virus particle 
enters the host cell it is uncoated and the RNA strand genome is liberated, a process not 
currently well understood. Unlike HIV, HCV is not integrated into the host genome, but 
fulfils 3 main roles, first as a messenger RNA for translation of the viral proteins, second as 
a template for the RNA to replicate, third as a newly generated genome to be packaged 
within new HCV particles ready to be released
344;347;348;350
. 
 
2.2.4 Genetic Variability 
Genetic variability exists at several different levels in HCV. Due to the lack of a proof-
reading function in the RNA replication it’s estimated that each time HCV replicates there is 
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a 25% chance of an error occurring resulting in genetic variantion
351-353
. Coupling this with 
the rate of virus production of up to 10
12
 virons per day produces a highly genetically 
diverse population
354
. 
 
The most obvious variability is found in the divergence of the genotypes and subtypes of 
HCV which often reflect different geographical populations and transmission risk groups
354
. 
Nucleotide sequencing has revealed 6 major genetic groups, which on average differ from 
each other by 30%-35%. Within each genotype there exist more closely related subtypes 
that typically differ by 20%-25% from each other, categorised as 1a, 1b, 2a, 2b and so on, 
the most commonly found of which are displayed in Figure 2.2.5
346;354;355
. 
 
The genotypes most commonly encountered in the clinical setting are those distributed 
widely as a result of transmission via blood transfusion and needle sharing between IDUs 
predominantly in Western countries, namely 1a, 1b and 3a
354;355
. However, the variability in 
the HCV genome found in parts of Africa and South East Asia is rather different, where 
there appears to be close association between genotype and specific geographical region. 
Infections in Western Africa are predominantly HCV genotype 2
356-358
, whereas those in 
Central Africa are caused by genotypes 1 and 4
359-361
. Similarly, in South East Asia 
infections are usually caused by genotypes 3 and 6 as shown in Figure 2.2.6
357;362;363
.  
 
In these regions the diversity of subtypes found within genotypes has been extraordinary, in 
a study of 23 HCV positive individuals in Ghana, 20 were infected with genotype 2 but all of 
them with a different and previously undescribed subtype
364
, while this diversity has also 
seen in other Western and Central African countries. These observations reflect the huge 
genetic diversity in genotypes 1, 2 and 4, while also hinting at the long term presence in 
human populations of HCV in these geographical regions
354
. Indeed the currently 
suggested model by these genotype distributions is that HCV has been endemic in sub-
Saharan Africa and South-East Asia for a considerable time, while the infections found in 
Western and other non-tropical countries represents a fairly recent emergence of new 
infections due to the spread of blood products and IDU
365;366
. 
 
Despite the genetic diversity of the 6 HCV genotypes, the main features of HCV structure, 
replication, transmission and ability to establish persistent infection are shared by all known 
variants
354
. The fact that all 6 genotypes are widespread throughout the human population 
is evidence in itself that each is equally successful in maintaining infections in humans. 
However, there is growing evidence that there may be genotypic differences in persistence 
and interactions with the immune system that have repercussions for current and probable 
future treatment. The clearest indication of this difference can be seen in the susceptibility 
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Figure 2.2.5 Genotypic diversity of HCV
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Figure 2.2.6 Genetic diversity of HCV subtypes in Africa and South-East Asia
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of the genotypes to treatment for HCV with pegylated-interferon in combination with 
ribavirin. For those with genotype 1, typically only 40%-50% of individuals on treatment will 
achieve complete and permanent clearance of the virus, whereas for genotypes 2 and 3 
between 70% and 80% are expected to permanently clear the virus
367;368
. 
 
A further interesting feature of the rapid mutation rate of HCV within an infected individual is 
its ability to adapt rapidly to environmental changes. The large amount of genetic 
heterogeneity present in the viral pool of an infected individual has led to HCV being 
defined as existing as a Darwinian quasispecies within a host, meaning that it could have 
the ability to rapidly evolve. It’s thought that this could be the reason why, through selection 
of virus with specific immune responses, HCV has seemingly found a niche in nature living 
human hosts. As a consequence of this it’s thought that HCV infections will, in a similar 
fashion to HIV, be quick to establish resistance to ARV drugs that target specific areas of 
the HCV life cycle. 
 
2.2.5 Clinical manifestation of HCV 
Infection with HCV can cause both acute and chronic hepatitis
269;369
. In both cases HCV 
RNA can be detected in almost all patients within the first 2 weeks of infection, with HCV 
RNA levels rising rapidly during the first few weeks and then more slowly before reaching 
levels between 10
5
 to 10
7
 International Units (IU)/ml
369
. Serum alanine aminotransferase 
(ALT) levels, which are indicative of injury to the liver, start to rise 2 to 8 weeks after 
exposure and reach levels of 10 times the upper limit of the normal range
369;370
. In cases of 
self-limiting acute infection, symptoms may last for several weeks and begin to subside as 
ALT and HCV RNA levels being to fall
369
. Chronic hepatitis is defined by the persistence of 
HCV RNA for at least 6 months after the onset of infection
369. It’s estimated that between 
75% and 85% of people infected with HCV will develop chronic infection and that 20% of 
those will develop liver cirrhosis
371
. 
 
HCV infection has been steadily assuming greater importance among HIV coinfected 
individuals. With the introduction of ART the rate of AIDS and death directly attributable to 
HIV has been declining (Section 2.1.6).  Recent trend studies have shown increasing 
relative importance of HCV-related death over the years of 1995 and 2010 among the HIV 
population
372;373
, as mortality rates for HIV-related death have declined rapidly over the 
same period. Other studies, mainly of HCV monoinfection, have also observed that for the 
first time it appears that the disease specific mortality rate associated with HCV surpassed 
that of HIV in 2007 (Figure 2.2.7)
374
. 
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Figure 2.2.7 Annual age-adjusted disease specific mortality rates in the USA 1999-
2007
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2.2.5.1 The effect of HIV on HCV 
HIV adversely affects each stage of the natural history of HCV
375
. Following acute HCV 
infection, 85-95% of those with HIV will develop chronic disease, more in those with low 
CD4 counts
376-379
. This is significantly higher than the risk of chronicity among HCV 
monoinfected individuals, in whom approximately 30% will spontaneously clear the 
virus
380;381
. Similarly, HIV infection has been associated with higher HCV RNA levels and a 
more rapid progression of HCV-related liver disease
382-384
. Eyster et al reported that HCV 
RNA levels were higher in haemophiliacs who became HIV infected compared to those 
who remained HIV negative, while liver failure occurred exclusively in those with HIV/HCV 
coinfection
383;384
. Further, other studies of HIV/HCV coinfected haemophiliacs have largely 
found similar results
385-387
. A detailed description of the natural history of HCV RNA in 
HIV/HCV coinfected individuals and its relationship to clinical outcomes is provided in the 
introduction to Chapter 4. 
 
In a case-control study of people mainly infected via injecting drug use it was found that 
HIV/HCV coinfected people had a greater extent of liver fibrosis than HCV monoinfected 
people after matching on factors that affect fibrosis progression, such as alcohol 
consumption
388
. A large meta-analysis of eight separate studies that investigated the role of 
HIV on liver disease in HCV coinfected people also found that coinfected individuals had 
approximately twice the risk of cirrhosis and six times the risk of decompensated liver 
disease
389
. 
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Similarly, a prospective study following HCV infected haemophiliacs estimated the 16 year 
cumulative incidence of end-stage liver disease (ESLD) among men with and without HIV 
to be 14% and 2.6%, respectively
390
. More recently the effect of HIV on HCV has been 
summarised in a meta-analysis which demonstrated that HIV coinfection was associated 
with 6-fold increased risk of ESLD and 2-fold increased risk of histological cirrhosis 
compared to HCV monoinfection
391
. Further, a cohort study looking at the short term 
prognosis of HIV/HCV coinfected individuals found that those with cirrhosis have a 
relatively good 3-year survival probability of 87%, whereas the 2-year survival of those with 
decompensated liver cirrhosis was only 50%
392
.  
 
Although it is well-established that low CD4 cell counts are associated with faster 
progression of liver fibrosis
393;394
, the mechanism by which accelerated fibrosis progression 
occurs in HIV/HCV coinfected people is not well understood. However, there are several 
hypotheses, including a direct viral effect of HIV on the hepatocytes and many immunologic 
alterations such as diminished HCV specific T-cell responses
376;395
. Evidence of this 
hypothesis is given by studies which have shown that effective treatment for HIV among 
coinfected individuals can also have an impact on the rate of mortality associated with 
HCV. In 2003 a study of 285 coinfected individuals with follow-up over the period 1990-
2002, spanning the introduction of effective treatment for HIV, showed that treatment with 
monotherapy, or in particular cART was not only associated with reduced overall mortality 
but also reduced liver-related mortality (Figure 2.2.8)
396
. 
 
However, successful treatment for HIV does not appear to completely reverse the impact of 
coinfection. A large recent study with follow-up between 1997-2010, including over 4,000 
coinfected individuals taking HIV therapy and over 6,000 HCV monoinfected individuals, 
has shown that coinfected individuals that maintain low HIV viral loads due to effective 
treatment still remain at increased risk of hepatic decompensation compared to HCV 
monoinfected individuals
397
. The authors estimate that the incidence of hepatic 
decompensation is 1.5 times higher among coinfected individuals with controlled HIV 
infection compared with HCV monoinfected individuals (Figure 2.2.9)
397
. 
 
2.2.5.2 The effect of HCV on HIV 
There are conflicting reports on the effect of HCV infection on the natural history of HIV 
disease
380
. Before the HAART era, in a prospective study of 416 HIV seroconverters, HCV 
coinfected persons had similar HIV progression rates to those without HCV infection
398
. 
While in another study of 1,955 individuals it was found that HCV infection was not 
independently associated with progression to AIDS of death, after adjusting for exposure to 
HAART and HIV RNA suppression
399
. Similarly, among 823 patients followed in the HIV  
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Figure 2.2.8 The effect of HIV treatment on all cause and liver-related mortality among coinfected individuals
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Figure 2.2.9 Cumulative incidence of hepatic decompensation for HCV monoinfected 
and ARV-treated coinfected individuals
397
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Outpatient Study it was found that HCV coinfection was not associated with survival
400
. On 
the other hand, a large study of 3,111 patients receiving HAART reported that HCV 
coinfected individuals had a modestly increased risk of progression to a new AIDS defining 
event or death, even among the subgroup with continuous suppression of HIV RNA
401
. 
 
Multiple studies have also looked at the effect of HCV coinfection on CD4 rebound after 
initiation of HAART. The Swiss HIV cohort study found that in the first year of HAART, 
those coinfected with HCV had smaller increases in CD4 lymphocytes than HCV 
seronegative individuals, but this difference disappeared during the 4 year follow-up of the 
study
402
. The EuroSIDA study on the other hand did not find an effect of HCV coinfection 
on HIV disease progression or CD4 cell recovery
403;404
. Further, a review of eight cohort 
studies showed that the CD4 cell count response for patients with HIV/HCV coinfection 
after they started receiving HAART was 33.4 cells/ml lower than those monoinfected with 
HIV, on average
405
. In addition, among a cohort of coinfected women it was shown that 
HIV/HCV coinfection was associated with an increase in a subset of CD4 and CD8 memory 
cells but did not alter the total number of CD4 cells or the immune response to HAART
406
. 
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The conflicting data on the relationship between HCV coinfection and HIV disease outcome 
is thought to be the result of confounding factors, mainly injecting drug use in patients with 
HCV, which may limit the effectiveness of HAART
380
. The mechanisms by which the two 
viruses interact at cellular level remain largely unexplored
376
; however, despite this and the 
conflicting cohort study results, at present the overall literature suggests that the major 
contribution of HCV to mortality in coinfected individuals is attributable to accelerated liver 
disease and not an increased incidence of AIDS-related complications
403;407
. 
 
Mortality associated with chronic HCV infection results mainly from the development of liver 
fibrosis and the subsequent occurrence of cirrhosis and ESLD, while further progression to 
hepatocellular carcinoma (HCC) is associated with a very high rate of mortality
408
. HCC is 
the third leading cause of cancer mortality worldwide and although 2- to 4-year survival 
rates have doubled in the general population since the early 1990s, due to screening and 
earlier diagnosis, the 1-year survival rate remains less than 50%
409
. Consequently, 
documentation of the level and rate of progression of liver fibrosis is essential in the 
management of persons infected with HCV. 
 
The rate and speed of disease progression from chronic infection to cirrhosis and on to 
HCC varies depending on many factors
369;378
. Though studies on the natural history of HCV 
infection in immunocompetent people have demonstrated cirrhosis typically develops 20-30 
years after the first exposure to the virus
408;410;411
, females and those who are young at the 
time of infection typically experience slow progression, more than 30 years to cirrhosis, 
while alcohol users and those coinfected with HIV typically experience faster progression, 
less than 20 years to cirrhosis
371
. Approximately 6% of monoinfected HCV individuals can 
be expected to develop hepatic decompensation due to cirrhosis during a 20 year period
412
, 
while for HIV/HCV coinfected individuals it is estimated that the risk of cirrhosis or hepatic 
decompensation is around 3 times greater
413
. Once cirrhosis has been established it is 
estimated that the risk of HCC developing is between 1% and 4% per year
371
. 
 
Progression of liver fibrosis 
The rate of fibrosis progression is dependent upon a number of factors and is often specific 
to each individual. Among HCV monoinfected individuals progression of liver fibrosis is 
known to be affected by age, alcohol consumption and HCV genotype. Progression rates 
from F0 to cirrhosis for HCV monoinfected individuals are shown in Table 2.2.1. 
 
In HIV/HCV coinfected individuals a number of HIV-related factors are known to further 
influence the rate of liver fibrosis progression. As mentioned above, low CD4 cell counts 
have been consistently associated with faster progression of liver fibrosis
393;394
. One study  
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Table 2.2.1 Rates of liver fibrosis progression
408
 
Risk factors Number of patients Rate of fibrosis 
progression per year 
Expected duration for 
progression to cirrhosis 
(years) 
One factor classification 
Age at infection 
  ≤20 268 0·091 (0·083 to 0·100) 44 (40–48) 
  21–30 404 0·105 (0·100 to 0·125) 38 (32–40) 
  31–40 183 0·138 (0·111 to 0·160) 30 (25–36) 
  41–50 166 0·200 (0·174 to 0·231) 20 (17–23) 
  >50 136 0·333 (0·272 to 0·375) 12 (11–15) 
Daily alcohol consumption (g) 
  0 598 0·125 (0·111 to 0·143) 32 (28–36) 
  1–49 330 0·143 (0·118 to 0·160) 28 (25–34) 
  ≥50 111 0·167 (0·133 to 0·174) 24 (23–30) 
Sex 
  Female 517 0·111 (0·100 to 0·125) 36 (32–40) 
  Male 639 0·154 (0·143 to 0·167) 26 (24–28) 
Genotype 
  1a 44 0·128 (0·091 to 0·200) 31 (20–44) 
  1b 111 0·091 (0·080 to 0·111) 44 (36–50) 
  2 30 0·088 (0·059 to 1·125) 45 (32–68) 
  3 39 0·167 (0·125 to 0·222) 24 (18–32) 
  4–5–6 22 0·167 (0·098 to 0·250) 24 (16–41) 
Three factors classification 
Age at infection ≤40 years 
  Alcohol <50 g       
  Female 313 0·095 (0·088 to 0·100) 42 (40–45) 
  Male 362 0·111 (0·091 to 0·130) 36 (31-44) 
  Alcohol ≥50 g    
  Female 13 0·083 (0·043 to 0·111) N/A 
  Male 77 0·154 (0·125 to 0·167) 26 (24–32) 
Age at infection >40 years 
  Alcohol <50 g       
  Female 136 0·200 (0·167 to 0·250) 20 (16–24) 
  Male 116 0·301 (0·235 to 0·333) 13 (12–17) 
  Alcohol ≥50 g 21 0·267 (0·200 to 0·500) 15 (8–20) 
  Female 4 0·633 (−0.489 to 2·206) N/A 
  Male 17 0·250 (0·109 to 1·117) N/A 
All patients with duration 
of infection 
1157 0·133 (0·125 to 0·143) 30 (28–32) 
 
N/A=not available because sample size was too small. All values are median (95% CI). 
Except for genotypes, there was a significant difference between medians for all 
classifications (P<0·05).  
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by Benhamou et al showed that CD4 cell counts <200cells/mm
3 
were associated with a 6.5-
fold increased risk of liver fibrosis progression
393
. Studies have also shown that HIV/HCV 
coinfected individuals with HIV viral loads above 400copies/ml have faster fibrosis 
progression rates than HCV monoinfected individuals
414
. However, the same study found 
that there was no difference between fibrosis progression rates of HCV monoinfected and 
HIV/HCV coinfected individuals when HIV viral load was undetectable
414
. Consequently, 
treatment with cART, which lowers HIV viral load and increases CD4 cell count, has been 
found to be protective against rapid progression of liver fibrosis in coinfected individuals
415
. 
As a result, current European treatment guidelines recommend early initiation of cART for 
HIV/HCV coinfected individuals to avoid time spent with low CD4 cell counts
416
. 
 
2.2.5.3 Estimation of liver fibrosis 
A number of classification systems exist for quantifying degrees of liver fibrosis, including 
the ISHTAK and Batts-Ludwig classification systems
417;418
. However, recently the 
METAVIR scoring system has become the prominent classification system in HIV/HCV 
coinfected individual research. In the mid-nineties the METAVIR group of 10 senior French 
pathologists experienced in the field of liver pathology developed a standard set of criteria 
for the grading and classification of fibrosis stage
419;420
. The assessment classifies liver 
fibrosis into five stages of increasing severity (F0, F1, F2, F3 and F4)
419;420
. The specific 
definitions of the stages are as follows F0 no fibrosis, F1 stellate enlargement of portal tract 
but without septa formation, F2 enlargement of portal tract with rare septa formation, F3 
numerous septa without cirrhosis, F4 cirrhosis
419;420
. More recently, any level of fibrosis 
graded as ≥F2 has been defined as significant fibrosis421. The scoring system has been 
validated and studies of HCV monoinfection have determined that the risk of progression 
from one stage to the next in each year is in the region of 13% (95% CI 12.5 – 
14.3)
408;419;420
. 
 
Fibroscan 
Traditionally, histological examination of liver biopsy was considered to be the gold 
standard for evaluating hepatic fibrosis
421;422
. However, liver biopsy is an invasive and 
painful procedure, often with poor patient acceptance and also carries a small risk of 
complications and potentially life-threatening consequences
421;423
. The accuracy of liver 
biopsy has also been called into question as there is potential for observer bias and studies 
have shown that even experienced physicians have a 20% error rate in disease staging
424
. 
 
Fortunately, a non-invasive method of liver fibrosis evaluation was developed in 2008 using 
transient elastography (TE) to measure liver stiffness
421
. TE is a rapid and user-friendly 
technique that can be performed at the bedside or outpatient clinic with immediate results  
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and good reproducibility
421
. Marketed as Fibroscan
®
 (Echosens, Paris, France), TE is now 
commonly used to determine liver fibrosis levels with scores below 7.0 kiloPascals (kPa) 
equivalent to absent or mild fibrosis (METAVIR levels F0-F1), scores between 7.0 - 9.5kPa 
reflect significant fibrosis (F2), scores between 9.5 – 12.5 indicate severe fibrosis (F3) while 
scores above 12.5kPa are attributed to cirrhosis (F4)
421
. 
 
AST to platelet ratio index (APRI) 
Prior to the development of Fibroscan®, other non-invasive measures of liver fibrosis used 
widely available laboratory measurements which were known to be affected by the 
presence of liver fibrosis. One such measure is the AST to platelet ratio index (APRI) which 
was developed in 2003
425
. The study by Wai et al initially described AST and platelets to be 
the most important predictors of fibrosis from a list of standard laboratory measurements
425
. 
The authors noticed that there was significant overlap between AST and platelets for 
individuals with different stages of liver fibrosis. Therefore, the authors attempted to amplify 
the difference between AST and platelets with a new novel index given below, where ULN 
is the upper limit of the normal range for AST
425
. 
 
𝐴𝑃𝑅𝐼 =
𝐴𝑆𝑇 𝑙𝑒𝑣𝑒𝑙 (/𝑈𝐿𝑁)
𝑃𝑙𝑎𝑡𝑒𝑙𝑒𝑡𝑠 (109/𝐿)
× 100 
 
The authors discovered that this new index performed significantly better than AST or 
platelets alone at determining significant liver fibrosis, with values above 1.5 providing the 
optimum level of prediction
425
. Following publication of this novel index, the APRI score was 
validated in a number of studies which have shown its accuracy as a non-invasive marker 
of fibrosis and it continues to be used today where other measures are not available
426
. 
 
2.2.6 Treatment 
 
2.2.6.1 The history of treatment for HCV 
Treatment for HCV has traditionally revolved around the use of interferon (IFN). IFNs are 
natural cellular proteins that perform a variety of functions, including the induction of an 
antiviral state in their target cells, recruitment of immune cells, and induction of cell 
differentiation
367
. Since the first clinical trials of IFN-alpha treatment in chronic HCV patients 
in the mid-1980s
427
, dose regimens have been progressively refined (Figure 2.2.10)
367
. 
Monotherapy with three megaunits of IFN three times a week for 24 weeks was associated 
with a 90% failure rate, which was reduced to 84% when treatment was extended to 48 
weeks
428
. The addition of ribavirin to treatment regimens reduced the failure rate to  
 
68 
 
Figure 2.2.10 Dosage refinement and treatment failure of IFN therapy
367
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
approximately 60%, while switching to pegylated-IFN once a week from standard IFN-alpha 
reduced failure rates by another 10%
428-430
. 
 
Pegylated-IFN is an IFN molecule linked to a polyethylene glycol molecule to ensure 
sustained IFN concentrations after weekly injections
367
. Ribavirin is a synthetic guanosine 
analog that has only a moderate effect on HCV in vivo
431
, but has a boosting  
effect on IFN by modulating the immune response and accelerating the clearance of 
infected cells, which is taken orally daily
367
. Treatment regimens were further optimised by 
adjusting doses of ribavirin and, in certain cases, pegylated-IFN to the body weight of 
recipients
430;432;433
. The success of pegylated-IFN plus ribavirin treatment reached a 
minimum failure rate of approximately 30% (40% for HCV genotype 1 and 10% for 
genotypes 2 or 3) when full adherence was ensured in clinical trials
432;433
. However, such 
low failure rates were never replicated in routine practice while this combination remained 
the gold standard for HCV treatment up to 2010
367;434-436
. 
 
2.2.6.2 Current HCV treatment regimens and guidelines 
In 2011 the first direct-acting antivirals (DAA) for HCV, boceprevir and telaprevir, became 
available for treatment of HCV genotype 1 infection
437-439
. In clinical trials these drugs have 
 
 
 
 
 
 
 
 
 
Image not available due to copyright restrictions 
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seen cure rates for HCV genotype 1 rise to 75% in treatment naïve patients
437;440
 and 60% 
in treatment experienced patients
437;441;442
. However, treatment with these early DAAs still 
retains the backbone of pegylated-IFN and ribavirin, referred to as triple therapy
437;442
. 
 
IFN is not well tolerated and causes flu like symptoms, while being contraindicated with 
some HIV medications
443
. Consequently, the uptake of treatment with boceprevir and 
telaprevir for HCV remained low with few patients eligible for therapy, typically less than 
30%
443;444
. Further, the estimated costs of triple therapy for HCV genotype 1 of 
approximately €30,000 proved restrictive in countries in the low income setting2. However, 
drug development for the treatment of HCV continues to be a rapidly advancing field, with 
many 2
nd
 generation agents undergoing phase II and phase III clinical trials
445
. These new 
agents are expected  to herald a new era of treatment for HCV with cure rates far in excess 
of those seen previously, approaching 90-100%
445;445
. 
 
The year 2014 saw the approval of a number of 2
nd
 generation DAAs for treatment of 
HCV
446
. These new drugs have shown superior treatment efficacy and fewer side effects in  
 
Table 2.2.2 EMA licensed IFN-free HCV treatment recommendations
416
 
HCV Genotype DAAs Treatment duration EMA approval date
252
 
1 & 4 Sofosbuvir + 
Ribavirin 
24 weeks
1 
Sofosbuvir: Jan 2014 
Simeprevir: May 2014 
Daclatasvir: Aug 2014 
 
Sofosbuvir + 
Simeprevir 
12 weeks
2 
Sofosbuvir + 
Daclatasvir 
12 weeks: non-cirrhotics 
24 weeks: with cirrhosis 
2 Sofosbuvir + 
Ribavirin 
12 weeks
3 
 
3 Sofosbuvir + 
Ribavirin 
24 weeks  
Sofosbuvir + 
Daclatasvir + 
Ribavirin 
24 weeks for cirrhotics and 
treatment experienced 
5 & 6 Without clinical trials data genotypes 5&6 are suggested to be treated 
similarly to genotypes 1&4 
 
1
Only licensed for those ineligible for IFN-containing treatment 
2
Can be extended to 24 weeks for treatment experienced cirrhotics, with or without ribavirin 
3
Can be extended to 16 weeks for treatment naïve cirrhotics; 24 weeks for treatment 
experienced 
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most cases, and IFN-free combinations of DAAs are now seen as the gold standard of 
therapy in HCV
416
. Further, treatment durations for these new drugs are potentially far 
reduced, often between 12 and 24 weeks for some drug combinations and HCV 
genotypes
416
. However, the second generation DAAs are currently even more expensive 
than the first, with treatment costs approaching €100,000 for all oral IFN-free DAA 
combinations. Consequently, the use of DAA therapy as the gold standard of care is 
currently limited by each country and clinical centre’s ability to pay for them and IFN-
containing regimens are still used in some circumstances
416
. 
 
Current European treatment guidelines from the European AIDS Clinical Society (EACS) 
recommend that IFN-free DAA combinations should be considered the standard of care for 
HCV treatment, especially in those who have advanced levels of liver fibrosis
416
. Specific 
treatment regimens and treatment durations vary depending on HCV genotype, the level of 
liver fibrosis and previous treatment history. Table 2.2.2 outlines current IFN-free HCV 
treatment recommendations. In brief, for HCV genotype 2 a combination of sofosbuvir plus 
weight-based ribavirin for 12 weeks is recommended, while for genotype 3 this regimen 
may be extended to 24 weeks
416
. For genotypes 1 and 4 a combination of sofosbuvir plus 
simeprevir is recommended for 12 weeks and should be extended to 24 weeks for 
treatment experienced cirrhotic individuals, with or without ribavirin
416
. The combination of 
 
 
Table 2.2.3 EMA licensed IFN-containing HCV treatment recomendations
416
 
HCV Genotype DAAs Treatment duration EMA approval date
252
 
1 & 4 Sofosbuvir + 
PEG-IFN/RBV 
12 weeks
1 
Sofosbuvir: Jan 2014 
Simeprevir: May 2014 
Daclatasvir: Aug 2014 Simeprevir + 
PEG-IFN/RBV 
24 weeks
2 
Daclatasvir + 
PEG-IFN/RBV 
24 weeks/48 weeks
3 
2 PEG-IFN/RBV 24 weeks/48 weeks
3 
 
3 Sofosbuvir + 
PEG-IFN/RBV 
12 weeks
1 
 
5 & 6 Without clinical trials data genotypes 5&6 are suggested to be treated 
similarly to genotypes 1&4 
 
1
Can be extended to 24 weeks for cirrhotics 
2
Extended to 48 weeks for cirrhotics, treatment experienced and relapsers 
3
24 weeks if there is a rapid response, otherwise 48 weeks 
 
71 
 
sofosbuvir and daclatasvir is recommended for all genotypes for 12 weeks in the absence 
of cirrhosis, with an extension to 24 weeks with cirrhosis
416
. 
 
Where there is limited availability or affordability of DAAs and combination IFN-free 
treatment is not possible, sofosbuvir plus pegylated-interferon and ribavirin for 12 weeks is 
considered the best alternative for genotypes 1, 3-6, and treatment should be extended to 
24 weeks for cirrhotics
416
. When sofosbuvir is not available then simeprevir plus pegylated-
interferon and ribavirin for 24 weeks can be used for genotypes 1 and 4, while a dual 
course of pegylated-interferon and ribavirin may be considered for 24 weeks for genotype 
2
416
. Table 2.2.3 outlines current IFN-containing HCV treatment recommendations. 
 
Finally, when second generation DAAs are not available and will not be available for some 
time, the first generation DAAs boceprevir and telaprevir may be used for genotype 1 
following response guided therapy
416
. Lead in times and stopping rules for DAA 
combinations with pegylated-interferon and ribavirin are shown in Figure 2.2.11. 
 
2.2.6.3 HCV treatment stages and response-guided therapy 
HCV does not integrate with the host genome of an infected cell (Section 2.2.3). Therefore, 
successful treatment for HCV which is defined as sustained virologic response (SVR), is 
akin to cure
367;447
. HCV RNA viral load measurements taken during and after treatment are 
then used to categorise patients into different viral response groups. SVR is defined as 
HCV RNA undetectability 24 weeks after the end of therapy
367;448
. Although not a perfect 
definition of a cure, it has been shown that 98% of people that achieve SVR are cured of 
HCV
449
. Patients that do not achieve SVR are said to be in ‘treatment failure’, which can 
correspond to different virological patterns.  
 
Non-responders have no significant fall in HCV RNA load (>1 log) at any point during 
treatment. Partial responders have a significant drop in HCV RNA during treatment, but 
HCV RNA remains detectable. Responder-relapsers become HCV RNA negative during 
treatment but relapse after treatment withdrawal. Finally, responders with breakthrough 
initially become HCV RNA negative but relapse during treatment, although these definitions 
lack clear precision as other factors such as dose reduction or discontinuation and poor 
adherence can all affect viral response
367
. Classifications of more use in the clinical setting 
are the rapid virological responder (RVR), which is defined by undetectable HCV RNA 4 
weeks after treatment initiation, the early virological response (EVR), defined by detectible 
HCV RNA at week 4 but undetectable at week 12, and the delayed virological responder 
(DVR), a greater than 2 log drop but detectible HCV RNA at week 12 and undetectable  
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Figure 2.2.11 Recommended use of Telaprevir, Boceprevir, Simeprevir or Sofosbuvir with PEG-IFN and Ribavirin
416
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HCV RNA at week 24
450
. A graphical illustration of HCV treatment responses can be seen 
in Figure 2.2.12. 
 
In practise treatment discontinuation decisions are made depending on whether a 2 log 
drop in HCV RNA has been observed by week 12 of treatment
367;450
. It has been shown 
that a fall of 2 log or greater (i.e. a 100-fold fall in baseline HCV RNA load) by week 12 of 
treatment has an excellent negative predictive value for SVR (98%-100%)
451
, which implies 
that people who do not achieve a 2 log fall in HCV RNA by week 12 have virtually no 
chance of achieving SVR. Treatment is also often stopped in persons with detectible HCV 
RNA at week 24, as these people also have a minimal chance of SVR (1%-3%)
450;452;453
. 
HCV RNA measurements taken at baseline, week 4, week 12 and week 24 are then used 
to classify people as RVR, EVR or DVR and this information combined with other factors, 
such as the genotype of HCV infection, is used to determine whether to discontinue 
treatment, treat for 24 weeks, 48 weeks or in some cases 72 weeks. In general those with 
slower falls in HCV RNA, genotype 1 and contraindication to triple therapy with DAAs are 
treated for longer, as summarised in Figure 2.2.13
193
. 
 
 
Figure 2.2.12 HCV treatment virologic responses
454
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Probability of treatment success 
The probability of achieving SVR depends on a number of factors, including HCV genotype, 
the IL28B polymorphism genotype, stage of fibrosis, HIV coinfection, baseline HCV RNA 
and host factors, with younger age, lower body mass index and  female gender all 
associated with a better treatment response
367;450
. However, the potency of 2
nd
 generation 
DAAs appears to have overcome most of these factors and they are of most relevance to 
treatment with pegylated-IFN and ribavirin alone
446
. 
 
When treated with pegylated-IFN and ribavirin rates of SVR among HCV monoinfected 
individuals are typically between 40%-45% for HCV genotype 1 and slightly higher for 
genotype 4
451;455;456
, when treated with triple therapy including either boceprevir or 
telaprevir rates of SVR increase to 75%
439
. For genotypes 2 and 3 SVR is more likely with 
rates of between 75%-80% reported
457;458
. However, among those coinfected with HIV, 
SVR falls to between 17%-32% for those with genotypes 1 and 4, and between 44%-73% 
for genotypes 2 and 3
434;435;448;459
. The IL28B polymorphism is in the vicinity of IFN genes 
on human chromosome 19 and has been linked with SVR in HCV. IL28B can take 3 
different genotype forms, CC, CT, and TT. The CC genotype, which is more common in 
Caucasians, has been found to be associated with spontaneous clearance of HCV
460
, while 
rates of SVR have also been found to be higher in those with the CC genotype, with 30% 
achieving SVR with non-CC genotypes and up to 70% in those with the CC genotype
461;462
. 
 
In comparison, modern DAA containing regimens have shown excellent HCV cure rates 
regardless of IL28B genotype and individual level factors. Two studies evaluating 
sofosbuvir taken with pegylated-IFN and ribavirin for 12 weeks found SVR rates between 
89% and 91% for HCV genotype 1
463;464
. While a recent study including difficult to treat 
patients, previous non-responders and those with advanced liver fibrosis, found that the 
combination of sofosbuvir and simeprevir with or without ribavirin for 12 or 24 weeks had an 
overall SVR rate of 92% for HCV genotype 1
465
. 
 
2.2.7 Reinfection 
HCV is different from other viral infections in that infection and the generation of an immune 
response does not necessarily protect an individual from reinfection
466
. There has been 
some disagreement between studies looking at the risk of reinfection with HCV, with rates 
of clearance following reinfection ranging from 29%
467
, similar to the rate of clearance of 
primary infection, to 90%
468
. However, these differences can probably be explained by 
study design and most would now agree that clearance of HCV offers some level of 
protection against reinfection
469
.  
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Figure 2.2.13 Optimal response-guided therapy for those not eligible for triple therapy with DAAs
193
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Studies of IDUs, who are at high risk of reinfection, have produced mixed results. Some 
studies have shown that reinfection with HCV after viral clearance is more common in 
those to have been previously infected compared to HCV-naïve patients
466;470
. Other 
studies have shown that reinfection rates are lower among those previously infected and 
suggest that there is some residual protection against reinfection following viral 
clearance
467;471
. However, the rate of reinfection after clearance of HCV is high in all 
studies of IDUs, with rates of reinfection approaching 50%
466;472
. Studies assessing the risk 
of HCV reinfection among MSM are less common, however, they also suggest that 
reinfection is frequent in this risk group, reporting cumulative risk of reinfection of 33% in 
the first two years following the initial infection and clearance
473;474
. 
 
Given the high rate of chronicity of HCV infection and the sizeable expense of treating the 
infection, reinfection rates for HCV are alarming
472
. Further, the lack of data suggesting 
immunity following initial infection complicates the development of an effective HCV 
vaccine
471
. Therapeutic HCV vaccine efficacy has so far been very poor, however, research 
continues in this important area with many vaccine candidates, which aim to induce a 
cellular immune response, under development in preclinical study
471;475;476
.  
 
2.2.8 Hepatitis B Virus 
Hepatitis B virus (HBV) is a member of the hepadnavirus family, simply meaning the 
hepatic DNA virus family
477;478
. HBV is one of the smallest animal viruses with each viron 
no more than 42 nanometres (nm) in diameter
477;478
. The virus consists of an outer lipid 
envelope containing the surface antigen and a nucleocapsid core, made of protein, 
containing a partially double stranded viral DNA and DNA polymerase, with reverse 
transcriptase activity (Figure 2.2.14)
477;478
. The virus releases three glycoproteins, S, L and 
M. The S protein is the most frequently produced
479
. The L and M proteins are based on 
the S structure and are produced in only 5-15% and 1-2% of the frequency of the S protein, 
respectively
479
. In the replication process, along with fully infectious particles, other non-
infectious particles made from the lipid layer and protein but without a core, known as the 
hepatitis B surface antigen (HBsAg), are produced in excess and released into the blood 
stream
477-479
. Consequently, tests for HBsAg are now commonly used to determine whether 
a person is infected with actively replicating HBV. 
 
2.2.8.1 Epidemiology 
HBV is one of the world’s most common infectious diseases with a global distribution480;481. 
The HBsAg carrier rate ranges from 0.1% to 20% in different populations around the world 
(Figure 2.2.15)
482. It is estimated that one third of the world’s population has been infected 
with HBV
480;481
. Approximately 5% are chronic carriers and approaching 25% of all chronic  
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Figure 2.2.14 Structure of the hepatitis B virus
271
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2.15 Global prevalence of HBV
480
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carriers develop serious liver-related diseases similar to those of HCV such as chronic 
hepatitis, cirrhosis and HCC, with HBV infection estimated to causes more than one million 
deaths each year
480-482
. Adults infected with HBV usually develop symptomatic acute 
hepatitis B and recover without intervention, with 5-10% developing the chronic carrier 
state
482
. Infected children, on the other hand rarely develop symptomatic acute infection, 
with 25-90% going on to become chronic carriers
482
. However, HBV is a vaccine-
preventable disease, with a safe and effective vaccine available for over 20 years
482;483
. 
Unfortunately, worldwide infection persists and although global control is achievable with 
current technology, it is yet to be attained
482;483
. 
 
2.2.8.2 Treatment for HBV 
Unlike HCV, HBV is a DNA polymerase virus that persists in the host nucleus as so called 
cccDNA
484
. This means that completely eradicating the infection is very difficult and 
consequently infection with HBV is a complicated and dynamic process
485
. The spectrum of 
disease and natural history of chronic HBV are diverse and variable, ranging from an 
inactive carrier state, which poses little risk to the carrier, to progressive chronic hepatitis B, 
which is responsible, via HBV-DNA replication, for the evolution of cirrhosis and HCC
485
. 
 
Fortunately, there are treatments available to control HBV infection
485
. Treatment is aimed 
at halting the progression of liver disease and improving the clinical outlook, while 
eliminating infectivity to prevent the transmission and spread of the virus
482;485;486
. These 
treatments are divided into two main classes, immune modulators which aim to help the 
immune system mount a defence against the virus, and antivirals which aim to suppress 
HBV by interfering with viral replication
482;485
. The drugs in both of these classes have been 
described in detail previously in this chapter. The immune modulators are interferons 
(Section 2.2.6) while the antivirals are tenofovir, emtricitabine and lamivudine, the same 
NRTIs used in the treatment of HIV (Section 2.1.9), plus telbivudine, entecavir and adefovir, 
which work in the same way
485
. Consequently, due to the dual activity of some ARVs 
against HIV and HBV, people coinfected with HIV/HBV do not have to make big changes to 
their treatment regimens. They are advised to take a cART regimen containing tenofovir, 
emtricitabine or lamivudine, plus a third agent active against HIV
193;485
. 
 
2.2.8.3 Dual hepatitis infection 
HBV is thought to be about 100 times more infectious than HIV
486;487
. Transmission of HBV 
occurs in much the same way as HIV and HCV, via blood to blood contact. However, HBV 
is known to transmit more frequently than HCV during sexual contact
483;486
. HBsAg has 
been found in all bodily secretions excretions, but only blood, vaginal and menstrual fluids, 
semen and in those with very high viral loads, saliva, have been shown to be 
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infectious
486;487
. Due to the routes of infection, infants born to infected mothers, injecting 
drug users sharing equipment, sexually active individuals (both heterosexuals and MSM) 
and those providing or receiving acupuncture or tattooing are all thought to be at high risk 
of contracting HBV
486;487
. 
 
As a consequence of shared transmission routes, the likelihood of being exposed to both 
HCV and HBV is high, particularly in areas with a high prevalence of HBV and HCV, 
therefore dual infection with both viruses is common
488
. Overall, the prevalence of dual 
infection is around 10-20% in those with chronic HBV, and 2-10% in those HCVAb 
positive
488
. However, the prevalence can be far higher in at risk populations, such as IDUs 
in incarceration (43% with dual infection)
489
, while in general the risk factors for dual 
infection are the same as for monoinfection with either virus
488
. 
 
Interference between the two viruses in a dually infected person has been well 
documented
488
. The titre of serum HBV-DNA in a person with actively replicating HCV RNA 
has been shown to be markedly lower than in a HBV monoinfected person
490;491
. Further, it 
has been suggested that HCV infection may suppress HBV completely and become the 
sole cause of persistent hepatitis and liver injury in some dually infected people
492
. 
Conversely, it has also been shown that HCV RNA levels are significantly decreased in 
persons with actively replicating HBV-DNA, compared to those HCV monoinfected, 
suggesting an inverse relationship between the replicative patterns of both viruses
490;493
. 
 
Despite the evidence to suggest that in many cases dual infection with HBV/HCV results in 
the suppression of one or the other virus, several studies have reported more severe 
clinical outcomes in these patients
488;494;495
, with higher rates of decompensated liver 
disease found in dually infected patients, compared with those monoinfected with either 
virus
496
. Other studies have also shown more severe histological lesions in dual infection, 
including a higher prevalence of cirrhosis
493
. Further, the clinical impact of multiple infection 
has been shown to be worse than infection with either virus, with accelerated progression 
to HCC as HCV and HBV replicate in the same hepatocytes
497-499
. 
 
However, it remains that in the majority of dual infection cases HBV-DNA levels are low or 
undetectable and HCV is responsible for the activity of chronic hepatitis
499
. Consequently, 
dually infected patients should usually receive treatment for HCV
500
, with SVR rates broadly 
comparable with HCV monoinfected individuals and those coinfected with HIV
501;502
. 
  
80 
 
Chapter 3 
 
Data and Methodology 
 
3.1 Data 
 
The data analysed in this thesis are predominantly from the EuroSIDA study group. 
EuroSIDA is a large European observational cohort study which is described in detail 
below. A small section of this thesis analyses data from the Swiss HIV Cohort Study 
(SHCS), to validate findings in EuroSIDA. The SHCS is introduced in Chapter 8 where it is 
analysed. 
 
3.1.1 EuroSIDA 
EuroSIDA is a large prospective observational cohort study, which at the time of the most 
recent data extraction in March 2015 included 18,795 individuals with HIV-1 infection and a 
total of 144,250 person years of follow-up. The study is one of the largest international 
cohort studies of HIV including 115 centres across 35 European countries, Israel and 
Argentina (Figure 3.1). EuroSIDA was initiated  in May 1994 when it took up the work 
generated by its predecessor, the AIDS in Europe study
503
. AIDS in Europe was an early 
European study of HIV which collected data on every AIDS-diagnosed patient in 
participating European centres between 1979 and 1989. The study included 17 European 
countries and a total of 6,572 patients. Using patient case notes they collected data on 
demographics, HIV antibody status, CD4 lymphocyte counts, use of available ART, 
pneumocystis jiroveci pneumonia prophylaxis, and details of AIDS-defining illnesses.  
 
AIDS in Europe was coordinated by a group of clinicians and scientists in Copenhagen led 
by Professor Jens Lundgren, director of the Copenhagen HIV Programme (CHIP). 
Professor Lundgren then established EuroSIDA upon the completion of AIDS in Europe 
with the aim of collecting detailed prospective data on treatment and illnesses associated 
with HIV. CHIP has since developed into a centre of excellence for the management and 
analysis of HIV cohort data. At the time of writing EuroSIDA have published 219 scientific 
papers in peer-reviewed journals and presented work at all major international conferences 
for many years. Further details of CHIP and the studies they coordinate can be found at 
www.chip.dk. 
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Figure 3.1 EuroSIDA countries and regions 
 
EuroSIDA regions: South, North, West Central, East Central, East and Argentina 
 
 
Primary support for EuroSIDA is provided by the European Commission BIOMED 1 (CT94-
1637), BIOMED 2 (CT97-2713), the 5th Framework (QLK2-2000-00773), the 6th 
Framework (LSHP-CT-2006-018632), and the 7th Framework (FP7/2007-2013, EuroCoord 
n° 260694) programmes. Current support also includes unrestricted grants by Janssen 
R&D, Merck and Co. Inc., Pfizer Inc., GlaxoSmithKline LLC. In addition, the participation of 
centres from Switzerland was supported by The Swiss National Science Foundation (Grant 
108787). 
 
EuroSIDA is guided by a steering committee of scientists and clinicians with 
representatives from around Europe. Professor Jürgen Rockstroh from Bonn, Germany, is 
the current chair of the steering committee. Positions on the steering committee are 
regularly rotated and decided by nominations and elections. Appendix I provides a full list of 
the current members of the EuroSIDA study group.  
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EuroSIDA has developed a robust review process for the consideration of new research 
proposals. A summary of a potential project’s background, aims, feasibility, statistical 
methodology and cost is sent to the coordinating centre and then reviewed by two 
members of the steering committee. After any amendments are incorporated the proposal 
is introduced and discussed by the steering committee at the next scheduled steering 
committee meeting. If there are no further comments or recommendations the project is 
approved and work may begin. The template for new study proposals can be found at 
http://www.chip.dk/Ongoing-Studies/EuroSIDA/Study-documents. 
 
EuroSIDA has close links to UCL and is supported by the Research Department of 
Infection and Population Health, which provides expert statistical advice and analysis. 
Genotypic resistance and subtype data are provided from the virology laboratory group 
originally based in London and since 2004 in Badalona, Spain. Co-ordinators of the 
statistical centre and the virology group are involved in the development of new proposals 
and analysis of EuroSIDA scientific projects and also have representation on the steering 
committee. 
 
EuroSIDA also contributes data to the D:A:D study (Data collection on Adverse events of 
anti-HIV Drugs), COHERE (Collaboration of Observational HIV Epidemiological Research 
in Europe), and ART-CC (Antiviral Therapy Cohort Collaboration) as well as other ad hoc 
projects after approval by the steering committee
504-506
. 
 
3.1.2 Data collection 
EuroSIDA have so far enrolled nine cohorts of consecutive HIV-positive individuals aged 16 
or over. Data are collected at the individual clinical centres by health care providers. 
Individuals with a routine, booked clinic outpatient appointment are enrolled consecutively 
to ensure that they represent an unbiased selection of those under clinical care at each 
clinical site. During each enrolment period, sites enrol until a predefined cap for each 
region/clinic is reached. A summary of each cohort and the corresponding date of inception 
is given in Figure 3.2.  
 
For the first three cohorts eligible individuals must have had a CD4 lymphocyte count of 
<500cells/mm
3
 in the four months prior to entry. This criterion was removed for the 
following cohorts. From cohort VI onwards, in order to increase the number of individuals 
from Eastern Europe, half of the total number of individuals enrolled have been from 
Eastern European countries. This was introduced so that a more comprehensive view of 
the HIV epidemic in Eastern Europe could be described. 
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Figure 3.2 Total patients, enrolment dates and number of follow-up forms available 
according to cohort in EuroSIDA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Data is collected at sites during routine visits to access clinical care on a standardised data 
collection form; the data are collected at baseline and collated every six months thereafter. 
The EuroSIDA enrolment and follow-up forms can be found at http://www.chip.dk/Ongoing-
Studies/EuroSIDA/Study-documents. The current working EuroSIDA database compiled in 
March 2015 contains follow-up to November 2013 (median date of last visit). At each  
EuroSIDA patients 
N=18,914 
Cohort I 
N=3115 
Spring 1994 
40 follow-up forms 
Cohort II 
N=1364 
Winter 1995 
38 follow-up forms 
Cohort III 
N=2835 
Spring 1997 
35 follow-up forms 
Cohort IV 
N=1224 
Spring 1999 
31 follow-up forms 
Cohort V 
N=1223 
Winter 2001 
26 follow-up forms 
Cohort VI 
N=2117 
Winter 2003 
23 follow-up forms 
Cohort VII 
N=2457 
Winter 2005 
18 follow-up forms 
Cohort VIII 
N=2103 
Summer 2008 
13 follow-up forms 
Cohort IX 
N=2476 
Spring 2012 
5 follow-up forms 
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follow-up visit all CD4 cell counts and viral load measures taken since last follow-up are 
collected. A total of 507,418 CD4 cell counts from 18,724 patients (median 21 (interquartile 
range (IQR) 9-41) per patient) and 444,891 viral load measurements from 16,773 patients 
(median 21 (IQR 10-40) per patient) have been collected so far.  
 
Dates of starting and stopping each antiretroviral drug, reasons for stopping each drug and 
the use of prophylaxis against opportunistic infections are also collected. All dates of 
diagnosis of AIDS-defining illnesses are collected using the 1993 CDC definition of 
AIDS
507
. Dosing levels of drugs are not collected in EuroSIDA, however, an assumption is 
made that if individuals start ritonavir (RTV) plus another PI at the same time, this is a 
boosted PI regimen with low dose RTV. 
 
EuroSIDA has been quick to react to the changing nature of the HIV epidemic over time. In 
2001 after the introduction of effective treatment for HIV in the mid-1990s and the 
subsequent reduction in AIDS-related mortality, focus shifted towards collecting data on 
non-AIDS defining illnesses and causes of death. In 2006 as focus shifted to coinfection 
with hepatitis, data collection forms were updated to include a host of hepatitis antibody 
and viral load tests, which will be discussed in detail shortly. 
 
3.1.2.1 Plasma sample repository 
Since 1997 EuroSIDA has also requested that plasma samples are collected from 
participants every six months. These samples are then transferred for storage in the central 
repository at the Copenhagen coordinating centre. Samples are stored at -80 degrees 
Celsius, which prevents degradation of the material and ensures their long term viability. 
The repository currently holds 118,614 plasma samples from 11,150 patients, with a 
median of 9 (IQR 4-18) samples available per patient. Samples may then be selected 
based on a number of criteria to be involved in on-going projects. Projects looking at HIV 
resistance mutations have used samples to extract HIV RNA for sequence analysis 
whereby genotypic resistance mutations can be identified. Other projects looking at 
coinfection with HCV have used the samples to extract HCV antibodies and HCV RNA viral 
loads to classify the status of HCV infection.  
 
Although samples are collected during prospective follow-up, analysis of the samples is 
undertaken retrospectively, therefore, the results of any analysis performed on the samples 
are not routinely passed on to the health care providers that obtained the samples. 
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3.1.2.2 EuroSIDA Hepatitis data 
EuroSIDA now collects a variety of information on hepatitis coinfection. Data on anti-HCV 
antibodies (HCVAb) have been collected on the standard EuroSIDA follow-up form since 
1997. Individuals that died or were lost to follow-up prior to this date did not routinely have 
HCVAb data collected. Clinical sites that have measured HCV RNA are requested to report 
the measurement to EuroSIDA along with HCV genotype if genotyping has been 
performed. In 2006 all EuroSIDA participants who had unknown HCVAb status were tested 
using stored plasma samples, where available, and those found to be HCVAb positive were 
then tested for HCV RNA and HCV genotype accordingly. Further, any individuals that 
were known to be HCVAb positive but were missing HCV RNA data were identified and 
where stored plasma was available, tested for HCV RNA and HCV genotype. 
Consequently, EuroSIDA now has a population of over 5,000 well-defined HCV coinfected 
individuals, with estimated coinfection rates ranging from 17.8% in the North to 57.4% in 
the East, based on the current dataset (Figure 3.3). 
 
Data on HBV coinfection has also been collected since 2006. EuroSIDA collect HBV 
antibodies, HBV DNA and hepatitis B surface antigen (HBsAg) which allows for an accurate 
description of each individual’s HBV infection status. In 2006 all HBsAg positive individuals 
were additionally tested for hepatitis D virus (HDV) antibodies, where stored plasma 
 
Figure 3.3 Estimated prevalence of HCVAb by region of EuroSIDA 
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East (N=2549)
Argentina (N=557)
Percentage of patients with known HCVAb status that are positive 
(95% C.I.) 
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samples were available. Treatment start and stop dates for both HCV and HBV therapy are 
collected in EuroSIDA as part of the main follow-up form. 
 
EuroSIDA has the ability to estimate liver fibrosis levels using surrogate markers such as 
the APRI score
425
. These markers are calculated based on an individual’s age and lab 
parameters such as ALT, AST and platelet counts and are described in detail in Section 
2.2.5.3 of the introduction to this thesis. However, recently EuroSIDA have also added 
other markers of liver fibrosis. Since 2010, clinical sites that perform liver biopsy or 
Fibroscan® elastography are required to report that information to the coordinating 
centre
421
. Further, in 2008, using the plasma sample repository data, the biomarker 
hyaluronic acid was determined for all coinfected patients, where plasma samples were 
available. 
 
3.1.2.3 Monitoring and causes of death 
EuroSIDA coordinating centre members visit all clinical sites participating in EuroSIDA to 
monitor patient selection criteria and to quality check the data supplied. EuroSIDA monitors 
check information in the EuroSIDA database against individual case notes for all individuals 
that experience a clinical event and a randomly selected 10% of all other patients per year. 
Further, occasionally monitoring is used to gather extra information from case notes that 
may have been missed off the original data submission. All EuroSIDA centres have ethical 
approval from their own local and national authorities. However, the contract EuroSIDA has 
with its funders, the European Commission, requires that EuroSIDA retain copies of each 
centre’s ethnical approval forms at the coordinating centre. The data collected in EuroSIDA 
are summarised in Table 3.1. 
 
Deaths and causes of death are also captured in EuroSIDA. Traditionally deaths in HIV-
positive individuals were coded using the international classification of diseases system 
(ICD), which classified deaths as HIV-related or non-HIV-related
508
. However, after the 
introduction of cART in 1996, the rate of AIDS-related death began to reduce over time. 
Consequently, the number of deaths attributed to non-AIDS-related causes, such as 
malignancies, liver-related death and cardiovascular disease, began to rise
509;510
. 
Therefore, in order to accurately monitor causes of death among HIV-positive individuals a 
new system of coding was required. 
 
In 2004 a group of European researchers, including the EuroSIDA study group, started a 
project to create a uniform classification system for coding deaths among HIV-positive 
individuals. The coding of causes of death in HIV (CoDe) classification system involves the 
collection of a wide range of data from individual demographics, potential risk factors for 
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death, treatment history, laboratory measurements, autopsy results and the potential role of 
toxicities in relation to death in order to determine the underlying cause of death
511;512
. The 
4-page CoDe form which is filled out for each death in EuroSIDA can be seen in Appendix 
II.  
 
Completed CoDe forms are reviewed by clinicians at CHIP. In most cases the cause of 
death is obvious. However, more complicated cases, which usually involve competing risks 
of death, are discussed by a panel of clinicians at CHIP. If the CHIP clinicians cannot come 
to an agreement about the cause of death then the case will be referred to an external 
reviewer. In instances where the external reviewer and clinicians at CHIP disagree on the 
underlying cause of death they are both asked to reconsider. If agreement still cannot be 
reached then a third expert reviewer is asked to make the tie-breaking decision
511;512
. The 
classification system for underlying cause of death is displayed in Table 3.2. 
 
For historical data, when a CoDe form has not been completed or insufficient information is 
available, EuroSIDA also have a process for determining whether each cause of death is 
classified as AIDS-related or non-AIDS related. If AIDS-defining events are diagnosed and 
reported then the proximity of these events to the time of death is used to determine 
whether the death was AIDS-related
511;512
. Deaths are classified as AIDS-related if the 
survival time following diagnosis with the underlying cause of death is lower than the upper 
quartile of the of survival time for that specific condition. For conditions where the survival 
time distribution is unknown a survival time of less than 17 or 12 months is used to 
determine whether the death was AIDS-related or not
511;512
. 
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Table 3.1 Outline of EuroSIDA data 
Demographics 
Date of birth 
Gender 
Mode of HIV infection 
Race 
Basic clinical information 
Height 
Weight 
Blood pressure  
Smoking  
Family history of MI  
Pregnancy in women  
Active injecting drug use 
Alcohol abuse 
Clinical events  
Diagnosed since last follow-up (with date of 
diagnosis): 
Cardiovascular events 
Metabolic events 
Other organ events 
Laboratory values (and dates of 
measurement) 
Serum total and HDL cholesterol 
Serum triglycerides  
Plasma glucose  
S-creatinine  
Haemoglobin 
Platelet count  
ALT  
AST  
INR  
Bilirubin  
S-lactate (not LDH)  
S-amylase  
CD4 counts 
HIV-RNA  
HIV subtyping  
Resistance testing  
Antiretroviral treatment 
History of antiretrovirals taken: 
Starting and stopping dates 
If discontinued, reason for 
discontinuation  
Adherence rating 
Hepatitis virology/serology results and 
dates*: 
HBV antibody 
HBsAg 
HBV DNA 
HCV antibody 
HCV RNA 
HCV genotype 
Liver fibrosis parameters 
Liver biopsy 
Fibroscan® elastography 
Hyaluronic acid 
APRI (calculation) 
FIB-4 (calculation) 
Treatment for HBV and HCV infection: 
Start and stop dates 
Treatment against infections 
Drugs to prevent or treat opportunistic 
infection: 
Start and stop dates 
Treatment related to risk of cardiovascular 
disease 
Medication related to risk of cardiovascular 
disease: 
Starting and stopping dates 
Severe opportunistic infections 
Dates and diagnosis (definitive, presumptive, 
autopsy) 
Other severe infections 
Dates and diagnosis (definitive, presumptive, 
autopsy)  
AIDS defining malignancies 
Dates and diagnosis (definitive, presumptive, 
autopsy) 
Non-AIDS defining cancers 
Dates and diagnosis (definitive, presumptive, 
autopsy) 
For patients who died 
Date of death 
Presumed cause 
CoDe case report form including autopsy 
report 
*HBV genotype and HDV antibodies are also tested from the central plasma repository 
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Table 3.2 Causes of death classification from CoDe methodology 
Code Cause of Death 
1 AIDS (ongoing active disease) 
1.1 Infection 
1.2 Malignancy 
2 Infection (other than 01.1) 
2.1 Bacterial 
02.1.1 Bacterial with sepsis 
2.2 Others 
02.2.1 Others with sepsis 
2.3 Unknown aetiology 
02.3.1 Unknown with sepsis 
3 Chronic viral hepatitis (progression of/complication to) 
3.1 HCV 
03.1.1 HCV with cirrhosis 
03.1.2 HCV with liver failure 
3.2 HBV 
03.2.1 HBV with cirrhosis 
03.2.2 HBV with liver failure 
4 Malignancy (other than 01.2 and 03, 03.1, 03.2) 
4.03 ANUS - Anal cancer 
4.04 BLAD - Bladder cancer 
4.05 BONE - Bone cancer 
4.06 BRAC - Brain cancer 
4.07 BRCA - Breast cancer 
04.10.1 ALL - Leukaemia: Acute lymphoid 
04.10.2 AML - Leukaemia: Acute myeloid 
04.10.3 CLL - Leukaemia: Chronic lymphoid 
04.10.4 CML - Leukaemia: Chronic myeloid 
04.10.9 LEUK - Leukaemia: unspecified 
4.18 COLO - Colon cancer 
4.11 COTC - Connective tissue cancer 
4.12 ESOP - Esophagus cancer 
4.13 GALL - Gallbladder cancer 
4.14 GYCA - Gynaecologic cancer 
4.15 HDL - Hodgkin lymphoma 
4.16 HENE - Head and neck (incl. face) cancers 
4.17 KIDN - Kidney cancer 
4.19 LIPC - Lip cancer 
4.2 LIVR - Liver cancer 
4.21 LUNG - Lung cancer 
4.22 MALM - Malignant melanoma 
4.27 MULM - Multiple myeloma 
4.29 PANC - Pancreas cancer 
4.31 PENC - Penile cancer 
4.32 PROS - Prostate cancer 
4.33 RECT - Rectum cancer 
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4.34 STOM - Stomach cancer 
4.35 TESE - Testicular seminoma 
4.36 UTER - Uterus cancer 
04.40.1 MEAC - Metastasis: of adenocarcinoma 
04.40.2 MEOC - Metastasis: of other cancer type 
04.40.3 MESC - Metastasis: of squamuos cell carcinoma 
04.40.9 META - Metastasis: unspecified 
4.9 OTH - Other Malignancy Type 
4.99 UNKP - Unknown Malignancy Type 
5 Diabetes Mellitus (complication to) 
6 Pancreatitis 
7 Lactic acidosis 
8 MI or other ischemic heart disease 
8.1 AMI 
08.1.1 Definitive AMI (Dundee 1) 
08.1.2 Possible AMI (Dundee 2/9) 
8.2 Other ischemic heart disease 
9 Stroke 
10 
Gastro-intestinal haemorrhage (if chosen, specify 
underlying cause) 
11 Primary pulmonary hypertension 
12 Lung embolus 
13 Chronic obstructive lung disease 
14 Liver failure (other than 03, 03.1, 03.2) 
15 Renal failure 
16 Accident or other violent death (not suicide) 
17 Suicide 
18 Euthenasia 
19 Substrance abuse (active) 
19.1 Chronic Alcohol abuse 
19.2 Chronic intravenous drug-use 
19.3 Acute intoxication 
20 Haematological disease (other causes) 
21 Endocrine disease (other causes) 
22 Psychiatric disease (other causes) 
22.1 
Mental and behavioural disorders due to use of 
psychoactive substances (other than alcohol and 
intravenous opioids) 
22.2 Schizophrenia, schizotypal and delusional Disorders 
22.3 
Mood /Affective disorders (Major depressive disorder, 
Bipolar disorder and other mood disorders) 
22.4 
Neurotic, stress-related and somatoform disorders 
(including anxiety disorders, phobias, OCD, stress 
reaction, dissociative disorders, somatoform disorders) 
22.5 
Behavioral syndromes associated with physiological 
disturbances and physical factors (including eating 
disorders, sleep disorders, sexual disorders) 
22.9 Other psychiatric disorders 
23 CNS disease (other causes) 
23.1 
Movement disorders (Parkinson’s disease; dystonias 
and Parkinson-like syndromes) 
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23.2 
Degenerative disorders of the central nervous system 
(Alzheimer's disease; Creutzfeldt–Jakob disease and 
other degenerative diseases of nervous system) 
23.3 
Demyelinating diseases of the central nervous system 
(Multiple sclerosis, other demyelinating diseases) 
23.4 
Epilepsy (including localised and generalized epilepsy 
and epileptic syndromes) 
23.5 
Polyneuropathies (Guillain–Barré syndrome and other 
polyneuropathies/disorders of the peripheral nervous 
system) 
23.6 
Diseases of myoneural junction and muscle (Miastenia 
gravis and other myoneural disorders) 
23.9 Other disorders of the nervous system 
24 Heart or vascular (other causes) 
25 Respiratory disease (other causes) 
26 Digestive system disease (other causes) 
27 Skin and motor system disease (other causes) 
28 Urogential disease (other causes) 
29 Obstetric complications 
30 Congenital disorders 
31 
Symptoms caused by mitochondrial toxicity (other 
than 06, 07) 
32 Bleeding (haemophilia) 
33 Sudden infant death 
33.1 Child abuse 
90 Other causes 
91 Unclassifiable causes 
92 Unknown 
92.1 Unknown, Competing risks 
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3.2 Methodology 
 
Many statistical methods have been used to analyse the data in this thesis. An introductory 
statistical methods section at the start of each chapter will describe which methods were 
used to perform the analysis along with inclusion and exclusion criteria, while they are also 
summarised here in Table 3.3. The remainder of this chapter will provide an overview of the 
statistical methods used throughout this thesis. All statistical analyses have been 
performed using SAS version 9.2 or above (SAS institute, Cary, North Carolina, USA). 
 
3.2.1 Summary statistics 
It is important when analysing data to provide summary statistics that give an overview of 
the population being studied. These initial analyses can help to find any obvious data errors 
that need to be amended and can be useful to compare different study populations before 
any formal analysis is performed. This is an important step in cohort study analysis as there 
will often be differences between the groups of patients being studied due to the absence 
of patient randomisation seen in clinical trials, as discussed in more detail below. 
 
Throughout this thesis, for categorical variables the total number of patients (N) and the 
percentage (%) in each category will be reported. For continuous variables the mean and 
standard deviation (SD) are presented when the data are normally distributed, while the 
median and interquartile range (IQR) are presented when the data are skewed. When data 
are approximately normally distributed the mean and median will be similar but they can be 
quite different from each other when data are highly skewed. 
 
When comparing categorical characteristics of different groups of patients the Pearson’s 
chi-square test is used. In cases where there are fewer than 5 patients in any category then 
Fisher’s exact test will be used. When continuous data are normally distributed unpaired t-
tests or f-tests will be used to compare different groups, while when comparing more than 1 
set of values between the same patients, HIV viral load at 2 separate time points for 
example, a paired t-test may be used. When comparing 2 groups of continuous data that 
are skewed the Wilcoxon rank sum test is performed, while for skewed continuous data 
with more than 2 groups the Kruskal-Wallis test will be used, which is an extension of the 
Wilcoxon rank sum test. Both the Wilcoxon and Kruskal-Wallis tests are non-parametric 
and make no assumptions about the underlying distribution of the data. 
 
All statistical tests are performed two-sided, unless stated otherwise, with a P-value less 
than 0.05 taken to be statistically significant, meaning there is sufficient evidence to  
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Table 3.3 Summary of data for each analysis 
Chapter EuroSIDA 
dataset 
N in 
dataset 
N included 
in analysis 
Inclusion criteria Study endpoints Publication details 
(Date accepted) 
4 D35 16,594 1,541 All chronically infected HIV/HCV 
coinfected individuals positive for 
both HCVAb and HCV RNA 
HCV RNA profiles HIV Medicine 
(February 2013) 
5 D35 16,594 1,984 All chronically infected HIV/HCV 
coinfected individuals positive for 
both HCVAb and HCV RNA 
Treatment for HCV with interferon-
based therapy 
HIV Medicine          
(May 2013) 
6 D37 18,913 9,535 All EuroSIDA participants to have 
initiated cART with known HCVAb 
status 
Discontinuation of ART 
components 
AIDS            
(September 2013) 
7 D38 18,786 3,987 All HCVAb positive individuals with 
follow-up available after 1/1/2000 
Liver-related death AIDS               
(February 2015) 
8 D40 18,914 4,011 All HCVAb positive individuals with 
follow-up available after 1/1/2000 
Liver-related death prognostic 
score 
Submission to CID 
planned in June 2015 
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conclude that the null hypothesis of no difference between the groups can be rejected. The 
clinical significance of all findings reported in this thesis will also be considered looking at 
the size of the effect and the width of the confidence intervals. 
 
3.2.2 Statistical models 
Statistical models are able to describe the relationship between variables of interest and 
also act as a predictive tool. They quantify the relationship between an outcome and 
explanatory variables, while incorporating a random element to account for the nature of 
chance as observed data deviate from predicted outcomes. Importantly, statistical 
modelling allows us to control for confounding. Confounding is the process by which a 
spurious relationship may be found between an outcome and explanatory variable via a 
correlated third variable. If a variable is correlated with the outcome of interest and the 
explanatory variable then confounding may occur. For example, a group of men over the 
age of 50 would be more likely to develop certain cancers and non-AIDS defining illnesses 
than a group of women below the age of 30. If age was not adjusted for in the analysis then 
it may be possible to come to the conclusion that men are more likely to develop some 
cancers and non-AIDS defining conditions than women. In this scenario it is said that age is 
confounding the relationship between sex and development of a non-AIDS-defining illness. 
 
In randomised clinical trials confounding is avoided because participants are randomised to 
each intervention arm. Therefore, in a large enough sample size, participant characteristics 
will be evenly balanced between intervention arms. However, in observational studies there 
is no randomisation of participants or allocation of interventions, so it is likely that there will 
be significant imbalances in the study population that may lead to spurious inference. 
Fortunately, the effect of measured and known confounding can be adjusted for by using 
multivariable models, assessing the impact of more than one explanatory variable including 
potential confounders, on an outcome of interest. Including potential confounding variables 
in the model means that adjusted estimates are calculated which can account for the role of 
confounding by variables included in the model. The difference between estimates from 
univariable analysis and multivariable analysis then describes the magnitude of the 
confounding effect. However, regardless of the steps taken to address confounding there 
will always be a level of unmeasured confounding in observational studies that cannot be 
adjusted for in the analysis. 
 
In some instances a factor may have a different effect on an outcome depending on the 
level of the factor. For example, HIV/HCV coinfected individuals aged 40 or below with a 
CD4 cell count of 500cells/mm
3
 may be less likely to have liver fibrosis than similar 
individuals over the age of 60. This describes an interaction between CD4 cell count and 
95 
 
age. Interaction terms may also be adjusted for in multivariable models; however, in a 
model with many explanatory variables there are many potential interaction terms. 
Therefore, interactions are not routinely tested in multivariable modelling as it will increase 
the risk of a false positive result due to repeated statistical testing. Instead, interactions 
which are of potential interest will selected a priori for testing based on empirical knowledge 
of the subject area. 
 
There are four main methods of statistical analysis used in this thesis: logistic regression, 
Cox proportional hazards regression, Poisson regression and mixed effects modelling. An 
overview of each of these methods, including in which scenarios they are used and how 
they are interpreted is given below. 
 
3.2.2.1 Logistic regression 
Logistic regression models are used when the outcome of interest is a binary variable 
which takes the form of a success or failure. For example, when modelling death, for each 
individual in the analysis the outcome of interest will be whether they have died or not, 
there are only two possible outcomes. In a simple analysis the proportion of individuals that 
have died could be compared between different groups, males and females for example. 
However, when using multivariable modelling to account for confounding or statistical 
interactions the binary outcome has to be transformed so that it takes values from −∞ to ∞ 
and can be treated as a continuous stochastic variable
513;514
. Logistic regression takes its 
name from the fact that the transformation used is called the logit function, shown below in 
Equation 3.1, where 𝑝 is the proportion of successes from the binary outcome variable. 
 
Equation 3.1 The logit function 
𝐿𝑜𝑔𝑖𝑡(𝑝) =
𝑙𝑜𝑔(𝑝)
𝑙𝑜𝑔(1 − 𝑝)
 
 
The logistic regression model then takes the form shown in Equation 3.2, where 𝛽𝑛 are the 
estimated linear regression coefficients and 𝑥𝑛 are the explanatory variables of interest. 
The regression coefficients then describe the effect of each explanatory variable on the 
outcome independent of, or adjusted for, the other explanatory variables. 
 
Equation 3.2 The logistic regression model 
𝐿𝑜𝑔𝑖𝑡(𝑝) = 𝛽0 + 𝛽1𝑥1 + 𝛽2𝑥2 + 𝛽3𝑥3 + ⋯ + 𝛽𝑛𝑥𝑛 
 
The logistic regression model has a number of desirable properties. The logit function is 
essentially the log of the odds of an event, which is the number of successes divided by the 
number of failures. When back-transforming the linear regression coefficient estimates 
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each coefficient is identical to the estimated odds ratio of association between 𝑥𝑖 and the 
outcome
513;514
. Therefore, logistic regression can be used to estimate the odds (and 95% 
C.I.) of an outcome given a set of explanatory variables. If the outcome is death and the 
explanatory variable of interest is sex then it would be possible to say that the odds of 
death are higher or lower for males compared to females. An odds ratio greater than one 
indicates increased odds of an outcome occurring, while an odds ratio below one, but 
greater than zero, indicates reduced odds of an outcome occurring. Consequently, a 
confidence interval that does not include one indicates a statistically significant finding. 
 
3.2.2.2 Time to event analysis 
Time to event analysis is used to study deviations in the time from a well-defined baseline 
common to all individuals to an event of interest. This is particularly common in the cohort 
study setting as it is often interesting to study time to death following the allocation of a 
treatment. In this case, when death is the outcome of interest, the method is referred to as 
survival analysis, as individual survival times are compared. Time to event analysis adds an 
extra level of information to simple logistic regression as it focuses on the time to an event 
rather than just whether the event occurred or not. 
 
An interesting and useful feature of time to event analysis is that it can still be used when 
individuals are lost to follow-up or drop out of the analysis. When an individual becomes 
lost to follow-up their survival time is capped at the last known time of contact, which is 
known as right censoring. The individual may have died after the last point of contact but 
that information is not observed in the study. Individuals can also be left censored, which is 
where information is available on an individual prior to the baseline date; however this 
follow-up is capped at baseline to ensure the baseline time point remains common to all 
individuals. In EuroSIDA left censoring is common as information is often available from 
case notes on some individuals prior to enrolment in the study. Including information from 
before recruitment may introduce survivor bias where only those well enough to survive 
long enough to enter the study are included. 
 
Censoring is an important element of time to event analysis as it allows for the inclusion of 
incomplete data. If data were only included for individuals with complete data, those with 
known baseline and last visit, then bias would be introduced to the analysis and potentially 
return spurious conclusions. Time to event analysis treats censoring as a random event 
which is not associated with the actual true survival time. Therefore, asymptotically 
censoring does not bias the results
513;514
. 
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Kaplan-Meier estimation 
Survival times from time to event analysis can be summarised by a mathematical function 
known as the survivor function. The survivor function describes the probability of survival at 
time 𝑡 and is shown in Equation 3.3 below, where 𝐹(𝑡) is the cumulative probability of 
failure at time 𝑡. 
 
Equation 3.3 The survivor function 
𝑆(𝑡) = 1 − 𝐹(𝑡) 
 
The probability of survival at time 𝑡 can be estimated using the non-parametric Kaplan-
Meier estimator. The Kaplan-Meier estimator is shown in Equation 3.4 below, where 𝑛𝑖 is 
the number of individuals at risk of death and 𝑑𝑖 is the cumulative number of deaths at time 
𝑡𝑖. 
 
Equation 3.4 The Kaplan-Meier estimator function 
?̂?(𝑡) = ∏
𝑛𝑖 − 𝑑𝑖
𝑛𝑖
𝑡𝑖<𝑡
 
 
Kaplan-Meier estimation can be used to plot the survivor function and estimate the 
probability of survival, or failure at a given time of interest. The probability of failure is 
simply one minus the probability of survival. Kaplan-Meier estimation is used to compare 
the survival function of categorical or grouping variables without adjusting for other 
variables. The difference between the survival functions can then be tested statistically, 
using the log-rank non-parametric test, to see if one group has a higher probability of 
success or failure over the follow-up period
513;514
. 
 
Poisson regression 
Poisson regression is a form of the generalised linear model where the errors, or 
differences between the observed and predicted values, belong to the Poisson 
distribution
513;514
. The formation of the Poisson regression model is similar to logistic 
regression except that it is used for time to event data and the outcome is the incidence 
rate of an event rather than the odds of an event. The incidence rate of an event is defined 
in Equation 3.5. 
 
Equation 3.5 The incidence rate 
𝐼𝑛𝑐𝑖𝑑𝑒𝑛𝑐𝑒 𝑟𝑎𝑡𝑒 =
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑒𝑣𝑒𝑛𝑡𝑠
𝑇𝑜𝑡𝑎𝑙 𝑝𝑒𝑟𝑠𝑜𝑛 𝑦𝑒𝑎𝑟𝑠 𝑓𝑜𝑙𝑙𝑜𝑤 𝑢𝑝
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The Poisson regression model then takes the form shown in Equation 3.6, where 𝑟 is the 
incidence rate, 𝛽𝑛 are the estimated linear regression coefficients and 𝑥𝑛 are the 
explanatory variables of interest. Notice that as the outcome is now a rate and not a binary 
outcome the link function becomes the log transformation. 
 
Equation 3.6 The Poisson regression model 
𝐿𝑜𝑔(𝑟) = 𝛽0 + 𝛽1𝑥1 + 𝛽2𝑥2 + 𝛽3𝑥3 + ⋯ + 𝛽𝑛𝑥𝑛 
 
Like logistic regression, Poisson regression also has desirable properties. When back-
transforming the estimated linear regression coefficients using the exponential function 
each coefficient is identical to the estimated incidence rate ratio of association between 𝑥𝑖 
and the outcome, also known as the risk ratio
513;514
. Therefore, Poisson regression can be 
used to estimate the risk (and 95% C.I.) of an outcome given a set of explanatory variables. 
If the outcome is death and the explanatory variable of interest is sex then it would be 
possible to say that the risk of death is higher or lower for males compared to females. A 
risk ratio greater than one indicates increased risk of an outcome occurring, while a risk 
ratio below one, but greater than zero, indicates a reduced risk of an outcome occurring. 
Consequently, a confidence interval that does not include one indicates a statistically 
significant finding. 
 
In Chapter 6 of this thesis generalised estimating equations are used to fit the parameters 
of the Poisson regression model. Generalised estimating equations are used to take 
account of within individual variability when each individual may contribute multiple 
endpoints
515
.  
 
Cox proportional hazards regression 
Cox proportional hazards regression is one of the most common ways to analyse time to 
event data. The model is defined in much the same way as logistic regression and Poisson 
regression except that the outcome is defined as the hazard function
513;514;516
. The hazard 
function is shown in Equation 3.7, where 𝑓(𝑡) is the density function of survival times and 
𝑆(𝑡) is the survivor function, as mentioned previously. 
 
Equation 3.7 The hazard function 
ℎ(𝑡) =
𝑓(𝑡)
𝑆(𝑡)
 
 
The Cox proportional hazards model then takes the form shown in Equation 3.8, where 𝛽𝑛 
are the estimated linear regression coefficients and 𝑥𝑛 are the explanatory variables of 
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interest. Notice that the intercept term 𝛽0 is missing and replaced by log(ℎ0(𝑡)), which is 
the baseline hazard where all explanatory variables are set to zero. Cox proportional 
hazards models take their name from this set up as it assumes that the ratio of the hazards 
comparing different explanatory variables remains constant over time, which is known as 
the proportional hazards assumption. 
 
Equation 3.8 The Cox proportional hazards model 
𝐿𝑜𝑔(ℎ(𝑡)) = log(ℎ0(𝑡)) + 𝛽1𝑥1 + 𝛽2𝑥2 + 𝛽3𝑥3 + ⋯ + 𝛽𝑛𝑥𝑛 
 
Although calculating 𝑓(𝑡), the density function of survival times, is not trivial, the 
proportional hazards assumption has the desirable property that when back-transforming 
using the exponential function, ℎ0(𝑡) cancels out so that calculation of 𝑓(𝑡) is not 
necessary
513;514;516
. This means that, in much the same way as Poisson regression, each 
coefficient is identical to the estimated hazard ratio of association between 𝑥𝑖 and the 
outcome. Therefore, Cox proportional hazards regression can be used to estimate the 
hazard ratio (and 95% C.I.) of an outcome given a set of explanatory variables. A hazard 
ratio greater than one indicates increased risk of an outcome occurring, while a hazard ratio 
below one, but greater than zero, indicates a reduced risk of an outcome occurring. 
Consequently, a confidence interval that does not include one indicates a statistically 
significant finding. 
 
Poisson regression and Cox proportional hazards models have many similarities; they are 
often used in similar situations and under certain circumstances produce the same results. 
The key difference between the two is that in Poisson regression the outcome of interest is 
a count of events, or a rate of events in a given period of follow-up, whereas in Cox models 
the outcome is the time to an event. Cox modelling also allows for censoring, where actual 
follow-up times may be unknown or unobserved. In this regard it is sometimes suggested 
that Poisson regression has less complicated inference, whereas Cox models are able to 
handle more complicated data structures. 
 
3.2.2.3 Competing risk in time to event analysis 
In some time to event analysis settings it is common for the outcome of interest to go 
unseen due to the occurrence of another event. For example, when studying liver-related 
death in HIV/HCV coinfection, individuals that could progress to liver-related death may die 
of an AIDS-defining illness in the meantime. These causes of death other than the outcome 
of interest are known as competing risks, events that prevent the outcome of interest from 
occurring. Competing risks are different from censoring, which prevents the event from 
being captured in the data. However, censoring is assumed to occur independently of the 
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outcome of interest and if censoring occurs systematically and is associated with the 
outcome of interest then it should also be considered a competing risk
517
. 
 
In the competing risks setting, when competing events are censored in the standard 
fashion, the Kaplan-Meier estimator is biased and may not accurately estimate the survival 
function
517
. Fortunately, a number of well-defined methods are available for handling 
competing risks analysis. The most widely used method in this setting is the Fine and Gray 
method
518;519
. In the Fine and Gray method, as the competing event prevents observation 
of the true survival time without the event of interest, all individuals that experience a 
competing event have their right censoring time replaced. Instead the event free survival 
time is estimated using the inverse probability of censoring. In other words, survival times 
are estimated as if the competing event had not occurred. This means that individuals are 
retained in the analysis population after a competing event even though they are not 
technically at risk of the event of interest. Modelling is then performed in the usual manner 
on this adjusted dataset with estimated true survival times. In Cox proportional hazards 
regression, this slightly abstract formulation leads to estimation of the sub-distribution 
hazard and hazard ratio, which is a good estimate of the true hazard ratio
518;519
. 
 
3.2.2.4 Mixed effects models 
Mixed effects models, otherwise known as random effects models, are used in the analysis 
of repeated measurements within individuals. They are known as mixed effects models as 
they can include fixed and random effects. A fixed effect is a standard variable which is 
assumed to have a fixed effect on each individual in the analysis
520
. Examples of fixed 
effects include the effect of a treatment, age or gender, they are all assumed to have the 
same effect on an individual level. A random effect is a variable which represents a sample 
of a larger population, where the effect is variable at the individual level
520
. An example of a 
random effect would be clinical centre as the centres included in a study are a sample of 
those from the whole population. In a mixed effects model the effect of each centre is not 
fixed and is allowed to vary around a mean of zero. The mixed model takes the form shown 
in Equation 3.9, where 𝑦 is a vector of observations for each individual, 𝛽 is a vector of 
fixed effects, 𝑢 is a vector of random effects, 𝜖 is a vector of random error terms and 𝑋 and 
𝑍 are matrices of regression coefficients. 
 
Equation 3.9 The mixed effects model 
𝑦 = 𝑋𝛽 + 𝑍𝑢 + 𝜖 
 
The inclusion of random effects, which vary for each individual, allows for the modelling of 
individual curves, or profiles, for each individual. If a random intercept term is included in 
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the model it allows the intercept to vary for each individual, while additionally including a 
random slope variable allows completely separate curves to be modelled for each 
individual, with different intercepts and slopes. The model then combines these individual 
curves to estimate an overall effect for each variable
520
. 
 
As mixed models analyse repeated measurements there is an additional level of variability 
to account for. Observations taken for one individual will be more similar than observations 
taken for another individual, while there may also be correlation between observations 
taken on one individual. For example, when analysing plasma HIV RNA levels over time in 
the same individual a high HIV RNA measurement would be more likely to be followed by 
another high measurement. This form of variability can be stipulated in the model 
specification by using the autoregressive covariance structure. An autoregressive structure 
assumes that observations which are taken close together are more similar than those 
taken further apart. The other covariance structure that is used in this thesis is the 
unstructured form. The unstructured covariance structure makes no assumptions about the 
relationship between observations and uses the data to estimate their relationship
520
. 
 
3.2.3 Model building strategies 
Each analysis chapter of this thesis includes a statistical methods section which outlines 
the statistical methods used to analyse the data. Explanatory variables will be introduced 
along with any transformations necessary to normalise the data. Most of the explanatory 
variables analysed in this thesis are well known in HIV and HCV research, however, 
detailed explanations will be given where new or novel approaches have been used. 
 
A mixture of baseline variables and time-updating variables are used where appropriate. 
Baseline variables, such as baseline age, sex and height, which by definition are fixed over 
time, are used to determine the long term association with an outcome of interest. Time-
updating variables make use of data that are collected at regular intervals, such as HIV 
viral load and CD4 cell count which are measured at 3-monthly intervals for many 
individuals in EuroSIDA, which vary over time and can reflect disease progression or 
pathogenesis. Time-updating variables determine the short term association with an 
outcome of interest. 
 
When using statistical models, univariable analysis is performed followed by multivariable 
analysis including all those variables statistically significant at the 10% level (p-value <0.1). 
In some cases variables that are not significant in univariable analysis will still be included 
in multivariable analysis. This is appropriate when clinical knowledge suggests that these 
variables are responsible for variability in the outcome of interest. In some analyses with 
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few endpoints it may have been decided a priori using empirical knowledge which variables 
it would be most interesting to analyse.  
 
Sensitivity analysis has also been used frequently to check the sensitivity of the model to 
specific variables. Further details are given in each subsequent chapter in the methodology 
and discussion sections. 
 
3.2.3.1 Handling missing data 
Where data are incomplete or missing various methods of missing data handling have been 
incorporated. When few data are missing and omitting cases with missing values does not 
drastically reduce the analysis population, the complete-case method has been used. This 
method has been showed to be unbiased when the missing data is not missing as a 
function of either the outcome of interest or the model error term
521
. However, when many 
data are missing the complete-case method is highly inefficient as it leads to a large 
number of cases being excluded.  
 
When fairly large amounts of data are missing indicator variables have been used to create 
missing categories that can be included in statistical modelling. However, this approach is 
known to produce biased estimates in some circumstances
521
. Therefore, in instances 
where further investigation of the effect of missing data is required multiple imputations 
have been used to impute the missing data. Multiple imputations fill in missing data by 
estimating what the data are likely to be multiple times using the characteristics of 
individuals with complete data. These multiple imputations are then combined so that 
variability associated with the multiple imputations is included in the standard error of the 
overall parameter estimates, which has been shown to provide unbiased estimates
522
. 
 
Comparing the results from a multiple imputations analysis with the main analysis using 
indicator variables then allows for description of what effect the missing data are having on 
the statistical inference. 
 
3.2.4 Summary 
The statistical models and methodology presented in this chapter provide an illustration of 
the statistical methods employed throughout this thesis. Each analysis that follows will use 
specific methodology tailored to the research question of interest. Although care has been 
taken to minimise the effect of inherent bias, each analysis will have its own strengths and 
weaknesses. A more detailed explanation of the methods employed for each analysis is 
included in each of the following five chapters, while the strengths and weaknesses of each 
piece of work are presented in the discussion as well as in Chapter 9 of this thesis.  
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Chapter 4 
 
The natural history of HCV RNA levels during chronic 
HCV infection among HIV/HCV coinfected individuals 
 
4.1 Introduction 
 
As discussed in Chapter 2 Section 2.2, coinfection with HCV is one of the most clinically 
important comorbidities in the HIV-positive population. Of the 35 million people currently 
living with HIV worldwide, approximately 20% have chronic HCV infection
383;523;524
. In 
recent years mortality rates attributable to HIV infection have decreased as a result of 
antiretroviral therapy
525
. As a result, end-stage liver disease has assumed increasing 
importance as a cause of death among the coinfected population
404;526;527
. This is 
especially true for people who acquired HIV via injecting drug use (IDU), in whom HCV is 
common as a result of shared transmission routes
383;524;526
. 
 
Anti-HCV antibody (HCVAb) positivity has been associated with a higher rate of any-cause 
death and liver-related death among the HIV-positive population
24;404;528-530
, while evidence 
presented in Section 2.2.6 suggests that plasma HCV RNA, along with HCV genotype and 
interleukin IL28B gene variant, has been shown to be one of the most important predictors 
of sustained virological response (SVR) to treatment with pegylated-interferon (peg-IFN) 
and ribavirin (RBV) in coinfected individuals
436;462;523;526;531
. Furthermore, it has been 
reported that an HCV RNA measurement taken early after HIV seroconversion can predict 
progression to AIDS and death in individuals with high HCV viral loads
532
. 
 
4.1.1 HCV and cART 
The use of combination antiretroviral therapy (cART) in coinfected individuals is 
complicated by an increased risk of antiretroviral-associated hepatotoxicity
533
. Coinfection 
with HCV has been consistently identified as the most significant risk factor for the 
development of liver enzyme elevations after initiation of cART
380
. One study reported that 
HCV coinfected individuals had a 2.5-fold greater risk of developing severe hepatotoxicity 
compared to HCV uninfected individuals
534
. Similarly, a study from the United States 
reported that HCV coinfection was independently associated with a greater than 2-fold 
increased risk of severe hepatotoxicity
535
. While these studies indicate that HCV coinfection 
increases the risk of elevations in liver enzymes after cART initiation, most studies indicate 
104 
 
that coinfected individuals treated with cART do not develop severe hepatotoxicity, with one 
study showing that 88% of coinfected people treated with cART did not develop 
hepatotoxicity, defined as a greater than 5-fold increase in alanine transaminase (ALT) or 
aspartate transaminase (AST)
536
. Accordingly, most HIV/HCV coinfected individuals can be 
treated safely with cART, though they should be monitored closely for the development of 
signs and symptoms of hepatotoxicity
537
. 
 
There is also some evidence that use of cART can partially restore CD4 T-cell responses to 
core HCV peptides, meaning that successful responses to cART among the HIV/HCV 
coinfected population can lead to increased immune responses to HCV. Further, an 
increased immune response to HCV may lead to long term reductions in HCV RNA levels 
and potential clearance of HCV
389;538;539
. Indeed the Swiss HIV Cohort Study group recently 
showed that, after successful treatment with cART, HIV/HCV coinfected individuals had an 
increased response to HCV core peptides and had a slight decrease in HCV RNA levels 
compared to pre-ART levels
540
. 
 
Despite the risk of hepatotoxicity, it is strongly suggested that successful responses to 
cART can restore cellular immune responses to HCV antigens and lessen the progression 
of chronic liver disease while improving the response to anti-HCV therapy. Therefore, the 
early initiation of cART is supported among HIV/HCV coinfected individuals
376;541
. However, 
cART does not appear to fully correct the adverse effect of HIV infection on HCV related 
outcomes and should not distract from the main aim of HCV therapy, which is HCV 
eradication with appropriate treatment
389;542
. 
 
4.1.2 HCV RNA and clinical outcomes 
HCV viral loads and their relationship to liver disease and other clinical outcomes have 
been the subject of many studies of HCV monoinfection with conflicting results. A study by 
De Moliner et al found no correlation between histological outcome and HCV RNA levels 
concluding that ‘the extent of replicative activity of HCV does not seem to play a role in the 
modulation of associated hepatic disease’543. However, other studies have reported that 
viral titre may well influence the severity of liver damage. Mita et al found that HCV RNA 
titres were significantly higher in individuals with chronic active HCV, with the highest viral 
loads seen among those with cirrhosis and hepatocellular carcinoma
544
, while Naito et al 
describe inflammatory changes in the portal tracts with the severity depending on the 
replicative levels of HCV
545
. However, all of these studies were cross-sectional and 
relatively small, including less than 100 participants. 
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Two larger studies by Gretch et al
546
 and Adinolfi et al
547
, which included 121 and 298 
participants respectively, also found that high HCV RNA titres correlate with the most 
severe forms of liver damage. Adinolfi in particular states that ‘liver damage is correlated 
with HCV RNA levels and that high HCV viral load acts together with steatosis in 
accelerating the progression of liver injury’547. The contradictions in the findings of these 
studies may be explained by the timing of the HCV RNA and liver damage determinations. 
A major limitation to these studies is that many of them compare the extent of liver injury at 
a given point in time to a single estimate of viral load, while none of them consider the 
predictive ability of HCV RNA or the role of coinfection with HIV. 
 
More recently HCV RNA levels and their association with liver-related death among 
coinfected individuals was the subject of a large EuroSIDA study with a long duration of 
follow-up. Rockstroh et al, in a study including 13,025 HIV-positive individuals, 30% of 
whom were HCVAb positive at baseline, over a median duration of follow-up of 7 years, 
found that HCVAb positive individuals had 9-fold increased risk of liver-related death, while 
among HCVAb positive individuals those with viremic infection were at 2-fold increased risk 
compared to those with aviremic infection
548
. However, when going on to examine the role 
of HCV RNA in more detail, using time updated HCV RNA measurements, there was no 
evidence of a dose response relationship between HCV RNA and liver-related death 
(Figure 4.1)
548
. 
 
Although HCV is primarily a disease of the liver it has been shown to have a detrimental 
effect on other organ systems. Recent studies of HIV/HCV coinfected individuals have 
shown an association between HCV viremia and progression to chronic kidney disease 
(CKD). Mocroft et al, in 3,441 participants taking antiretroviral therapy from a clinical trial of 
HIV-positive individuals, reported that those with high levels of HCV RNA (>800,000 IU/ml) 
had 3-fold higher odds of developing CKD compared to HCVAb negative participants
549
. 
Further, the authors found some evidence to suggest that the odds of developing CKD 
increased as HCV RNA levels increased. A similar study from the EuroSIDA cohort by 
Peters et al also found that participants with high HCV RNA (>500,000 IU/ml) were at the 
highest risk of developing CKD, suggesting a contribution from active HCV infection 
towards the pathogenesis of CKD
26
. 
 
4.1.5 Natural history of HCV RNA 
The natural history of HCV RNA levels and how they vary over time is the subject of recent 
research. A study of 60 chronically HCV monoinfected individuals by Yeo et al
550
, including 
445 HCV RNA measurements with a median of 8 measured per person, analysed changes  
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Figure 4.1 Progression to clinical events according to HCV RNA titre
548
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
over time in HCV RNA levels. The authors found that HCV RNA levels varied over time by 
less than one log in 62% of individuals and less than 1.5 logs in 84%, while also noting no 
apparent association between HCV RNA titre and disease severity, as measured by raised 
transaminases (Figure 4.2). However, although this study included a relatively high number 
of measurements per person, the findings are limited by the short duration of the study, 
which was conducted over a median of 40 months. 
 
In a study by Thomas et al that included 969 IDU HCV infected individuals, 48% of whom 
were coinfected with HIV, changes over time in HCV RNA were analysed using 
consecutive pairs of HCV RNA measurements
551
. In total 901 pairs of measurements were 
analysed, with a median of 5.7 (interquartile range (IQR): 5.5 - 6.0) months between 
measurements, and the median change in the magnitude of HCV RNA from visit-to-visit 
was 0.26 log10 copies/ml
551
. The authors found that reported IDU in the interval between 
HCV RNA measurements was associated with higher visit to visit increases in HCV RNA 
than those not reporting IDU. HIV infection, along with other sociodemographic factors, was 
not found to influence changes over time in HCV RNA levels. During the relatively short 
observation period in this study, less than 2 years, nearly equal proportions of individuals 
experienced increases or decreases in HCV RNA levels. However, duration of HCV 
infection was found to be a significant predictor of higher HCV RNA levels, indicating that 
serum HCV RNA may increase over time
551
. 
 
 
 
 
 
 
 
 
 
Image not available due to copyright restrictions 
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Figure 4.2 Stability of HCV‐RNA and its lack of correlation with disease severity in 
asymptomatic chronic hepatitis C virus carriers
550
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A small study of 17 HIV/HCV coinfected patients by Eyster et al found that after an initial 
increase in HCV RNA following HIV seroconversion, HCV RNA levels remained stable 
during the 2 to 5 years following HIV seroconversion, however, after 5 to 13 years post 
seroconversion, HCV RNA had increased markedly
384
. In a more recent prospective study 
of 264 coinfected IDUs, 54% HIV-positive, with a median of 3 HCV RNA measurements per 
individual each separated by a median interval of 1 year, Fishbein et al report that HCV 
RNA levels did increase significantly over time in HCV monoinfected individuals, albeit a 
small increase of 0.025 log10 per year, but remained stable in HIV-positive individuals. The 
authors also note that HCV RNA levels were strongly positively associated with HIV RNA 
levels and identified HIV coinfection and HCV genotype 1 as predictors of higher HCV RNA 
levels
526
. 
  
 
 
 
 
 
 
 
 
 
 
Image not available due to copyright restrictions 
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4.2 Aims 
 
The main aim of this chapter was to examine the natural history of HIV/HCV coinfection 
with regards to changes over time in HCV RNA levels prior to treatment for HCV. This 
study can add to the body of work on this topic by including a large number of individuals 
prospectively followed over a long period time. Of particular interest is to investigate which 
factors affect baseline HCV RNA levels and which factors affect changes over time in HCV 
viral load. It is also important to consider the role of treatment with cART with regards to its 
effect on HCV RNA levels as this is of potential interest to the clinical management of these 
individuals. 
 
A further aim of this study was to discover if any factors of interest were predictive of HCV 
RNA levels reaching a clinically significant threshold. HCV viral loads >800,000 IU/ml have 
been associated with a poor response to traditional HCV treatment with pegylated-
interferon and ribavirin, and progression to CKD in coinfected individuals.  
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4.3 Methods 
4.3.1 Patient selection 
The D35 update of the EuroSIDA database included 16,594 HIV-positive individuals from 
105 centres across Europe, Israel and Argentina. Figure 4.3 shows the breakdown of how 
HIV/HCV coinfected individuals were selected for inclusion in this study. There were 14,324 
individuals with known HCVAb status of whom 4,664 were antibody positive. From those 
2,670 had data available on HCV RNA levels and of those 2,115 were positive (79.2%). 
From the 2,115 individuals positive for HCV RNA there were 1541 individuals with data 
recorded in international units (IU)/ml. 
 
EuroSIDA HCV RNA data is recorded in either IU/ml, which has now become the universal 
standard of measurement, or copies/ml from historical data. In order for data that are 
recorded in copies/ml to be converted to IU/ml information about the assay used to 
determine the HCV RNA titre is required. Unfortunately, this information is not available in 
EuroSIDA for data in copies/ml. Efforts have been made to find an applicable conversion 
factor for these data, however, the nature of this study which specifically looks at changes 
over time in HCV RNA means that it is important to only include data collected in IU/ml. 
This way I can be sure that any observed changes between serial HCV RNA 
measurements are genuine and not due to measurement error associated with conversion 
from copies/ml to IU/ml. 
 
HCV RNA measurements that were below the level of detection, which is 615 IU/ml, were 
taken as 615 IU/ml. The follow-up of those who clear the virus and remain undetectable 
was censored at the date of their first undetectable test. Measurements that were above 
the upper limit of detection, which varied between centres and was as low as 8,000 IU/ml 
from some historical data, were excluded from this study as participants that had multiple 
measurements above the range of detection would appear to have a perfectly flat HCV 
RNA level over time, which is highly unlikely to be the case. However, this was a minor 
occurrence with just 41 measurements from 39 individuals having to be excluded. Further, 
this did not alter the number of individuals included in the analysis shown in Figure 4.3. 
 
4.3.2 Statistical methods 
For the purpose of this study baseline was defined as the first positive HCV RNA 
measurement during prospective follow-up. Individuals were followed from baseline until 
their last HCV RNA measurement while HCV treatment naïve and HCV RNA positive. 
There were 399 participants that started HCV therapy and had their follow-up right 
censored at the date of initiating HCV treatment. 
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Figure 4.3 Analysis population inclusion criteria 
 
 
 
 
Linear mixed models were used to assess which factors were associated with HCV RNA 
levels measured on the log10 scale. Such models allow for investigation into whether HCV 
RNA levels vary at baseline and whether HCV RNA levels change over time by accounting 
for within subject variability in the covariance structure. An unstructured covariance 
structure was used which allows the model to estimate the covariance between sequential 
HCV RNA measurements within subjects. The explanatory variables considered were: 
 
 Time from first HCV RNA measurement 
 Age/Sex/Race 
 Region of EuroSIDA (see Chapter 3 Section 3.1.1) 
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 HIV transmission risk group 
 HCV genotype 
 Time HIV antibody positive 
 Calendar year of baseline HCV RNA measurement 
 HBsAg status (time updated) 
 HIV viral load (time updated) 
 CD4 cell count (time updated) 
 cART status (time updated) 
 
cART status is a definition of whether a patient is receiving certain elements of an HIV 
treatment regimen. A PI regimen is defined as containing a PI and at least two other ARVs 
not including an NNRTI. An NNRTI regimen is defined as containing an NNRTI and at least 
two other ARVs not including a PI, and a more inclusive definition of any cART was defined 
as at least three ARVs from any drug class. Time from baseline HCV RNA measurement 
and the intercept were included as random effects in the model, all other variables were 
included as fixed effects.  
 
To test the linearity of HCV RNA changes over time 2 indicator variables were tested which 
allowed the rate of change in HCV RNA over time to vary at 3 months and 12 months after 
baseline. Further, interactions between time and the covariates included in the mixed 
model were tested to see whether the rate of change in HCV RNA levels over time differed 
according to the levels of the covariates. 
 
Secondary analyses in this chapter focused on assessing which factors were associated 
with rapid increases and decreases in HCV RNA over time, and with reaching a clinically 
significant threshold of 800,000 IU/ml. Rapid increases and decreases over time were 
defined a priori as those greater than the 90
th
 percentile among the individuals with more 
than 1 HCV RNA measurement in the analysis based on individual-level linear regression. 
Separate multivariable logistic regression models were used to describe factors associated 
with the odds of rapid increases or decreases in HCV RNA adjusted for the factors listed 
above. A similar multivariable logistic regression model was used to describe factors 
associated with having an HCV viral load ≥800,000IU/ml at any time during the course of 
follow-up, adjusted for the factors listed above. 
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4.4 Results 
4.4.1 Generalizability and baseline characteristics 
During the patient selection process for this chapter 1,994/4,664 HCVAb positive 
individuals were excluded as they did not have HCV RNA data available. To consider the 
generalizability of the results in this chapter multivariable logistic regression, adjusting for 
the covariates listed above, was used to assess how the excluded individuals differed from 
those that were included in the analysis. Individuals without HCV RNA data available were 
older at the time of their HCVAb positive test result (odds ratio (OR): 1.37 (95% confidence 
interval (CI) 1.20 – 1.56; P<0.0001), per 10 years older) and were more likely to reside in 
Eastern Central or Eastern Europe (OR: 3.31 (95% CI 2.29 – 4.79; P<0.0001) and OR: 
8.05 (95% CI 5.45 – 11.88; P<0.0001) compared with Western Europe, respectively) than 
those with HCV RNA data. 
 
Baseline characteristics of the 1,541 individuals that were included in the analysis are 
shown in Table 4.1, stratified by whether taking cART at baseline, defined as 3 ARVs from 
any class. Included individuals were predominantly white (91%), male (69%), IDUs (73%), 
and from Southern (35%) and Western Central Europe (23%); the HCV genotype 
distribution was G1 (58%), G2 (3%), G3 (36%) and G4 (14%). Eighty one percent were 
HBsAg negative, with 6% HBsAg positive and 13% with unknown HBsAg status. 
 
There were significant differences between the populations on and off cART at baseline. 
Those that were off cART were younger (33.9 vs. 38.4 years; P<0.0001), while a higher 
proportion of individuals on cART were from Southern Europe and a lower proportion from 
Eastern Europe (37.4% vs. 28.2% and 4.9% vs. 22.7%; P<0.0001). Though HIV 
transmission risk groups and HCV genotypes were generally well matched between those 
on and off cART; there were a higher proportion of MSM that were on cART (10.5% vs. 
5.3%; P=0.02) and a higher proportion with HCV genotype G3 among those off cART 
(31.8% vs. 23.7%; P=0.0003). Median CD4 cell count was well matched between those on 
and off cART, however, HCV viral loads were higher among those on cART (5.85 vs. 5.78 
IU/ml; P=0.0019) and HIV viral loads were more often below the level of detection (60.1% 
vs. 11.8%; P<0.0001) as one might expect of cART-treated individuals. 
 
It is important to point out that while on the log10 scale a difference in HCV RNA of 5.78 vs. 
5.85 IU/ml looks minimal it actually equates to a rather large difference in absolute 
numbers. The log10 scale is exponential and a change from 5 to 6 equates to a change from 
100,000 to 1,000,000 in absolute numbers. Therefore, the difference between an HCV viral 
load of 5.78 IU/ml and 5.85 IU/ml corresponds to a change of 105,386 IU/ml on the 
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Table 4.1 Baseline characteristics 
N (%) 
Total 
(N=1541) 
Off cART* 
(N=393) 
On cART* 
(N=1148) 
P-value
1 
Gender     
Male 1070 (69.4) 263 (66.9) 807 (70.3) 0.21 
Female 471 (30.6) 130 (33.1) 341 (29.7)  
Race     
White 1405 (91.2) 365 (92.9) 1040 (90.6) 0.17 
Non White 136 (8.8) 28 (7.1) 108 (9.4)  
Age (Years (Median (IQR))) 37.5 (32.1 – 42.1) 33.9 (27.6 – 39.0) 38.4 (33.6 – 43.0) <0.0001 
Region of Europe     
South 540 (35.0) 111 (28.2) 429 (37.4) <0.0001 
West Central 348 (22.6) 78 (19.9) 270 (23.5)  
North 229 (14.9) 69 (17.6) 160 (13.9)  
East Central 246 (16.0) 42 (10.7) 204 (17.8)  
East 145 (9.4) 89 (22.7) 56 (4.9)  
Argentina 33 (2.1) 4 (1.0) 29 (2.5)  
HIV Exposure Group     
MSM 142 (9.2) 21 (5.3) 121 (10.5) 0.020 
IDU 1117 (72.5) 303 (77.1) 814 (70.9  
Haemophiliac 49 (3.2) 9 (2.3) 40 (3.5)  
Heterosexual 186 (12.1) 49 (12.5) 137 (11.9)  
Other 47 (3.1) 11 (2.8) 36 (3.1)  
HCV Genotype     
1 896 (58.1) 227 (57.8) 669 (58.3) 0.0003 
2 39 (2.5) 4 (1.0) 35 (3.1)  
3 397 (25.7) 125 (31.8) 272 (23.7)  
4 209 (13.6) 37 (9.4) 172 (15.0)  
Baseline HBsAg Status     
Positive 95 (6.2) 31 (7.9) 64 (5.6) 0.012 
Negative 1241 (80.5) 325 (82.7) 916 (79.8)  
Unknown 205 (13.3) 37 (9.4) 168 (14.6)  
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Baseline CD4 Cell Count  
Cells/mm
3
 (Median (IQR)) 
 
347 (200 – 518) 
 
356 (204 – 510) 
 
340 (197 – 526) 
 
0.12 
Baseline Log10 HCV RNA  
IU/ml (Median (IQR)) 
 
5.82 (5.31 – 6.25) 
 
5.78 ( 5.15 -6.13) 
 
5.85 (5.37 – 6.30) 
 
0.0019 
HIV RNA <400 copies/ml 702 (47.6) 45 (11.8) 657 (60.1) <0.0001 
 
IQR - Inter quartile range; MSM – Men who have sex with men; IDU – Injecting drug user; HCV – Hepatitis C virus; HBsAg – Hepatitis B surface antigen; 
cART – Combination antiretroviral therapy 
Baseline in this study was defined as the date of the first available HCV RNA measurement 
*cART defined as at least 3 antiretrovirals from any class 
1
P-value from Chi-square test for comparison of proportions or Kruskal-Wallis test for comparison of population medians 
Baseline CD4 cell count and HIV viral load are taken as the closest measurement prior to baseline, up to 6 months prior, if no measurement is available in 
this window then a value up to 3 months after baseline is used 
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unlogged scale, or a 17.5% increase. To ensure that the magnitude of change in HCV RNA 
is properly conveyed, results in this chapter will refer to changes on the log10 scale and the 
percentage change in absolute numbers. This simply entails back-transforming the 
estimates from the model so that they become multiplicative, therefore, both estimates are 
from the same model. 
 
At baseline the median time from the first documented HIV antibody positive test result 
among the included individuals was 9.2 years (inter quartile range (IQR): 4.8 – 12.9), while 
the median follow-up time, i.e. the time from the first till the last HCV RNA measurement, 
was 5.0 years (IQR: 2.8 – 8.3). There were 575 individuals that had at least two HCV RNA 
measurements, while the median number of measurements per person was 2 (IQR: 1 – 3, 
range: 1 – 10). The median time between consecutive HCV RNA measurements within 
individuals was 1.7 years (IQR: 0.7 – 4.1). There were 2.580 HCV RNA measurements 
included in total. 
 
4.4.2 Exploratory data analysis 
 
4.4.2.1 Correlation between HCV RNA and liver transaminases 
Of the 2,580 HCV RNA measurements included in this analysis, there were 1,144 from 765 
individuals that had alanine transaminase (ALT) and aspartate transaminase (AST) 
measured within 3 months of the HCV RNA measurement. These data were pooled and 
used to describe correlations between HCV RNA, ALT and AST. 
 
Figure 4.4 displays scatter plots showing the correlation between HCV RNA on the log10 
scale, and ALT and AST in IU/ml. Whereas there was strong agreement between ALT and 
AST measurements and a clearly identifiable positive correlation (Pearson’s correlation 
coefficient (R)=0.82; P<0.0001), as one would expect, neither ALT (R=0.08; P=0.0083) or 
AST (R=0.05; P=0.071) displayed any meaningful correlation with HCV RNA levels. The 
correlation between HCV RNA and ALT may have been statistically significant and the 
correlation between AST and HCV RNA borderline statistically significant, however, this 
was most likely a consequence of the relatively large sample size and the power of the 
statistical test rather than the identification of a meaningful association. 
 
4.4.2.2 Individual HCV RNA profiles 
Figure 4.5 displays 20 randomly selected individual HCV RNA profiles from those with at 
least three HCV RNA measurements, stratified by whether they were taking cART at 
baseline or not. Clearly there appears to be a large amount of natural variation in HCV RNA   
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Figure 4.4 Scatter plots showing correlation between HCV RNA, ALT and AST 
 
 
HCV RNA measured on the log10 scale; ALT and AST measured in IU/ml 
 
levels. Though this is a small subset of the whole population there appears to be less 
variation among patients that were on cART at baseline compared to those that were not, 
with more drastic increases and decreases in HCV viral load seen among those not on 
cART at baseline. 
 
4.4.3 HCV RNA levels at baseline and changes over time 
The least squares mean estimates of HCV RNA levels within each stratum of covariates 
included in the mixed model, along with percentage differences within stratum and changes 
over time in HCV RNA, are shown in Table 4.2. Least squares mean estimates estimate 
the mean HCV viral load in each strata controlling for confounding by other factors. All   
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Figure 4.5 Twenty randomly selected individual HCV RNA profiles split by baseline 
use of cART 
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1,541 individuals in this study population contribute to estimates of baseline levels of HCV 
RNA, while the 575 individuals with at least two HCV RNA measurements contribute to the 
estimates for the change over time in HCV RNA. 
 
4.4.3.1 Baseline HCV RNA 
Baseline HCV RNA levels were lower for HCV genotypes 2 to 4 compared with genotype 1 
(percent difference -25.5% (95% CI -39.1% to -8.8%; P=0.0044)). There was also some 
evidence to suggest that baseline HCV RNA levels were lower among those in the 
haemophiliac HIV transmission group compared with the IDU transmission group (percent 
difference -42.9% (95% CI -68.5% - 3.6%; P=0.065)) although the number included in the 
haemophiliac risk group was low and this only reached borderline statistical significance. 
Examples of these baseline differences are shown in graphical form in Figures 4.6 and 4.7. 
As the differences are at baseline only, these differences represent parallel lines, the small 
increase over time common to each stratum is associated with taking any form of cART as 
discussed below. 
 
There was borderline to weak statistical evidence to suggest that HIV RNA levels above 
400 copies/ml were associated with higher HCV RNA levels (percent differences 28.0% 
(95% CI -1.4% - 66.3%; P=0.064), 32.4% (95 CI -0.8% - 76.7%; P=0.057) and 32.5% (95% 
CI -6.5% - 87.6%; P=0.11) for HIV RNA 400-1,000, 1,000-10,000 and >10,000 copies/ml, 
respectively, compared with <400 copies/ml). Refitting the model including HIV RNA as a 
binary variable (<400 copies/ml vs. ≥400 copies/ml), unsuppressed HIV RNA was a strong 
predictor of HCV RNA, with HCV RNA levels 30.4% higher when HIV RNA was above 400 
copies/ml (95% CI 4.9% – 62.0%; P=0.017), compared to HIV RNA levels <400 copies/ml. 
Further, when fitting HIV RNA as a continuous variable on the log10 scale a 1 log change in 
HIV RNA was associated with an 10.9% increase in HCV RNA (95% CI 2.3% – 20.2%; 
P=0.012).  
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Table 4.2 Least squares estimates of HCV RNA levels and changes through time 
 
LS means 
at baseline* 
(Log10 IU/ml) 
Difference within strata Change in HCV RNA over time 
 
 
 
% 95% C.I. 
 
 
p-value
1
 
 
% per 
year 95% C.I. p-value
† 
cART status        
None 5.50 0 - - 27.6 (6.1, 53.5) 0.0098 
All cART 5.61 26.8 (-3.0, 65.8) 0.083 2.6 (-1.1, 6.5) 0.17 
PI regimen 5.59 9.4 (-13.4, 38.4) 0.45 3.4 (-0.2, 7.2) 0.068 
NN regimen 5.65 27.4 (-24.0, 113.5) 0.35 2.0 (-5.2, 9.7) 0.59 
HCV Genotype        
1 5.62 0 - -    
2, 3, 4 5.49 -25.5 (-39.1, -8.8) 0.0044    
Baseline Age 
< 30 
30 – 40 
40 – 50 
> 50 
 
5.48 
5.56 
5.58 
5.60 
 
0 
20.9 
27.3 
30.8 
- 
(-12.8, 67.5) 
(-12.3, 84.8) 
(-21.0, 116.5) 
 
- 
0.25 
0.20 
0.30 
 
 
  
Gender        
Male 5.58 0 - -    
Female 5.53 -11.0 (-28.9, 11.4) 0.31    
Race        
White 5.53 0 - -    
Non White 5.58 10.6 (-24.9, 62.3) 0.61    
Region of Europe        
South 5.56 0 - -    
West Central 5.60 10.7 (-17.1, 47.8) 0.49    
North 5.59 8.4 (-21.4, 49.7) 0.62    
East Central 5.63 19.7 (-15.0, 68.4) 0.31    
East 5.54 -2.6 (-39.5, 56.9) 0.92    
Argentina 5.41 -29.2 (-66.3, 48.6) 0.36    
HIV Transmission Group        
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Injecting Drug User 5.65 0 - -    
MSM 5.52 -25.3 (-48.1, 7.4) 0.12    
Haemophiliac 5.41 -42.9 (-68.5. 3.6) 0.065    
Heterosexual 5.57 -17.2 (-40.0, 14.3) 0.25    
Other 5.63 -3.5 (-45.1, 69.5) 0.90    
HIV RNA (copies/ml) 
< 400 
400 – 1,000 
1,000 – 10,000 
> 10,000 
5.47 
5.58 
5.59 
5.59 
 
0 
28.0 
32.4 
32.5 
- 
(-1.4, 66.3) 
(-0.8, 76.7) 
(-6.5, 87.6) 
 
- 
0.064 
0.057 
0.11 
 
  
CD4 Cell Count (cells/mm
3
) 
> 500 
350 – 500 
200 – 350 
< 200 
5.54 
5.55 
5.54 
5.59 
 
0 
2.2 
-1.1 
11.7 
- 
(-22.6, 35.0) 
(-23.0, 27.2) 
(-11.7, 41.4) 
 
- 
0.88 
0.93 
0.36 
 
  
HBsAg Status        
Negative 5.61 0 - -    
Positive 5.50 -21.9 (-47.9, 16.9) 0.23    
Unknown 5.55 -13.6 (-36.9, 18.4) 0.36    
 
*Least squares mean estimates of HCV RNA levels at baseline in each stratum averaging other confounding factors 
1
P-value for comparisons of absolute HCV RNA levels within stratum 
†
P-value for increase through time of HCV RNA 
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Figure 4.6 Differences in baseline HCV RNA levels by HCV genotype for individuals 
taking cART 
 
Figure 4.7 Differences in baseline HCV RNA levels by HIV transmission route for 
individuals taking cART 
 
IDU: injecting drug user, MSM: men who have sex with men, Haemo: haemophiliac, Hetero: 
heterosexual  
5.4
5.5
5.6
5.7
5.8
0 1 2 3 4 5
H
C
V
 R
N
A
 (
lo
g
1
0
) 
Time from baseline 
(Years) 
G1 G2-4
26% difference (P=0.0044) 
5.4
5.5
5.6
5.7
5.8
0 1 2 3 4 5
H
C
V
 R
N
A
 (
lo
g
1
0
) 
Time from baseline 
(Years) 
IDU MSM Haemo Hetero Other
43% difference (P=0.065) 
122 
 
When fitting age per 10 years and CD4 cell count on the log2 scale as continuous variables 
neither approached statistical significance (P=0.31 and P=0.81, respectively). 
 
4.4.3.2 Changes over time in HCV RNA 
Among individuals not taking cART, HCV RNA levels increased by a mean of 27.6% per 
year (95% CI 6.1% – 53.5%; P=0.0098). Among individuals taking any form of cART, HCV 
RNA levels remained stable over time, with an estimated non-significant increase of 2.6% 
per year (95% CI -1.1% - 6.5%; P=0.17). When separating the different cART regimens 
HCV RNA levels also remained stable through time among those taking PI-containing and 
NNRTI-containing regimens (non-significant increases of 3.4% per year (95% CI -0.2% - 
7.2%; P=0.068) and 2.0% per year (95% CI -5.2% - 9.7%; P=0.59), respectively). Figure 
4.8 shows the estimated HCV RNA trajectories for each cART category. 
 
Two indicator variables that allowed the change over time in HCV RNA to vary 3 months 
and 12 months after baseline were tested in the model, however, neither approached 
statistical significance (both P>0.4). Further, a quadratic time variable was tested and did 
not approach statistical significance (P>0.5). Therefore, there was no evidence to suggest 
that the change in HCV RNA over time was non-linear.  
 
Figure 4.8 Estimated HCV RNA trajectories by cART regimen 
 
Estimated HCV RNA trajectories match the baseline HCV RNA levels and change through 
time estimated from the mixed model. 
5.4
5.5
5.6
5.7
5.8
5.9
6
6.1
0 1 2 3 4 5
H
C
V
-R
N
A
 (
lo
g
1
0
) 
Time from baseline 
(Years) 
None All PI NN
27.6% increase per year (P=0.0098) 
Average 2.6% increase per year (P=0.17) 
123 
 
Apart from the interaction between cART use and time (P=0.023), interactions between the 
other covariates and time in the mixed model did not reach statistical significance (all 
P>0.15). This finding indicates that the rate of change in HCV RNA over time was affected 
by use of cART in this population but not by the other covariates. For example, although 
the results in Table 4.2 show that baseline HCV RNA is significantly higher for HCV 
genotype 1 versus HCV genotypes 2, 3 and 4, there is no evidence to suggest that the rate 
of change in HCV RNA after baseline differs by HCV genotype, as shown by the parallel 
lines in Figure 4.6. The effect of the significant interaction between cART use and time is 
displayed in Figure 4.8 where individuals that are not taking cART clearly appear to have a 
greater increase in HCV RNA through time compared to those taking cART. 
 
4.4.3 Rapid changes in HCV RNA and reaching a clinically important threshold 
Among the 575 individuals with multiple HCV RNA measurements, rapid increases and 
decreases in HCV RNA through time were defined using the 90
th
 percentiles of the study 
population. For increases, this equated to a 10% increase per year, while for decreases this 
equated to a 7% decrease per year. In multivariable logistic regression adjusting for the 
covariates listed above those that had rapidly increasing HCV RNA were more likely to 
have HCV genotype 1 than 2, 3 or 4 (adjusted odds ratio (aOR) 1.37 (95% CI 1.01 – 1.86; 
P=0.042)), all other covariates were non-significant predictors of rapid HCV RNA increases 
(P>0.15). In a separate model, individuals with rapidly decreasing HCV RNA were less 
likely to reside in Eastern Central or Eastern Europe compared with Southern Europe (aOR 
0.43 (95% CI 0.22 – 0.84; P=0.013) and aOR 0.40 (95% CI 0.17 – 0.94; P=0.035), 
respectively), all other covariates were non-significant predictors of rapid HCV RNA 
decreases (P>0.15). 
 
A clinically important threshold for HCV RNA levels was discussed in the introduction to this 
thesis and briefly at the beginning of this chapter, with 800,000 IU/ml considered to be a 
clinically important titre. In multivariable logistic regression including the whole study 
population adjusting for the covariates listed above, HCV genotype 1 was a significant 
predictor of having an HCV viral load ≥800,000 IU/ml (aOR 1.45 (95% CI 1.17 – 1.77; 
P=0.0006) compared with genotypes 2, 3 and 4), along with residing in Western Europe 
(aOR 1.71 (95% CI 1.24 – 2.34; P=0.0010) compared with Southern Europe). All other 
covariates were non-significant predictors of reaching an HCV viral load of 800,000 IU/ml. 
 
4.4.4 Sensitivity analyses 
A number of sensitivity analyses were performed in order to further examine the increase in 
HCV RNA levels over time and to test the robustness of this finding (summarised in Table 
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4.3). First the patient population was restricted to those with ≥3 HCV RNA measurements 
available. The generalizability of the subset of individuals with ≥3 HCV RNA measurements 
available was assessed in logistic regression. In multivariable logistic regression adjusted 
for the covariates listed above, those with ≥3 HCV RNA measurements were less likely to 
have HCV genotype 1 (aOR: 0.83 (95% CI 0.69 – 1.0; P=0.049) compared with HCV 
genotypes 2-4), were younger (aOR: 0.75 (95% CI 0.65 – 0.86; P<0.0001) per 10 years), 
were more likely to reside in Western Europe (aOR: 4.0 (95% CI 3.1 – 5.1; P<0.0001)) and 
less likely to reside in Eastern Europe (aOR: 0.2 (95% CI 0.1 – 0.5; P<0.0001) compared 
with Southern Europe) and were more likely to be taking cART (aOR: 1.6 (95% CI 1.2 – 
2.1; P=0.0043)), compared with those with <3 HCV RNA measurements. 
 
Similar to the results in the main analysis, although with wider confidence intervals 
reflecting the decreased statistical power, the increase in HCV RNA levels through time 
among those not on cART was 38.9% per year (95% CI 0.7% – 91.8%; P=0.046). For 
those taking any form of cART HCV RNA was stable through time, with an estimated non-
significant increase of 1.2% per year (95% CI -4.7% - 7.4%; P=0.70). For those taking a PI-
based cART regimen, HCV RNA was again stable, with an estimated non-significant 
increase of 3.2% per year (95% CI -3.2% - 10.1%; P=0.33), while for those taking an 
NNRTI-base cART regimen HCV RNA was also stable, with an estimated non-significant 
increase of 0.2% per year (95% CI -33.2% - 56.3%; P=0.92). 
 
A further sensitivity analysis focused on ensuring that poor quality of HCV RNA samples 
was not having an effect on the results presented in this chapter. Performing the main 
analysis of this chapter again in those with at least three HCV RNA measurements, this 
time using only data that were collected from clinical sites and not using data from stored 
samples. By doing so it is possible to exclude the possibility that changes in HCV RNA over 
time could be explained by degradation in stored plasma samples. In this sub-population of 
169 individuals, HCV RNA levels increased 20.9% per year (95% CI -16.9% - 75.9%; 
P=0.32) among individuals not taking cART, although without reaching statistical 
significance as a consequence of the reduced power of this analysis. In those taking any 
cART HCV RNA levels were again remained stable over time, with an estimated non-
significant decrease of 3.1% per year (95% CI -11.1% to 5.6%; P=0.47). 
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Table 4.3 Summary of cART-related effects examined in sensitivity analyses 
Analysis Criteria N included % change in HCV RNA over time (95% CI) 
Main All EuroSIDA HIV/HCV coinfected individuals with 
HCV RNA data available in IU/ml 
1,541 No cART: 27.6% (6.1 – 53.5; P=0.0098) 
Any cART: 2.6% (-1.1 – 6.5; P=0.17) 
PI cART: 3.4% (-0.2 – 7.2; P=0.068) 
NN cART: 2.0% (-5.2 – 9.7; P=0.59) 
Multiple HCV RNA 
measurements 
Only those with ≥3 HCV RNA measurements 258 No cART: 38.9% (0.7 – 91.8; P=0.046) 
Any cART: 1.2% (-4.7% - 7.4%; P=0.70) 
PI cART: 3.2% (-3.2% - 10.1%; P=0.33) 
NN cART: 0.2% (-33.2% - 56.3%; P=0.92) 
Multiple HCV RNA 
measurements reported from 
clinical sites only 
Only those with ≥3 HCV RNA measurements 
reported from clinical sites 
169 No cART: 20.9% (-16.9% - 75.9%; P=0.32) 
Any cART: 3.1% (-11.1% - 5.6%; P=0.47) 
 
PI cART: PI-containing cART regimen, NN cART: NNRTI-containing cART regimen 
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4.5 Discussion 
 
The natural history of HCV RNA 
The analysis in this chapter examined the natural history of plasma HCV RNA in chronically 
infected HIV/HCV coinfected individuals. The main findings of this analysis show that 
among individuals not taking cART, HCV RNA levels increased significantly by 27.6% per 
year. This is in comparison to a non-significant 2.6% increase per year among coinfected 
individuals being treated with any form of cART. Furthermore, similar stability of HCV RNA 
levels was demonstrated when further classifying cART into PI- and NNRTI-based 
regimens, with small non-significant increases in the order of 3.4% and 2.0% per year, 
respectively.  
 
These findings are in agreement with other work on the subject. Fishbein et al
526
, as 
mentioned in the introduction to this chapter, reported small increases in HCV RNA in the 
region of 2% per year for coinfected individuals and 6% per year for HCV monoinfected 
individuals. The Fishbein study included only coinfected IDUs but remains comparable to 
this study as the majority of those included here were also IDU (73%). Unfortunately, the 
Fishbein study does not mention whether the individuals they included were treated with 
cART, however, the similarities between the two sets of results and the low level of HIV 
RNA reported suggest that they were. 
 
In 2000 Thomas et al reported from a study of haemophiliacs in the UK that HCV RNA 
levels were stable in the long run
551
. However, the authors also reported on increasing HCV 
RNA levels during the first four years after HIV seroconversion
551
. One of the main benefits 
of the analysis presented in this chapter is that follow-up was included over a long period of 
time. The median time from the first HIV antibody positive test result to the first HCV RNA 
measurement was 9.2 years (IQR 4.8 – 12.9). Therefore, this analysis presents contrasting 
evidence to suggest that the increase in HCV RNA continues beyond the four year period 
after HIV seroconversion in the absence of treatment for HIV infection, assuming that the 
individuals included here were infected with HCV prior to or at the same time they became 
infected with HIV. For IDUs this is considered reasonable because of the shared 
transmission routes of HIV and HCV, as mentioned in the introduction to this thesis. This is 
considered less likely for MSM and heterosexuals, as sexual transmission of HCV is less 
efficient than that of HIV
313
, however, as the majority of individuals included in this study 
were IDU, invalidity of this assumption is not a major concern. 
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The reported increase in HCV RNA levels among those not taking cART of 27.6% per year 
appears to be a striking finding, although due to the limited power the 95% CI is quite wide. 
However, this analysis has identified an association between treatment with cART and 
stable HCV RNA levels in coinfected individuals. It is unclear how much influence 
increasing HCV RNA levels will have on clinician choice when deciding whether to treat 
individuals for HCV while the association between HCV viral load, disease severity and 
liver disease remains unclear
550;552
. More weight will often be given to other factors, such 
as the level of fibrosis, HCV genotype, IL-28B gene variant and an individual’s readiness 
for treatment
523;553
. However, as pointed out in the introduction to this chapter, with recent 
studies suggesting a link between high HCV viral loads (>500,000IU/ml and 
>800,000IU/ml) and progression to chronic kidney disease
26;549
, increasing HCV RNA could 
potentially become more clinically important in the future. 
 
HCV viral loads were seen to be higher among those with detectible HIV RNA. The least 
squares mean estimate for HCV RNA levels among individuals with detectible HIV RNA 
was 5.59 IU/ml compared to 5.47 IU/ml for those with HIV RNA below 400 copies/ml. This 
equates to 32% lower levels of HCV RNA among those with controlled HIV infection. 
Further, when fitting HIV viral load on a log10 continuous scale it was found to have a 
significant relationship with HCV RNA. A log10 increase in HIV RNA was associated with an 
11% increase HCV RNA, which further supports the finding that treatment with cART can 
help to control HCV infection.  
 
These findings, building on the evidence presented from the Fishbein
526
 study, have 
potential implications for the treatment of individuals with HIV/HCV coinfection. Lower HIV 
viral loads predict lower HCV viral load, which is known to be one of the most important 
predictors of successful HCV treatment outcome with interferon-based therapy
554
. 
Therefore, it may be possible to improve the chances of SVR to HCV treatment by 
controlling HIV viral load and indirectly stabilising HCV RNA levels in the absence of HCV 
therapy. However, a short term transient increase in HCV RNA levels has been reported in 
coinfected individuals initiating cART
555;556
. Further, another study has reported that 
individuals with low CD4 cell counts (<350 cells/mm
3
) at cART initiation experienced a 
continuous increase in HCV RNA levels for the 48 week duration of the study
557
. A recent 
study with a long follow-up period also found that there was a small increase in HCV RNA 6 
months after cART initiation, but a significant decrease in HCV RNA at 70 months after 
cART initiation
540
. 
 
Other studies which have examined the course of HCV RNA levels at three and 12 months 
after the initiation of cART have produced conflicting results
555
. Different studies have found 
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increases and decreases in HCV RNA levels at these time points following cART initiation, 
although often the changes were not statistically significant and the results were based on 
a small number of individuals
558
. It is difficult to examine the potential non-linearity of the 
course of HCV RNA due to cART initiation in EuroSIDA at these time points as 75% of 
individuals in this study were already taking cART at baseline, with a median time on cART 
of 2.7 years (IQR 1.0 – 5.3). Adding interaction terms to the multivariable mixed model 
allowing the rate of change in HCV RNA to differ at 3 and 12 months after baseline were 
excluded from the final model as they were not statistically significant, along with a 
quadratic time variable. Therefore, the current analysis presents no evidence to suggest 
that HCV RNA changes over time are non-linear. However, the ability of this study to detect 
deviations from a linear change over time is limited by the low number of HCV RNA 
measurements available per participant. 
 
Predictors of clinically significant levels of HCV RNA 
HCV genotype 1 was a significant predictor of higher HCV RNA levels at baseline 
compared with genotypes 2, 3 and 4, although changes in HCV RNA over time did not 
differ significantly between genotypes. Similarly, previous studies have shown an 
association between higher HCV RNA levels and HCV genotype 1
524;526
, although this is 
not true of all studies
550;552
. However, these studies have tended to include relatively few 
individuals, especially with genotypes other than G1. Increases in HCV RNA of more than 
10% per year (the 90
th
 percentile) were also found to be associated with HCV genotype 1, 
as was reaching a threshold of 800,000 IU/ml, which has been reported to be a predictor of 
a poor response to interferon-based treatment for HCV
436
. These findings highlight HCV 
genotype 1 as the most difficult for which to control HCV RNA levels. EuroSIDA has 
previously published a comparison of baseline HCV RNA levels by genotype
559
, but this 
study adds important information by considering longitudinal changes in HCV RNA and the 
effect of cART use for genotypes 1, 2 , 3 and 4 in a large number of individuals. 
 
This study found no evidence that HBsAg status influenced HCV RNA levels, baseline HCV 
RNA levels were 22% lower among HBsAg positive individuals compared to HBsAg 
negative individuals (5.50 IU/ml vs. 5.61 IU/ml), but the difference did not reach statistical 
significance. Many previous studies have reported that the presence of HBV may favour 
the clearance of HCV RNA in individuals with multiple chronic viral hepatitis infections
559-
561
, including a previous EuroSIDA study
559
. That this analysis did not find HBsAg status to 
be associated with HCV RNA levels could be explained by a number of reasons. Firstly, 
there are very few individuals included in the study that were HBsAg positive at baseline, 
just 6.2%, which would make it difficult to detect statistically significant differences. 
Conversely, it is possible that among the previously multiply coinfected individuals, 
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suppression of HCV had already occurred as a result of the presence of HBV some time 
ago, that these individuals were HCV RNA negative when testing began and therefore 
excluded from the analysis in this chapter. 
 
When testing interactions between covariates and time, this study found no evidence to 
suggest that the rate of change in HCV RNA differed by any of the factors included in the 
mixed model, other than use of cART. However, the analysis had limited power to detect 
these differences in the rate of change because of the relatively low number of HCV RNA 
measurements per individual. Further studies are required to fully understand the rate of 
change in HCV RNA levels and how it may differ according to genotype or other factors, 
which could potentially be revisited in time when more data are collected. 
 
With increasing interest in HCV coinfection in the HIV population EuroSIDA has committed 
to collecting as much HCV-related data as possible, including HCV RNA, with the aim of 
improving the quality and quantity of this data. Monitoring efforts have since been tailored 
to focus on sites with HIV/HCV coinfected individuals and monitors are instructed to collect 
all previously recorded HCVAb, HCV RNA and HCV genotype data that may have 
previously been missed during data collection. More recently, EuroSIDA has begun to 
recruit a new cohort of participants. In keeping with the HIV/HCV coinfection research 
agenda it was decided to recruit coinfected individuals only and data on HCV RNA, HCV 
genotype along with liver fibrosis and a range of fibrosis biomarkers will collected from 
entry into the study for the new cohort. 
 
4.5.1 Limitations 
The analysis presented in this chapter has several limitations, most importantly it must be 
noted that there were relatively few individuals included in EuroSIDA with multiple HCV 
RNA measurements. Of the 1,541 individuals included in this analysis, 575 had at least 2 
HCV RNA measurements and contributed to the estimates of changes over time in HCV 
RNA. At least 2 measurements are required per individual in order to estimate not only the 
change over time in HCV RNA but interactions between time and the other covariates. The 
reduced number of individuals with at least 2 HCV RNA measurements will have had an 
effect on the model’s ability to detect these interactions. Further, there were 258 individuals 
included with at least 3 HCV RNA measurements. At least 3 measurements are required 
per individual in order to estimate non-linear trends in HCV RNA. Therefore, the relatively 
few individuals with at least 3 measurements would have had an effect on the model’s 
ability to describe non-linear trends in HCV RNA. Many more measurements per person 
would ideally be required to accurately describe these patterns. As such I have focused this 
analysis on long term changes in HCV RNA which assume a linear trend over time, 
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allowing for random variation around the mean. Although there are valuable conclusions to 
draw from the analysis, more data per person would have allowed me to perform more 
detailed analyses. 
 
Another limitation of this analysis is that HCV RNA data were included from both stored 
samples and routine clinical care. While there is the possibility that stored samples could 
degrade over time during storage it is also possible that data from stored samples and 
clinical care are inherently different. Whereas collection of a stored sample does not 
necessarily reflect a change in the clinical condition of the patient, it is likely that a clinician 
would decide to perform an HCV RNA test as part of routine care as a response to a 
change in the condition of the patient. However, sensitivity analysis using only the data that 
were collected during the clinical setting resulted in similar conclusions to the main analysis 
of increasing HCV RNA in those not taking cART and stability among those that were, 
indicating that this bias is not a major concern. 
 
Further limitations relate to which data are collected in EuroSIDA. The route of HIV 
transmission is collected but the route and date of HCV transmission are not. Therefore I 
have assumed the same route of transmission applies to both viruses. As the majority of 
people included in this analysis are IDU, it is probably reasonable to assume that they also 
acquired HCV via this medium due to the effectiveness of HCV to transmit via blood to 
blood contact, as was discussed in the introduction to this thesis. However, it is less likely 
to be the case in MSM due to the less frequent transmission of HCV during sexual contact. 
 
4.5.2 Conclusion 
The analysis in this chapter demonstrated that, while HCV RNA levels increased during 
long-term follow-up in HIV/HCV coinfected individuals not taking cART, among those who 
had initiated cART HCV RNA levels were stable over time. This and the fact that there was 
an association between HCV RNA and HIV RNA suggest that earlier treatment with cART 
could help to prevent increases in HCV RNA levels in HIV/HCV coinfected individuals. 
Further, HCV genotype 1 was associated with higher baseline HCV viral load, increased 
odds of having a rapid increase in HCV RNA and an HCV viral load ≥800,000 IU/ml. 
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Chapter 5 
 
Temporal changes and regional differences in the 
uptake of treatment for HCV among HIV/HCV coinfected 
individuals in EuroSIDA 
 
5.1 Introduction 
 
The substantial declines in HIV-related mortality, as a consequence of the introduction of 
combination antiretroviral therapy (cART), have seen liver-related mortality assume 
increasing importance among HIV-positive individuals
562-564
. Progression of liver disease is 
common with hepatitis C virus (HCV) infection and known to be accelerated in the 
presence of HIV
413;565
. Treatment for HCV offers the possibility of eradicating HCV within a 
defined treatment period. This is potentially advantageous for the subsequent management 
of the individual with HIV and every coinfected individual should therefore be considered for 
treatment when the benefits of therapy outweigh the risks. 
 
As discussed in Chapter 2 Section 2.2.6, development of new direct-acting antivirals 
(DAAs) for treatment of HCV has been a fast moving area of research over the past few 
years. As such, many second line DAAs with fewer side effects and excellent cure rates are 
now available, including interferon-free regimens, subject to cost
2
. However, the analysis 
presented in this chapter focuses on data collected over the period just before the release 
of second line DAAs, when interferon-based treatment was still the standard of care and 
first line DAAs boceprevir and telaprevir were the state of the art, known as triple therapy. 
Consequently, the introduction and discussion relating to treatment for HCV in this chapter 
refers to the period around the year 2011. 
 
5.1.1 European treatment guidelines 
A detailed description of the evolution of care for HCV is given in Section 2.2.6 of the 
introduction of this thesis. In short, treatment of HCV has traditionally revolved around the 
use of interferon (IFN), which is a natural cellular protein that can induce an antiviral state 
in target cells and recruit immune cells to help fight infection
367
. The first clinical trials of IFN 
for treatment of HCV monoinfection were published in the mid-1980s, with poor treatment 
response rates of approximately 10-15%
367
. However, refinement of IFN-based therapy 
meant that by the mid-1990s, approximately when follow-up in EuroSIDA began, HCV 
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positive individuals were treated with IFN plus ribavirin with cure rates in monoinfection 
approaching 40% and 30% in HIV/HCV coinfection
428
.  
 
The final refinement of IFN-based therapy was a switch to pegylated-IFN (peg-IFN) plus 
ribavirin. Peg-IFN is a slow release formulation of IFN which can be administered once a 
week. Clinical trials in the early 2000s showed that this new formulation cured 
approximately 50-60% of HCV monoinfected and up to 40% of HIV/HCV coinfected 
individuals
428-430
. By 2011, the first generation of direct-acting antivirals (DAAs), boceprevir 
and telaprevir, for treatment of HCV were coming to market. These new drugs introduced 
an era of triple therapy, peg-IFN plus ribavirin and a DAA, and saw cure rates approach 
75% for easy-to-treat HCV genotype 1 infected individuals
437;441;442
.  
 
In 2011, European AIDS Clinical Society (EACS) guidelines recommended that all 
HIV/HCV coinfected individuals with significant liver fibrosis should be considered for HCV 
therapy given their increased risk of liver-related death
1
. Information on liver fibrosis staging 
is important for making therapeutic decisions in coinfected individuals; however, liver 
biopsy is no longer mandatory for considering treatment of chronic HCV
1
, as discussed in 
Section 2.2.5.3. Interferon-based therapy was particularly recommended for individuals with 
a high likelihood of achieving sustained virological response (SVR), such as those with 
HCV genotypes 2 or 3, genotype 1 patients with an IL28B CC genotype or genotype 1 
patients with a previous relapse under dual therapy which could be retreated with triple 
therapy (telaprevir or boceprevir, plus interferon and ribavirin)
1
. 
 
Where fibrosis staging was available, whether from liver biopsy or Fibroscan
®421
, for results 
demonstrating lack of or minimal liver fibrosis (METAVIR F0-F1
420
), regardless of HCV 
genotype, treatment for HCV could be deferred
1
. While this was also the case for 
individuals with low chances of SVR with interferon-based treatments, for whom improved 
treatment options were expected to become available in the coming years
1
. Individuals with 
genotype 1 infection who could potentially be treated with DAA-based therapy but had 
expected adherence issues could also have had treatment deferred until easier to take, 
better-tolerated second line DAAs become available
1
. In such cases, fibrosis assessment 
should have been carried out periodically to monitor fibrosis progression
1
. 
 
When fibrosis staging showed significant liver fibrosis or worse (F2-F4) treatment was 
recommended but could have been deferred according to prior treatment history
1
. HCV 
treatment naïve individuals with easier to treat genotypes 2 and 3 were recommended to 
start dual therapy
1
, while those with genotype 1 were recommended to start triple therapy, 
as shown in Figure 5.1
1;439
. The only exception being those who were non-responders to 
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previous therapy, in whom it may be beneficial to wait for future more efficacious treatment 
options
1
. 
 
HCV treatment should be preferentially offered to individuals with controlled HIV infection or 
those where HCV is detected early in the course of HIV infection
1
. In individuals where 
HCV infection is detected before the initiation of cART is necessary, treatment for HCV is 
advised
1
. For individuals with CD4 cell counts below 500cells/mm
3
 but above 350cells/mm
3
 
early initiation of ART is recommended along with HCV treatment in order to maximise the 
potential for a successful treatment outcome
1;450;566
. However, in individuals with significant 
immunodeficiency categorised by CD4 cell counts below 350cells/mm
3
, the CD4 cell count 
should be improved using cART prior to commencing anti-HCV treatment
1;450;566
. 
 
However, data from the APRICOT study of the efficacy of dual HCV therapy in HIV/HCV 
coinfected individuals
436
 have shown that HCV therapy can be effective at lower CD4 cell 
counts. Opravil et al
567
 showed that for individuals treated with optimum dual HCV therapy 
and well-controlled HIV infection, the rates of SVR were similar between those with CD4 
cell counts below 200cells/mm
3
 and those above 350cells/mm
3
. With the exception of HCV 
genotype 1 where SVR rates were 13% in those with baseline CD4 below 200cells/mm
3
 
and 32% in those with baseline CD4 above 350cells/mm
3
 (Figure 5.2)
567
. 
 
 
Figure 5.1 Management of HIV/HCV coinfected patients with HCV genotype 1 
according to fibrosis stage and prior treatment outcome
439
 
   
 
 
 
 
 
 
Image not available due to copyright restrictions 
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Figure 5.2 SVR rates according to baseline CD4 cell count strata for all patients (A), 
patients with genotype 1 (B), and patients with genotype 2/3 (C)
567
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EACS guidelines in 2011 also stated that individuals with a CD4 relative percentage greater 
than 25% were more likely to achieve SVR than those with a lower CD4 percentage
1
. The 
same study by Opravil et al
567
 mentioned above also showed a clear trend of greater rates 
of SVR with higher levels baseline CD4 percentage. Specifically, for those taking optimal 
dual therapy the rates of SVR were 33%, 36%, 41% and 47% for those with baseline CD4 
percentages of 2.5-19.1, 19.1-25.0, 25.0-32.1 and 32.1-69.3 respectively. 
 
5.1.2 HCV drug pipeline – Direct-acting antivirals (DAAs) 
Although the data analysed in this chapter include follow-up to 2011, when the gold 
standard of treatment for HCV infection was dual therapy with peg-IFN and ribavirin (RBV), 
it is important to consider which new drugs are on the horizon for the treatment of HCV as 
the potential availability and increased efficacy of these new drugs are factors that may 
have influenced clinicians to defer treatment over the study period. 
 
As mentioned above and in more detail in Section 2.2.6, the approval of triple therapy for 
HCV with telaprevir or boceprevir and peg-IFN/RBV increased the cure rate among 
HIV/HCV coinfected individuals. However, triple therapy remains unsuitable for individuals 
either intolerant of or with contraindications to IFN or RBV
445
. Therefore, new therapeutic 
approaches offering improvements in efficacy, safety and tolerability are needed to address 
the currently unmet medical need
445
. Fortunately, research in the area of HCV treatment is 
fast-moving and it is hoped that new direct-acting antivirals (DAAs) will be able to fill the 
current gaps in available therapy
445
. 
 
More than 60 DAAs are now in clinical trials with a much greater number in preclinical 
development
445
. While data from early phase clinical trials are scarce for HIV/HCV 
coinfected individuals, there are a number of published studies of HCV-monoinfected 
individuals. The inclusion of telaprevir to peg-IFN/RBV has seen SVR rates increase from 
45% to 75% and shortened the duration of treatment from 48 weeks to 24 weeks in over 
half of patients
440
. While the inclusion of boceprevir to peg-IFN/RBV has seen SVR rates 
increase from 40% to 68%
437
, with important similarly sized improvements seen in 
treatment of previously treated responder-relapsers
441;442
.  
 
The most promising form of triple therapy in development currently includes TMC-435, 
which is another potent protease inhibitor
445
. In a large phase II clinical trial of treatment-
naïve HCV genotype 1 individuals treated with TMC-435/peg-IFN/RBV there was 
documented SVR in over 90% of patients
568
. This combination also appears to be very well 
tolerated with no significant drug-related toxicity or direct drug interactions
568
. Further, 
similarly high SVR rates have been observed in phase II studies in HCV genotype 1 
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patients for triple therapy with the following experimental protease inhibitors; BI201335
569
, 
MK7009
570;571
, and the NS5A inhibitor BMS-790052
572
. 
 
Triple therapy incorporating a new DAA fails when HCV variants that are resistant to the 
protease inhibitor are not fully supressed by peg-IFN/RBV. In this case quadruple therapy 
has been trialled, including two different DAAs without cross-resistance and peg-
IFN/RBV
445
. In a small phase II study of the DAA combination of protease inhibitor BMS-
650032 and NS5A inhibitor BMS-790052 plus peg-IFN/RBV, virological breakthrough was 
prevented in all 10 individuals with 100% SVR
573
. However, while the newer triple and 
quadruple treatment combinations have better efficacy, safety and tolerability than the first 
wave of DAAs telaprevir and boceprevir, they are still not able to cater for individuals with 
contraindications to peg-IFN/RBV, with the real goal of HCV drug development targeting 
IFN-free regimens
445
. 
 
Development of a multiple DDA regimen for treatment of HCV is based on the lessons 
learned from HIV drug development. Different DAAs which target different steps of HCV 
viral replication are combined to attack the virus from multiple angles and increase viral 
suppression and reduce the emergence of resistance
445
. The first study of IFN-free 
combinations of DAAs in individuals with chronic HCV was the INFORM-1 study
574
. This 
proof of concept study, including 87 individuals with HCV genotype 1, demonstrated 
excellent viral suppression and prevented the emergence of resistance to either compound 
when treated with the nucleoside polymerase inhibitor meracitabine and the NS3/4A 
protease inhibitor danoprevir
574
. However, this was not a curative study and all patients 
rolled over onto peg-IFN/RBV after 14 days of DAA treatment. 
 
More recently, promising results from the combinations of a number of DAAs have led to 
rapid progress in this area. The nucleoside polymerase inhibitor sofosbuvir (formerly known 
as GS-7977) has been combined with the NS5A inhibitor daclatasvir (formerly BMS-
790052), with or without RBV with remarkable results
575;576
. Cure rates ranged from 88% to 
100% after 12 or 24 weeks of treatment, regardless of prior treatment history, ribavirin use 
or HCV genotype
575;576
. Unfortunately, this combination looks to be left behind as Gilead 
(the owner of sofosbuvir) is looking to create a fixed dose combination with its own NS5A 
inhibitor ledipasvir.  
 
The COSMOS phase II study of 167 individuals is pairing simeprevir (formerly TMC435) 
and sofosbuvir for 12 and 24 weeks, with and without RBV
577
. Again early results were 
outstanding, at post treatment week 8 (SVR-8) 96% of those receiving triple therapy and 
92% of those receiving dual therapy without RBV were undetectable
577
. So far 24 
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individuals have been followed to post treatment week 12 (SVR-12) and all were 
undetectable
577
. 
 
The Gilead owned combination of sofosbuvir plus ledipasvir with or without RBV has also 
produced excellent results. In the ELECTRON trial, 100% of 25 treatment-naïve and 10 
null-responder participants were cured after 12 weeks of treatment including RBV
578
. 
Sofosbuvir and ledipasvir are now available as a co-formulation in a single fixed-dose pill. 
In the LONESTAR phase II trial 100% of individuals treated with the fixed-dose combination 
for 12 weeks maintained undetectable HCV RNA 4 weeks after finishing treatment
579
. While 
40/41 (97.6%) treated for 8 weeks remained undetectable 8 weeks after treatment
579
. The 
fixed-dose combination has since entered phase III trials. 
 
Further, AbbVie’s quad regimen containing ABT-450/r, a boosted HCV protease inhibitor 
co-formulated with ABT-267, an NS5A inhibitor, plus ABT-333, a non-nucleoside 
polymerase inhibitor, and RBV has resulted in almost universal cure rates among 
treatment-naïve and null-responder patients
580
. Bristol-Myers Squibb are also developing a 
three drug IFN/RBV-free in-house combination containing daclatasvir, a protease inhibitor 
(asunaprevir), and a non-nucleoside polymerase inhibitor (BMS-791325), with SVR rates 
almost 100% in early stage trials
581
. 
 
The above review of DAAs drug development reflects the state of drug development in 
2011, when follow-up for this analysis ended. Consequently, some of the drugs mentioned 
are now approved for treatment of HIV/HCV coinfection in Europe and the United States. 
The full list of current state of the art treatments for HCV are discussed in Section 2.2.6.2. 
 
5.1.3 Previous studies of HCV treatment uptake 
Despite the recommendations detailed above, the extent to which HIV/HCV coinfected 
individuals are eligible for and start HCV therapy is not well documented in Europe, with 
previous studies from 2003-2006 showing a low proportion of individuals initiating therapy. 
In a small study by Fleming et al in 2003 the authors found that eligibility for treatment was 
low, out of 149 individuals with HIV/HCV coinfection just 30% were eligible for treatment, 
citing missed clinic visits, active psychiatric illness, active drug or alcohol use, 
decompensated liver disease, or medical illness as the main barriers to treatment
444
. 
 
A single cohort study from the Swiss HIV cohort by Rauch et al in 2005 also found low 
eligibility for HCV treatment among HIV/HCV coinfected individuals
443
. Among 107 
chronically infected HIV/HCV individuals the authors found that 77% were not eligible for 
interferon-based treatment, with 73% of ineligible individuals having more than one 
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exclusion criteria and 33% having more than three
443
. The most frequent reasons given for 
exclusion were low CD4 cell counts, cytopenia, hepatic disorders other than hepatitis C, 
psychiatric illnesses, uncontrolled addiction, and poor adherence. Further, among the 25 
individuals eligible for treatment 16 (64%) decided not to proceed, mainly due to fear of 
side effects
443
. 
 
A previous EuroSIDA study in 2006 by Mocroft et al documented increasing use of HCV 
treatment, however, its uptake remained scarce with variability across the regions of 
Europe
582
. By including 2,356 individuals enrolled in EuroSIDA and positive for HCVAb, the 
authors found that there was a 38% increase in the incidence of uptake of HCV treatment 
from before 1998 to 2004, but that in total just 7.6% of individuals had started interferon-
based therapy
582
. However, as this study was only able to categorise HCV status using 
HCVAb testing and not HCV RNA, it is likely that the proportion of individuals eligible for 
treatment had been underestimated, as the denominator will have been inflated by 
individuals with aviremic HCV infection, who were HCVAb positive but did not require 
treatment as they had already cleared the virus. 
 
In the largest European study to date including 6,433 HIV/HCV coinfected individuals, the 
COHERE collaboration in 2012 reported that 780 (12%) were treated for HCV
583
. However, 
this study also included a large proportion of individuals (71%) that were categorised as 
HCV positive on the sole basis of an HCVAb test, meaning that the proportion treated is 
likely to have been underestimated for the same reasons as the above previous EuroSIDA 
study. Further, although this study included a large number of individuals the median length 
of follow-up per individual was quite short at just 72 months (IQR: 39 - 108)
583
. 
 
Outside Europe the rates of treatment uptake also appear to be low. Three studies from the 
United States using the Veterans Affairs National Patient Care Database have documented 
modest increases in the proportion of eligible HIV/HCV coinfected individuals receiving 
interferon-based treatment. The first study in 2003 by Fultz et al found a high level of HCV 
treatment contraindications, including both medical and psychiatric comorbidities
584
. Of 65 
coinfected individuals with indications for HCV therapy and free of contraindications for 
treatment, just 3% received interferon-based therapy
584
.  
 
The second study in 2006 by Butt et al included 6,502 coinfected individuals of which 12% 
were prescribed HCV treatment
585
. The authors state say that those of black race, Hispanic 
race, drug users, those with anaemia, bipolar disorder, major depression and mild 
depression were less likely to start treatment from fitting a multivariable logistic 
regression
585
. A more recently published study in 2012 by Kramer et al of 99,166 HCV 
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monoinfected individuals with detectable HCV viremia also found that 12% had received 
interferon-based treatment, with 55% of those going on to achieve SVR
586
. 
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5.2 Aims 
 
The aims of this chapter were to describe temporal changes and regional differences in the 
uptake of anti-HCV therapy among those with chronic HCV/HIV coinfection enrolled in the 
EuroSIDA cohort, and to identify factors associated with treatment uptake across Europe. 
One of the strengths of this analysis is the fact that EuroSIDA includes a large number of 
HIV/HCV coinfected individuals with well-characterised chronic HCV infection via HCVAb 
and HCV RNA testing. Further, this study includes a long period of follow-up, spanning 12 
years, and can document how the incidence of treatment uptake has changed over time 
comparing the regions of EuroSIDA. It is also of particular interest to document the rate of 
completion of HCV treatment among those that receive therapy and factors that are 
associated with completing treatment. 
 
A further aim of this study was to identify whether individuals with significant liver fibrosis 
(those with METAVIR stages ≥F2), in the most urgent need of treatment, have been 
selected for treatment. This is also an important feature of this analysis as no other 
European study of HCV treatment uptake has been able to categorise the importance of 
liver fibrosis when selecting individuals for treatment. 
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5.3 Methods 
5.3.1 Patient selection 
The D35 update of the EuroSIDA database included 16,594 individuals from 105 centres 
across Europe, Israel and Argentina. However, after consultation with Marcelo Losso, the 
EuroSIDA primary investigator for Argentina, it was decided that Argentina would not be 
included in these analyses as they were likely to include few individuals treated for HCV 
and the focus of the study is treatment uptake in Europe. In addition, as enrolment of 
EuroSIDA cohort IX had just initiated at the time of the D35 update, these individuals were 
excluded as they had no available follow-up. Figure 5.3 shows the breakdown of how 
individuals were selected for inclusion in this study. There were 16,097 individuals in 
EuroSIDA after excluding those from Argentina and cohort IX, of whom 4,224 had at least 
one HCVAb positive test. Of those 2,633 had data available on HCV RNA levels and 2,008 
(76.2%) of these were positive. Finally, there were 1,984 coinfected individuals who had yet 
to receive treatment for HCV and were eligible for inclusion in this analysis. 
 
Data on alanine transaminase (ALT), aspartate transaminase (AST) and platelet counts 
have been collected in individuals enrolled in the cohort since 1999 and 2005, respectively, 
and were used to calculate the AST to platelet ratio index (APRI
425
) as a marker for liver 
fibrosis. Data on liver biopsy and Fibroscan
®421
 have been collected since 2010, with 
clinical sites requested to list all previous test results where liver biopsy was graded using 
the METAVIR scoring system
420
, and return the histological report for internal validation. 
Plasma hyaluronic acid (HA) has been measured in all HCVAb positive individuals with 
stored plasma samples available, as has been described in Chapter 3 Section 3.1.2.2. 
 
5.3.2 Statistical methods 
As individuals included in this analysis were both HCVAb and HCV RNA positive, baseline 
was defined as the date of the first HCVAb/HCV RNA positive test result or recruitment to 
EuroSIDA, whichever occurred later. In analysis with the outcome of HCV treatment 
initiation, individuals are followed until their last visit, death or the date of starting HCV 
therapy. Throughout this analysis treatment for HCV is defined as treatment with at least 
interferon, although interferon-free regimens are today on the horizon they were not in 2011 
when follow-up for this study ended. The gold standard for HCV treatment over the study 
period was peg-IFN/RBV
566
, however, in earlier years interferon may have been given in its 
non-pegylated form. No distinction was made between the two possible formulations of 
interferon.  Interferon may also have been previously prescribed without RBV, but IFN 
would have formed the backbone of all HCV treatment regimens over the study period
1
. 
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Figure 5.3 Inclusions criteria; baseline is defined as the date of first HCVAb/HCV 
RNA positive test result or recruitment to EuroSIDA 
 
 
 
 
Trends over time in starting HCV treatment were described using univariable Poisson 
regression models. Factors associated with HCV treatment uptake were investigated using 
univariable Poisson regression and those that were significant at the P<0.1 level were 
included in a multivariable model. The following explanatory variables were considered with 
time-updated variables noted in brackets: 
 
 Age/Sex/Race 
 Region of EuroSIDA (see Chapter 3 Section 3.1.1) 
 HIV transmission risk group 
 AIDS diagnosis before baseline 
 CD4 cell count (time-updated) 
 HIV RNA (time-updated) 
 HCV RNA (time-updated) 
 HCV genotype 
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 HBsAg status (time-updated) 
 cART status (time-updated, defined as currently receiving ≥3 ARVs of any class 
(yes/no)) 
 Calendar year 
 ALT/AST levels (time-updated) 
 
5.3.2.1 Fibrosis markers 
Fibrosis levels among treated and untreated individuals have been summarised. A study by 
Thein et al
389
 in 2008 found that the rate of progression of fibrosis staging is constant in 
HIV/HCV coinfected individuals, reporting annual transition probabilities of progressing to 
the next fibrosis grade of approximately 11%. Bearing this in mind, the last available 
fibrosis marker data was included up to two years prior to HCV treatment from individuals 
treated for HCV, along with the last available measurement in those that remain untreated. 
The proportions of treated and untreated individuals with significant fibrosis were compared 
using a combined definition of ≥F2 fibrosis from biopsy and Fibroscan®, HA > 100ng/ml and 
an AST to platelet ratio index (APRI) > 1.5, which have been shown to be accurate markers 
of significant fibrosis
587;588
. A Fibroscan
®
 reading of >7.6kPa was used to identify ≥F2 
fibrosis in accordance with a recent review of the subject
589
. 
 
5.3.2.2 Treatment completion 
A full course of treatment with interferon was defined according to each individual’s HCV 
genotype; see Chapter 2 Section 2.2.6. A full course is considered to have been completed 
after a minimum of 48 weeks of exposure to IFN for genotype 1 or 4 and a minimum of 24 
weeks exposure for genotype 2 or 3
566
. However, because in the clinical setting treatment 
duration can occasionally be shorter than the standard 24/48 weeks, individuals who 
completed at least 80% of the expected minimum treatment duration were also considered 
to have completed a full course of therapy (i.e. 38.4 weeks for genotype 1 or 4 and 19.2 
weeks for genotype 2 or 3), which is an established method also used in other studies of 
HCV treatment duration
586;590
. The median length of treatment duration by HCV genotype, 
along with the percentage of individuals completing a full course of treatment, were 
determined in individuals with known genotype and sufficient follow-up to have completed 
80% of their treatment duration. 
 
Predictors of completing a full course of HCV therapy were identified using a multivariable 
logistic regression model adjusted for the factors listed below: 
 
 Age/Sex/Race 
 HIV transmission risk group 
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 Region of EuroSIDA (see Chapter 3 Section 3.1.1) 
 cART use at treatment initiation 
 AIDS diagnosis before baseline 
 HCV genotype 
 CD4 cell count at treatment initiation 
 HIV viral load at treatment initiation 
 HCV viral load at treatment initiation 
 Calendar year of treatment initiation 
 
Where cART use at treatment initiation represents whether an individual was receiving 
cART (defined as ≥3 ARVs of any class) at the initiation of treatment for HCV. CD4 cell 
count, HIV viral load and HCV viral load at treatment initiation are the closest measurement 
prior to treatment initiation up to 6 months prior. 
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5.4 Results 
5.4.1 Generalizability and baseline characteristics 
The median follow-up time for the individuals included in this analysis was 168 months 
(IQR: 121 – 204 months). During the patient selection process for this analysis 1,591/4,224 
HCVAb positive individuals were excluded as they did not have HCV RNA data available. 
In a multivariable logistic regression model adjusted for the factors listed above, HCVAb 
positive individuals without HCV RNA data available, had lower CD4 cell counts at baseline 
(adjusted odds ratio (aOR): 0.91 (95% C.I. 0.87 – 0.96; P=0.0002) per doubling), were 
more likely to reside in Eastern Europe (aOR: 6.45 (95% C.I. 4.63 – 8.99; P<0.0001) 
compared with Southern Europe), and were recruited to EuroSIDA in more recent years 
(aOR: 1.09 (95% C.I. 1.07 – 1.12; P<0.0001) per year later), compared with those positive 
for HCV RNA and included in the study. 
 
Table 5.1 shows characteristics of the 1,984 coinfected individuals included in this analysis 
at baseline, and at the date of HCV treatment initiation or last follow-up for those not 
starting treatment. The populations of treated and untreated individuals were well matched 
on age at baseline, while a higher proportion of treated individuals were male (72.6% vs. 
67.9%; P=0.048). A higher proportion of individuals that were treated for HCV resided in 
Southern Europe (41.1% vs. 33.0% for untreated individuals; global region P=0.0039) and 
belonged to the men who have sex with men (MSM) HIV transmission risk group (12.1% 
vs. 8.4%). A lower proportion of treated individuals belonged to the injecting drug use (IDU) 
HIV transmission risk group (68.9% vs. 74.5%; global transmission P=0.09). A higher 
proportion of individuals who went on to receive HCV treatment as opposed to remaining 
untreated were on cART at baseline (26.4% vs. 21.1%; P=0.014), consequently there was 
a higher baseline CD4 cell count in these individuals (median 290 cells/mm
3
 (IQR 158.5 – 
429) vs. 269 (145 – 400); P=0.017) and a higher proportion with undetectable HIV RNA 
(defined as <500copies/ml) (34.3% vs. 26.8%; P=0.0013). 
 
At the time of HCV treatment or last follow-up, ALT levels were higher in treated individuals 
(data available in 409 vs. 1,308) (median 76 (IQR 49 – 120) vs. 44 (37 – 49) U/L for 
untreated individuals; P<0.0001), as were CD4 cell counts (median 479 cells/mm
3
 (IQR 349 
– 650) vs. 391 (227 – 614) for untreated individuals; P<0.0001). The proportion of 
individuals with HIV RNA <500 copies/ml was also higher among those treated for HCV 
(80.3% vs. 71.2%; P<0.0001). 
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Table 5.1 Patient characteristics at baseline and the date of last follow-up or HCV treatment initiation 
 
% 
At Baseline At Treatment or last follow-up 
Untreated 
(N=1483) 
Treated 
(N=501) 
P-value*
 
Untreated 
(N=1483) 
Treated 
(N=501) 
P-value*
 
Age Med (IQR) 33 (28 - 38) 32 (28 - 37) 0.29 44 (37 - 49) 41 (35 - 46) <0.0001 
Male 67.9 72.6 0.048    
White 91.5 93.1 0.27    
Region of Europe South 
West Central 
North 
East Central 
East 
33 
21.6 
17.5 
16.2 
11.7 
41.1 
18.1 
12.9 
17.7 
10.3 
0.0039    
HIV transmission group MSM 
IDU 
Heterosexual 
Other 
8.4 
74.5 
10.4 
6.7 
12.1 
68.9 
11.7 
7.4 
0.09    
HCV genotype 1 
2 
3 
4 
Unknown 
45.2 
2.8 
23.4 
11.9 
16.7 
41.2 
2.2 
28.8 
13.5 
14.5 
0.084    
HBsAg status Negative 
Positive 
60.8 
4.3 
65.1 
4.2 
0.21 85.0 
8.3 
88.7 
6.2 
0.12 
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Unknown 34.9 30.8  6.7 5.2  
Started cART 21.1 26.4 0.014 86.7 86.3 0.85 
ALT N 
Med (IQR) 
123 
51 (26 - 83) 
38 
49.5 (30 - 106) 
0.44 1308 
44 (37 - 49) 
409 
76 (49 - 120) 
<0.0001 
CD4 N 
Med (IQR) 
1482 
268.5 (145 - 400) 
501 
290 (158.5 - 429) 
0.017 1482 
391 (227 - 614) 
490 
479 (349 - 650) 
<0.0001 
HIV RNA <500 copies/ml % (95% CI) 26.8 (24.5 – 29.1) 34.3 (30.2 – 38.5) 0.0013 71.2 (68.8 – 73.5) 80.3 (76.7 – 83.9) <0.0001 
HCV RNA N 
Med (IQR) 
1483 
5.75 (5.17 - 6.23) 
501 
5.76 (5.21 - 6.21) 
0.89 1470 
5.83 (5.18 - 6.30) 
430 
5.80 (5.36 - 6.29) 
0.64 
 
ALT: alanine transaminase; cART: combination antiretroviral therapy; CI: confidence interval; HBsAg: hepatitis B surface antigen; IDU: injecting drug 
user; IQR: interquartile range; MSM: men who have sex with men. 
ALT, CD4 cell count, HIV RNA and HCV RNA are the closest measurement prior to baseline, treatment or last follow-up up to 6 months prior. 
*P-values from Kruskal-Wallis test for difference in population distribution 
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5.4.2 Temporal changes in the uptake of HCV treatment 
The median date of last follow-up for the study population was May 2011 (IQR: Sep 2005 – 
Nov 2011). By the end of follow-up, 501/1,984 (25.3%) coinfected individuals included in 
this study had received treatment for HCV with IFN/RBV or at least IFN, over a total of 
18,303 person-years of follow-up (PYFU), giving an overall crude incidence of treatment 
initiation of 2.74 per 100 PYFU (95% C.I. 2.50 – 2.97). 
 
Figure 5.4 displays how the incidence of treatment initiation has changed over time from 
1998 to 2010. The overall incidence of HCV treatment in EuroSIDA increased from 0.33 
(95% C.I. 0.16 – 0.50) per 100 PYFU in 1998 to 5.93 (4.49 – 7.38) in 2007 before it 
decreased to 3.78 (2.50 – 5.07) in 2009. Dividing the follow-up period into two sections, 
prior to the peak observed in 2007 and after 2007, univariable Poisson regression testing 
for temporal trends found that the incidence of treatment initiation increased by 27% per 
year between 1998 and 2007 (incidence rate ratio (IRR): 1.27 (95% C.I. 1.23-1.31; 
P<0.0001)), while in the period after 2007 there was a 12% decline per year in the 
incidence of treatment (IRR: 0.88 (0.79-0.98; P=0.020)). 
 
Table 5.2 shows univariable and multivariable Poisson regression estimates for predictors 
of HCV treatment initiation. In the multivariable model, individuals who started treatment 
were more likely to reside in Southern Europe (adjusted incidence rate ratio (aIRR): 1.38 
(95% C.I. 1.06-1.82; P=0.019) compared to Western Europe) and belong to the MSM HIV 
transmission risk group (aIRR: 1.36 (1.00-1.83; P=0.046) compared with IDU), compared 
with those not yet treated. Individuals that have been treated for HCV were also more likely 
to have current CD4 cell counts >350 cells/mm
3
 (aIRR: 1.33 (1.06-1.67; P=0.013) 
compared to those with CD4 cell counts between 200 and 350 cells/mm
3
) and were less 
likely to have CD4 cell counts <200cells/mm
3
 (aIRR: 0.42 (0.27-0.65; P=0.0001) compared 
to people with CD4 cell counts between 200 and 350cells/mm
3
), compared with untreated 
individuals.  
 
Individuals treated for HCV were more likely to have current HIV RNA levels below 500 
copies/ml (aIRR: 1.39 (95% C.I. 1.07-1.80; P=0.012) compared with HIV RNA >500 
copies/ml), which along with the higher CD4 cell counts seen in treated individuals, 
indicates a better rate of well-controlled HIV infection through the use of cART compared 
with untreated individuals. Treated individuals were also more likely to have current HCV 
RNA >800,000 IU/ml (aIRR: 1.21 (1.00-1.47; P=0.049) compared with HCV RNA between 
616 and 800,000 IU/ml) and raised ALT levels (upper normal range (uNR) < ALT < 3 times 
uNR, aIRR: 2.33 (1.83-2.96; P<0.0001); ALT > 3 times uNR, aIRR: 3.56 (2.61-4.86; 
P<0.0001) compared with ALT within the normal range), than untreated individuals. 
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Figure 5.4 Temporal changes in the uptake of treatment for HCV 
 
 
IRR: incidence rate ratio; IRR calculated from Poisson regression 
 
Figure 5.5 Temporal trend in the uptake of HCV treatment adjusted for the factors in 
Table 5.2 
 
0.08 
0.34 
0.50 
0.78 
0.76 
0.64 
0
0.2
0.4
0.6
0.8
1
1.2
A
d
ju
st
ed
 in
ci
d
en
ce
 r
at
e 
ra
ti
o
 (
9
5
%
 C
I)
 
Year 
150 
 
Table 5.2 Poisson regression parameter estimates for factors associated with HCV treatment initiation 
 
 
Variable 
Univariable Multivariable 
Estimate 95% Confidence 
Interval 
P-value Estimate 95% Confidence  
Interval 
P-value 
Age Per 10 years 1.02 (0.91 – 1.15) 0.68 0.96 (0.84 - 1.08) 0.49 
Male Vs. Female 1.20 (0.99 – 1.46) 0.070 1.19 (0.97 - 1.47) 0.10 
White Vs. Non-white 0.69 (0.49 – 0.98) 0.037 0.87 (0.60 - 1.28) 0.48 
Calendar year: 1998 Vs. 2007-2008 0.04 (0.02 – 0.07) <0.0001 0.08 (0.04 - 0.17) <0.0001 
1999-2000 0.23 (0.15 – 0.33) <0.0001 0.34 (0.22 - 0.51) <0.0001 
2001-2002 0.40 (0.29 – 0.54) <0.0001 0.50 (0.37 - 0.69) <0.0001 
2004-2005 0.67 (0.52 – 0.88) 0.0040 0.78 (0.59 - 1.02) 0.074 
2006-2007 0.70 (0.53 – 0.92) 0.0094 0.76 (0.58 – 1.00) 0.049 
2009-2010 0.69 (0.52 – 0.91) 0.0093 0.64 (0.48 – 0.85) 0.0021 
Started cART *  3.29 (2.54 – 4.26) <0.0001 1.33 (0.93 - 1.90) 0.12 
CD4 <200 cells/mm
3
 * Vs. 200≤ CD4 ≤350cells/mm
3 
0.21 (0.14 – 0.32) <0.0001 0.42 (0.27 - 0.65) 0.0001 
CD4 >350 cells/mm
3
 * 2.86 (2.35 – 3.48) <0.0001 1.33 (1.06 - 1.67) 0.013 
CD4 unknown * 0.30 (0.18 – 0.51) <0.0001 1.41 (0.70 - 2.83) 0.34 
HIV RNA <500 copies/ml * Vs. ≥500 copies/ml 3.08 (2.51 – 3.78) <0.0001 1.39 (1.07 - 1.80) 0.012 
HIV RNA unknown * 0.23 (0.16 – 0.33) <0.0001 1.26 (0.74 - 2.15) 0.40 
HCV RNA >800,000 IU/ml * Vs. 615< HCV RNA ≤800,000IU/ml 1.90 (1.59 – 2.29) <0.0001 1.21 (1.00 - 1.47) 0.049 
South  Vs. West Central Europe 1.17 (0.98 – 0.40) 0.081 1.38 (1.06 - 1.82) 0.019 
North 0.74 (0.57 – 0.95) 0.021 1.02 (0.73 - 1.44) 0.89 
East Central 1.20 (0.96 – 1.51) 0.12 1.03 (0.74 - 1.43) 0.85 
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East  1.38 (1.03 – 1.84) 0.030 1.18 (0.78 - 1.78) 0.45 
MSM  Vs. IDU 1.48 (1.13 – 1.94) 0.0042 1.36 (1.00 - 1.83) 0.046 
Heterosexual 1.17 (0.89 – 1.53) 0.27 1.19 (0.90 - 1.59) 0.22 
Other 1.07 (0.76 – 1.51) 0.68 1.25 (0.88 - 1.78) 0.21 
HCV genotype 2 Vs. HCV genotype 1 0.75 (0.41 – 1.36) 0.35 1.05 (0.56 - 1.94) 0.89 
HCV genotype 3 1.26 (1.04 – 1.53) 0.018 1.20 (0.96 - 1.49) 0.10 
HCV genotype 4 1.09 (0.84 – 1.41) 0.51 1.20 (0.90 - 1.59) 0.21 
HCV genotype unknown 0.92 (0.72 – 1.19) 0.53 1.02 (0.77 - 1.34) 0.91 
HBsAg +  Vs. HBsAg - 0.95 (0.66 – 1.36) 0.77 0.84 (0.58 - 1.21) 0.35 
HBsAg unknown 0.28 (0.19 – 0.41) <0.0001 0.50 (0.33 - 0.76) 0.0012 
NR < ALT < 3*NR* Vs. upper limit NR 2.93 (2.46 – 3.49) <0.0001 2.33 (1.83 - 2.96) <0.0001 
ALT > 3*NR* 3.39 (2.65 – 4.34) <0.0001 3.56 (2.61 - 4.86) <0.0001 
ALT unknown* 0.25 (0.20 – 0.31) <0.0001 1.62 (1.17 - 2.25) 0.0039 
 
ALT: Alanine transaminase; cART: combination antiretroviral therapy; IDU: injecting drug user; MSM: men who have sex with men; NR: normal range for 
ALT, defined as <50U/L for men and <40U/L for women; 3*NR: 3 times the upper normal range 
*Time-updated variable 
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In the multivariable model, the calendar year effect mirrored that shown in Figure 5.4 from 
the univariable analysis.  
 
Figure 5.5 shows that the adjusted incidence of treatment initiation increased until the years 
2007-2008 before falling in 2009-2010. Taking 2007-2008 as the reference group, both 
2004-2005 and 2006-2007 had slightly lower incidence of HCV treatment uptake (aIRR: 
0.78 (95% CI 0.59 – 1.02; P=0.074) and 0.76 (0.58 – 1.00; P=0.049), respectively) 
compared with 2007-2008, with borderline statistical significance. The drop in the incidence 
of HCV treatment uptake in the years after 2007-2008 was also statistically significant 
(aIRR: 0.64 (0.48 – 0.85; P=0.0021)). 
 
5.4.2.1 HCV genotype distribution among treated patients 
There was insufficient evidence of a difference in the proportion of individuals treated for 
HCV according to HCV genotypes. The frequency distribution of treatment initiation among 
genotypes was G1: 23.6%, G2: 21.2%, G3: 29.5% and G4: 27.8%, with a borderline 
significant chi-square p-value for differences between the proportions (P=0.084). As was 
shown in Chapter 2 Section 2.2.6 coinfected individuals in the acute phase of HCV infection 
are treated regardless of HCV genotype because there is evidence that the chance of 
treatment success is much higher than that observed in chronic infection. Outbreaks of 
acute HCV among the MSM population have been well documented in Europe
332;339;340;591
. 
However, removing individuals in the MSM HIV transmission risk group, on the assumption 
that they were treated during the acute phase of HCV infection, did not change the 
proportion of individuals treated by genotype (G1:23.2%, G2:20.9%, G3:28.0%, G4:26.2%, 
P=0.29).  
 
The fact that HCV genotype was not associated with HCV treatment uptake is also 
evidenced by the multivariable Poisson regression model in Table 5.2. In univariable 
models HCV genotype 3 was associated with treatment initiation (IRR: 1.26 (95% C.I. 1.04-
1.53; P=0.018) compared to HCV genotype 1), however, when adjusting for other factors 
there were no significant associations between HCV genotype and treatment uptake. 
 
5.4.2.2 Factors affecting the rate of change in HCV treatment uptake 
Interaction terms for categorical covariates were examined to see whether the incidence of 
HCV treatment uptake varied according to the different levels of the categorical covariates. 
In particular the interactions between calendar year, HIV transmission risk group and region 
of EuroSIDA were tested. These interaction terms were individually added to the 
multivariable model in turn; however, both were non-significant (P=0.48 and P=0.80, 
respectively) indicating that there was no evidence to suggest that the incidence of HCV 
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treatment uptake varied according to HIV transmission risk group or region of EuroSIDA. 
That the incidence of HCV treatment initiation changed over time in a similar fashion for 
each of the regions of EuroSIDA is shown in Figure 5.6. The increasing incidence of 
treatment is noticeable for all regions with a period of tapering off towards the end of the 
follow-up period. The most obvious difference between regions is seen for the South and 
West, where the South is constantly above the West, except for 2004, while the tapering off 
appears to occur two years earlier in the West. This Figure provides further insight into the 
difference in incidence of treatment uptake between South and West of Europe identified 
by the Poisson regression model. Further, Northern Europe appears to be the only region 
yet to experience a drop in the uptake of treatment. 
 
5.4.3 Liver fibrosis levels among treated and untreated patients 
Liver biopsy, Fibroscan
®
 and liver fibrosis biomarker data were available for 800 of the 
1,984 (40.3%) individuals included in this study. In a multivariable logistic regression model 
adjusted for the factors listed above, individuals who did not have fibrosis data available 
were more likely to be MSM (adjusted odds ratio (aOR): 1.53 (95% C.I. 1.07 – 2.18; 
P=0.019) vs. IDUs), reside in Northern Europe (aOR: 1.54 (1.12 – 2.13; P=0.0007) vs. 
Western Europe) and had lower CD4 cell counts at treatment or last follow-up (aOR: 0.72 
(0.67 – 0.79; P<0.0001) per doubling), than those for whom fibrosis levels could be 
determined. 
 
Table 5.3 summarises the level of fibrosis among treated patients prior to treatment 
initiation and at the time of last available follow-up for those yet to be treated. Among 
individuals with liver biopsy or Fibroscan
®
 data available, a similar proportion of treated 
patients and those yet to be treated for HCV had ≥F2 fibrosis (43.9% vs. 40.8%, 
respectively; P=0.65). In individuals with HA measured, median HA levels were higher 
among treated individuals (41.2 ng/mL vs. 28.4ng/mL, respectively; P=0.015) and a higher 
proportion also had HA >100ng/mL (25.5% vs. 12.3%, respectively; P=0.011). In individuals 
with data available to calculate the APRI score, there was no difference between the 
median APRI score of those treated for HCV and those yet to be treated (0.78 vs. 0.94, 
respectively; P=0.63), nor was there a difference between the proportion of individuals with 
APRI scores >1.5 (24.1% vs. 29.0%, respectively; P=0.55). 
 
When fibrosis was defined using any of the above markers, a higher proportion of 
individuals treated for HCV were found to have significant fibrosis (≥F2) compared to those 
yet to be treated (36.0% vs. 22.0%; P=0.0003). In multivariable analysis, additionally 
adjusting the model for predictors of starting HCV treatment in Table 5.2, individuals with   
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Figure 5.6 Incidence of HCV treatment uptake by region of EuroSIDA 
 
 
significant current liver fibrosis were 60% more likely to start treatment for HCV than those 
with <F2 fibrosis (aIRR: 1.60 (95% C.I. 1.14 – 2.25; P=0.0065)). However, it is important to 
note that the majority (64.0%) of individuals with fibrosis data available who started HCV 
treatment did not have significant fibrosis at the time of their latest fibrosis measurement 
(median 5.7 months prior to treatment (IQR 2.7 – 11.9)). Furthermore, a large proportion of 
untreated individuals had significant fibrosis and should, therefore, have been considered 
for treatment (22.0%). Figure 5.7 shows that many coinfected individuals in Europe appear 
to remain untreated despite evidence of having significant liver fibrosis. The proportion of 
people with fibrosis that remain untreated is shown by geographical region in those with 
fibrosis data available. Southern (23.0%), West Central (15.3%), Northern (31.1%) and 
East Europe (14.3%) all have a large proportion of coinfected individuals with significant 
liver fibrosis yet to be treated for HCV. On the other hand, Southern (13.9%), East Central 
(14.7%) and East Europe (12.7%) all have a large proportion of individuals who have 
started HCV treatment in the absence of significant liver fibrosis. 
 
In multivariable analysis on this subset of people with fibrosis data available, extending the 
analysis shown in Table 5.2 by adding a significant fibrosis covariate and an interaction 
term between significant fibrosis and region of EuroSIDA, individuals with significant 
fibrosis were found to be less likely to be treated for HCV in Southern Europe (aIRR: 0.37  
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Table 5.3 Liver fibrosis markers prior to HCV treatment and last follow-up 
 
Fibrosis Marker 
Treated 
(N=501) 
Untreated† 
(N=1154) 
 
P-value 
Any marker n (%) 150 (29.9) 650 (56.3)  
Significant fibrosis* 54 (36.0) 143 (22.0) 0.0003 
Fibroscan/biopsy n (%) 66 (13.2) 184 (15.9)  
<F2 
≥F2 
37 (56.1) 
29 (43.9) 
109 (59.2) 
75 (40.8) 
0.65 
Hyaluronic Acid n (%) 47 (9.4) 488 (42.3)  
Median (IQR) 
>100ng/ml 
41.2 (23.4 - 106.9) 
12 (25.5) 
28.4 (15.2 - 59.9) 
60 (12.3) 
0.015 
0.011 
APRI n (%) 54 (10.8) 62 (5.4)  
Median (IQR) 
>1.5 
0.78 (0.48 - 1.47) 
13 (24.1) 
0.94 (0.46 - 1.72) 
18 (29.0) 
0.63 
0.55 
Time prior to treatment/last follow-up that 
fibrosis measurement was taken 
Median (IQR), 
months 
   
5.7 (2.7 – 11.9) 57.1 (12.2 – 110.9) <0.0001 
 
APRI: AST to platelet ratio index; †Untreated patients that are alive at last follow-up; *Significant fibrosis defined using a combined definition of ≥F2 
fibrosis from Fibroscan/biopsy, HA >100ng/ml and APRI >1.5 
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Figure 5.7 Proportion of patients who have been treated for HCV without significant 
fibrosis or have yet to be treated and have significant fibrosis by region of EuroSIDA 
 
 
 
(95% C.I. 0.17 – 0.82; P=0.014)) and Northern Europe (aIRR: 0.32 (0.11 – 0.97; P=0.044)), 
compared to those with significant fibrosis in Western Europe.  
 
5.4.4 Completion of full HCV treatment duration 
As mentioned in the introduction to this chapter, treatment duration of interferon-based 
therapy for HCV depends on HCV genotype and is often not well tolerated. The median 
duration of HCV treatment along with the percentage of individuals who completed at least 
80% of the full treatment duration, is shown in Figure 5.8 by HCV genotype. Excluding 
individuals with unknown HCV genotype, 271 individuals out of 416 (65.1%) completed at 
least 80% of the full treatment duration. The longest median HCV treatment durations were 
seen for HCV genotypes 1 and 4 (46.8 and 45.8 weeks, respectively), in which treatment 
guidelines recommend the longest treatment duration. However, the highest proportions of 
individuals completing at least 80% of the full treatment duration were seen for HCV 
genotypes 2 and 3 (72.7% and 80.9%, respectively). Treatment completion rates among 
the more difficult to treat HCV genotypes 1 and 4 were just over a half (57.7% and 52.9%, 
respectively). 
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Figure 5.8 Percentage of patients completing the full duration of HCV treatment and 
the median duration of treatment by HCV genotype 
 
 
 
 
Table 5.4 shows multivariable logistic regression odds ratios for factors associated with 
completing at least 80% of the full duration of treatment. Individuals who are younger (aOR: 
0.70 (95% C.I. 0.50 – 0.98; P=0.038) per 10 years), with HCV genotypes 2 or 3 (aOR: 3.31 
(1.92 – 5.70; P<0.0001) vs. HCV genotype 1) and HIV-RNA <500copies/ml at treatment 
initiation (aOR: 2.25 (1.22 – 4.17; P=0.0095) vs. HIV-RNA ≥500 copies/ml), were more 
likely to complete the full duration of HCV treatment. There was also borderline statistical 
significance to suggest that individuals with CD4 cell counts <200 cells/mm
3
 at the time of 
HCV treatment initiation were more likely to complete therapy (aOR: 3.24 (0.99 – 10.59; 
P=0.051) vs. CD4 cell count between 200 and 350 cells/mm
3
). 
 
Of the 416 individuals with known HCV genotype, 44 (10.6%) discontinued their treatment 
before completing 12 weeks of therapy (G1: 8.7%, G2: 27.3%, G3: 10.6%, G4:13.2%). In a 
multivariable logistic regression model similar to that shown in Table 5.4, but with the 
endpoint of discontinuing HCV treatment before 12 weeks of therapy, baseline use of cART 
was the only factor significantly associated with early treatment discontinuation. In 
particular, those not taking cART at treatment initiation were at 4-fold increased risk of 
discontinuing HCV treatment before reaching 12 weeks of therapy (aOR: 3.85 (95% C.I. 
1.35 – 11.11; P=0.12)) compared to those taking cART at HCV treatment initiation. 
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Table 5.4 Multivariable logistic regression factors associated with completion of a full duration of HCV treatment 
Parameter Odds Ratio 95% Confidence Interval P-value 
Age 
Male 
White 
Per 10 years 
Vs. Female 
Vs. Non-white 
0.70 
1.25 
0.93 
(0.50 - 0.98) 
(0.73 - 2.14) 
(0.36 - 2.41) 
0.038 
0.42 
0.88 
MSM  
Heterosexual 
Other 
Vs. IDU 1.09 
1.70 
1.37 
(0.49 - 2.43) 
(0.80 - 3.61) 
(0.57 - 3.26) 
0.84 
0.17 
0.48 
South  
North 
East Central 
East 
Vs. West Central Europe 0.55 
0.47 
1.32 
0.85 
(0.27 - 1.12) 
(0.20 - 1.14) 
(0.54 - 3.24) 
(0.27 - 2.65) 
0.10 
0.094 
0.54 
0.78 
Baseline cART 1.37 (0.78 - 2.43) 0.27 
Prior AIDS diagnoses 0.65 (0.31 - 1.37) 0.26 
CD4 <200 cells/mm
3
 * 
CD4 >350 cells/mm
3
 * 
Vs. 200 ≤ CD4 cells/mm
3
 ≤ 350 3.24 
1.30 
(0.99 - 10.59) 
(0.73 - 2.31) 
0.051 
0.36 
HCV genotype 2/3 
HCV genotype 4 
Vs. HCV genotype 1 
 
3.31 
0.68 
(1.92 - 5.70) 
(0.36 - 1.27) 
<0.0001 
0.23 
HCV RNA  > 800,000 IU/ml* 
HIV RNA < 500 copies/ml* 
Vs. 615 < HCV RNA IU/ml ≤ 800,000 
Vs. HIV-RNA ≥ 500 copies/ml 
1.15 
2.25 
(0.69 - 1.94) 
(1.22 - 4.17) 
0.59 
0.0095 
Calendar year* Per year 0.99 (0.91 - 1.07) 0.82 
 
*At the time of HCV treatment initiation 
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5.5 Discussion 
 
Uptake of HCV treatment 
This chapter describes the rate of uptake of HCV treatment among HIV-positive individuals 
chronically infected with HCV. One of the main findings of this analysis is that 25% of 
coinfected individuals with viremic HCV infection were treated with interferon-based therapy 
for HCV infection in EuroSIDA between 1998 and 2010. This is a higher prevalence of 
treatment for HCV than has been reported in previous work on the topic where treatment 
uptake has typically been very low. Studies from around the beginning of 2000 from 
Fleming et al
444
 and Fultz et al
584
 found that eligibility for HCV treatment among HIV/HCV 
coinfected individuals was low, citing missed clinic visits, psychiatric illness and a high rate 
of alcohol abuse as barriers to treatment. 
 
In particular, Fultz et al reported that due to these contraindications just 3% of the study 
population of coinfected individuals went on to receive interferon-based treatment
584
. A 
more recent study from 2005 by Rauch et al also found very low eligibility for interferon-
based treatment among coinfected individuals
443
. The authors reported that 77% of 
coinfected individuals in the Swiss HIV Cohort were ineligible due to low CD4 cell counts or 
on-going illicit drug use. However, even among those eligible for treatment, uptake of 
therapy remained low with 62% rejecting treatment as they were fearful of side-effects, 
leading to an overall treatment uptake of just 8%
443
. 
 
One of the strengths of this study is that each individual’s HCV status was characterised 
using HCVAb and HCV RNA, including a large number of individuals over a long period of 
follow-up. In the absence of HCV RNA data, the proportion of individuals selected for 
treatment is likely to be underestimated as clinicians would only consider treating 
individuals with active on-going HCV viral replication. If it is unknown whether individuals 
are positive for HCV RNA or they have cleared the virus spontaneously, the denominator 
for the proportion of individuals treated is typically inflated by the inclusion of individuals 
who would not be considered for treatment.  
 
This may potentially explain the discrepancy in frequency of treatment initiation observed in 
the present analysis and that estimated in previous analysis of EuroSIDA data. In 2006, 
Mocroft et al report on limited but increasing incidence of treatment for HCV in EuroSIDA, 
classifying individuals as HCV positive on the basis of an HCVAb test but not an HCV RNA 
measurement. The authors reported the proportion of treated individuals to be just 7.6%, 
but also documented a 38% increase in the incidence of treatment over time and up to 
2004
582
. It would seem from the current analysis that this increase in the incidence of 
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treatment year-on-year has continued until 2007/08 and accounts partially for the difference 
between the results of the two studies. 
 
Another recent European study by the Cohere collaboration, with data to December 2009, 
reported an uptake of treatment of 12% among 6,433 coinfected individuals
583
. However, 
this study only had HCV RNA data available for 12% of the study population and was 
geared towards looking at the effect of HCV treatment on short-term CD4 cell count 
changes and the long-term effect on overall mortality, rather than specifically documenting 
the rate of HCV treatment uptake. The study included a median follow-up of 72 months 
(IQR: 39 – 108) per individual, which is far fewer than the 168 months (IQR: 121 – 204) per 
individual that were included in the current study, and goes some way to explaining the 
differences in treatment uptake between the two studies. 
 
By fitting a univariable Poisson regression model, I found that the uptake of HCV treatment 
increased by 27% per year between 1998 and 2007, before falling by 12% per year 
between 2007 and 2010. In multivariable analysis, accounting for the demographic 
differences in the study population, a similar increase in treatment uptake was described 
from 1998 to 2007/2008 with a significant drop in treatment uptake in 2009/2010. 
 
The increasing uptake of HCV treatment most likely reflects improvements made in 
controlling HIV infection and the introduction of peg-IFN. Peg-IFN introduced a longer 
lasting interferon treatment with a longer circulatory time, leading to improved SVR rates for 
treatment of HCV. In 2004, Chung et al reported the results of a clinical trial showing that 
although SVR rates remained modest for HCV genotype 1, they were significantly improved 
for other HCV genotypes when using peg-IFN with ribavirin compared with standard 
interferon plus ribavirin, indicating that 41% and 12% of treated individuals achieved SVR, 
respectively
435
.  
 
In another clinical trial of HIV/HCV coinfected individuals from the same year, Carrat et al 
also reported a significant increase in SVR with the use of peg-IFN plus ribavirin compared 
to standard interferon plus ribavirin (27% and 20%, respectively), noting that the difference 
was more marked for HCV genotypes 1 and 4
434
. Further, studies have since gone on to 
document the effect of baseline CD4 cell count on the effectiveness of treatment based on 
peg-IFN
567
, and the comparative efficacy of different types of peg-IFN
448
. 
 
While the introduction of peg-IFN is the most likely explanation for the increase in HCV 
treatment uptake up to 2007, the decreases in treatment uptake seen after 2007 have 
multiple possible explanations. It is possible that there has been treatment saturation of the 
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easy-to-treat individuals eligible for therapy, meaning the pool of individuals with the 
potential to be treated has diminished over time. However, EuroSIDA is not a closed cohort 
and new individuals added after 2007 could add to the pool of individuals eligible for 
treatment. 
 
Another explanation is that clinicians are waiting for new potent treatments to come to 
market. As described in the introduction of this chapter, the first generation of DAAs for 
HCV became available in 2011
439
 with expected SVR rates of approximately 75% in 
patients with HCV genotype 1
437;440
. Because a greater chance of HCV treatment success 
was associated with younger age, low HCV RNA (<800,000IU/ml) and non-HCV genotype 
1
554
, clinicians and their patients in EuroSIDA in the years 2009/2010 with low fibrosis 
stages, high HCV RNA or HCV genotype 1 may have felt that they should wait for the more 
efficacious HCV therapy to be licenced for use in the clinic 
592
, therapies which also might 
avoid the unpleasant side effects associated with treatment with interferon
593
. 
 
Factors associated with starting HCV therapy 
Coinfected individuals initiating HCV therapy in this analysis were more likely to have CD4 
cell counts greater than 350 cells/mm
3
, ALT values above the normal range and HIV RNA 
below 500 copies/ml, which is in line with current treatment guidelines to treat HIV infection 
first to attain immune-sufficiency before initiating HCV treatment
1
. High HCV RNA levels 
(greater than 800,000 IU/ml) were also associated with treatment uptake, even though high 
HCV RNA has been identified as a predictor of poor treatment response
554
. Interestingly, 
individuals residing in Southern Europe compared with Western Europe and those 
belonging to the MSM HIV transmission risk group compared with the IDU risk group, were 
also more likely to be treated.  
 
One potential explanation for the differences between European region and mode of HIV 
transmission with respect to HCV treatment uptake, could be the HCV genotype 
distribution, however, HCV genotype does not appear to explain the differences reported 
here. A similar proportion of patients were treated among each of the HCV genotypes and 
HCV genotype was included in the multivariable model to identify factors associated with 
HCV treatment uptake. 
 
The higher rate of treatment in Southern Europe could have a variety of explanations. A 
higher prevalence of HCV infection in that region may have led to greater clinician 
experience in dealing with HIV/HCV coinfection. Further, differences between national 
treatment guidelines and local traditions will play a role in determining the rate of treatment 
from region to region. Treatment uptake may be expected to be lower in Eastern Europe 
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compared to other regions but was not the case in this analysis. This may be due to the 
inclusion criteria employed in this study. Many individuals from the Eastern region were 
excluded from the study as both HCVAb and HCV RNA positive test results were required 
and many individuals residing in Eastern Europe did not have available HCV RNA. 
 
The most likely explanation of the higher rate of HCV treatment uptake seen among MSM 
is the recently reported outbreak of acute HCV in this population in Europe. Rauch et al 
from the Swiss HIV cohort recently reported that among HIV-positive individuals unsafe sex 
was associated with an increased risk of HCV seroconversion, and that an increase in the 
prevalence of HCV in this population was most likely caused by sexual transmission
591
. 
Van Der Laar et al also reported on the emergence of an MSM-specific HCV transmission 
network in Amsterdam in 2006, suggesting that HIV-positive MSM with high-risk sexual 
behaviours were at increased risk of HCV infection
339
.  
 
Treatment for acute HCV infection is associated with far better cure rates than chronic HCV 
infection, regardless of HCV genotype
594;595
, which could lead to preferential treatment in 
this group. Further, MSM are also often considered to be easier to treat and more adherent 
to therapy than IDU, who are often not considered for treatment due to on-going drug 
abuse
443
. Unfortunately, data on active drug abuse was added to EuroSIDA in 2012 after 
the follow-up period of this study. Therefore, controlling for differences between the active 
drug users across regions of EuroSIDA was not possible. 
 
Fibrosis levels in treated and untreated individuals 
Among those who had available fibrosis marker data, a higher proportion of individuals 
treated for HCV infection had significant fibrosis prior to treatment, as evaluated using liver 
biopsy, Fibroscan, HA and the APRI score, compared with those yet to receive treatment 
for HCV at last follow-up. In a sensitivity analysis, significant fibrosis (≥F2 fibrosis as 
defined by the METAVIR scoring system
420
) was associated with a 60% increased 
incidence of treatment uptake. However, looking closely at the number of individuals with 
fibrosis I noticed that although those with fibrosis are more likely to be treated, just one-
third of individuals treated for HCV infection were known to have significant fibrosis. 
Further, 22% of individuals yet to receive treatment for HCV did have significant liver 
fibrosis and should have been considered for treatment for HCV.  
 
Fibrosis data was included up to 2-years prior to treatment in this analysis; therefore it is 
possible that some individuals may have progressed to significant fibrosis in this time. 
However, the median time prior to initiating HCV treatment that fibrosis data was available 
was 5.7 months and liver fibrosis progression rates have been shown to be slow in this 
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patient population
389
. The median time prior to last follow-up that fibrosis data was 
measured in those yet to be treated for HCV was 57 months, meaning that it is far more 
likely that fibrosis progression would have occurred in untreated individuals prior to last 
follow-up and that if anything the analysis is likely to be underestimating the level of fibrosis 
in individuals yet to be treated for HCV. 
 
In a multivariable model, individuals with significant fibrosis were also found to be less likely 
to be treated in Southern and Northern Europe compared to those with significant fibrosis in 
Western Europe. Although the fibrosis data were not complete, this finding is likely to some 
degree to be due to unmeasured confounding where there is contraindication to treatment. 
Of the individuals with significant fibrosis that have yet to be treated for HCV, 77% were 
IDU, which is often associated with contraindications to therapy
443
. However, it is clear that 
there needs to be renewed focus on correctly identifying eligible patients for treatment for 
HCV. 
 
Duration of HCV treatment 
The median duration of HCV treatment was close to the guideline minimum duration of 
therapy for HCV genotypes 1 and 4 and surpassed it for genotypes 2 and 3. However, the 
rate of discontinuation before completing the full duration of therapy was high, with one-
third of all patients who started HCV therapy discontinuing before the end of treatment.  
 
The lowest rates of treatment completion were seen for HCV genotypes 1 and 4 which 
reflects the heightened difficulty in treating these individuals, with anticipated lower 
response rates and treatment discontinuation more likely when following response-guided 
therapy
1;450
. Further, in adjusted logistic regression, younger age, HCV genotype 2 or 3 and 
HIV RNA <500 copies/ml at HCV treatment initiation, were found to be independently 
associated with increased likelihood of treatment completion. In addition, initiating cART 
early during clinical care was associated with a lower rate of early HCV treatment 
discontinuation (before 12 weeks of therapy). Younger age and HCV genotype 2 or 3 are 
well-known predictors of HCV treatment success
439
, while controlling HIV infection with 
cART, lowering HIV RNA and raising CD4 cell counts prior to initiating HCV therapy is best 
practice to ensure the highest chance of completing the full treatment duration, in line with 
current HCV treatment guidelines
1;450
. 
 
5.5.1 Limitations 
The main limitation of this study was that HCV RNA data was not available for a large 
proportion of HCVAb-positive individuals. Individuals that have cleared HCV spontaneously 
without treatment would not be considered for HCV therapy, as they are already cured, so 
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this information is vital to the study. Consequently, a large number of HCVAb-positive 
individuals were excluded from Eastern Europe where HCV RNA data is not as frequently 
documented, despite the fact that in the absence of treatment >75% are likely to be 
chronically infected. Therefore, the results presented here are likely to be less applicable to 
Eastern Europe. 
 
Another limitation of this study is that in clinical practice many individuals who initiate HCV 
therapy will stop treatment early due to severe adverse events; unfortunately these are not 
recorded in EuroSIDA and cannot be analysed. This might have resulted in an 
underestimation of the rate of treatment discontinuation prior to completing a full course of 
therapy. Further, coinfected individuals may have other contraindications to therapy which 
are not recorded (unmeasured confounding factors) and clinicians will most likely use their 
own judgment when selecting who to treat. 
 
Liver fibrosis levels were estimated using a combined definition including liver biopsy, 
Fibroscan® measurements as well as the non-invasive biomarkers HA and the APRI score. 
Although the use of these biomarkers has been well described and widely reported in other 
studies, they will be less precise than biopsy at determining liver fibrosis. 
 
5.5.2 Conclusions 
The analysis in this chapter documented an increase in the incidence of treatment for HCV 
infection in EuroSIDA from 1998 to 2010. In multivariable analysis adjusting for a number of 
measured potential confounding factors, increasing incidence of treatment was found to 
have peaked in 2007/2008. This result probably reflects the introduction of peg-IFN, which 
offers a longer lasting circulatory time and increased chance of SVR. This increase was 
followed by a plateau in the incidence of treatment uptake which may have a larger number 
of explanations, including the fact that most clinicians are reluctant to start current regimens 
knowing that more efficacious and better tolerated drugs will be soon available.   
 
Individuals who were selected for HCV treatment were mostly aligned with current 
treatment guidelines, with well controlled HIV infection and high CD4 cell counts. However, 
there were important deviations from the guidelines referring to the level of liver fibrosis 
among treated individuals, with as many as two-thirds of patients treated for HCV lacking 
significant liver fibrosis which indicates treatment. 
 
Further, the results have also shown that younger age, HCV genotypes 2 or 3 and 
undetectable HIV RNA at the time of HCV treatment initiation were all associated with an 
increased likelihood of completing a full duration of therapy. In the opening of the results in 
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this chapter the HCV treatment prevalence is documented as 25% among HIV/HCV 
coinfected individuals in EuroSIDA. Although this figure is higher than in previous studies 
there remain individuals, including some with significant liver fibrosis, who have yet to be 
exposed to HCV treatment and emphasis should be placed on continuing to promptly 
diagnose people with HCV infection and identify those in need of HCV treatment. 
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Chapter 6 
 
The incidence of antiretroviral drug discontinuation 
among HIV/HCV coinfected patients and those with 
significant liver fibrosis 
 
6.1 Introduction 
 
Antiretroviral treatment (ART) for HIV infection has led to a dramatic decrease in AIDS-
related mortality and morbidity
509;596-599
. In some countries liver end-stage related disease is 
now the leading cause of death among HIV-positive individuals due to on-going hepatitis C 
virus (HCV) coinfection
600
. Coinfection with HIV and HCV is common due to shared 
transmission routes and in Europe coinfection rates among HIV-positive individuals are 
estimated to range from 20% in Central and Northern regions to 50% in Southern and 
Eastern regions
404
. Although great strides have been made in the management of HIV/HCV 
coinfected individuals, longer life expectancy has led to more individuals presenting with 
hepatic and renal impairment requiring treatment, consequently pharmacokinetic 
considerations are now central to appropriate antiretroviral (ARV) dosing strategies
601
. 
Therefore, analysis of ARV drug discontinuation among HIV/HCV coinfected individuals is 
important to identify those with inappropriate HIV treatment regimens. 
 
6.1.1 The cytochrome P450 enzyme system 
Cytochrome P450 (CYP450) enzymes are essential for the production of cholesterol, 
steroids, the detoxification of foreign chemical and the metabolism of drugs
602;603
. The 
CYP450 enzyme group is named as such because they are bound to membranes in a cell 
(cyto) and contain a heme pigment (chrome and P) that absorbs light at a wavelength of 
450nm when exposed to carbon monoxide
603
. The term CYP450 covers a wide range of 
more than 50 individual enzymes, however, the CYP1A2, CYP2C9, CYP2D6, CYP3A4 and 
CYP3A5 enzymes are responsible for metabolising 90 percent of drugs, the two most 
significant enzymes being CYP3A4 and CYP2D6
603-605
. While these enzymes are 
predominantly found in the liver, they can also occur in the small intestine, lungs and 
kidneys
605
. 
 
Many drug interactions are a direct result of a change in CYP450 metabolism, while drugs 
interact with CYP450 in many ways
603;606
. Some drugs are metabolised by just one enzyme 
167 
 
and others by multiple enzymes
607
. Drugs that interfere with CYP450 metabolism are called 
either inhibitors or inducers. For example, ordinary grapefruit juice is known to be an 
inhibitor of CYP3A4, consequently drugs such as diazepam (Valium), which has a 
metabolic contribution from CYP3A4, will be available in the blood stream for longer if 
grapefruit juice is taken at the same time
603;608
. These interactions, via inhibitors and 
inducers, can often cause standard drug doses to lead to adverse effects as they can lead 
to longer than intended expose to drugs in the body
603;609
. 
 
6.1.2 Antiretroviral drug metabolism 
Most ARV drugs are metabolised in the liver by the hepatic CYP450 enzyme system or 
removed from the body via renal excretion, often with metabolising contributions from both 
the liver and the kidneys
601
. Most nucleoside reverse transcriptase inhibitors (NRTI) are 
water soluble and relatively well absorbed by the body so are broken down and excreted 
via the kidneys
601;610
. However, abacavir, zidovudine and didanosine all undergo extensive 
hepatic metabolism by alcohol dehydrogenase, glucuronidation, and purine nucleoside 
phosporylase (PNP), respectively
610
. Although these mechanisms are not via CYP450, 
drug interactions can still occur that interfere with these processes
610
. 
 
The non-nucleoside reverse transcriptase inhibitor (NNRTI) drug class on the other hand is 
predominantly metabolised by the CYP450 enzyme system, while individual drugs play the 
role of inducer or inhibitor to various CYP enzymes
601;611
. Therefore, hepatic impairment is 
likely to affect NNRTI pharmacokinetics and metabolism. Similarly, protease inhibitors (PI) 
have complex effects on CYP activity, being extensively metabolised by the liver. In 
addition, in most cases the current standard of care recommends using ritonavir as a 
booster to a partner PI
1;601
. Ritonavir is known to be a powerful inhibitor of CYP3A4 and 
slows down the metabolism of PIs considerably, leading to higher blood plasma 
concentrations of the boosted PIs
601;612
. 
 
As many ARV drugs are metabolised in the liver advanced hepatic disease as a result of 
HCV infection could be considered a risk factor for ARV drug discontinuation and drug-
related toxicity. Liver damage and metabolic impairment have the potential to interfere with 
the pharmacokinetic processes of the NNRTI and PI drug classes in particular. 
 
6.1.3 HCV coinfection and ARV-related hepatotoxicity 
Hepatotoxicity is defined by elevation of the liver transaminases alanine transaminase 
(ALT) and aspartate transaminase (AST)
613
. The AIDS Clinical Trials Group have proposed 
a standardised grading system for changes in ALT and AST relative to the upper limit of the 
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normal range (ULN), ranging from grade 0 (<1.25 x ULN) to grade 4 (>10 x ULN)
613
. 
Grades 1 and 2 represent mild hepatotoxicity with grades 3 and 4 considered to be severe 
hepatotoxicity
613
.  
 
In 2000, Sulkowski et al described the incidence of severe hepatotoxicity events among 
298 patients prescribed ART, 154 positive for HCVAb. The authors found that 
hepatotoxicity of any grade was seen in 54% of individuals coinfected with HIV/HCV 
compared to 39% of those with HIV monoinfection (P=0.009)
536
. However, the authors also 
state that 88% of individuals with HCV or HBV infection did not experience toxic effects of 
ART and that coinfected individuals did not need to avoid the use of any particular drug 
class
536
. 
 
Many studies have since confirmed these findings
614;615
, with some studies specifically 
focusing on the role of HCV and HBV coinfection. Den Brinker et al studied liver enzyme 
elevations (LEE), defined as five times the ULN and absolute increases of over 100U/l, in 
394 patients of whom 7% were HBsAg positive and 14% were HCVAb positive. The 
authors reported that LEE were more frequent among those coinfected with hepatitis and 
that after adjustment for baseline transaminases the presence of HCVAb was associated 
with 146% increased risk of LEE compared to HIV monoinfected individuals
534
. However, 
the authors also stated that although LEE was more common in coinfected individuals it 
was not necessary to modify antiretroviral therapy in these patients
534
. 
 
In 2001, Aceti et al performed a retrospective study of 1,325 HIV-positive individuals 
treated with ART for at least 6 months, with the intention of studying the occurrence of 
hepatotoxicity in those receiving ART specifically containing PIs
616
. The authors reported 
that there were significantly higher levels of hepatotoxicity among coinfected individuals 
and in logistic regression viral hepatitis coinfections were independent risk factors for 
hepatotoxicity
616
. After six months of treatment the authors found that ritonavir was the ARV 
most strongly associated with hepatotoxicity, with higher rates of severe hepatotoxicity  
seen in the coinfected group
616
. The authors noted that among HIV monoinfected 
individuals there were no differences in the occurrence of hepatotoxicity with different 
PIs
616
. 
 
In 2005, Nunez reviewed the subject of hepatotoxicity and ART, summing up that liver 
toxicity is important since it can often lead to ARV discontinuation, particularly in HIV-
positive individuals with HCV or HBV coinfection
617
. The review also emphasises that the 
incidence of drug-induced liver toxicity is not well known for most antiretrovirals and that it 
is difficult to determine the role of specific drugs in a combination of treatments
617
. Despite  
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Figure 6.1 Mechanisms of hepatotoxicity linked with antiretroviral therapy
617
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
the published studies, questions remain about the mechanisms involved in the 
development of hepatotoxicity and the process is thought to be multifactorial. Nunez 
suggested that the development of raised liver transaminases was potentially dependent 
upon a number of factors, including HCV or HBV coinfection, ART, methadone therapy, 
alcohol use and the development of steatosis, Figure 6.1
617
. 
 
These studies have provided important information but they are subject to a number of 
important limitations. First, most were based on a relatively low number of individuals, with 
a small proportion coinfected with HCV. Second, all relied on HCVAb in order to define 
HCV infection. As discussed in Chapter 5 of this thesis, it is not possible to accurately 
categorise HCV-infected individuals without the use of HCV RNA data to document on-
going viral replication. Third, the clinical consequences of the observed raised 
transaminases in terms of drug discontinuation are not discussed. Finally, information on 
the level of liver fibrosis among coinfected individuals was not available or was limited in 
these studies; consequently, the role of HCV viral replication and liver fibrosis in causing 
ART-related toxicity and drug discontinuation remains unclear. 
 
6.1.4 Impaired liver function as a cause of hepatotoxicity 
The Nunez study identified steatosis combined with mitochondrial toxicity as one of the 
potential causes of raised liver transaminases
617
. Steatosis is the first stage in the spectrum 
of non-alcoholic fatty liver disease (NAFLD), which can progress to severe inflammation 
with extensive fibrosis or cirrhosis
618
. While hepatitis steatosis without inflammation is 
thought to have a good prognosis, non-alcoholic steatohepatitis is known to progress to 
cirrhosis in a number of cases
618
. Given that steatosis has been identified as a potential 
 
 
 
 
 
 
Image not available due to copyright restrictions 
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cause for raised liver transaminases, the hypothesis follows that further advanced stages of 
NAFLD will also contribute to hepatotoxicity. 
 
A recent study from 2010 by Dominguez et al and the HEPDOSE study compared plasma 
ARV drug concentrations between matched HCV coinfected individuals and HIV 
monoinfected individuals
619
. Although only including 73 HIV/HCV coinfected individuals and 
66 HIV monoinfected individuals, the authors found that minimum ARV plasma 
concentrations were higher among coinfected individuals taking NNRTIs compared with 
HIV monoinfected individuals, especially in those with advanced liver fibrosis
619
. This 
finding indicates that high levels of liver fibrosis among coinfected individuals may lead to 
overdosing of ARVs via inhibition of the CYP450 activity
620
, which in turn could lead to 
hepatotoxicity manifested clinically as ARV drug discontinuation
621
. 
 
6.1.5 Hyaluronic acid as a marker of liver fibrosis 
Historically, liver biopsy has been considered the gold standard for detecting and 
monitoring the progress of liver fibrosis among HIV/HCV coinfected individuals
622
. 
However, liver biopsy is an invasive procedure with a small risk of complications and 
death
623
, and repeated biopsy would not be acceptable for most individuals
624;625
. In 
addition, there is potential for considerable observer bias in the histological staging of a 
liver biopsy
626
. Therefore, data on liver fibrosis levels has been limited in previous studies. 
 
Non-invasive biomarkers have previously been identified as useful tools in identifying 
individuals at risk of liver-related complications, such as the AST to platelet ratio index 
(APRI) (see Chapter 2 Section 2.2.5.3). Among these, hyaluronic acid (HA) has recently 
been shown to be an accurate marker for liver fibrosis
627
. Importantly, in 2005 Nunes et al 
showed that the diagnostic performance of HA as a marker for liver fibrosis was not 
affected by HIV/HCV coinfection
628
. In fact the authors found that the diagnostic 
performance of HA tended to be better among HIV/HCV coinfected individuals compared to 
HIV monoinfected individuals, however, this was likely due to a small sample size of 
coinfected individuals
628
. 
 
Other studies have focused on determining what is to be considered the normal range for 
HA and the optimal cut-off points for the histological stages of liver fibrosis. Consensus 
seems to suggest that the normal range for HA in healthy controls lies between 0-75ng/ml, 
with any HA measurement above 100ng/ml being indicative of significant hepatic fibrosis 
(METAVIR score ≥F2)587;622;628. 
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6.1.6 Previous EuroSIDA studies of antiretroviral drug discontinuation 
EuroSIDA have previously published analyses investigating ARV drug discontinuation in 
relation to HIV/HCV coinfection. In 2005, Mocroft et al published two papers on the 
subject
629;630
. The first dealt with reasons for stopping ARV treatment in HIV monoinfected 
and HIV/HCV coinfected individuals
629
. Including 1,198 individuals (30% HCVAb positive) 
starting cART after 1999 the authors reported that after one year of treatment 70% of 
patients remained on their original regimen, 24% switched treatments and 6% stopped 
treatment all together
629
. The most frequent reason for discontinuation reported was toxicity 
in 30% of cases, followed by patient or physician choice in 30% of cases
629
. Further, those 
positive for HCVAb were more likely to discontinue all or part of their cART regimen due to 
toxicity or patient/physician choice. HCVAb positive individuals also had 46% increased risk 
of ARV drug discontinuation due to toxicity compared to those without HCV
629
. 
 
The second of the two papers focused more specifically on which components of cART 
were stopped and whether there were specific drug classes that were at higher risk of drug 
discontinuation
630
. Including 4,929 individuals (28% HCVAb positive) the authors reported 
over 4,500 ARV drug discontinuations for nucleoside pairs and third drugs (the cART 
component other than the nucleoside pair)
630
. Table 6.1 shows the estimated incidence of 
ARV drug discontinuation by exposure group. For nucleoside pairs and third drugs those 
HCVAb positive had higher rates of discontinuation compared to those HCVAb negative 
(19.1 per 100 person years follow-up (PYFU) vs. 15.8 and 22.4 vs. 18.4, respectively)
630
. 
Overall those HCVAb positive were at 21% and 22% higher risk of discontinuing nucleoside 
pairs and third drugs, respectively
630
. Further, although there were a relatively low number 
of ARV drug discontinuations due to liver-related toxicity 56 cases in total, they were 
significantly more frequent among those HCVAb positive compared to those HIV 
monoinfected (2.3% vs. 0.7%, respectively)
630
. 
 
These two previous EuroSIDA studies are important in that they bridge the gap between 
the scientific understanding of hepatotoxicity and the clinical implications regarding ARV 
drug discontinuation. They report a substantial rate of drug discontinuation with some 20% 
of patients stopping their nucleoside pair and third drug each year, while clearly showing 
that the problem is more pronounced among those HCVAb positive. However, they suffer 
from some of the same limitations as the previous studies, mainly that HCV status is 
classified solely on HCVAb body testing and not HCV RNA as an indication of on-going 
viral replication, and there was no available information on the role of liver fibrosis as a risk 
factor for ARV drug discontinuation. In addition, the investigators note that it was virtually 
impossible to disentangle HCVAb status from IDU due to strong co-linearity. 
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Table 6.1 Incidence of antiretroviral drug discontinuation stratified by hepatitis C status
630
 
 
 
 
 
 
 
 
 
 
 
 
 
Image not available due to copyright restrictions 
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6.2 Aims 
 
The aims of this chapter were to describe the incidence of ARV drug discontinuation among 
HIV monoinfected and HIV/HCV coinfected individuals in EuroSIDA, in order to give insight 
into the relationship between hepatotoxicity and the clinical manifestation of drug 
discontinuation. This study can add to the body of work on this topic by including a large 
number of HIV monoinfected and HIV/HCV coinfected individuals with well characterised 
chronic HCV infection via HCVAb and HCV RNA testing. This allows for comparison of the 
rate of ARV drug discontinuation between those HCVAb negative, those that are HCVAb 
positive but have cleared the virus and those with on-going HCV viral replication.  
 
A further aim of this analysis is to examine the effect of liver fibrosis on ARV drug 
discontinuation using the biomarker hyaluronic acid. This study can build on current 
knowledge by describing the relationship between on-going HCV viral replication and the 
presence of liver fibrosis with regards to ARV drug discontinuation. Of particular interest 
was to identify drug classes and individual drugs with the highest risk of discontinuation 
among those with viremic HCV infection and liver fibrosis, which could prove to be valuable 
information for clinicians when deciding which treatments to recommend in these hard to 
treat patients. 
 
  
174 
 
6.3 Methods 
6.3.1 Patient selection 
The D37 update of the EuroSIDA database included 18,913 HIV-positive individuals from 
108 centres across Europe, Israel and Argentina. Patient follow-up of the current study 
population is to the end of December 2012. All EuroSIDA patients receiving cART, defined 
as at least three ARVs of any class, with known HCVAb status during prospective follow-up 
were eligible for inclusion in this study. Figure 6.2 shows the breakdown of how individuals 
were selected for inclusion in this study. Excluding individuals yet to have initiated cART 
there were 11,749 individuals in EuroSIDA. Of those, 9,535 had known HCVAb status at or 
before cART initiation during prospective follow-up. At baseline the largest proportion of 
individuals included were HCVAb negative (72.7%). Among HCVAb positive individuals 
with known HCV RNA status at baseline 77.5% were HCV RNA positive. HCVAb negative 
individuals are retained in this study to compare the rate of drug discontinuation among 
HIV-monoinfected individuals with those coinfected with HCV. 
 
HA was previously measured in EuroSIDA among a subset of individuals that were positive 
for HCVAb and/or HBsAg with available stored plasma samples
622
. All individuals that 
developed a liver-related event during follow-up had HA measured in a baseline sample 
and in the last available sample prior to their event, plus at most twice between these dates 
if stored samples were available. A control group was also randomly selected among 
coinfected individuals those that did not develop a liver-related event with HA measured at 
similar time points. For the purpose of this study there are a maximum of four HA 
measurements available for each patient. As HA was measured from stored plasma 
samples all measurements are taken per protocol and not as a result of clinical disease 
management. Further, the technicians that performed the measurements were blinded as 
to whether a liver-related event had occurred. 
 
6.3.2 Statistical methods 
Throughout the study baseline was defined as the date of initiating a new cART regimen, 
defined as three ARV drugs of any class (referring either to the first cART regimen or a new 
regimen due to drug switching or treatment breaks), recruitment to EuroSIDA, or 1
st
 
January 1999 (when EuroSIDA began collecting reasons for treatment discontinuation), 
whichever occurred later. Follow-up was counted from baseline until any component of 
cART was discontinued. Patients were censored one month prior to the initiation of 
interferon-based therapy due to the potential for drug switches in order to avoid drug 
interactions with HCV treatment. If after a discontinuation an individual remained on three 
or more ARVs or subsequently initiated cART again at a later date, they re-entered the 
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Figure 6.2 Inclusion criteria; baseline is defined as the date of first initiating cART, 
recruitment to EuroSIDA or 1
st
 January 1999, whichever occurred later 
 
 
 
 
analysis with a new baseline and follow-up was counted until the next ARV drug 
discontinuation. 
 
The endpoints of this study were instances of stopping an ARV drug where the reason for 
stopping was attributed to toxicity or patient/physician choice (TOXPC). The inclusion of a 
toxicity-related discontinuation is clear, but patient and physician choice could potentially be 
attributed to a number of underlying reasons. However, it was decided that many of the 
underlying causes of an ARV drug discontinuation due to patient or physician choice could 
be due to side effects relating to ARV toxicity and hepatotoxicity. 
 
Switches from single agent drugs to combination pills containing the same drugs were not 
considered to be treatment discontinuations, for example switching a 2 pill regimen of 
efavirenz and Truvada to a single pill regimen of Atripla. In EuroSIDA clinical sites have 
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different methods of reporting ARV drug regimens and their start and stop dates. Some 
sites will always list the individual components of a regimen even if the regimen consists of 
a single combination pill, while other sites would simply list the name of the combination 
pill. Therefore, it is not always possible to differentiate between combinations pills and 
single agents. Consequently, for the purposes of this study, when more than one drug is 
stopped at the same time the reasons for discontinuing those drugs are attributed to all the 
drugs. 
 
Multivariable Poisson regression models were used to assess the risk of ARV drug 
discontinuation due to TOXPC among different HCV infection profiles for drug classes and 
individual drugs. A separate model was used for each ARV drug class and individual ARV 
drug. Generalised estimating equations incorporating an unstructured covariance structure 
and robust standard errors were used allowing for multiple discontinuation endpoints per 
individual included in the study.  
 
The analysis of this study is split into two sections, the first deals with the population of 
individuals with known HCVAb. In the analysis of this population the following variables are 
adjusted for in multivariable regression: 
 
 Age/Sex/Race 
 Region of EuroSIDA (see Chapter 3 Section 3.1.1) 
 HIV transmission risk group 
 HCV genotype 
 HCV RNA (time-updated) 
 HIV RNA (time-updated) 
 CD4 cell count (time-updated) 
 HBsAg status (time-updated) 
 Baseline calendar year 
 
The second section of the analysis in this chapter deals with the subgroup of individuals 
with HA measured. Studies have shown that HA remains relatively stable over time in 
individuals that do not develop liver-related events, typically increasing by no more than 
1ng/ml per year
622
. With this in mind it was decided to count follow-up within a 2-year 
window either side of available HA measurements in order to maximise the power of the 
study. Multivariable Poisson models were again used to assess the risk of ARV drug 
discontinuation due to TOXPC for drug classes and individual drugs, adjusting for the same 
covariates listed above plus a binary variable for HA (>100ng/ml vs. ≤100ng/ml). 
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To analyse as many individual ARV drugs as possible while retaining statistical power, 
analysis of individual ARV drugs was restricted to those in which there were at least 25 
discontinuation events in the HCV RNA population and the HA population. 
 
6.3.3 Sensitivity analyses 
Two sensitivity analyses were performed. The first was to further adjust for time-updating 
alanine transaminase (ALT) and aspartate transaminase (AST) levels, in patients with 
these data available. ALT and AST levels above the normal range are by definition 
considered to be signs of hepatotoxicity and in many cases would indicate the need to 
discontinue ARV treatment
1
. Therefore, these sensitivity analyses aim to examine whether 
HCV RNA and HA levels are predictors of ARV drug discontinuation independent of raised 
liver enzymes. 
 
Figure 6.2 shows that at baseline a large proportion of HCVAb positive individuals had 
unknown HCV RNA levels. During the course of follow-up the proportion of individuals with 
known HCV RNA increased greatly. In the second sensitivity analysis, to see if missing 
HCV RNA data during the early stages of follow-up were a source of bias in the results, an 
analysis using multiple imputations was used to replace the missing HCV RNA data. 
Multiple imputations were performed using the PROC MI procedure in SAS. This procedure 
uses the whole spectrum of available data for each individual to estimate whether 
individuals with unknown HCV viremia are positive or negative. The full list of variables 
above was used to impute the missing HCV RNA data. The data were imputed three times, 
generating three independent sets of complete data and then analysed together to obtain 
overall estimates incorporating uncertainty relating to the missing data.  
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6.4 Results 
6.4.1 HCV RNA and ARV drug discontinuation 
 
6.4.1.1 Generalizability and baseline characteristics 
In the patient selection process for this analysis, 9,378/18,913 EuroSIDA participants were 
excluded as they had not yet started cART or had unknown HCVAb status. In multivariable 
logistic regression, compared with the whole EuroSIDA population, those with documented 
history of cART use and known HCVAb status were more likely to be male (aOR: 1.19 
(95% C.I. 1.08 – 1.31; P=0.0003) vs. female) and reside in Southern or Northern Europe 
(aOR: 1.28 (95% C.I. 1.15 – 1.42; P<0.0001) and aOR: 1.15 (95% C.I. 1.03 – 1.28; 
P=0.011), respectively) but not East Central Europe (aOR: 0.64 (95% C.I. 0.56 – 0.73; 
P<0.0001)), compared with Western Europe. Those eligible for inclusion were also less 
likely to belong to the men who have sex with men (MSM) or heterosexual HIV 
transmission risk groups (aOR: 0.74 (95% C.I. 0.67 – 0.84; P<0.0001) and aOR: 0.84 (95% 
C.I. 0.75 – 0.93; P=0.0009)) compared with injecting drug users. The population eligible for 
inclusion also had more recent enrolment to EuroSIDA (aOR: 1.77 (95% C.I. 1.70 – 1.84; 
P<0.0001) per 5 years). 
 
Baseline characteristics of this population, split by HCV status, are shown in Table 6.2. The 
majority of individuals were white (88.3%) men (73.3%) with a median age of 41 (IQR: 35 – 
48). In general, individual demographics were similarly distributed by HCV status. Though 
notably, 75.1% of those positive for HCVAb with detectible HCV RNA were injecting drug 
users, compared with 2.9% of those HCVAb negative. Other minor differences at baseline 
included, a lower proportion of HCV RNA positive individuals with NNRTI treatment 
experience compared to HCVAb positive individuals with undetectable HCV RNA (33.7% 
vs. 38.7%), and a lower proportion of HCV RNA positive individuals HBsAg positive, with 
multiple viral hepatitis, compared to HCVAb positive individuals with undetectable HCV 
RNA (5.9% vs. 12.3%). Among HCVAb positive individuals with detectible HCV RNA, the 
HCV genotype distribution was genotype 1 (48.4%), genotype 2 (3.0%), genotype 3 
(24.7%) and genotype 4 (13.4%). There were a further 10.5% that had no HCV genotype 
data available. The median baseline HCV viral load for the HCV RNA positive group was 
5.8log10 IU/ml (IQR: 5.3 – 6.3). 
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Table 6.2 Baseline characteristics by HCV status 
 
Median (IQR) / % All 
(N=9535) 
HCVAb- 
(N=6939) 
HCVAb+ /  
HCV RNA- 
(N=310) 
HCVAb+ /  
HCV RNA+ 
(N=1067) 
HCVAb+ /  
HCV RNA Unk. 
(N=1219) 
 
 
P-value
1 
Age 
Male 
White 
41 (35 - 48) 
73.3 
88.3 
42 (36 - 50) 
75.6 
86.5 
40 (35 - 45) 
63.6 
90.0 
39 (34 - 44) 
68.0 
91.8 
37 (33 - 41) 
67.4 
95.3 
<0.0001 
<0.0001 
<0.0001 
Diabetic No 
Yes 
Unknown 
83.7 
3.7 
12.6 
83.2 
4.0 
12.8 
82.6 
5.2 
12.3 
82.6 
2.9 
14.5 
88.0 
2.5 
9.5 
0.0002 
Hypertensive No 
Yes 
Unknown 
49.9 
18.5 
31.6 
49.1 
20.9 
30.0 
53.2 
14.5 
32.3 
51.4 
12.7 
36.0 
52.0 
11.2 
36.8 
<0.0001 
Smoking status Never 
Current 
Former 
Unknown 
24.8 
26.0 
3.0 
46.2 
29.0 
21.3 
2.8 
46.9 
13.6 
41.9 
4.2 
40.3 
12.9 
36.8 
3.0 
47.2 
14.4 
39.2 
3.5 
42.9 
<0.0001 
ART use NRTI 
NNRTI 
PI 
Other 
98.7 
41.3 
61.6 
4.1 
98.5 
42.3 
61.4 
4.8 
99.4 
38.7 
63.9 
3.6 
98.7 
33.7 
68.7 
2.5 
99.4 
43.2 
56.0 
1.6 
0.052 
<0.0001 
<0.0001 
<0.0001 
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Region South 
West Central 
North 
East Central 
East 
Argentina 
24.3 
24.7 
22.7 
13.4 
11.7 
3.2 
22.9 
27.7 
26.1 
12.5 
7.5 
3.3 
27.4 
24.2 
16.5 
21.0 
10.0 
1.0 
27.7 
23.9 
15.8 
19.4 
11.1 
2.3 
29.0 
8.4 
10.7 
11.3 
37.0 
3.7 
<0.0001 
Transmission 
group 
MSM 
IDU 
Heterosexual 
Other 
40.9 
22.0 
30.1 
6.9 
53.4 
2.9 
36.3 
7.4 
11.0 
71.0 
11.9 
6.1 
7.2 
75.1 
11.0 
6.8 
7.0 
71.9 
16.5 
4.7 
<0.0001 
HBsAg Negative 
Positive 
Unknown 
87.4 
6.6 
88.7 
6.2 
82.3 
12.3 
86.3 
5.9 
82.6 
7.6 
<0.0001 
6.0 5.1 5.5 7.8 9.8  
CD4 cell count 
HIV RNA 
Cells/mm
3
 
<500 copies/ml 
334 (209 - 512) 
51.6 
354 (225 - 532) 
53.4 
331 (194 - 483) 
53.1 
306 (184 - 485) 
49.5 
265 (161 - 399) 
41.2 
<0.0001 
<0.0001 
 
ART: Antiretroviral therapy; NRTI: Nucleoside reverse transcriptase inhibitor; NNRTI: Non-nucleoside reverse transcriptase inhibitor; PI: Protease 
inhibitor 
Baseline defined as known HCVAb status, the date of first initiating a cART regimen (at least 3 antiretrovirals of any class), recruitment to the study, or 1
st
 
January 1999 (when EuroSIDA began collecting reasons for treatment discontinuation), whichever occurred later. 
1
P-value from chi-square test for difference in proportions or Kruskal-Wallis tests for difference in population distributions. 
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In total 8,873 ARV drug discontinuations due to TOXPC were included in this population of 
9,535 individuals with known HCVAb status who had initiated cART, contributing a total of 
49,215 PYFU. Over the course of follow-up 2,744 individuals tested HCVAb positive and of 
those HCV RNA data were available for 1,904 (69.4%). Among individuals with HCV RNA 
data available 1,538 (80.8%) tested positive.  
 
The overall incidence of ARV drug discontinuation due to TOXPC in the whole population 
was 18.0 (95% C.I. 17.7 – 18.4) per 100 PYFU. The breakdown of reasons for ARV drug 
discontinuation was patient and physician choice (69%) and toxicity (31%). Among 
toxicities the most commonly reported reasons for discontinuation were from the 
gastrointestinal tract (35%), other toxicities (21%), from the nervous system (20%), from the 
kidneys (13%), and liver-related toxicity (7%). 
 
6.4.1.2 HCV status and ARV discontinuation 
 
Table 6.3 shows crude TOXPC ARV discontinuation rates for each ARV drug class 
stratified by HCVAb/HCV RNA status. TOXPC ARV discontinuation rates were consistently 
higher in those positive for HCV RNA. The rate of ARV discontinuation increased from 16.6 
(16.3 – 17.0) per 100 PYFU among HCVAb negative individuals to 18.5 (16.7 – 20.2) and 
23.6 (22.5 – 24.7) for those HCVAb positive negative for HCV RNA and positive for HCV 
RNA, respectively. The rate of ARV discontinuation among those with unknown HCV RNA 
was similar to those positive for HCV RNA (24.1 (22.6 – 25.6)). 
 
Table 6.3 Crude TOXPC discontinuation rates by HCV status 
Rate /100 PYFU  
(95% CI) All ARVs PIs NNRTIs NRTIs 
HCVAb negative 
 
16.6  
(16.3 - 17.0) 
12.7 
(12.2 - 13.1) 
7.8  
(7.4 - 8.2) 
11.2  
(10.8 - 11.5) 
 
HCVAb positive / 
HCV RNA negative 
18.5  
(16.7 - 20.2) 
13.9  
(12.0 - 15.9) 
10.6  
(8.4 - 12.7) 
13.8  
(12.2 - 15.4) 
 
HCVAb positive / 
HCV RNA positive 
23.6 
 (22.5 - 24.7) 
17.8  
(16.6 - 19.0) 
15.3  
(13.7 - 17.0) 
17.3  
(16.3 - 18.3) 
 
HCVAb positive / 
HCV RNA unknown 
24.1 
 (22.6 – 25.6) 
19.6  
(17.8 – 21.4) 
14.9  
(12.9 - 16.1) 
17.9  
(17.3 - 18.5) 
 
 
In multivariable analysis adjusted for the variables listed in the statistical methods section 
above, HCVAb positivity (including all HCV RNA types, positive, negative and unknown) 
was associated with an overall increased risk of TOXPC drug discontinuation (adjusted 
incidence rate ratio (aIRR): 1.28 (95% C.I. 1.15 – 1.43; P<0.0001) vs. HCVAb negative) 
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and across all ARV drug classes. Figure 6.3 shows the results after expanding this to look 
at the role of HCV viremia. This figure shows the adjusted rate of TOXPC drug 
discontinuation for those HCVAb negative and HCVAb positive with HCV viremia, 
compared with those HCVAb positive without HCV viremia. After adjustment, over all drug 
classes there was a 44% increased risk of TOXPC drug discontinuation for those with 
viremic HCV infection compared to those with aviremic HCV infection (aIRR: 1.44 (95% C.I. 
1.22 – 1.69; P<0.0001)). However, there was no significant difference between the rate of 
drug discontinuation among those HCVAb negative and those with aviremic HCV infection 
(aIRR: 0.96 (95% C.I. 0.82 – 1.13; P=0.65)). 
 
Similar patterns were observed within the different ARV drug class with viremic HCV 
infection associated with 41% (95% C.I. 1.13 – 1.78; P=0.0027), 59% (95% C.I. 1.18 – 
2.14; P=0.0021) and 43% (95% C.I. 1.18 – 1.74; P=0.0003) increased risk of drug 
discontinuation compared with aviremic HCV infection, for PIs, NNRTIs and NRTIs, 
respectively. For NNRTIs and NRTIs, there was also borderline statistical significance  
 
 
Figure 6.3 Adjusted incidence rate ratios for TOXPC drug discontinuation by HCV 
status
 
Adjusted for: age, sex, race, region of EuroSIDA, HIV transmission risk group, HCV genotype, 
HIV RNA, CD4 cell count, HBsAg status, and baseline calendar year 
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for a reduced risk of TOXPC drug discontinuation among HCVAb negative individuals 
compared with those with aviremic HCV infection (aIRR: 0.78 (95% C.I. 0.59 – 1.03; 
P=0.078) and aIRR: 0.83 (95% C.I. 0.69 – 1.01; P=0.059), respectively). 
 
Figure 6.4 shows the difference between viremic HCV infection and aviremic HCV infection 
stratified by individuals ARV drugs. The number of events, PYFU and adjusted incidence 
rate ratios for TOXPC drug discontinuation for ARV drug classes and individual drugs are 
shown. For all drug classes viremic HCV infection was associated with an increased risk of 
ARV drug discontinuation compared with aviremic HCV infection. For all individual ARVs 
included in the analysis those with viremic HCV infection tended to have a higher rate of 
discontinuation than those with aviremic HCV infection. In particular, viremic HCV infection 
was significantly associated with discontinuation of the NNRTI efavirenz (aIRR: 1.75 (95% 
C.I. 1.23 – 2.49; P=0.0020)), and with the NRTIs lamivudine (aIRR: 1.35 (95% C.I. 1.05 – 
1.74; P=0.022)), tenofovir (aIRR: 1.50 (95% C.I. 1.12 – 2.00; P=0.0065)), stavudine (aIRR: 
1.51 (95% C.I. 1.01 – 2.23; P=0.042)) and didanosine (aIRR: 2.02 (95% C.I. 1.30 – 3.15; 
P=0.0019)), compared with aviremic HCV infection. 
 
 
Figure 6.4 Incidence rate ratios for TOXPC drug discontinuation for viremic HCV 
infection versus aviremic HCV infection by ARV drug/class 
 
Adjusted for: age, sex, race, region of EuroSIDA, HIV transmission risk group, HCV genotype, 
HIV RNA, CD4 cell count, HBsAg status, and baseline calendar year 
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6.4.1.3 ALT and AST adjustment in the HCV status population 
In the set of individuals with known HCVAb status, ALT or AST was measured over the 
follow-up period in 8,690 of 9,535 (91.1%). The median number of measurement per 
individual was eight (IQR: 3 – 13) and 1,378 (14.5%) developed liver transaminase levels 
three times the upper limit of the normal range. Additionally adjusting for liver 
transaminases in the models presented in Figure 6.3, including a dummy variable for those 
without transaminase data, transaminase levels three times the upper limit of the normal 
range were consistently associated with ARV drug discontinuation for each ARV drug 
class. For the PI, NNRTI and NRTI ARV drug classes, liver transaminases three times the 
upper limit of the normal range were associated with 34% (aIRR: 1.34 (95% C.I. 1.13 – 
1.59; P=0.0007)), 54% (aIRR: 1.54 (95% C.I. 1.22 – 1.93; P=0.0002)), and 25% (aIRR: 
1.25 (95% C.I. 1.09 – 1.43; P=0.0012)) increased risk of drug discontinuation compared 
with liver transaminases within the normal range. 
 
Although raised liver transaminases were clearly associated with ARV drug discontinuation, 
the size of the effect of viremic HCV infection compared with aviremic HCV infection 
remained highly significant and comparable to those shown in Figure 6.3 for all ARV drug 
classes. After adjustment for liver transaminases, viremic HCV infection was associated 
with 36% (aIRR: 1.36 (95% C.I. 1.08 – 1.71; P=0.0079)), 49% (aIRR: 1.49 (95% CI 1.11 – 
2.01; P=0.0089)), and 37% (aIRR: 1.37 (95% CI 1.13 – 1.67; P=0.0015)) increased risk of 
drug discontinuation for PIs, NNRTIs and NRTIs, respectively, compared to aviremic HCV 
infection. Further, adjustment for liver transaminases did not alter the finding that HCVAb 
negative individuals were at borderline reduced risk of drug discontinuation compared with 
those with aviremic HCV infection among the NNRTIs and NRTIs (aIRR: 0.78 (95% C.I. 
0.60 – 1.03; P=0.083) and aIRR: 0.84 (95% C.I. 0.70 – 1.02; P=0.081), respectively). 
 
6.4.2 Hyaluronic acid and ARV drug discontinuation 
 
6.4.2.1 Generalizability and patient characteristics 
Analysis of the association between hyaluronic acid and ARV discontinuation was carried 
out in the subset of individuals with HA measured. HA acid has been measured from stored 
samples taken from patients with HCV or HBV coinfection. Therefore, the most important 
difference between this subset population and the main analysis is that all individuals in the 
subset analysis are HCVAb positive, HBsAg positive, or both. 
 
HA was measured in 935/9535 of the main analysis population. In multivariable logistic 
regression, compared with the main analysis population, individuals with HA measured and 
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eligible for inclusion in this subset analysis were more likely to be white (aOR: 1.32 (95% 
C.I. 1.04 – 1.67; P=0.022) vs. non-white) and reside in Southern, Northern or Eastern 
Europe (aOR: 2.17 (95% C.I. 1.75 – 2.70; P<0.0001), aOR: 1.32 (95% C.I. 1.07 – 1.61; 
p=0.0085) and aOR: 2.21 (95% C.I. 1.43 – 3.42; P=0.0004), respectively), but not East 
Central Europe (aOR: 0.67 (95% C.I. 0.51 – 0.87; p P=0.0030)) compared with Western 
Europe.  
 
Those included in the subset analysis were also more likely to belong to the men who have 
sex with men and heterosexual HIV transmission risk groups (aOR: 6.67 (95% C.I. 5.48 – 
8.12; P<0.0001) and aOR: 7.40 (95% C.I. 5.89 – 9.30; P<0.0001), respectively) compared 
with injecting drug users. Patients included in the HA subset also had higher baseline CD4 
cell counts and HIV RNA levels (aOR: 1.07 (95% C.I. 1.03 – 1.11; P=0.0002) per 100 cells 
and aOR: 1.11 (95% C.I. 1.04 – 1.17; P=0.0009) per log10 change), while they also had 
more recent entry to EuroSIDA (aOR: 2.04 (95% C.I. 1.83 – 2.28; P<0.0001) per 5 years), 
compared to the full main analysis population. 
 
Plasma HA levels were measured in 935 HCVAb positive or HBsAg positive individuals. 
The median number of HA measurements per individual in this subset was 2 (IQR: 2 – 2; 
range 1 – 4). In total there were 455 ARV drug discontinuations due to TOXPC observed in 
1,707 PYFU, giving an overall incidence of 26.7 (95% C.I. 24.6 – 28.8) TOXPC drug 
discontinuations per 100 PYFU. Of note, as this subset only includes HCVAb or HBsAg 
positive individuals, the overall incidence of TOXPC drug discontinuation was somewhat 
higher than in the main analysis (18.0 (95% C.I. 17.7 – 18.4) per 100 PYFU). 
 
Baseline characteristics of the HA subset are shown in Table 6.4. The HA categories were 
generally well-balanced, though there were more individuals from the West Central region 
(40.1% vs. 30.5%) and fewer individuals HCVAb negative (19.7% vs. 32.4%) with HA more 
than 100ng/ml compared with those with HA ≤100ng/ml. However, all HCVAb negative 
individuals in this population subset were HBsAg positive. Those with HA more than 
100ng/ml also had lower median baseline CD4 cell counts (241 (IQR 140 -390) vs. 308 
(IQR 190 – 450)) compared with those with HA ≤100ng/ml. 
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Table 6.4 Baseline characteristics by HA status 
 
Median (IQR) / % 
All 
(N=935) 
HA ≤100ng/ml 
(N=788) 
HA >100ng/ml 
(N=147) 
 
P-value
1 
Age 
Male 
White 
39 (34 - 44) 
75.0 
85.8 
38 (34 - 43) 
74.1 
86.2 
41 (38 - 47) 
79.6 
83.6 
<0.0001 
0.16 
0.45 
Region South 
West Central 
North 
East Central 
East 
Argentina 
22.8 
32.0 
23.2 
17.9 
3.7 
0.4 
22.7 
30.5 
22.6 
19.5 
4.2 
0.5 
23.1 
40.1 
26.5 
8.8 
1.4 
0 
0.0074 
Transmission group MSM 
IDU 
Heterosexual 
Other 
24.6 
54.8 
12.7 
7.9 
25.4 
54.7 
13.3 
6.6 
20.4 
55.1 
9.5 
15.0 
0.0035 
HCV status HCVAb - 
HCVAb + / HCV RNA Negative 
HCVAb + / HCV RNA Positive 
HCVAb + / HCV RNA Unk. 
30.4 
12.3 
49.5 
7.8 
32.4 
12.6 
48.4 
6.7 
19.7 
10.9 
55.8 
13.6 
0.0013 
HBsAg Negative 
Positive 
Unknown 
62.0 
30.1 
7.9 
61.8 
30.7 
7.5 
63.3 
26.5 
10.2 
0.38 
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CD4 cell count 
HIV RNA 
Cells/mm
3
 
<500 copies/ml 
298 (177 - 445) 
54.9 
308 (190 - 450) 
55.1 
241 (140 - 390) 
53.7 
0.0005 
0.76 
 
IDU: injecting drug user; MSM: men who have sex with men; Unk: unknown; HCV: hepatitis C virus; HBsAg: hepatitis B surface antigen. 
1
P-value from chi-square test for difference in proportions or Kruskal-Wallis tests for difference in population distributions. 
All patients in the HA subset are either HCVAb positive and/or HBsAg positive. 
Baseline defined as known HCVAb status, the date of first initiating a cART regimen (at least 3 antiretrovirals of any class), recruitment to the study, or 1
st
 
January 1999 (when EuroSIDA began collecting reasons for treatment discontinuation), whichever occurred later. 
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6.4.2.2 HA status and ARV discontinuation 
The crude ARV discontinuation rate was higher among those with HA >100ng/ml compared 
with those with HA ≤100ng/ml (35.6 (95% CI 30.0 – 41.3) and 24.9 (95% CI 22.7 - 27.2), 
respectively). Figure 6.5 shows adjusted incidence rate ratios for comparing HA >100ng/ml 
with HA ≤100ng/ml in regard to TOXPC drug discontinuation for ARV drug classes and 
individual drugs. After adjustment, HA greater than 100ng/ml was associated with 37% 
increased risk of TOXPC drug discontinuation compared with HA ≤100ng/ml (aIRR: 1.37 
(95% C.I. 1.08– 1.73; P=0.010)) (Figure 6.5). 
 
Interestingly in this population subset, when HA was not included as a covariate, viremic 
HCV infection was associated with 43% increased risk of ARV drug discontinuation (aIRR: 
1.43 (95% C.I. 1.21 – 1.68; P<0.0001)). However, after adjustment for HA, the effect of 
viremic HCV infection compared with aviremic HCV infection did not approach statistical 
significance (aIRR of 1.00 (95% C.I. 0.66 – 1.50; P=0.99)). For each ARV drug class, the 
effect of HA greater than 100ng/ml was in the positive direction compared with HA 
≤100ng/ml, reaching statistical significance among the PIs (aIRR: 1.40 (95% C.I. 1.04 – 
1.89; P=0.029)) and borderline significance among the NRTIs (aIRR: 1.33 (95% C.I. 0.99 – 
1.78; P=0.057)). The size of the effect among NNRTIs was comparable but did not 
approach statistical significance (aIRR: 1.29 (95% C.I. 0.75 – 2.21; P=0.35)). 
 
Figure 6.5 Incidence rate ratios for TOXPC drug discontinuation for HA >100ng/ml 
versus HA ≤100ng/ml by ARV drug/class 
 
Adjusted for: age, sex, race, region of EuroSIDA, HIV transmission risk group, HCV genotype, 
HIV RNA, CD4 cell count, HBsAg status, and baseline calendar year 
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For individual ARV drugs, the general tendency was for higher rates of TOXPC 
discontinuation among those with HA >100ng/ml compared with HA ≤100ng/ml. However, 
this effect only reached statistical significance for the NRTIs zidovudine (aIRR: 1.87 (95% 
C.I. 1.04 – 3.38; P=0.037)) and didanosine (aIRR: 2.55 (95% C.I. 1.43 – 4.55; P=0.0015)) 
(Figure 6.5). 
 
6.4.2.3 ALT and AST adjustment in the HA status population 
In the HA population subset ALT or AST was measured in 716/935 (76.6%) individuals over 
the follow-up period. The median number of measurements per person was 3 (IQR: 2 – 5) 
and 134 (14.3%) developed liver transaminase levels three times the upper normal range. 
Additionally adjusting for liver transaminases in the models shown in Figure 6.5, including a 
dummy variable for those without liver transaminase data, transaminases three times the 
upper normal range were consistently associated with an estimated 15% increased risk of 
TOXPC drug discontinuation. However, this effect did not approach statistical significance 
for any ARV drug class (aIRR: 1.16 (95% C.I. 0.65 – 2.07; P=0.62), aIRR: 1.13 (95% C.I. 
0.44 – 2.93; P=0.80) and aIRR: 1.17 (95% C.I. 0.67 – 2.05; P=0.58), for PIs, NNRTIs and 
NRTIs, respectively). Consequently, additionally adjusting for liver transaminases did not 
alter the size or significance of the estimated effects shown in Figure 6.5. 
 
6.4.3 Sensitivity analyses 
 
6.4.3.1 Multiple imputations for missing HCV RNA data 
The first stage of analysis in this chapter focused on the role of HCV status, in particular the 
role of on-going HCV viral replication, with regards to TOXPC ARV drug discontinuations. 
Table 6.2 shows that at baseline 1,219 of 2,596 (47.0%) HCVAb positive individuals had 
unknown viremia. This could have been because HCV RNA data was not available at all 
clinical sites, or that HCV RNA testing had not been performed at that time point potentially 
far in the past. Indeed, over the course of follow-up the number of HCVAb positive 
individuals with known viremia status increased to 69.4%. However, there remain a large 
proportion of individuals with unknown viremia, which could potentially bias the results 
presented in Figure 6.3. 
 
To test the impact of this potential bias a multiple imputations analysis replacing the 
missing HCV RNA data was performed repeating the analysis in Figure 6.3. The data were 
imputed three times and then analysed as a whole to take account of the uncertainty in 
estimating missing values. Figure 6.6 displays the results of the multiple imputations 
analysis and overall the results are similar to the original analysis. Overall in the imputed 
analysis, viremic HCV infection was associated with 37% increased risk of TOXPC drug 
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discontinuation compared with aviremic HCV infection (aIRR: 1.37 (95% C.I. 1.21 – 1.56; 
P<0.0001)), which is similar to the 44% increased risk shown in the main analysis. For 
individual drug classes, the imputed analysis estimated increased risks for viremic HCV 
infection of 31% (aIRR: 1.31 (95% C.I. 1.08 – 1.60; P=0.0080)), 47% (aIRR: 1.47 (95% C.I. 
1.14 – 1.91; P=0.0036)), and 42% (aIRR: 1.42 (95% C.I. 1.22 – 1.65; P<0.0001)) for the 
PIs, NNRTIs and NRTIs, respectively, which is comparable to the 41%, 59% and 43% 
increased risks estimated in the main analysis (Figure 6.6). 
 
In the main analysis, there was borderline significance to suggest that HCVAb negative 
individuals were at reduced risk of TOXPC drug discontinuations compared with those with 
aviremic HCV infection, for the NNRTIs and NRTIs. Interestingly, in the imputed analysis, 
overall there was a 12% reduced risk of drug discontinuations for HCVAb negative 
individuals (aIRR: 0.88 (95% C.I. 0.80 – 0.98; P=0.016)) compared with those with aviremic 
HCV infection. This reduced risk for HCVAb negative individuals was also reproduced 
among each ARV drug class (aIRR: 0.86 (95% 0.74 – 1.00; P=0.053), aIRR: 0.71 (95% C.I. 
0.58 – 0.88; P=0.0014), and aIRR: 1.42 (95% C.I. 0.22 – 0.65; P<0.0001), for PIs, NNRTIs 
and NRTIs, respectively) (Figure 6.6). 
 
Figure 6.6 Incidence rate ratios for TOXPC drug discontinuation by HCV status using 
multiple imputations to replace missing HCV RNA data 
 
Adjusted for: age, sex, race, region of EuroSIDA, HIV transmission risk group, HCV genotype, 
HIV RNA, CD4 cell count, HBsAg status, and baseline calendar year 
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6.4.3.2 Toxicity endpoints only 
So far this analysis has been based on ARV drug discontinuations due to toxicity or 
patient/physician choice. While definitions of toxicities are fairly clear, patient and physician 
choice could include a variety of different reasons for stopping ARV treatment. To see the 
effect that the patient and physician choice endpoints were having on the results sensitivity 
analysis was performed using only the toxicity endpoints. Figure 6.7 shows the main 
analysis repeated using toxicity endpoints only. In this analysis viremic HCV infection was 
associated with 77% increased risk of ARV drug discontinuation compared with aviremic 
HCV infection (aIRR: 1.77 (95% CI 1.36 – 2.31; P<0.0001)), with similar results seen for all 
ARV drug classes, similar to the results of the main analysis. 
 
The main difference between this sensitivity analysis and the main analysis is that the 
difference between HCVAb negative individuals and those with aviremic HCV infection did 
not approach statistical significance overall or for any of the ARV drug classes. 
 
 
 
Figure 6.7 Incidence rate ratios for toxicity related ARV drug discontinuations by 
HCV RNA status 
 
Adjusted for: age, sex, race, region of EuroSIDA, HIV transmission risk group, HCV genotype, 
HIV RNA, CD4 cell count, HBsAg status, and baseline calendar year 
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6.4.3.3 Summary of findings 
Table 6.5 summarises the findings of the analysis in this chapter. The main finding, that 
those with viremic HCV infection were at 35-45% increased risk of ARV drug 
discontinuations compared to those with aviremic HCV, was evident for all ARV drug 
classes. Additionally adjusting for liver transaminases, and using multiple imputations to 
replace the missing HCV RNA data did not alter this finding. Further, when restricting the 
endpoints to toxicity related discontinuation only, the effect of viremic HCV was somewhat 
increased, with viremic HCV patients consistently associated with >70% increased risk of 
ARV drug discontinuation. 
 
In the main analysis HCVAb negativity was associated with reduced risk of TOXPC drug 
discontinuation for the NNRTI and NRTI ARV drug classes, with borderline statistical 
significance. This was also the case when additionally adjusting for liver transaminases. 
Further, when using multiple imputation to fill in the missing HCV RNA data, being HCVAb 
negative was significantly associated with a reduced risk of TOXPC drug discontinuation for 
all ARV drug classes. However, when restricting to toxicity endpoints only there was no 
difference between HCVAb negative individuals and those with aviremic HCV. 
 
In the HA subset analysis, HA ≥100ng/ml was consistently associated with approximately 
30% increased risk of TOXPC drug discontinuation for all ARV drug classes, compared 
with HA <100ng/ml. Further, additionally adjusting for liver transaminases did not alter this 
finding. 
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Table 6.5 Summary results and sensitivity analyses 
Analysis population Effect aIRR (95% CI) 
  
All ARVs PI NNRTI NN 
Main 
 
 
 
HCVAb –  
Vs. aviremic HCV 
0.96  
(0.82 - 1.13; P=0.65) 
0.95  
(0.75 - 1.20; P=0.66) 
0.78  
(0.59 - 1.03; P=0.078) 
0.83  
(0.69 - 1.01; P=0.059) 
Viremic HCV  
Vs. aviremic HCV 
1.44  
(1.22 - 1.69; P<0.0001) 
1.41  
(1.13 - 1.78; P=0.0027) 
1.59  
(1.18 - 2.14; P=0.0021) 
1.43  
(1.18 - 1.74; P=0.0003) 
    
Main: with adjustment 
for liver 
transaminases 
 
HCVAb negative  
Vs. aviremic HCV 
0.97  
(0.83 - 1.14; P=0.74) 
0.96 
(0.76 - 1.21; P=0.71) 
0.78  
(0.60 - 1.03; P=0.083) 
0.84  
(0.70 - 1.02; P=0.081) 
Viremic HCV  
Vs. aviremic HCV 
1.38  
(1.17 - 1.62; P=0.0002) 
1.36  
(1.08 - 1.71; P=0.0079) 
1.49  
(1.11 - 2.01; P=0.0089) 
1.37  
(1.13 - 1.67; P=0.0015) 
    
Main: with multiple 
imputation for missing 
HCV RNA data 
HCVAb negative 
Vs. aviremic HCV 
0.88 
 (0.80 - 0.98; P=0.016) 
0.86 
(0.74 - 1.00; P=0.053) 
0.71  
(0.85 - 0.88; P=0.0014) 
0.80  
(0.70 - 0.90; P=0.0003) 
Viremic HCV 
Vs. aviremic HCV 
1.37 
 (1.21 - 1.56; P<0.0001) 
1.31  
(1.08 - 1.60; P=0.0080) 
1.47  
(1.14 - 1.91; P=0.0036) 
1.42  
(1.22 - 1.65; P<0.0001) 
    
Main: toxicity 
endpoints only 
 
 
HCVAb negative  
Vs. aviremic HCV 
1.09 
 (0.84 - 1.43; P=0.51) 
1.04  
(0.72 - 1.51; P=0.82) 
0.90  
(0.56 - 1.43; P=0.64) 
0.96  
(0.67 - 1.38; P=0.82) 
Viremic HCV  
Vs. aviremic HCV 
1.77  
(1.36 - 2.31; P<0.0001) 
1.70  
(1.18 - 2.44; P=0.0041) 
1.79  
(1.13 - 2.85; P=0.014) 
1.85  
(1.29 - 2.67; P=0.0009) 
    
HA subset 
 
HA ≥100ng/ml  
Vs. HA <100ng/ml 
1.37  
(1.08 - 1.73; P=0.010) 
1.40  
(1.04 - 1.89; P=0.029) 
1.29  
(0.75 - 2.21; P=0.35) 
1.33 
(0.99 - 1.78; P=0.057) 
    
HA subset: with 
adjustment for liver 
transaminases 
HA ≥100ng/ml  
Vs. HA <100ng/ml 
1.35  
(1.03 - 1.77; P=0.032) 
1.39  
(0.97 - 1.98; P=0.072) 
1.28  
(0.75 - 2.20; P=0.36) 
1.29  
(0.91 - 1.83; P=0.15) 
 
 
194 
 
6.5 Discussion 
 
Liver fibrosis is associated with ARV drug discontinuation 
The analysis presented in this chapter described the incidence of ARV treatment 
discontinuation due to TOXPC according to HCV infection status and the level of liver 
fibrosis, as measured by HA. Study of this topic is of particular interest as it represents the 
clinical manifestation of hepatotoxicity and other toxicity caused by ARV drugs. Data from 
large clinical cohorts are scarce on the effect of HCV viremia and liver fibrosis on the rate of 
ARV drug discontinuation as they have required HCV RNA assays and in particular, liver 
biopsy. In this study, using the biomarker plasma HA as a surrogate for liver fibrosis, 
patients with HA more than 100ng/ml were found to be at increased risk of TOXPC drug 
discontinuations compared to those with HA less than 100ng/ml. This was true overall 
including all ARV drug classes and individually among the PIs, with borderline statistical 
significance also among the NRTIs. The effect of high HA was in the same direction, but 
did not reach statistical significance among the NNRTIs, which is likely due to the reduced 
number of events and PYFU for this drug class. 
 
Adjustment for the liver transaminases ALT and AST did not alter these findings, which 
suggests that high HA, or significant liver fibrosis, is an independent predictor of ARV 
treatment discontinuation from raised liver enzymes. This is a particularly interesting finding 
for the PI drug class as although there is some degree of toxicity associated with all ARV 
drugs, PIs have been considered to be a more liver-friendly class of ARV
631-634
. PIs have 
not been strongly associated with raised liver transaminases
634
, but the findings presented 
in this chapter could suggest that liver fibrosis can lead to PI toxicity. 
 
Many studies have documented rapid progression of liver fibrosis in HIV/HCV coinfected 
individuals
376;389;395
, while other studies have shown an association between liver fibrosis 
and ARV-related hepatotoxicity
619;635
. In one study of ARV drug induced liver injury, 
Sulkowski suggests that although the mechanism by which viral hepatitis increases the risk 
of drug induced hepatotoxicity is unknown, individuals with cirrhosis could have decreased 
P450 enzyme activity leading to increased exposure to ARVs
636
. As PIs are predominantly 
metabolised by the P450 enzyme system
601
, the findings presented here could suggest that 
liver damage inhibiting P450 metabolization is causing overdosing of these ARV drugs 
which leads to toxicity and is manifest clinically by ARV drug discontinuation.  
 
A plausible explanation for this finding could relate to the use of ritonavir. Except for 
nelfinavir, the current standard of care recommends using ritonavir as a pharmacokinetic 
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enhancer of PIs
1
. The basis of this recommendation is that ritonavir is known to be a potent 
CYP3A4 inhibitor, which acts to slow down the metabolism of PIs in the blood stream and 
increase exposure to these drugs
603;608;612
. It could be suggested that in individuals with 
high HA, or significant liver fibrosis, who may already experience decreased CYP450 
activity, the inhibitory effect of ritonavir is causing the metabolism of PIs to slow down to 
such an extent that they are being overdosed in a normal dosage schedule. Alternatively, 
individuals with advanced liver fibrosis could be less tolerant to side-effects attributed to 
PIs, nausea, diarrhoea and insulin resistance
19
. 
 
Perhaps somewhat surprisingly, the same effect of high HA on TOXPC drug 
discontinuation did not reach statistical significance among NNRTIs, which are metabolised 
in much the same way as PIs via the P450 enzymes
601
. Potentially this could have been 
due to reduced statistical power in this ARV drug class, with less than half the events and 
PYFU observed in the other classes. Further, HA more than 100ng/ml was associated with 
37% increased risk of drug discontinuation of efavirenz, though it did not reach statistical 
significance. In comparison, high levels of HA did not appear to be associated with 
discontinuation of nevirapine. Other studies to have examined the relationship between 
liver fibrosis and ARV-associated toxicity have acknowledged a higher risk of hepatotoxicity 
and raised liver transaminases during NNRTI use
637;638
, specifically for nevirapine
639;640
. 
 
In this study, it is possible that HA was not found to be associated with discontinuation of 
nevirapine as the drug’s link to liver fibrosis and tendency to raise liver transaminases is 
most important within the first six weeks of use
641
. In this study the median time for 
discontinuation of nevirapine was 7.7 months. Further, it is not possible to rule out the 
strong possibility of confounding by indication. The deleterious influence of nevirapine and 
NNRTI drug class may have been underestimated because of less frequent use of these 
drugs in individuals with HIV/HCV coinfection. Patients and clinicians, aware of the 
literature that has shown a relationship between NNRTIs, specifically nevirapine, and 
hepatotoxicity may have decided to avoid that drug class. Supporting evidence of this 
selection bias can be found in the lower number of events and PYFU for NNRTIs compared 
to the other drug classes. 
 
The borderline effect of high HA seen for the NRTI drug class is driven mostly by the 
significant effects seen for zidovudine and didanosine, which have previously been 
associated with liver toxicity
642-645
. Although zidovudine and didanosine are no longer in 
routine use in the Western world, it remains important to study these drugs as they are still 
used in the resource-limited setting. These two drugs along with stavudine are 
contraindicated when initiating treatment for HCV
1;646;647
, and ARV treatment switches away 
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from these drugs prior to initiating HCV treatment are likely. However, in this analysis 
patients were censored one month prior to initiating HCV treatment. Further, in an extra 
sensitivity analysis censoring patients six months prior to initiation of HCV treatment the 
results were identical to those presented here (data not shown). 
 
The use of nucleoside analogues, in particular didanosine and stavudine, has been 
associated with increased levels of liver fibrosis among HIV-positive individuals
643;645
. It is 
likely that this increased liver fibrosis is leading to hepatotoxicity via reduced metabolic 
rates and increased exposure to ARVs. Zidovudine, although primarily removed from the 
body via renal excretion, has a metabolising contribution from the P450 enzyme system, 
and as with PIs, it may be this mechanism hindered by liver fibrosis that leads to ARV-
related toxicity and treatment discontinuation
601
. 
 
HCV antibody and HCV RNA are associated with ARV drug discontinuation 
HCVAb positivity was associated with an increased risk of TOXPC drug discontinuation in 
this study, in line with other work on the topic
536;629;630
. Expanding this to study the effect of 
HCV viremia on the risk of ARV drug discontinuation, individuals with viremic HCV infection 
were found to be at consistently higher risk of TOXPC drug discontinuation compared with 
those with aviremic HCV infection, with the strongest association seen among NNRTIs. 
Further, there was sufficient statistical power to detect significant associations between 
viremic HCV infection and discontinuation of the NNRTI efavirenz and NRTIs lamivudine, 
tenofovir, stavudine and didanosine.  
 
HCV viral load, along with duration of HCV infection, have previously been identified as 
predictors of liver fibrosis
645;648
. Interestingly, as the effect of HCV viremia became non-
significant when adjusting for HA in this study, these results suggest that liver fibrosis 
possibly caused by HCV viral replication, as measured by elevated HA, is the driving force 
behind ARV drug discontinuation and not viral replication per se. 
 
The significant associations between viremic HCV infection and discontinuation of the 
NRTIs lamivudine and tenofovir can partially be explained by their use in combination pills. 
In EuroSIDA, due to the way data is collected at different clinical sites, it is not always 
possible to differentiate between combination pills and single agent regimens. In the HCV 
viremia analysis, there were 669 drug discontinuations of lamivudine, however, upon 
further examination just 25 (3.7%) of these were instances where lamivudine was the only 
drug stopped at that time. Further, it is also true that the effects of lamivudine and 
emtricitabine could have been inflated by switches from one drug to the other, as these are 
often considered to be equivalent treatments. 
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The common combination of efavirenz and tenofovir in the combination pill Atripla could 
explain some of the effect seen for tenofovir. Viremic HCV infection was strongly 
associated with discontinuation of efavirenz, those with viremia having 75% increased risk 
of discontinuation compared to aviremic patients. Therefore, it is possible that some of the 
discontinuations of Truvada were as a result of efavirenz toxicity, but these discontinuations 
were also attributed to tenofovir. Alternatively, viremic HCV infection has been associated 
with an increased risk of chronic kidney disease
26;549
, which due to the primary renal 
excretion of tenofovir
601
 and its link with chronic renal impairment
649
, could often lead to 
discontinuation of tenofovir as a precautionary measure. 
 
One possible explanation for the excess risk of ARV drug discontinuation among viremic 
HCV patients could be heightened transaminase levels among individuals with chronic 
HCV. These patients will have less room for treatment-induced transaminase increases 
before treatment will be discontinued due to hepatotoxicity. ALT and AST levels three times 
the upper limit of the normal range were highly significant predictors of treatment 
discontinuation in the HCV viremic population, which is to be expected given their indication 
of treatment withdrawal due to hepatotoxicity
614
. However, after adjustment for ALT and 
AST, the effect of viremic HCV infection overall and among all drug classes remained 
highly significant, indicating that HCV viremia is a significant predictor of drug 
discontinuation independent of raised liver transaminases. 
 
There was borderline statistical evidence to suggest that individuals with aviremic HCV 
infection remained at higher risk of drug discontinuation than HCVAb negative individuals, 
for the NNRTI and NRTI drug classes. This finding was also given further evidence by the 
multiple imputations analysis, in which HCVAb negative individuals were at significantly 
decreased risk of drug discontinuation than aviremic HCV patients for all drug classes, 
although with borderline significance for the PIs. One potential explanation for the residual 
excess in TOXPC drug discontinuations after successful clearance of HCV viremia, in 
comparison to HIV monoinfected individuals, could be continuing HBV infection. In a further 
sensitivity analysis removing HBV positive individuals, the association between HCVAb 
negativity and reduced risk of drug discontinuation became non-significant among NNRTIs, 
but remained for the NRTIs, which suggests that confounding HBV infection can only 
partially explain this finding (data not shown).  
 
It is likely that unmeasured lifestyle factors associated with HCV coinfection explain some 
of the differences between HCVAb negative and HCVAb positive individuals. Further, the 
significant differences seen between these groups in the multiple imputations analysis 
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could potentially be explained by the misclassification of some viremic patients to the 
aviremic category by the imputation method. 
 
6.5.1 Limitations 
This study has several limitations. Although HA has been identified as a promising 
biomarker for significant liver fibrosis, an important limitation to its use in daily clinical 
practise is a substantial postprandial increase in the first two hours after food intake
650
. 
However, the influence of food intake on this study would adversely affect both individuals 
that experience many drug discontinuations and those that have very few, meaning that the 
effect of food intake is to cloud the true relationship between HA and drug discontinuations. 
Therefore, rather than produce false inference, the influence of food intake would serve to 
underestimate the effect of HA in this study. 
 
Due to the limited number of HA measurements available per individual in the subset 
analysis, a two year window either side of an HA measurement was allowed for the accrual 
of follow-up. This was to allow as many individuals and PYFU as scientifically feasible to be 
included in the subset analysis. However, the consequence of this method means it is 
possible that HA measurements attributed to the time of a drug discontinuation could have 
occurred after the event. Furthermore, in the analysis of individual drugs, especially for the 
HA subset analysis, the number of discontinuation events and PYFU included for each drug 
often meant that there was insufficient power to detect small differences in the rate of 
treatment discontinuation.  
 
A combined endpoint of drug discontinuation due to toxicity or patient and clinician choice 
was used in this study. Whereas the definition of toxicity is clear and well-defined in 
EuroSIDA follow-up data collection forms, patient and clinician choice could potentially 
reflect many different reasons. In sensitivity analysis, the models presented here were re-
run using only the toxicity discontinuations as study endpoints. This reduced the power of 
the analysis substantially; however, the results did not differ greater from those in the main 
analysis. In fact, any differences from the main analysis were to further enhance the 
associations between HCV viremia, HA and ARV drug discontinuation. 
 
A further limitation of this study is that HCV RNA data were not complete. In a sensitivity 
analysis multiple imputations were performed in order to impute the missing data; however, 
this is a well-known statistical technique that produces unbiased estimates when data are 
missing completely at random (MCAR) or missing at random (MAR)
522
. The missing data in 
this analysis were HCV RNA. Section 4.4.1 of this thesis showed that missing HCV RNA 
data was associated with Eastern Europe. Eastern Europe is more likely to have missing 
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data than Western Europe due to differences in the quality of clinical management. 
However, this does not mean that the underlying distribution of people positive or negative 
for HCV RNA would be different in this region. Therefore, it is reasonable to assume these 
data are MAR. 
 
It is likely that there are a number of inherent differences between HCV-positive and HCV-
negative individuals. Detailed data on socio-economic factors and lifestyle may have 
helped to further describe patterns of ARV discontinuation among HCV-positive and HCV-
negative individuals. Unfortunately, this data is not currently available in EuroSIDA and, as 
with all observational studies, it is not possible to exclude the influence of unmeasured 
confounding on the analysis. 
 
6.5.2 Conclusions 
The analyses in this chapter have documented the rate of ARV treatment discontinuation 
according to HCV viremia status and levels of HA. The key findings presented here are that 
HIV/HCV coinfected individuals with on-going viral replication were at greater risk of ARV 
drug discontinuation compared with coinfected individuals with aviremic infection (those 
who have cleared the virus), for all ARV drug classes. Interestingly, this effect seems to be 
explained by more advanced liver fibrosis among those with detectible HCV viremia, as 
HCV viremia was no longer a predictor of drug discontinuation after adjustment for HA. 
 
The largest effect of liver fibrosis on the risk of treatment discontinuation was seen for the 
PI drug class, which is potentially explained by the powerful CYP450 inhibition associated 
with the use of ritonavir as a pharmacokinetic enhancer of PI therapy. High HA also 
appeared to have an effect on discontinuation of NRTIs, however, this was restricted to 
some of the older drugs that have been previously associated with the development of liver 
fibrosis and toxicity. Importantly, after adjusting for the liver transaminases ALT and AST, 
the effects of HCV viremia and high HA remained, suggesting they are independent risk 
factors for ARV treatment discontinuation from liver transaminases. 
 
These findings have implications for the management of HIV/HCV coinfected individuals in 
that it may be preferable to avoid certain ARV drug classes when treating those with 
significant liver fibrosis. In particular, it may be advisable to avoid the use of a ritonavir 
boosted PI–based regimen in the presence of liver fibrosis. The combined effect of reduced 
CYP450 activity as a consequence of liver damage and ritonavir inhibition may lead to the 
overdosing of these drugs and hepatotoxicity. 
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Chapter 7 
 
Liver-related death among HIV/HCV coinfected 
individuals, what are the implications for treatment with 
direct-acting antivirals? 
 
7.1 Introduction 
 
The substantial decline in HIV- and AIDS-related mortality, as a consequence of the 
introduction of highly potent combination antiretroviral therapy (cART), has seen liver-
related death (LRD) assume increasing relative importance among HIV-positive 
individuals
372;373
. Although progression of liver disease is common with HCV infection and 
known to be accelerated further still in the presence of HIV coinfection
413
, LRD is often 
associated with older age as complications of HCV-related liver disease usually take 
decades to develop
651
. During this period HCV coinfected individuals have many competing 
risks of death, such as mortality associated with injecting drug use (IDU), AIDS, 
cardiovascular disease, malignancies, bacterial infections, violent death and renal 
disease
373
. Therefore, a better understanding of the spectrum of causes of death, 
particularly LRD, among HIV/HCV coinfected individuals is essential so that new therapies 
for HCV can be channelled to those who need them most. 
 
7.1.1 Causes of death among HIV/HCV coinfected individuals 
The next decade promises to be a crucial period in the treatment of people with HCV. The 
development of new direct-acting antivirals (DAA) for treatment of HCV means there is now 
a considerable amount of optimism in the field of HCV research
446;652
. However, it will be 
important to ensure these treatments are applied appropriately. Causes of death among 
those with HCV vary according to a number of factors including the duration of chronic 
disease, access to effective treatments, age distribution and competing risks in the 
population
652
. Therefore, causes of death among those with HCV tend to fall within three 
categories, drug-related death, including overdose and suicide which can be common 
among injecting drug users (IDU), LRD, including death as a consequence of liver cirrhosis 
and hepatocellular carcinoma (HCC), and HIV-related death, such as AIDS-related 
mortality
652
. 
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As discussed in the introduction to this thesis (Sections 1.2.5 and 1.2.6), coinfection with 
HIV has a negative effect on all aspects of the course of HCV infection. HIV/HCV 
coinfected individuals have a lower chance of spontaneous clearance of the HCV virus, 
higher HCV RNA levels, faster progression of liver fibrosis and lower response rates to 
interferon-based treatments for HCV
390;436;653-655
. In addition, although the life expectancy of 
HIV-positive individuals has increased dramatically as a result of modern combination 
antiretroviral therapy (cART), the life expectancy of HIV/HCV coinfected individuals still lags 
behind
655
. A recent Danish study has compared mortality rates of HIV-positive individuals 
and the general population. This study found that although mortality among the HIV-
positive community had fallen to 19 per 1,000 person years follow-up (PYFU) after 2005 
and the introduction of contemporary cART regimens, it was three-fold higher among the 
HIV/HCV coinfected population in the same time period (57 per 1,000 PYFU)
656
. 
 
Causes of death among HIV-positive individuals have been well-studied in recent years. In 
2006, from a large study of 23,441 HIV-positive individuals, Weber et al reported from the 
D:A:D study that more than half of all deaths among HIV-positive individuals were from 
causes other than those associated with AIDS. Further, death from causes associated with 
HCV- and HBV-coinfection accounted for an increasing proportion of overall mortality
564
. 
LRD accounted for 14.5% of all deaths recorded in the study with the majority of these 
deaths occurring in those with active HCV coinfection (66.1%), active HBV infection 
(16.9%) or both (7.1%)
564
.  
 
Interestingly, after adjustment the authors described a strong relationship between 
immunodeficiency and LRD. While there were similar numbers of deaths for those with 
CD4 cell counts <200 cells/mm
3 
and ≥200 cells/mm3 (87 and 94, respectively), the adjusted 
rate of LRD in those with low CD4 cell counts was far higher (0.92 (95% CI 0.73 – 1.12) 
compared with 0.14 (0.11 – 0.17) per 100 person years follow-up, respectively)564. Further, 
they were able to show a clear dose-response relationship between CD4 cell count and 
AIDS-related death or LRD (Figure 7.1), while also reporting associations between older 
age, injecting drug use, HCV or HBV positivity and LRD
564
. 
 
In 2014 the D:A:D study reported an update on the underlying causes of death in people 
with HIV. In this large scale analysis, including nearly 50,000 participants and 4,000 deaths 
over the years 1999 to 2011, LRD accounted for 13% of all deaths. LRD was the third most 
frequent cause of death behind AIDS-related death (29%) and non-AIDS cancer (15%), but 
ahead of cardiovascular disease (11%)
373
. Although LRD remained one of the most 
important causes of death over the study period they noted a substantial decline in the  
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Figure 7.1 Factors associated with AIDS- and liver-related death from the DAD study, 
2006
564
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
number of deaths attributable to liver-related causes, decreasing by 50% from 1999-2000 
to 2009-2011 (Figure 7.2)
373
. The authors propose that the fall in the incidence of death 
from all causes from 1999-2000 to 2009-2011 can be attributed to improvements in CD4 
cell count and the introduction of less toxic ARV drugs. However, the authors also point out 
that the number of LRDs in those without either HBV or HCV coinfection was minimal, 
accounting for less than 5% of all LRDs, and that the reduction in LRD was potentially 
attributable to a decrease in the percentage of coinfected individuals included in the study 
over time
373
. 
 
Another factor contributing to the reduction in LRD over time is thought to be the increased 
use of ARV drugs with activity against HBV
373
. Lamivudine, emtricitabine and tenofovir are 
all potent inhibitors of HBV DNA and at least 2 are now included in most ARV regimens, 
including combination pills such as Atripla and Eviplera which both contain emtricitabine 
and tenofovir
416
. Interestingly, the authors go on to say that treatment for HCV was 
uncommon during the course of the study and was unlikely to have significantly affected  
 
 
 
 
 
 
 
 
 
Image not available due to copyright restrictions 
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Figure 7.2 Declining age-standardised incidence rates for specific causes of death 
1999-2011
373
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
the rate of LRD
373
. The French national survey also reported on causes of death among 
HIV-positive individuals in 2014
372
. In a large cross-sectional study looking at trends in 
causes of death in the years 2000, 2005 and 2010 the authors followed individuals from 90 
clinical centres representing approximately 82,000 HIV-positive people in France. A total of 
728 deaths were reported in 2010 with AIDS (25%), non-AIDS-non-hepatitis-related 
malignancies (22%) and LRD (11%) the most frequent causes of death
372
. During all three  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Image not available due to copyright restrictions 
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Figure 7.3 Distribution of the underlying cause of death among HIV-positive 
individuals in the French national survey
372
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
editions of the survey LRD has consistently been the third most frequent cause of death 
among those with HIV (Figure 7.3)
372
. 
 
A total of 77 deaths due to liver-related causes were reported in 2010, with 32 (41.6%) due 
to hepatocellular carcinoma (HCC) and 42 (54.5%) due to cirrhosis. Importantly, the 
authors report that 92% of the LRDs in the study were as a consequence of HBV- or HCV-
coinfection
372
. Further, when analysing the coinfected individuals separately LRD became 
the most frequent cause of death (24%), followed by non-AIDS-non-hepatitis-related 
malignancies (21%) and AIDS (13%)
372
. Among those with HIV-monoinfection hepatic 
diseases accounted for just 1% of deaths
372
. 
 
7.1.2 Can new HCV treatments lower liver-related death rates? 
The uptake of treatment for HCV remains low among HIV/HCV coinfected individuals in 
Europe with only approximately 25% being exposed to therapy by 2010
657
. However, in 
Chapter 5 of this thesis it was shown that the low uptake of treatment can at least be 
partially explained by the prohibitive costs of treatment, potential contraindication to 
 
 
 
 
 
 
 
 
 
Image not available due to copyright restrictions 
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interferon-based treatments, anticipated poor treatment adherence and low treatment 
efficacy of pegylated-interferon plus ribavirin
657
.  
 
However, with the recent approval of less toxic, oral direct-acting antivirals (DAAs) for HCV 
fewer coinfected individuals will have contraindications to HCV treatment
446;658
. Further, as 
was discussed in detail in Section 2.2.6 of Chapter 2 of this thesis, treatment outcomes will 
be significantly improved with DAA therapy in comparison with interferon-based treatments. 
Treatment of coinfected individuals with pegylated-interferon plus ribavirin is successful for 
approximately 17-32% of those with HCV genotypes 1 and 4, and between 44-73% for 
genotypes 2 and 3
434;435;448;459
, whereas gold standard DAA therapy has been shown to be 
successful in >90% of individuals regardless of HCV genotype or HIV-coinfection
446;465;658
.  
 
The potential benefits of curative treatment with DAA therapy are numerous, including 
reductions in liver fibrosis levels and therefore reductions in LRD rates and extrahepatic 
manifestations, as well as helping to reduce on-going transmission of the virus
659
. However, 
regardless of the advances made in HCV drug development, the approximate costs of 
treatment with these new therapies approaches €90,000 per patient with the expectation 
that all oral combination regimens will be more expensive still
2
. These costs will be difficult 
to meet in most countries and prioritisation of individuals in the greatest need of treatment 
will be essential. 
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7.2 Aims 
 
The initial aim of this chapter was to describe causes of death among HIV/HCV coinfected 
individuals in EuroSIDA, paying attention to how the rate of LRD has changed over time. As 
AIDS-related mortality has declined in the era of highly effective cART for treatment of HIV, 
focus has shifted towards comorbidities among HIV-positive individuals. Therefore, a better 
understanding of the spectrum of causes of death among HIV/HCV coinfected individuals is 
essential in determining who to prioritise for expensive new treatments for HCV infection. 
Hence, a further aim of this chapter was to describe specific factors associated with 
progression to LRD, so that those at the highest risk may be prioritised for new DAA 
therapy. This study can add to the body of work on these topics by including a large 
number of coinfected individuals with well documented causes of death over a long period 
of follow-up. 
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7.3 Methods 
7.3.1 Patient selection 
The D38 update of the EuroSIDA database included 18,786 HIV-positive individuals from 
107 centres across Europe, Israel and Argentina. Figure 7.4 shows the breakdown of how 
individuals were selected for inclusion in this study. All EuroSIDA individuals under 
prospective follow-up with documented HIV/HCV coinfection, as evidenced by a positive 
HCVAb test, and follow-up available after the 1
st
 January 2000 were eligible for inclusion in 
this study. The D38 EuroSIDA database included 16,205 individuals with known HCVAb 
status, of whom 4,826 were positive and 3,941 had follow-up data recorded after 1
st
 
January 2000. 
 
Follow-up prior to 1
st
 January 2000 was excluded from this study as I wanted the study 
population to reflect the current state of clinical management of coinfected individuals. 
Follow-up prior to 1
st
 January 2000 would likely include individuals receiving what today 
would be considered sub-optimal antiretroviral therapy. As one of the aims of this study 
was to provide guidance on who to prioritise for treatment with new DAA drugs for HCV, 
follow-up was also censored at the date of starting interferon-based treatment for HCV. 
 
7.3.2 Statistical methods 
Causes of death in this analysis were classified using the CoDe methodology described in 
the methodology chapter of this thesis. For the purpose of analysis deaths were classified 
into the following categories: LRD, AIDS-related death, non-LRD/non-AIDS-related death 
and unknown causes of death. Non-LRD/non-AIDS-related death includes causes of death 
such as bacterial infections, cardiovascular events, drug and accidental death, and cancer. 
However, hepatocellular carcinoma is included in the LRD category along with liver failure, 
cirrhosis or complications as a result of HCV or HBV infection. 
 
Throughout this analysis baseline was defined as 1
st
 January 2000, entry into EuroSIDA if 
this was after 1
st
 January 2000, or the first fibrosis measurement available after HCVAb 
positivity if this occurred after entry into EuroSIDA. Crude death rates were calculated per 
1000 person years follow-up (PYFU), with follow-up counted till the last study visit, death or 
initiation of interferon-based treatment. Crude death rates were calculated using time-
updated variables so that an individual negative for HCV RNA contributed PYFU to the 
HCV RNA negative category until they became HCV RNA positive, at which point they 
contributed PYFU to the HCV RNA positive category. Crude death rates were stratified by: 
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Figure 7.4 Analysis population inclusion criteria and baseline HCV RNA and liver 
fibrosis status 
 
 
 
 
 HIV transmission risk group 
 Age 
 Region of EuroSIDA (see Chapter 3 Section 3.1.1) 
 HCV viremia status (positive, negative, unknown) 
 Hepatitis B surface antigen status (HBsAg) (positive, negative, unknown) 
 CD4 cell count 
 HIV RNA 
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 Reported alcohol abuse (none, current, unknown) 
 Liver fibrosis staging (estimated Metavir stages F0/F1, F2/F3, F4 and unknown) 
 
Qualitative clinician-reported data on alcohol abuse was added to the EuroSIDA data 
collection form in 2010. Alcohol abuse is defined as >25 units consumed per week for 
males and >20 units consumed per week for females. Based on these criteria the acting 
clinician records whether the individual is an alcohol abuser or not. Unfortunately, the 
number of units consumed each week is not collected, partially due to the difficulty in 
accurately collecting this data in the clinical setting. 
 
A combined definition of the liver fibrosis staging was used throughout the analysis 
presented in this chapter according to the Metavir scoring system
420
 (see Chapter 2 Section 
2.2.5.3 for a description of liver fibrosis staging). F0/F1 fibrosis was defined from validated 
liver biopsy, Fibroscan® measurements <7.6Kpa, an APRI score <1.5 and hyaluronic acid 
(HA) measurements <100ng/ml. F4 fibrosis was defined from validated liver biopsy, 
Fibroscan® measurements >12.5Kpa, and APRI score >2 and HA measurements 
>250ng/ml, in line with previous EuroSIDA work and other studies of HCV infection
660-662
. 
Where more than one fibrosis measurement is available for each individual at each time 
point they are prioritised in the order given above. For example, if an individual had liver 
biopsy and Fibroscan® data at the same time point the liver biopsy would take precedence. 
 
Univariable Poisson regression was used to model changes in the overall incidence of LRD 
over time. An interaction term comparing Western Europe and Argentina with Eastern 
Europe was tested to determine whether the incidence of LRD over time differed by region 
of EuroSIDA. Separate Poisson models were then used to describe changes in the 
incidence of LRD in both of these regions over time. Time-updated CD4 cell count and liver 
fibrosis staging variables were then added in turn to these models to assess the impact 
they have had on changes in the incidence of LRD. 
 
Cox proportional hazards regression, adopting the Fine and Gray methodology of 
competing risks, was used to describe factors associated with progression to LRD
519
. The 
competing risks accounted for were death from causes other than LRD and loss to follow-
up, defined as no contact with a EuroSIDA clinical site in the year prior to the median date 
of last follow-up for the entire EuroSIDA cohort. Multiple imputations, with four sets of 
replication, were used to impute missing data on HCV RNA, HCV genotype, HBsAg status 
and fibrosis staging, only those who were positive for HCV RNA were then included in the 
analysis. The following baseline covariates were included in the model: 
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 Age 
 Gender 
 Race 
 Calendar year 
 HIV transmission risk group 
 Region of EuroSIDA (see Chapter 3 Section 3.1.1) 
 Previous cardiovascular events (stroke, myocardial infarction, angina, 
endarterectomy, high blood pressure) 
 Previous diabetes diagnosis 
 HCV genotype 
 CD4 cell count 
 Nadir CD4 cell count 
 HIV RNA 
 HBsAg status (positive, negative) 
 Minimum duration of HCV infection 
 Liver fibrosis staging (estimated Metavir stages F0/F1, F2/F3 or F4) 
 
Minimum duration of HCV infection is the length of time prior to baseline that each 
individual had their first documented positive HCV antibody (HCVAb) or HCV RNA test 
result. Interaction terms between liver fibrosis staging, CD4 cell count and age were also 
tested to see if the effect of liver fibrosis on LRD was modified by CD4 cell count or age. 
 
For comparison, a similar Cox Proportional hazards model using the Fine and Gray 
methodology of competing risks was used to describe factors associated with AIDS and 
non-AIDS/non-LRD death. The competing risks accounted for in this analysis were death 
from causes other than AIDS and non-AIDS/non-LRD and loss to follow-up, defined in the 
same way as above. The baseline covariates listed above were also adjusted for in this 
model. 
 
Non-parametric cumulative incidence functions, which are not biased by the presence of 
competing risks, were then calculated to estimate the 5-year probability of LRD according 
to liver fibrosis staging and CD4 cell count.  
 
Fine and Gray models and cumulative incidence functions were estimated using the 
%PSHREG and %CIF validated SAS macros
663;664
.  
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7.4 Results 
7.4.1 Generalizability and baseline characteristics 
During the population selection process for this analysis 885/4,826 HCVAb positive 
individuals were excluded from the study as they did not have follow-up available after 1
st
 
January 2000. A total of 3,941 coinfected individuals were included in the analysis (see 
Figure 7.4). Multivariable logistic regression, adjusted for the covariates listed above, was 
used to consider how those included in the analysis differed from those that were excluded. 
 
Those without follow-up after 1
st
 January 2000 were less likely to reside in Western Europe 
(adjusted odds ratio (aOR): 0.70 (95% CI 0.52 – 0.95; P=0.0041)) and more likely to reside 
in Eastern Europe (aOR: 2.03 (1.38 – 2.99; P<0.0001)), compared with Southern Europe. 
They also had lower CD4 cell counts (aOR: 0.77 (0.69 – 0.86; P<0.0001) per doubling), 
higher CD4 cell count nadirs (aOR: 1.16 (1.07 – 1.26; P=0.0005) per doubling) and were 
far more likely to have unknown fibrosis staging (aOR: 82.4 (57.5 – 118.2; P<0.0001)) at 
last follow-up, compared to those included in the analysis. 
 
A total of 670 deaths were recorded in the study population of 3,941 HIV/HCV coinfected 
individuals contributing a total of 16,091 person years of follow-up (PYFU) (median 3.5 
years per person (inter-quartile range (IQR) 1.3 – 6.4)) to January 2013. The overall 
incidence of all-cause mortality was 41.6 (95% CI 38.6 – 44.7) per 1000 PYFU. 145/670 
(21.6%) of all deaths were classified as liver-related giving an overall incidence of LRD of 
9.0 (7.6 – 10.5) per 1000 PYFU. 
 
Baseline characteristics of the 3,941 coinfected individuals included in the analysis are 
shown in Table 7.1 stratified by cause of death. The study population was mostly white 
(93.6%), males (67.9%) with a median age of 37 years. The majority of the study 
population resided in either Eastern (31.0%) or Southern Europe (25.5%), although all 
European regions were well represented. By far the most common route of HIV 
transmission was via injecting drug use (IDU) (70.0%) followed by heterosexual exposure 
(15.3%). The most frequent HCV genotype was G1 (24.3%) followed by G3 (14.2%), G4 
(6.8%) and G2 (1.3%), while 53.4% had no data on HCV genotype at baseline. 
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Table 7.1 Baseline Characteristics of all HIV/HCV coinfected individuals included in the analysis stratified by cause of death 
 
 Causes of death   
Median (IQR) 
%  
All 
(N=3941) 
LRD 
(N=145) 
AIDS 
(N=162) 
Non-LRD 
non-AIDS 
(N=233) 
Unknown causes 
(N=130) P-Value* 
Age  37 (31 - 43) 39 (35 - 43) 36 (31 - 42) 39 (34 - 46) 40 (35 - 46) 0.0004 
Baseline date  OCT2005 
(JUL2002 - 
JUL2008) 
DEC2001 (JAN2000 
- AUG2005) 
JAN2005 
(FEB2001 - 
JAN2008) 
MAR2003 (JAN2000 
- AUG2005) 
JUN2004 
(JAN2000 - 
JUL2006) 
<.0001 
Male  2677 (67.9) 103 (71.0) 117 (72.2) 180 (77.3) 95 (73.1) 0.52 
White  3687 (93.6) 136 (93.8) 158 (97.5) 221 (94.8) 112 (86.2) 0.0008 
Region of EuroSIDA South 1005 (25.5) 42 (29.0) 29 (17.9) 46 (19.7) 17 (13.1) <.0001 
 West Central 551 (14.0) 28 (19.3) 12 (7.4) 25 (10.7) 34 (26.2)  
 North 495 (12.6) 37 (25.5) 24 (14.8) 74 (31.8) 34 (26.2)  
 East Central 562 (14.3) 13 (9.0) 10 (6.2) 29 (12.4) 12 (9.2)  
 East 1223 (31.0) 23 (15.9) 80 (49.4) 54 (23.2) 31 (23.8)  
 Argentina 105 (2.7) 2 (1.4) 7 (4.3) 5 (2.1) 2 (1.5)  
HIV transmission 
route 
MSM 344 (8.7) 8 (5.5) 9 (5.6) 17 (7.3) 7 (5.4) 0.41 
 IDU 2760 (70.0) 113 (77.9) 122 (75.3) 188 (80.7) 106 (81.5)  
 Heterosexual 603 (15.3) 12 (8.3) 23 (14.2) 19 (8.2) 11 (8.5)  
 Other 234 (5.9) 12 (8.3) 8 (4.9) 9 (3.9) 6 (4.6)  
HCV-RNA status Negative 409 (10.4) 10 (6.9) 13 (8.0) 32 (13.7) 15 (11.5) <.0001 
 Positive 1831 (46.5) 87 (60.0) 55 (34.0) 120 (51.5) 67 (51.5)  
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 Causes of death   
Median (IQR) 
%  
All 
(N=3941) 
LRD 
(N=145) 
AIDS 
(N=162) 
Non-LRD 
non-AIDS 
(N=233) 
Unknown causes 
(N=130) P-Value* 
 Unknown 1701 (43.2) 48 (33.1) 94 (58.0) 81 (34.8) 48 (36.9)  
Minimum duration of 
HCV infection 
Years 2.8 (0.7 - 6.0) 4.1 (2.2 - 7.0) 2.1 (0.2 - 5.2) 4.0 (1.5 - 6.7) 3.9 (0.8 - 7.5) <.0001 
HCV genotype G1 959 (24.3) 47 (32.4) 25 (15.4) 52 (22.3) 34 (26.2) 0.0020 
 G2 52 (1.3) 2 (1.4) 4 (2.5) 3 (1.3) 4 (3.1)  
 G3 558 (14.2) 22 (15.2) 16 (9.9) 45 (19.3) 20 (15.4)  
 G4 268 (6.8) 8 (5.5) 4 (2.5) 9 (3.9) 9 (6.9)  
 Unknown 2104 (53.4) 66 (45.5) 113 (69.8) 124 (53.2) 63 (48.5)  
HBsAg status Negative 3338 (84.7) 116 (80.0) 136 (84.0) 202 (86.7) 104 (80.0) 0.0021 
 Positive 281 (7.1) 23 (15.9) 17 (10.5) 18 (7.7) 8 (6.2)  
 Unknown 322 (8.2) 6 (4.1) 9 (5.6) 13 (5.6) 18 (13.8)  
CD4 cell count Cell/mm
3
 382 (239 - 563) 216 (100 - 393) 200 (76 - 357) 303 (153 - 515) 277 (140 - 485) <.0001 
CD4 nadir Cell/mm
3
 166 (72 - 288) 96 (36 - 200) 101 (28 - 205) 115 (52 - 220) 113 (50 - 211) 0.29 
HIV RNA <400copies/m
l 
2048 (59.0) 60 (44.8) 27 (24.1) 105 (49.1) 51 (45.5) 0.0002 
Liver fibrosis F0/F1 2543 (64.5) 33 (22.8) 66 (40.7) 116 (49.8) 52 (40.0) <.0001 
 F2/F3 211 (5.4) 17 (11.7) 7 (4.3) 11 (4.7) 10 (7.7)  
 F4 322 (8.2) 38 (26.2) 13 (8.0) 19 (8.2) 15 (11.5)  
 Unknown 865 (21.9) 57 (39.3) 76 (46.9) 87 (37.3) 53 (40.8)  
 
*P-value from Kruskal-Wallis or Chi-square test comparing the individual causes of death 
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LRD: Liver-related death; MSM: Men who have sex with men; IDU: Injecting drug users; HBsAg: Hepatitis B surface antigen 
Alcohol abuse is omitted from this table as it was added to the EuroSIDA CRF in 2010. During follow-up, 60.5% of the study population have information 
on alcohol abuse with 13.4% reporting current alcohol abuse. 
Baseline defined as 1
st
 January 2000, entry into EuroSIDA if this was after 1
st
 January 2000, or the first fibrosis measurement available after HCVAb 
positivity if this occurred after entry into EuroSIDA. 
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Interestingly, Eastern Europe, as the largest contributor of participants to the study, 
accounted for 49.4% of all AIDS-related deaths but only 15.9% of LRDs. In comparison, 
Southern Europe, the second largest contributor of participants in the study, accounted for 
far fewer AIDS-related deaths (17.9%) and more LRDs (29.0%) (P<0.0001). Further, 60% 
of those who died of LRD were HCV RNA positive compared with 34.0% of those who died 
of AIDS (P<0.0001), although a large proportion of those who died of AIDS had unknown 
HCV RNA (58.0%). A higher proportion of those who died of LRD were also hepatitis B 
surface antigen (HBsAg) positive (15.9%) compared with those who died of AIDS (10.5%) 
(P=0.0021). 
 
At baseline 78.1% of the coinfected individuals included in the analysis had available data 
on liver fibrosis. Overall, 64.5% had F0/F1 fibrosis, 5.4% F2/F3 fibrosis and 8.2% F4 
fibrosis. Among those who died of LRD, 26.2% had F4 fibrosis at baseline and 22.8% had 
F0/F1. In comparison, of those who died of AIDS just 8.0% had F4 fibrosis at baseline and 
40.7% had F0/F1 (P<0.0001). 
 
7.4.2 Crude death rates 
The most common causes of death recorded in this study were AIDS (24.2%) and LRD 
(21.6%), followed by unknown causes (19.4%), drug/violent death (9.6%), bacterial 
infection (7.9%), cardiovascular disease (6.9%) and cancer (4.5%). Crude death rates 
(cDR) for LRD, AIDS, non-LRD/non-AIDS and unknown causes of death, stratified by 
demographics and HCV-related factors are shown in Table 7.2. 
 
All-cause mortality and non-LRD rates were consistently higher in those aged 55 and over, 
however, LRD rates peaked in the years 35-45 at 12.0 (95% CI 9.4 – 14.7) per 1000 PYFU 
before tapering off in later life (45-55: 9.9 (6.9 – 12.8); >55: 6.7 (1.4 – 12.0)). LRD rates 
were 2-fold higher among those positive for HCV RNA compared with those negative for 
HCV RNA (cDR 10.1 (8.1 – 12.2) and 5.6 (2.5 – 8.6) per 1000 PYFU, respectively). LRD 
rates were also 2.5-fold higher in those positive for HBsAg compared with HBsAg negative 
(cDR 21.3 (12.9 – 29.7) and 8.3 (6.8 – 9.8) per 1000 PYFU, respectively). 
 
Current alcohol abuse was consistently associated with higher cDRs overall and for each 
cause of death. LRD rates were 13-fold higher among current alcohol abusers compared 
with those reporting no alcohol abuse (cDR 36.8 (95% CI 18.5 – 55.0) and 2.9 (1.0 – 4.8) 
per 1000 PYFU, respectively). Advanced levels of liver fibrosis were also consistently 
associated with higher cDRs for each cause of death. Those with F4 fibrosis were at 4-fold 
increased risk of non-LRD/non-AIDS-related death (cDR 30.7 (21.0 – 40.5) and 7.9 (6.1 – 
9.7) per 1000 PYFU, respectively) and 2.5-fold increased risk of AIDS-related death  
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Table 7.2 Crude Death Rates among the whole analysis population stratified by cause of death 
 
 Cause of death  
Patient Strata 
Overall 
(N=670) 
Liver-related 
(N=145) 
AIDS 
(N=162) 
Non-LRD/ Non-
AIDS 
(N=233) 
Unknown 
(N=130) 
Age 
  < 35 31.8 (26.6 - 37.1) 4.0 (2.1 - 5.9) 11.7 (8.5 - 14.9) 11.5 (8.3 - 14.7) 4.7 (2.6 - 6.7) 
  35 ≤ age < 45 44.0 (39.1 - 49.0) 12.0 (9.4 - 14.7) 11.0 (8.5 - 13.5) 13.6 (10.8 - 16.4) 7.5 (5.4 - 9.5) 
  45 ≤ age < 55 40.6 (34.7 - 46.5) 9.9 (6.9 - 12.8) 6.7 (4.2 - 9.1) 14.2 (10.7 - 17.7) 9.9 (6.9 - 12.8) 
  ≥ 55 75.6 (58.3 - 92.8) 6.7 (1.4 - 12.0) 12.2 (5.0 - 19.4) 36.7 (24.4 - 49.0) 20.0 (10.9 - 29.2) 
Region of EuroSIDA 
  South 30.9 (25.7 - 36.0) 9.7 (6.8 - 12.6) 6.7 (4.3 - 9.1) 10.6 (7.6 - 13.7) 3.9 (2.1 - 5.8) 
  West Central 40.9 (33.0 - 48.7) 11.6 (7.3 - 15.8) 5.0 (2.2 - 7.7) 10.3 (6.3 - 14.3) 14.0 (9.4 - 18.7) 
  North 81.0 (69.3 - 92.7) 17.7 (12.1 - 23.4) 11.5 (6.9 - 16.1) 35.5 (27.5 - 43.4) 16.3 (10.9 - 21.7) 
  East Central 22.3 (16.9 - 27.7) 4.5 (2.1 - 7.0) 3.5 (1.3 - 5.6) 10.1 (6.4 - 13.8) 4.2 (1.8 - 6.5) 
  East 48.1 (41.4 - 54.8) 5.9 (3.5 - 8.3) 20.5 (16.0 - 24.9) 13.8 (10.2 - 17.5) 7.9 (5.1 - 10.7) 
  Argentina 34.4 (17.8 - 50.9) 4.3 (0.0 - 10.2) 15.0 (4.0 - 26.1) 10.7 (1.4 - 20.1) 4.3 (0.0 - 10.2) 
HCV RNA Status* 
  HCV RNA Negative 32.5 (25.3 - 39.6) 5.6 (2.5 - 8.6) 6.4 (3.2 - 9.6) 13.7 (9.0 - 18.4) 6.8 (3.5 - 10.2) 
  HCV RNA Positive 39.1 (35.1 - 43.0) 10.1 (8.1 - 12.2) 6.7 (5.0 - 8.3) 14.3 (11.9 - 16.7) 8.0 (6.2 - 9.8) 
  Unknown 51.8 (45.3 - 58.3) 8.5 (5.8 - 11.2) 19.1 (15.0 - 23.1) 15.2 (11.7 - 18.8) 9.0 (6.2 - 11.7) 
HBV Status* 
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 Cause of death  
Patient Strata 
Overall 
(N=670) 
Liver-related 
(N=145) 
AIDS 
(N=162) 
Non-LRD/ Non-
AIDS 
(N=233) 
Unknown 
(N=130) 
  HBsAg Negative 40.3 (37.0 - 43.5) 8.3 (6.8 - 9.8) 9.6 (8.0 - 11.2) 14.8 (12.8 - 16.8) 7.6 (6.2 - 9.1) 
  HBsAg Positive 61.3 (47.3 - 75.3) 21.3 (12.9 - 29.7) 16.9 (9.3 - 24.4) 15.1 (8.0 - 22.2) 8.0 (2.8 - 13.2) 
  Unknown 38.1 (24.9 - 51.2) 4.9 (0.1 - 9.7) 8.6 (2.3 - 14.9) 8.6 (2.3 - 14.9) 16.0 (7.4 - 24.6) 
Transmission Risk Group 
  MSM 32.7 (22.9 - 42.6) 6.4 (2.0 - 10.8) 7.2 (2.5 - 11.9) 13.6 (7.2 - 20.0) 5.6 (1.5 - 9.7) 
  IDU 45.5 (41.7 - 49.3) 9.7 (7.9 - 11.5) 10.5 (8.6 - 12.4) 16.2 (13.9 - 18.5) 9.1 (7.4 - 10.9) 
  Other 31.0 (25.0 - 37.0) 7.4 (4.5 - 10.4) 9.6 (6.3 - 13.0) 8.7 (5.5 - 11.9) 5.3 (2.8 - 7.8) 
CD4 Cell Count* 
  < 200 145.5 (130.7 - 
160.3) 
37.1 (29.1 - 45.0) 51.7 (42.4 - 61.0) 37.5 (29.6 - 45.5) 19.2 (13.5 - 25.0) 
  200 ≤ CD4 < 350 41.9 (35.3 - 48.4) 8.9 (5.8 - 12.0) 6.7 (4.0 - 9.4) 15.6 (11.6 - 19.7) 10.6 (7.3 - 14.0) 
  350 ≤ CD4 < 500 21.1 (16.5 - 25.7) 4.0 (2.0 - 6.0) 2.6 (1.0 - 4.3) 10.3 (7.1 - 13.5) 4.2 (2.2 - 6.3) 
  ≥ 500 16.1 (13.1 - 19.2) 2.2 (1.0 - 3.3) 1.1 (0.3 - 1.9) 7.8 (5.6 - 9.9) 5.1 (3.4 - 6.9) 
HIV RNA* 
  < 500 27.7 (24.6 - 30.7) 5.3 (4.0 - 6.7) 4.3 (3.1 - 5.5) 12.2 (10.2 - 14.3) 5.9 (4.4 - 7.3) 
  500 - 1,000 46.3 (24.8 - 67.7) 8.2 (0.0 - 17.4) 19.1 (5.1 - 33.0) 10.9 (0.3 - 21.5) 8.2 (0.0 - 17.4) 
  > 1,000 74.3 (65.8 - 82.8) 20.3 (15.8 - 24.9) 19.8 (15.3 - 24.3) 20.9 (16.3 - 25.5) 13.3 (9.6 - 17.0) 
Alcohol Abuse* 
  None 26.9 (21.2 - 32.6) 2.9 (1.0 - 4.8) 8.7 (5.5 - 12.0) 9.1 (5.7 - 12.4) 6.2 (3.4 - 8.9) 
  Current 110.3 (79.9 - 140.7) 36.8 (18.5 - 55.0) 34.3 (16.7 - 52.0) 27.0 (11.2 - 42.7) 12.3 (1.6 - 22.9) 
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 Cause of death  
Patient Strata 
Overall 
(N=670) 
Liver-related 
(N=145) 
AIDS 
(N=162) 
Non-LRD/ Non-
AIDS 
(N=233) 
Unknown 
(N=130) 
  Unknown 43.0 (39.5 - 46.6) 9.6 (7.9 - 11.3) 9.6 (7.9 - 11.3) 15.4 (13.3 - 17.6) 8.4 (6.8 - 10.0) 
Liver Fibrosis* 
  F0/F1 18.7 (16.0 - 21.5) 1.2 (0.5 - 1.9) 5.6 (4.1 - 7.1) 7.9 (6.1 - 9.7) 4.0 (2.7 - 5.3) 
  F2/F3 27.2 (15.1 - 39.2) 10.0 (2.6 - 17.4) 5.7 (0.1 - 11.3) 8.6 (1.7 - 15.4) 2.9 (0.0 - 6.8) 
  F4 103.8 (86.6 - 121.0) 42.4 (31.0 - 53.7) 14.1 (7.5 - 20.8) 30.7 (21.0 - 40.5) 16.6 (9.4 - 23.8) 
  Unknown 73.6 (66.2 - 81.1) 16.0 (12.5 - 19.6) 18.6 (14.7 - 22.4) 24.3 (19.9 - 28.6) 14.8 (11.3 - 18.2) 
 
All rates and 95% confidence intervals per 1000 PYFU 
*Time-updated variables 
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(cDR 14.1 (7.5 – 20.8) and 5.6 (4.1 – 7.1) per 1000 PYFU, respectively), compared with 
those with F0/F1 fibrosis. The rate of LRD clearly progressed as liver fibrosis levels 
increased. Those with F2/F3 (cDR 10.0 (2.3 – 17.4)) and F4 fibrosis (cDR 42.4 (31.0 – 
53.7)) were at 8-fold and 35-fold increased risk of LRD compared with those with F0/F1 
fibrosis (cDR 1.2 (0.5 – 1.9)). 
 
Low CD4 cell counts were also consistently associated with increased cDRs for all causes 
of death. The rates of all causes of mortality increased as CD4 cell count decreased with 
the most striking increase in mortality seen once CD4 cell counts fell below 200cell/mm
3
. In 
those with CD4 cell counts >500cells/mm
3
 the rates of AIDS and LRD were 1.1 (95% CI 0.3 
– 1.9) and 2.2 (1.0 – 3.3) per 1000 PYFU, whereas for those with <200cells/mm3 the rates 
were 51.7 (42.4 – 61.0) and 37.1 (29.1 – 45.0) per 1000 PYFU, respectively. 
 
7.4.3 Temporal changes in the rate of LRD 
Although LRD was one of the leading causes of death recorded over the study period, the 
overall incidence of LRD has declined from 23.3 (95% CI 11.2 – 35.3) per 1,000 PYFU in 
the year 2000 to 6.8 (0.9 – 12.8) in 2013. In univariable Poisson regression the overall 
incidence of LRD has declined 15% per year since 2000 (incidence rate ratio (IRR): 0.85 
(0.82 – 0.89; P<0.0001)) (Figure 7.5). However, there was also a highly significant 
interaction between the incidence of LRD over time and region of EuroSIDA (P=0.0071), 
including when restricting the follow-up period to 2005 onwards when data began to be 
collected in Eastern Europe (P=0.022). This indicates that changes in the incidence of LRD 
over time are different depending on region of EuroSIDA. 
 
Stratifying the analysis of LRD incidence by Western and Eastern European regions it 
appears that LRD rates in these groups have behaved quite differently over time. In 
Western Europe and Argentina the incidence of LRD has declined 16% per year since 
2000 (IRR: 0.84 (95% CI 0.80 – 0.88; P<0.0001)). However, in Eastern Europe the 
incidence of LRD has remained stable over time since 2005, when data began to be 
collected in the region, (IRR: 0.98 (0.87 – 1.09; P=0.76)) (Figure 7.6). 
 
Adjusting the model for Western Europe and Argentina for demographic factors and time-
updated CD4 cell count saw the yearly decline in the incidence of LRD reduced to   
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Figure 7.5 Incidence of liver-related death in EuroSIDA since 2000 
 
  
Figure 7.6 Incidence of liver-related death in EuroSIDA by region 
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Table 7.3 Effect of CD4 cell count and liver fibrosis levels on the incidence of LRD 
over time in EuroSIDA 
 
IRR (95% CI) per year 
Region 
Western Europe & Argentina Eastern Europe 
Univariable 0.84 (0.80 – 0.88; P<0.0001) 0.98 (0.87 – 1.09; P=0.76) 
Adjusted: Demographics* 0.82 (0.78 – 0.86; P<0.0001) 0.98 (0.88 – 1.09; P=0.66) 
 + CD4 0.87 (0.83 – 0.92; P<0.0001) 0.96 (0.86 – 1.08; P=0.54) 
+ Fibrosis 0.86 (0.81 – 0.91; P<0.0001) 1.02 (0.91 – 1.14; P=0.75) 
+ CD4 + Fibrosis 0.90 (0.85 – 0.96; P=0.0007) 0.99 (0.88 – 1.12; P=0.87) 
 
*Demographics: age, sex, race, HIV transmission risk group 
 
13% per year (aIRR: 0.87 (0.83 – 0.92; P<0.0001)) (Table 7.3). Similarly, adjusting this 
model for demographic factors and time-updated liver fibrosis levels saw the yearly decline 
in the incidence of LRD reduced to 14% per year (aIRR: 0.86 (0.81 – 0.91; P<0.0001)). 
When adjusting for demographic factors plus both CD4 cell count and liver fibrosis levels 
the decline in the incidence of LRD reduced to 10% per year (aIRR: 0.90 (0.85 – 0.96; 
P=0.0007)). 
 
Adjusting the Eastern Europe model for demographic factors, time-updated CD4 cell count 
and liver fibrosis levels did not make any notable change to the stability of the incidence of 
LRD over time seen in this region (Table 7.3). 
 
7.4.4 Factors associated with liver-related death 
Multivariable sub-distribution hazard ratio (sHR) estimates of factors associated with the 
cumulative incidence of LRD from Cox proportional hazards modelling, using the Fine and 
Gray methodology for handling competing risks, are shown in Figure 7.7. The strongest 
association with LRD was seen for liver fibrosis staging. F4 liver fibrosis was associated 
with a 6-fold increased risk of LRD (sHR: 6.25 (95% CI 4.08 – 9.58; P<0.0001)), while 
F2/F3 fibrosis was associated with a 2.5-fold increased risk of LRD (sHR: 2.52 (1.53 – 4.15; 
P<0.0001)), compared with F0/F1 fibrosis. 
 
HBsAg positive individuals were also at 2-fold increased risk of LRD (sHR: 2.15 (95% CI 
1.31 – 3.51; P=0.0024)) compared with those negative for HBsAg. Those with a minimum 
duration of HCV infection of more than 10 years were at 2-fold increased risk of LRD (sHR: 
1.95 (1.03 – 3.71; P=0.041)), compared with those with minimum durations of infection less 
than 2 years. Individuals with minimum durations of HCV infection between 2 and 10 years   
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Figure 7.7 Factors associated with sub-distribution hazards of liver-related death 
 
 
Additionally adjusted for: gender, race, calendar year, HIV transmission risk group, previous 
cardiovascular events, previous diabetes diagnosis, and HCV genotype  
 
were estimated to have 20% increased risk of LRD, however, this effect did not approach 
statistical significance (sHR: 1.21 (0.78 – 1.88; P=0.39)). Interestingly, middle age and not 
older age was found to be associated with an increased risk of LRD. Those aged between 
35 and 45 were at 60% increased risk of LRD compared with those aged less than 35 
(sHR: 1.61 (95% CI 1.01 – 2.57; P=0.045)). A similar effect was seen for those aged 
between 45 and 55 (sHR: 1.73 (0.94 – 3.16; P=0.078)), however, it did not quite reach 
statistical significance. 
 
CD4 cell count was also strongly associated with LRD. Each doubling of CD4 cell count 
was associated with a 17% reduction in the risk of LRD (sHR: 0.83 (95% CI 0.73 – 0.95; 
P=0.0052)). While baseline CD4 cell count was included in the model, nadir CD4 cell count 
was a non-significant predictor of LRD (P>0.2). However, when baseline CD4 cell count 
was omitted from the model nadir CD4 cell count became a significant predictor of LRD, 
with each doubling of nadir CD4 cell count associated with a 10% reduction in the risk of 
LRD (sHR: 0.90 (0.83 – 0.97; P=0.0045)). 
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Interaction terms between liver fibrosis staging and either CD4 cell count or age were 
tested in the multivariable model and found to be non-significant (P>0.3 and P>0.7, 
respectively), meaning that there was no evidence to suggest the effect of liver fibrosis on 
progression to LRD was modified by CD4 cell count or age. 
 
7.4.5 Factors associated with AIDS and non-AIDS/non-liver-related death 
Multivariable sub-distribution hazard ratio (sHR) estimates of factors associated with the 
cumulative incidence of AIDS and non-AIDS/non-LRD from Cox proportional hazards 
modelling, using the Fine and Gray methodology for handling competing risks, are shown in 
Figure 7.8. Older age was strongly associated with AIDs and non-AIDS/non-LRD, with 
increasing risk as age increased from 35-45 (sHR: 1.63 (95% C.I. 1.25 – 2.12; P=0.0003)) 
to 45-55 (sHR: 2.53 (1.83 – 3.50; P<0.0001)) and greater than 55 (sHR: 4.30 (2.46 – 7.53; 
P<0.0001)), compared with ages less than 35. As expected, low CD4 cell count was the 
strongest predictor of AIDS and non-AIDS/non-LRD (sHR: 0.79 (0.73 – 0.86; P<0.0001), 
per doubling). Similarly, higher HIV viral load was also strongly associated with AIDS and 
non-AIDS/non-LRD (sHR: 1.13 (1.05 – 1.23; P=0.0022) per log10 higher). The male sex 
(sHR: 1.39 (1.12 – 1.71; P=0.0022) compared with female) and residence in Northern 
Europe (sHR: 1.85 (1.34 – 2.55; P=0.0002)) or Eastern Europe (sHR: 2.33 (1.49 – 3.63; 
P=0.0002) compared with West Central Europe), were also associated with AIDS and non-
AIDS/non-LRD. However, in this multivariable model, the effects of minimum HCV infection 
duration and liver fibrosis staging did not approach statistical significance. 
 
7.4.6 Cumulative incidence of liver-related death 
The association between liver fibrosis staging, CD4 cell count and progression to LRD can 
be further illustrated by stratifying the cumulative incidence of LRD by these groups. 
Cumulative incidence functions for time to LRD, stratified by liver fibrosis staging, are 
shown in Figure 7.9. The cumulative incidence of LRD was strongly influenced by liver 
fibrosis stage, with highly statistically significant separation between the stratified 
cumulative incidence functions (P<0.0001). The 5-year probability of LRD was low in those 
with F0/F1 fibrosis (2.2% (95% CI 1.7 – 2.9)), but substantial in those with F2/F3 fibrosis 
(10.3% (7.6 – 13.5)) and higher still in those with F4 fibrosis (14.0% (10.3 – 18.3); P=0.038 
for comparison of F2/F3 and F4). 
 
Cumulative incidence functions for time to LRD, stratified by CD4 cell count and liver 
fibrosis staging, are shown in Figure 7.10. Due to low numbers of events and individuals in 
some groups fibrosis stages F2-F4 have been collected together while CD4 cell count is 
dichotomised at 300cells/mm
3
. The cumulative incidence of LRD was strongly influenced  
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Figure 7.8 Factors associated with sub-distribution hazards of non-liver-related 
death 
 
Additionally adjusted for: gender, race, calendar year, HIV transmission risk group, previous 
cardiovascular events, previous diabetes diagnosis, and HCV genotype 
 
by liver fibrosis staging and CD4 cell count, with highly statistically significant separation 
between the cumulative incidence functions (P<0.0001). The 5-year probability of LRD was 
low in those with F0/F1 fibrosis and CD4 cell count ≥300cells/mm3 (1.7% (95% CI 1.1 – 
2.5)), although a little higher in those with <300cells/mm
3
 (3.3% (2.2 – 4.8)). However, the 
5-year probability of LRD was substantial in those with ≥F2 fibrosis and ≥300cells/mm3 
(8.6% (5.9 – 11.9)) and higher still in those with <300cells/mm3 (15.3% (11.7 – 19.3)). 
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Figure 7.9 Cumulative incidence of LRD stratified by baseline liver fibrosis 
 
 
Figure 7.10 Cumulative incidence of LRD stratified by baseline liver fibrosis and CD4 
cell count 
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7.5 Discussion 
 
Liver fibrosis strongly associated with LRD 
This chapter described causes of death among HIV/HCV coinfected individuals, temporal 
changes in the incidence of LRD and factors associated with progression to LRD. The main 
findings of this analysis show that LRD, along with AIDS, was the most common cause of 
death in this population, highlighting the importance of appropriate HCV disease 
management in order to reduce the burden of LRD among HIV/HCV coinfected individuals. 
LRD occurred almost exclusively among those with ≥F2 fibrosis at baseline, with cDRs for 
LRD 8-fold and 35-fold higher among those with F2/F3 and F4 fibrosis compared with 
F0/F1 fibrosis. Further, the 5-year probability of LRD was low among those with F0/F1 
fibrosis, but substantial at 10.3% in those with F2/F3 fibrosis and as high as 14.0% in those 
with F4 fibrosis. 
 
Interestingly, high levels of liver fibrosis were not only associated with higher rates of LRD. 
AIDS and non-AIDS/non-LRD crude death rates were also substantially higher among 
those with F4 fibrosis, suggesting that high levels of liver fibrosis may be associated with a 
number of poor clinical outcomes not just those considered to be linked to the liver. 
However, in multivariable analysis while traditional risk factors for progression to AIDS and 
non-AIDS/non-LRD were present, such as low CD4 cell count, high HIV viral load and older 
age, liver fibrosis staging was not found to be a significant predictor. Clearly there are many 
competing risks encountered by HIV/HCV coinfected individuals and identifying those most 
likely to progress to LRD is essential when deciding who to treat with new DAAs for 
treatment of HCV. 
 
These findings are in agreement with a recent study from the Veterans Aging Cohort Study. 
Including 4,280 ART-treated HIV/HCV coinfected individuals over a follow-up period of 
1997-2010 the authors found that low levels of liver fibrosis (Metavir F0/F1), as measured 
by the FIB-4 index, were associated with a minimal 5-year risk of end stage liver disease 
(ESLD). However, the 5-year risk of ESLD increased to 17% for those with F3/F4 
fibrosis
665
. The agreement of these two large studies suggests that liver fibrosis staging 
should be considered the most important risk factor for LRD. Further, after assessing the 
risk of death from non-liver-related causes, treatment with new DAAs should be prioritised 
for those with ≥F2 fibrosis. 
 
Current European HCV treatment guidelines recommend deferring HCV treatment in those 
with F0/F1 liver fibrosis, while treatment is encouraged for those with significant liver 
fibrosis (≥F2)416. Given the very low risk of LRD seen for those with F0/F1 fibrosis in this 
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study, this is a stance that is strongly supported by the findings presented here. However, 
these recommendations also require that treatment of HCV remains successful in those 
with higher levels of liver fibrosis and that fibrosis levels may regress when HCV RNA is 
eradicated, leading to fewer LRDs. Although DAA therapy is in its infancy and will require 
long-term follow-up to detail the full benefits of treatment, data is available from more 
traditional interferon-based treatment.  
 
In 2009 George et al reported on 150 HCV-monoinfected individuals followed-up for 5 
years after achieving SVR from HCV treatment. Those with significant liver fibrosis at SVR 
had subsequent liver biopsies performed after 4 years of follow-up and 82% had improved 
liver fibrosis scores, while 92% improved at least one component of liver inflammation
666
. 
However, the authors also state that there were 16 individuals with cirrhosis prior to 
treatment and that two of these (12.5%) developed HCC even after achieving SVR. 
Therefore, although there is evidence that liver histology improves after SVR, there remains 
a residual risk of HCC, especially in those with cirrhosis
666
.  
 
In 2007 Bruno et al reported retrospective data on 920 HCV-monoinfected individuals with 
cirrhosis between 1992 and 1997, showing that those who did not achieve SVR were at 7-
fold increased risk of LRD and 2.5-fold increased risk of HCC
667
. While these data are 
based on HCV-monoinfection, the lower rates of SVR from interferon-based treatment 
typically seen for HIV/HCV coinfected individuals appears to be a thing of the past with new 
DAA therapies
668;669
. 
 
CD4 cell count and HBV coinfection strongly associated with LRD 
In this study, in addition to significant liver fibrosis, concurrent HBV coinfection, lower CD4 
cell count and minimum duration of HCV infection were all associated with LRD in 
multivariable analysis. Further, when baseline CD4 cell count was omitted from the model, 
nadir CD4 cell count was also strongly associated with LRD. Taken together these findings 
suggest that efforts to reduce late presentation of coinfected individuals are essential so 
that current treatment guidelines can be employed in HIV/HCV coinfected individuals. ART 
should be initiated early during the course of HIV progression and in the case of concurrent 
HBV coinfection should contain potent HBV-active treatment
416
. These recommendations, if 
applied correctly, should reduce the risk of prolonged time spent with low CD4 cell counts 
and uncontrolled HBV coinfection, which would reduce the risk of progression to LRD. 
 
Although the interaction between CD4 cell count and liver fibrosis staging did not approach 
statistical significance during multivariable modelling, there was some evidence from the 
stratified cumulative incidence of LRD to suggest that the risk of LRD was higher among 
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those with ≥F2 fibrosis when baseline CD4 cell counts were below 300cells/mm3. Previous 
studies have consistently shown that low CD4 cell count, high HIV viral load and circulating 
HBV DNA are all associated with rapid progression of liver fibrosis levels
414;670;671
. Each of 
these risk factors can be controlled by initiating appropriate cART early in coinfected 
individuals, potentially reducing progression of liver fibrosis levels and therefore the need 
for expensive DAA therapy, which highlights the public health problems brought about by 
late presentation of HIV/HCV coinfection. 
 
Interestingly, ages between 35 and 45 were found to be associated with increased risk of 
LRD in this study, while ages between 45 and 55 were associated with LRD with borderline 
statistical significance. However, the effect sizes were comparable for those aged 35-45, 
45-55 and >55, which may suggest that the risk of LRD is increased but stable after the 
age of 35. Similarly, minimum duration of HCV infection was associated with LRD, with 
those diagnosed for ≥10 years at increased risk. As expected, older age was strongly 
associated with death from non-AIDS/non-LRD and unknown causes. In terms of 
competing risks this may serve to lower the risk of LRD in later life as death from other 
causes becomes more prominent, which may explain the flat association between age after 
35 and LRD. 
 
Alcohol abuse and LRD rates 
Coinfected individuals reporting current alcohol abuse were found to have 13-fold higher 
cDRs for LRD. However, data on alcohol abuse were only added to EuroSIDA in 2010 and 
40% of the study population had no alcohol abuse data available. Collection of data on 
alcohol abuse is often difficult in the clinical setting. Many factors are believed to affect the 
quality and reliability of data on alcohol abuse including, the characteristics of the 
participants, the question being asked and the manner of the assessor
672
. This and the fact 
that many individuals had missing data for alcohol abuse, means that the association 
between alcohol abuse and LRD should be interpreted with caution. 
 
Estimation of Fine and Gray competing risks models does not allow for simple 
interpretation of time-updating variables, while the aims of this study were to identify 
medium to long term risk factors associated with LRD, rather than the short term 
associations represented by time-updating covariates. Therefore, the effect of alcohol 
abuse on LRD was not assessed in the competing risks model. However, alcohol 
consumption is a known contributor to the rapid progression of liver fibrosis and acts 
synergistically with HCV infection to speed up the process further
393;673
. 
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HIV/HCV coinfected individuals should be warned of the potential for accelerated liver 
damage caused by drinking excessively during routine clinical care, with the aim to reduce 
alcohol intake and prevent the rapid development of fibrosis
674
. However, the reality is that 
many coinfected individuals belong to difficult to treat populations engaging in active IDU 
and alcohol abuse
675;676
, where optimal clinical management is not always possible. 
 
The incidence of LRD over time 
LRD rates were found to have decreased significantly over the period of follow-up of this 
study. This finding is in agreement with other recent studies mentioned in the introduction, 
which report reducing mortality rates among HIV-positive individuals from 2000 to 2010, 
particularly for LRD
372;373
. However, this study adds to this topic by presenting data on a 
large number of HIV/HCV coinfected individuals. While the overall trend was for reducing 
LRD rates, when stratifying by region of EuroSIDA it became clear that the reduction is 
driven by a fall in the rate of LRD in Western Europe and Argentina seen since 2005. Data 
available in Eastern Europe show that the rate of LRD has remained stable since the region 
was added to EuroSIDA in 2005.  
 
The reduction in the incidence of LRD seen in Western Europe was partly explained by 
changes in CD4 cell count and liver fibrosis levels over time. When adjusting for 
demographic factors, time-updating CD4 cell count and liver fibrosis stage the decline in 
LRD incidence reduced from 16% to 10% per year, a reduction of 38%. EuroSIDA is an 
open cohort that continues to recruit participants. These results suggest that improvements 
in CD4 cell counts over time, as a result of improvements in the efficacy and tolerability of 
cART regimens, along with lower fibrosis stages in newly recruited individuals, has 
contributed to the reduction in the incidence of LRD in Western Europe. However, a large 
proportion of this reduction over time cannot be accounted for in this analysis. One possible 
explanation could be a cohort effect where the individuals most likely to die of LRD do so 
early during follow-up leaving a relatively low-risk population with regards to LRD. 
 
Eastern Europe is well-known to have a large number of HIV/HCV coinfected individuals 
and accounted for 31.0% of the total study population
404
. However, the region accounted 
for just 15.9% of the LRDs recorded in this study. In comparison 49.4% of all AIDS-related 
deaths occurred in Eastern Europe, which illustrates the competing risks these individuals 
face. However, it is also highlights the imbalance in access to HIV treatment and care by 
region of Europe that has been reported previously in EuroSIDA
677
. Adjusting for CD4 cell 
count and liver fibrosis levels over time showed that 38% of the 16% reduction in the rate of 
LRD per year in Western Europe and Argentina was attributed to CD4 cell count and liver 
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fibrosis levels. However, adjusting for the same variables in Eastern Europe made little 
difference.  
 
With this in mind it is hard to imagine a scenario where wide-ranging access to expensive 
DAA therapies will be possible in Eastern European regions. Although the region contains 
the highest prevalence of HIV/HCV coinfection in Europe
678
, a comprehensive cART 
program aiming to reduce the excess AIDS-related death in the region is likely to see more 
benefit to public health than introduction of DAAs. Further, increasing CD4 cell counts with 
appropriate cART may also lead indirectly to lower rates of LRD
387
. 
 
HCV reinfection, sustained virologic response and all-cause mortality  
Unlike other viral infections, clearance of HCV infection with or without treatment infers only 
partial protection against reinfection
468
. Many studies have documented a high incidence of 
reinfection with HCV after viral clearance, particularly among IDUs
472
. In a recent EuroSIDA 
study 18% of all coinfected individuals that achieved spontaneous clearance became 
reinfected within a few years, with 94% of those having acquired HIV via IDU
679
. However, 
reinfection is not restricted to IDUs. Studies have also documented reinfection rates as high 
as 15% among MSM
474
. Consequently, in the setting of treatment prioritisation for DAA 
therapy, risk behaviour associated with reinfection must be a key consideration before 
initiating expensive treatment regimens. 
 
While HCV has traditionally been considered a disease of the liver, data is beginning to 
emerge which suggests that HCV eradication may lead to a reduction in all-cause 
mortality
680
. A recent study of a large number of HCV seropositive and seronegative 
individuals found that those positive for HCV were at increased risk of death from hepatic 
and extrahepatic diseases
681
. Potential reasons for the association between HCV infection 
and all-cause mortality include complications associated with fibrosis and cirrhosis or an 
inflammatory effect of circulating HCV RNA
682
. This study was designed to describe factors 
associated with progression to LRD among HIV/HCV coinfected individuals with chronic 
HCV infection prior to treatment for HCV. Therefore, it was not possible to determine the 
effect of HCV RNA eradication on overall mortality. However, in exploratory analysis I also 
found consistently higher cDRs among those HCV RNA positive compared with those HCV 
RNA negative. 
 
This emerging evidence, taken together with observed higher SVR rates among those with 
low levels of liver fibrosis and the potential reduction of onward transmission
446;659
, may 
mean that eventually it will be beneficial to treat all HIV/HCV coinfected individuals 
regardless of fibrosis staging
683
. In addition, recent analysis of the cost-effectiveness of 
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treating all HCV monoinfected individuals shows that it may indeed be a cost saving 
intervention
461;684
. However, while the pathways by which active HCV infection may be 
linked with non-LRD remain unclear and treatment remains prohibitively expensive, 
prioritisation of those at greatest risk of LRD is still necessary. The pathogenesis of liver 
disease varies among individuals and those who are not initially prioritised for new DAA 
therapies should maintain clinical care so that they may be monitored frequently for signs of 
progression of liver fibrosis. 
 
7.5.1 Limitations 
The main limitation of this study was that, due to limited power, it was not possible to 
compare the individual stages of liver fibrosis which were grouped as F0/F1, F2/F3 and F4 
fibrosis. Further, as the fibrosis data in this study are collected from a combination of 
clinical procedures and biomarkers, consensus on the definitions of the stages of fibrosis is 
difficult to attain. However, cut-off points at either end of the scale, low levels of fibrosis or 
cirrhosis, are relatively well-defined
589
. In particular, the APRI score, which is where the 
majority of fibrosis data are taken from in this study, has been validated in a number of 
studies
425;685
. However, misclassification of liver fibrosis levels in this study would make 
differentiation between the fibrosis stages less precise, which would lead to an under 
estimation of the differences between fibrosis stages with respect to progression to LRD. 
 
This study clearly identified a significant relationship between lower CD4 cell counts and 
progression to LRD. However, due to few LRDs among those with high CD4 cell counts it 
was not possible to perform analysis to determine the optimum time to start cART in to 
order to prevent progression to LRD.  
 
A further limitation of this study is that data were not complete at baseline. Multiple 
imputations were performed in order to impute the missing data; however, this is a well-
known statistical technique that produces unbiased estimates when data are missing 
completely at random (MCAR) or missing at random (MAR)
522
. The missing data in this 
analysis were HCV RNA, HCV genotype, HBsAg and fibrosis staging. Section 4.4.1 of this 
thesis showed that missing HCV RNA data was associated with Eastern Europe. Eastern 
Europe is more likely to have missing data than Western Europe due to differences in the 
quality of clinical management. However, this does not mean that the underlying 
distribution of people positive or negative for HCV RNA would be different in this region. 
Therefore, it is reasonable to assume these data are MAR. Similarly, any differences in the 
underlying distributions of HBsAg, HCV genotype and fibrosis staging between Eastern and 
Western Europe are likely to be explained by the observed variable region of EuroSIDA. 
Consequently, I believe it is reasonable to assume these data are MAR. In addition, the 
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amount of missing data was low for key variables in this analysis, such as liver fibrosis 
staging (21.9% missing). 
 
Alcohol abuse data was only available from 2010 onwards, meaning that for a large 
number of individuals this data was missing and it could not be included in competing risks 
modelling. Further, the quantitative nature of this data means that the amount of alcohol 
being consumed was not recorded, just whether the individual was considered an alcohol 
abuser. Therefore, it is not possible to determine a level of alcohol consumption that 
increases the risk of liver fibrosis and progression to LRD. Finally, minimum duration of 
HCV infection was found to be associated with progression to LRD in this study, calculated 
using each individual’s first recorded positive HCVAb or HCV RNA test result. However, 
this method is likely to underestimate the true duration of HCV infection in this population 
as seroconversion likely occurred around the same time as HIV infection. 
 
7.5.2 Conclusion 
New DAAs for treatment of HCV infection appear ready to offer impressive outcomes with 
better toxicity profiles than historical treatments. However, the costs of treatment will 
necessitate prioritisation of those at the greatest risk of LRD for therapy. In this regard, after 
considering the risk of death from competing risks and of potential reinfection, those with 
significant liver fibrosis (≥F2) should be prioritised for treatment with DAA therapy. Further, 
as part of a comprehensive strategy to prevent LRD in HIV/HCV coinfected individuals, 
greater emphasis should be given to identifying coinfected individuals as soon as possible. 
Coinfected individuals may then start cART early in the course of HIV infection, which in the 
case of concurrent HBV infection includes potent HBV active treatment, to prevent rapid 
progression of liver fibrosis and reduce the need for expensive DAA therapy. 
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Chapter 8 
 
A validated prognostic score for estimating the risk of 
liver-related death among HIV/HCV coinfected 
individuals 
 
8.1 Introduction 
 
The analysis in the previous chapter identified a number of factors that were associated 
with progression to liver-related death (LRD) among HIV/HCV coinfected individuals. 
Although useful, interpretation of these individual risk factors may prove to be difficult in the 
clinical setting due to interplay between the individual risk factors. Therefore, it may be 
beneficial to condense the information into a single prognostic score which can predict an 
individual’s risk of progression to LRD. 
 
Prognostic scores have been developed in many areas of clinical research. The main aim 
of developing tools such as these is to establish a single, directly comparable among 
individuals, statistic from a group of independent variables which have an effect on the 
course of disease or outcome of interest. One well-known prognostic score is the 
Framingham risk score, developed to predict progression to coronary heart disease (CHD) 
in the general population
686
.  
 
The Framingham risk score takes information derived from a population study associating 
progression to CHD with blood pressure, total cholesterol, LDL cholesterol, HDL 
cholesterol, diabetes, smoking status and age, and combines them into one single score 
from which each individual, or their clinician, can estimate their 10-year risk of CHD and 
compare themselves to an average person of a similar age
686
. Importantly, the authors of 
the score provide easy to follow step-by-step instructions on how to calculate the risk score 
based on clinical markers, without the need for detailed knowledge of the background 
statistical process. It is this step that I want to emulate here so that the information derived 
in the previous chapter can be readily used in the clinical setting. 
 
The c-statistic 
The receiver operating characteristic (ROC) curve provides a global standardised method 
for comparing the accuracy of markers and prognostic scores in predicting binary events. 
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The ROC curve plots the sensitivity of a prognostic score against one minus its specificity 
(1-specificity). In other words, the curve plots the true-positive rate against the false-
positive rate of a marker of a binary outcome
687
. Plotting the ROC curve then allows for 
calculation of the area under the ROC curve, which is known as the c-statistic
687
.  
 
The c-statistic allows direct comparison between independent prognostic scores in order to 
compare their ability to predict an event. A c-statistic of 1 indicates perfect identification of 
those who will and won’t progress to an event. A c-statistic of 0.5 indicates that the marker 
or score performs no better than chance at determining progression to the event
687
. 
Consequently, the c-statistic takes values between 0.5 and 1, with improving performance 
as the value moves towards 1. As a rule of thumb a marker with a c-statistic greater than 
0.7 is considered to have reasonable predictive ability, above 0.8 strong predictive ability, 
and above 0.9 excellent predictive ability
687
. 
 
8.1.1 Prognostic scores in HIV- and HCV-related research 
 
8.1.1.1 The VACS Index 
A number of prognostic risk scores have been developed in HIV- and HCV-related 
research. In 2013 the veterans aging cohort study (VACS) group set out to explain excess 
mortality among HIV-positive individuals taking cART. For HIV-positive individuals taking 
cART, AIDS-defining events are rare and HIV viral loads are usually very low or 
undetectable. However, these individuals continue to have excess mortality in comparison 
to demographically matched controls without HIV. Further, the excess mortality does not 
appear to be explained simply by differences in CD4 cell count
688-690
.  
 
In an attempt to predict mortality among HIV-positive individuals taking effective cART the 
VACS study group developed two prognostic scores for predicting all-cause mortality, the 
VACS Index and the Restricted Index. The Restricted Index contained the traditional HIV-
associated risk factors CD4 cell count, HIV viral load and age, while the VACS index also 
included haemoglobin, a FIB-4 estimation of liver fibrosis staging, eGFR and whether an 
individual had HCV infection
688. For each index an individual’s score is calculated by 
summing the appropriate score contributions associated with their demographic and clinical 
characteristics. 
 
The results of the study show that higher scores from the VACS Index and the Restricted 
Index were associated with progression to all-cause mortality
688
. Further, the VACS Index 
outperformed the Restricted Index at discriminating between those who died and did not 
die after 5-years of follow-up. The VACS Index had a c-statistic of 0.78 in the derivation 
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cohort and 0.82 in the validation cohort, while the Restricted Index had c-statistics of 0.72 
and 0.78, respectively
688
. As the VACS Index outperformed the Restricted Index the 
authors concluded that accounting for multiple organ system injury, including the liver and 
kidneys by using fibrosis staging and eGFR, allowed for more accurate identification of 
HIV-positive individuals taking cART at increased risk of death compared to the general 
population
688
. 
 
One of the strengths of the VACS index is that it was validated in an external cohort. The 
validation took place in the antiretroviral treatment cohort collaboration (ART-CC), which is 
a set of six HIV cohorts independent of the VACS
688
. Validation of prognostic scores is 
important to show that they are generalizable to the general population. It is possible that a 
prognostic score developed in one cohort will not accurately reflect the risk of an event in 
another cohort because there are underlying differences in the population characteristics. 
For this reason it is usually expected that the ability of a prognostic score to predict an 
event will be somewhat lower in a validation cohort compared to the derivation cohort. 
However, the VACS index actually performed slightly better in the validation cohort, 
illustrating its excellent generalisability
688
. 
 
8.1.1.2 Child-Pugh and MELD scores 
A number of prognostic scores exist to quantify the risk of mortality in the general 
population in individuals with cirrhosis. The Child-Pugh score, originally derived as the 
Child score in the 1960s, has five components which were selected empirically based on 
clinical expertise
691-693
. The five components include 3 continuous variables (bilirubin, 
albumin and prothrombin) and 2 quantitative variables (the degree of encephalopathy and 
ascites) which are believed to reflect the function of the liver (Table 8.1)
691-693
. The Child-
Pugh score is calculated by summing the points associated with each component for a 
patient’s profile. 
 
The main application of the Child-Pugh score has been as a descriptive tool at the bedside 
to quantify an individual’s risk status693; however, it has also been used as patient selection 
criteria for hepatocellular carcinoma surgical removal or for extrahepatic surgery
694;695
. In 
addition, the Child-Pugh score has been shown to have prognostic value in the setting of 
liver surgery, alcoholic cirrhosis, HCV-related cirrhosis and subclinical encephalopathy
696-
699
. 
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Table 8.1 The Child-Pugh score
693
 
Points 1 2 3 
Encephalopathy None Minimal Advanced 
Ascites Absent  Controlled Refractory 
Bilirubin (µmol/l) <34 34 - 51 >51 
Albumin (g/l) >35 28 - 35 <28 
Prothrombin (s) <4 4 - 6 >6 
 
 
Although the Child-Pugh score is simple to calculate and has been shown to have many 
useful applications, it is often considered limited by the fact the components were chosen 
empirically and that they are all weighted equally
693
. The MELD score, which was 
developed to predict survival in cirrhotic patients following transjugular intrahepatic 
portosystemic shunt (TIPS), attempts to address these issues
700
. The MELD score was 
derived using a multivariable Cox proportional hazards model to identify variables which 
had an independent effect on survival. The current score is calculated based on three 
continuous variables (creatinine, bilirubin and international normalised ratio (INR)) plus a 
constant (Equation 8.1)
693
. 
 
Equation 8.1 The MELD score formula
693
 
𝑀𝐸𝐿𝐷 = 9.6𝑙𝑜𝑔𝑒(𝑐𝑟𝑒𝑎𝑡𝑖𝑛𝑖𝑛𝑒 𝑚𝑔/𝑑𝑙) + 3.8𝑙𝑜𝑔𝑒(𝑏𝑖𝑙𝑙𝑖𝑟𝑢𝑏𝑖𝑛 𝑚𝑔/𝑑𝑙) + 11.2𝑙𝑜𝑔𝑒(𝐼𝑁𝑅) + 6.4 
 
The MELD score has since been used for prioritising cirrhotic patients for the allocation of 
liver grafts and determining the optimal indication for liver transplantation and has been 
validated in many independent samples
693;700;701
. However, the MELD score does not allow 
for direct estimation of an individual’s probability of survival. Survival probabilities must be 
computed from the survival function or looked up using a reference normogram. 
Unfortunately, this means the MELD score is often not considered applicable for use at the 
bedside in a clinical setting
693;700
. 
 
The Child-Pugh and MELD scores have been compared in many settings with regards to 
short term mortality. In general they appear to display similar levels of discrimination, with 
c-statistics ranging from 0.65 to 0.85, indicating reasonable to strong predictive capabilities 
(Table 8.2)
702-705
. However, none of these studies included HIV or HCV positive individuals 
and to my knowledge these scores have never been validated in these populations. They 
instead focus on individuals from the general population with advanced liver disease or 
cirrhosis.  
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Table 8.2 Prognostic ability of the Child-Pugh and MELD scores as measured by the 
c-statistic 
Study population (Year) N. 
included 
(deaths) 
Study endpoints c-statistic 
Child-Pugh MELD 
TIPS (2002)
702
 475 (230) 1-month mortality 0.78 0.73 
3-month mortality 0.70 0.72 
1-year mortality 0.66 0.66 
TIPS (2003)
703
 162 (81) 1-month mortality 0.71 0.72 
3-month mortality 0.67 0.73 
1-year mortality 0.74 0.73 
Cirrhosis (2003)
704
 3,437 (412) 3-month mortality 0.76 0.83 
Liver disease (2004)
705
 1,611 (321) 3-year mortality 0.83 0.79 
 
 
8.1.2 Prioritisation of direct-acting antiviral therapy for HCV 
The new direct-acting antivirals (DAA) for HCV were discussed in detail in Section 2.2.6 of 
the introduction to this thesis. However, the anticipated costs of new DAAs for treatment of 
HCV are expected to approach €90,000 per individual treatment, with the expectation that 
all-oral regimens will be more expensive still
2
. Therefore, a number of studies have turned 
their attention to the cost-effectiveness of these new therapies. Two recent studies in 2014 
by Younossi et al and Leleu et al have used Markov chain models to simulate the 
progression of liver-disease among HCV-monoinfected individuals
684;706
.  
 
Using sustained virologic response (SVR) rates estimated from clinical trials data, the 
Younossi study found that treating HCV-monoinfected individuals with all-oral interferon-
free DAA regimens drastically reduced the number of individuals developing advanced liver 
disease
706
. The reduced lifetime costs associated with fewer people progressing to 
advanced liver disease meant that the authors concluded that treating all HCV-
monoinfected individuals would be a cost effective strategy in the long term. The authors 
estimated that treating all individuals with all-oral DAAs would lead to an effective cost of 
each quality adjusted life year added (QALY) of $18,391, compared to interferon-based 
triple therapy. This means that each additional year of life that would have otherwise been 
lost in the absence of treatment will cost $18,391
706
. In the United States treatments are 
considered to be cost effective up to $50,000 per QALY
706
. However, the study also reports 
that a fibrosis staging guided approach would be the most cost effective strategy. When all-
oral DAA regimens were given only to those with F2-F4 liver fibrosis the effective cost of 
each QALY reduced to $17,529
706
. 
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The Leleu study followed a very similar methodology but only considered treatment 
regimens including the recently approved DAA sofosbuvir. Here the authors also noted that 
vast reductions in expensive-to-treat advanced liver diseases lead to generally acceptable 
levels of cost effectiveness for sofosbuvir treatments, in comparison to interferon-based 
triple therapy
684
. The authors concluded that sofosbuvir-based treatment would lead to an 
effective $40,653 cost per QALY added among individuals with F0 fibrosis. However, this 
figure was $31,348 among those with F1 fibrosis and reduced to $17,651, $11,359 and 
$12,080 among those with F2, F3 and F4 fibrosis, respectively
684
. Treating individuals with 
more advanced levels of fibrosis becomes more cost effective as they are more likely to 
progress to advanced liver disease without therapy, which would necessitate expensive 
care and may lead to LRD. 
 
Current European HCV treatment guidelines tend to reflect these findings as they 
recommend treatment for people with ≥F2 liver fibrosis while suggesting treatment may be 
postponed in those with <F2 fibrosis
416
. However, they do not address how patients should 
be prioritised when treatments are restricted due to costs or supply issues. The cost of 
treatment with new DAAs means that cost restrictions are likely to occur in many settings, 
not just those traditionally seen as resource-limited. Earlier this year the National Institute 
for health and Care Excellence (NICE) approved the use of sofosbuvir and simeprevir for 
treatment of HCV in the UK and concluded that they were cost-effective interventions
707
. 
However, for the first time since NICE started making cost-effectiveness recommendations 
the NHS postponed approval of these drugs on the basis that the upfront costs were 
currently too high to bear, regardless of the fact they were considered cost-effective in the 
long-term
708
. 
 
Given that the costs of DAAs are proving to be prohibitive in the UK, it is certain that many 
other countries and regions will struggle to meet the upfront costs of treatment in the short-
term. Two recent studies by Obach et al have attempted to provide guidance to those 
working in the resource-limited setting with regards to who should be prioritised for 
treatment for HCV in order to have the greatest impact on public health
709;710
. These 
studies also used Markov chain models to estimate the effect of different treatment 
strategies on the outcome of those infected with HCV. The authors state that treating HCV-
monoinfected individuals with ≥F2 fibrosis is cost-effective in Egypt, but that assuming new 
DAAs will be more readily available in a few years, those with F1 fibrosis should have 
treatment delayed
709
. In addition, using data from Egypt, Thailand and Ivory Coast the 
authors conclude that when the number of treatments available per year is fixed, whether 
interferon-free or interferon-based, the number of life years saved with treatment in the 
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countries listed above increases by 3.9%, 15.3% and 11.0% when restricting treatment to 
those with F3 or F4 fibrosis compared to treating those with ≥F2 fibrosis, respectively710. 
 
When considering HIV/HCV coinfection the issue of HCV treatment prioritisation becomes 
somewhat more complicated. Commentators and guidelines now suggest that, due to 
excellent and comparable efficacy of DAA treatments for HCV monoinfected and HIV/HCV 
coinfected individuals, HIV infection should no longer be considered a barrier to HCV 
treatment
416;711
. However, clinicians must bear in mind HIV- and HCV-related factors when 
considering the risk of progression to LRD. Liver fibrosis is one of the key markers of 
progression to LRD, but low CD4 cell counts as a consequence of HIV are known to 
contribute to rapid progression of liver fibrosis as well as being strongly linked with AIDS-
related death
414;671
. Consequently, analysis of competing risks is essential when deciding 
who to prioritise for treatment with new DAA therapies. 
  
240 
 
8.2 Aims 
 
The aims of this analysis were to identify factors associated with progression to LRD 
among HIV/HCV coinfected individuals and to create a simple, easily applicable prognostic 
score to identify those at the greatest risk of LRD. A prognostic score that can be calculated 
with ease by a clinician or HIV/HCV coinfected individual. Creating such a score will add to 
the body of research on HIV/HCV coinfection by making it possible to directly compare 
individual risk profiles with respect to progression specifically to LRD in the presence of 
competing HIV-related risks. In instances where new DAA treatments for HCV are limited 
by costs or availability to treatments, the prognostic score will aid clinicians when making 
difficult decisions on which HIV/HCV coinfected individuals should be prioritised for therapy. 
  
241 
 
8.3 Methods 
8.3.1 Patient selection  
The D40 update of the EuroSIDA database included 18,914 HIV-positive individuals from 
107 centres across Europe, Israel and Argentina. Figure 8.1 shows the breakdown of how 
individuals were selected for inclusion in this study. All EuroSIDA patients under 
prospective follow-up with documented HIV/HCV coinfection, as evidenced by a positive 
HCVAb test, and follow-up available after the 1st January 2000 were eligible for inclusion in 
this study. The D40 EuroSIDA database included 16,423 individuals with known HCVAb 
status, of whom 4,878 were positive and 4,011 had follow-up data recorded after 1st 
January 2000. 
 
Follow-up prior to 1st January 2000 was excluded from this study as I wanted the study 
population to reflect the current state of clinical management of coinfected individuals. 
Follow-up prior to 1st January 2000 would likely include individuals receiving what today 
would be considered sub-optimal antiretroviral therapy. As the main aim of this study was 
to create a prognostic score to help prioritise who should receive treatment with new DAA 
drugs for HCV, follow-up was also censored at the date of starting interferon-based 
treatment for HCV. 
 
8.3.2 Statistical methods 
Causes of death in this analysis were classified using the CoDe methodology described in 
the methodology chapter of this thesis
511;512
. For the purpose of analysis deaths were 
classified into the following categories: LRD and non-LRD. Non-LRD includes causes of 
death such as AIDS, bacterial infections, cardiovascular events, drug and accidental death, 
and cancer. However, hepatocellular carcinoma is included in the LRD category along with 
liver failure, cirrhosis or complications as a result of HCV or HBV infection. 
 
A combined estimated definition of liver fibrosis staging was used throughout this analysis 
according to the Metavir scoring system
420
 (see Chapter 2 Section 2.2.5.3 for a description 
of fibrosis staging). F0/F1 fibrosis was defined from validated liver biopsy, Fibroscan® 
measurements <7.6Kpa, an APRI score <1.5 and hyaluronic acid (HA) measurements 
<100ng/ml. F4 fibrosis was defined from validated liver biopsy, Fibroscan® measurements 
>12.5Kpa, and APRI score >2 and HA measurements >250ng/ml, in line with previous 
EuroSIDA work and other studies of HCV infection
660-662
.   
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Figure 8.1 Analysis population inclusion criteria and baseline HCV RNA and liver 
fibrosis status 
 
 
 
Where more than one fibrosis measurement was available for each individual at each time 
point they are prioritised in the order given above. For example, if an individual had both 
liver biopsy and Fibroscan® data available at one time point; the liver biopsy would take 
precedence. 
 
Throughout this analysis baseline was defined as 1
st
 January 2000, entry into EuroSIDA, or 
the first available fibrosis measurement, whichever occurred later. Cox proportional 
hazards regression, adopting the Fine and Gray methodology of competing risks, was used 
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to describe factors associated with progression to LRD
519
. The competing risks accounted 
for were death from causes other than LRD and loss to follow-up, defined as no contact 
with a EuroSIDA clinical site in the year prior to the median date of last follow-up for the 
entire EuroSIDA cohort, which is a standard EuroSIDA measure of loss to follow-up
712
. 
 
Multiple imputations, with four sets of replication, were used to impute missing baseline 
data on HCV RNA, HCV genotype, HBsAg status and fibrosis staging. Only those that were 
positive for HCV RNA after imputation were included in the analysis. The following baseline 
covariates were included in the model: 
 
 Age 
 Gender 
 Race 
 Calendar year 
 HIV transmission risk group 
 Region of EuroSIDA (see Chapter 3 Section 3.1.1) 
 Previous cardiovascular events (stroke, myocardial infarction, angina, 
endarterectomy, high blood pressure) 
 Previous diabetes diagnosis 
 HCV genotype 
 CD4 cell count 
 Nadir CD4 cell count 
 HIV RNA 
 HBsAg status (positive, negative) 
 Minimum duration of HCV infection 
 Liver fibrosis staging (Metavir F0/F1, F2/F3 or F4) 
 
Minimum duration of HCV infection is the length of time prior to baseline that each 
individual had their first documented positive HCV antibody (HCVAb) or HCV RNA test 
result. 
 
Stepwise variable selection was used to identify factors associated with progression to 
LRD. Covariates significant at the P<0.1 level were selected for entry into the model and 
those that remained significant at the P<0.05 level were selected to stay in the model. The 
LRD score was then calculated based on the estimated coefficients associated with the 
selected covariates included in the model. The coefficients were scaled so that the effect of 
not taking cART at baseline, compared with taking cART, represented a 1-unit increase in 
the LRD score. The other score components were then calculated by rounding each 
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coefficient to the nearest 0.5. An individual’s LRD score is then calculated by summing all 
the LRD score components associated with their risk profile. 
 
A univariable Fine and Gray Cox proportional hazards model with the LRD score as the 
only covariate and LRD as the endpoint was computed to describe the association between 
LRD and a 1-unit increase in the LRD score. Summary statistics were used to compare the 
LRD score between those that progressed to LRD and those that did not. The ability of the 
LRD score to correctly identify those who progressed to LRD was assessed using the area 
under the receiver-operating characteristics (ROC) curve and the c-statistic, in addition to 
calculating the sensitivity and specificity of the LRD score
687
, and compared to an 
alternative score which only includes liver fibrosis staging. 
 
The risk of progression to LRD was then categorised as low, medium-low, medium-high or 
high based on the quartiles of the LRD score distribution among those who progressed to 
LRD. Non-parametric cumulative incidence functions, which are not biased in the presence 
of competing risks, were then calculated to estimate the 5-year probability of LRD 
according to the categorised risk levels of the LRD score. The number of individuals 
needed to treat (NNTT) to prevent one LRD was then calculated for each LRD score risk 
category. The NNTT is derived as the inverse of the absolute risk reduction associated with 
a treatment
713
. The NNTT was calculated assuming a modest effect of treatment with DAAs 
(that on average treatment with DAA therapy would result in a 50% reduction of LRD) and 
an optimistic effect of treatment with DAAs (an 80% reduction of LRD). 
 
Fine and Gray Cox proportional hazards models and cumulative incidence functions were 
estimated using the %PSHREG and %CIF validated SAS macros
663;664
. 
 
8.3.2.1 Validation of the LRD score in the Swiss HIV Cohort Study 
In order to assess the prognostic ability of the LRD score outside of EuroSIDA, the score 
was externally validated using data provided by the Swiss HIV Cohort Study (SHCS). LRD 
score summary statistics, ROC curve and c-statistic, and non-parametric cumulative 
incidence functions were computed using the external SHCS data and compared with the 
results seen in the EuroSIDA cohort. 
 
The SHCS is a prospective cohort study with ongoing enrolment of HIV-positive 
individuals
714
. Established in 1988 as a collaboration of Swiss universities, outpatient 
clinics, laboratories, smaller hospitals and private clinicians caring for HIV-positive 
individuals, the study remains representative of the Swiss HIV epidemic
714
. The SHCS 
currently includes data for 56% of all known HIV-positive individuals in Switzerland
714
.  
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The SHCS study collects a large amount of data on patient demographics, results of HIV-
specific tests (including CD4 cell counts, HIV RNA, liver biopsy results and liver 
transaminases), history of cART, and hepatitis-related data (including HCV antibody, HCV 
RNA and HBsAg) at 6-monthly intervals. At study entry and at each follow-up clinical visit a 
spectrum of laboratory tests belonging to the standard of care for HIV-positive individuals 
are also performed
714
.  
 
The SHCS has a well-established track record of excellent data quality, with quality control 
taking place at local sites by study nurses and again at the coordinating centre by qualified 
collaborators and computer programs when data are entered into the central database. 
Further, each time a follow-up visit is added to the database a graphical summary of key 
data is sent to the physician in charge of the individual for a supplementary round of quality 
control. More information on the SHCS can be found at www.shcs.ch. 
 
In order to facilitate sharing of data between HIV cohort studies, in 2003 the SHCS together 
with the Copenhagen HIV Programme (CHIP) established the HIV Cohorts Data Exchange 
Protocol (HICDEP, www.hicdep.org)
715
. This data sharing platform has since been widely 
used in international HIV cohort collaborations and allows for consistent and accurate 
sharing of data. Upon establishment of collaborative interest in the LRD score analysis, the 
SHCS shared data on all their HIV/HCV coinfected individuals with EuroSIDA via the 
HICDEP format. 
 
Although the SHCS is a contributor to the EuroSIDA study they also collect a large amount 
of data from individuals that are not included in EuroSIDA. For the purpose of validating the 
LRD score presented here, the validation SHCS cohort was restricted to those individuals 
that are not included in the EuroSIDA study.  
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8.4 Results 
8.4.1 Generalizability and baseline characteristics 
During the population selection process for this analysis 867/4,878 HCVAb positive 
individuals were excluded from the study as they did not have follow-up available after 1st 
January 2000 (see Figure 8.1). To consider the generalizability of the results in this chapter 
I used multivariable logistic regression, adjusted for the covariates listed above, to assess 
how these excluded individuals differed from those that were included in the final analysis 
population. 
 
Those without follow-up after 1
st
 January 2000 and therefore excluded from the analysis, 
were less likely to reside in Western Europe (adjusted odds ratio (aOR): 0.62 (95% CI 0.45 
– 0.84; P=0.0013)) and more likely to reside in Eastern Europe (aOR: 1.62 (1.11 – 2.38; 
P=0.0013)), compared with Southern Europe. They also had lower CD4 cell counts at 
baseline (aOR: 0.77 (0.69 – 0.86; P<0.0001) per doubling) but higher nadir CD4 cell counts 
(aOR: 1.17 (1.08 – 1.28; P=0.0003) per doubling). In addition, they had longer minimum 
HCV infection durations (aOR: 1.09 (1.05 – 1.13; P<0.0001) per year) and were more likely 
to have HCV RNA data available (aOR: 1.85 (1.48 – 2.32; P<0.0001)), however, they were 
substantially more likely to have no data on liver fibrosis (aOR: 82.5 (57.7 – 118.1; 
P<0.0001)), compared to those with follow-up after 1
st
 January 2000. 
 
In the total study population of 4,011 HIV/HCV coinfected individuals, 787 deaths from any 
cause were recorded during a total of 17,389 person years follow-up (PYFU) (median 3.3 
years per person (inter-quartile range (IQR) 1.5 – 6.7)) to June 2014. The overall incidence 
of all-cause mortality was 45.3 (95% CI 42.2 – 48.3) per 1,000 PYFU. LRD accounted for 
180/787 (22.9%) of all recorded deaths, giving an incidence of LRD of 10.4 (8.8 – 11.9) per 
1,000 PYFU. 
 
Baseline characteristics of the 4,011 HIV/HCV coinfected individuals included in this 
analysis are shown in Table 8.3, stratified by study endpoint. The study population was 
mostly white (93.0%) males (68.2%) with a median age of 37 (IQR 31 - 43). The largest 
contributing regions of EuroSIDA were Eastern Europe (31.0%) and Southern Europe 
(25.0%), although all European regions were well represented. The predominant mode of 
HIV transmission reported was via injecting drug use (IDU) (69.2%), followed by 
heterosexual contact (15.3%).  
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Table 8.3 Baseline Characteristics of all HIV/HCV coinfected individuals included in the analysis stratified by endpoint 
   Endpoint   
Median (IQR) 
%  
All 
(N=4011) 
LRD 
(N=180) 
Non-LRD 
(N=607) 
Censored/Alive 
(N=3224) P-Value* 
Age  37 (31 - 43) 40 (36 - 45) 39 (33 - 45) 37 (30 - 43) <.0001 
Male  2734 (68.2) 126 (70.0) 448 (73.8) 2160 (67.0) 0.0037 
White  3732 (93.0) 167 (92.8) 563 (92.8) 3002 (93.1) 0.94 
Region of EuroSIDA South 1004 (25.0) 55 (30.6) 107 (17.6) 842 (26.1) <.0001 
 West Central 564 (14.1) 38 (21.1) 92 (15.2) 434 (13.5)  
 North 519 (12.9) 44 (24.4) 151 (24.9) 324 (10.0)  
 East Central 578 (14.4) 13 (7.2) 56 (9.2) 509 (15.8)  
 East 1243 (31.0) 27 (15.0) 187 (30.8) 1029 (31.9)  
 Argentina 103 (2.6) 3 (1.7) 14 (2.3) 86 (2.7)  
HIV transmission route MSM 372 (9.3) 13 (7.2) 35 (5.8) 324 (10.0) <.0001 
 IDU 2774 (69.2) 136 (75.6) 478 (78.7) 2160 (67.0)  
 Heterosexual 612 (15.3) 17 (9.4) 65 (10.7) 530 (16.4)  
 Other 253 (6.3) 14 (7.8) 29 (4.8) 210 (6.5)  
HCV-RNA status Negative 254 (6.3) 5 (2.8) 38 (6.3) 211 (6.5) 0.010 
 Positive 2459 (61.3) 131 (72.8) 356 (58.6) 1972 (61.2)  
 Unknown 1298 (32.4) 44 (24.4) 213 (35.1) 1041 (32.3)  
Duration of HCV infection Years 2.4 (0.4 - 5.4) 4.0 (1.8 - 7.7) 2.9 (0.7 - 6.0) 2.2 (0.3 - 5.1) <.0001 
HCV genotype G1 997 (24.9) 65 (36.1) 138 (22.7) 794 (24.6) 0.0001 
 G2 54 (1.3) 4 (2.2) 13 (2.1) 37 (1.1)  
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   Endpoint   
Median (IQR) 
%  
All 
(N=4011) 
LRD 
(N=180) 
Non-LRD 
(N=607) 
Censored/Alive 
(N=3224) P-Value* 
 G3 578 (14.4) 27 (15.0) 97 (16.0) 454 (14.1)  
 G4 281 (7.0) 15 (8.3) 26 (4.3) 240 (7.4)  
 Unknown 2101 (52.4) 69 (38.3) 333 (54.9) 1699 (52.7)  
HBsAg status Negative 3199 (79.8) 139 (77.2) 472 (77.8) 2588 (80.3) 0.0002 
 Positive 276 (6.9) 26 (14.4) 47 (7.7) 203 (6.3)  
 Unknown 536 (13.4) 15 (8.3) 88 (14.5) 433 (13.4)  
CD4 cell count Cell/mm
3
 385 (240 - 569) 232 (120 - 430) 270 (140 - 465) 411 (272 - 589) <.0001 
CD4 nadir Cell/mm
3
 163 (67 - 285) 103 (37 - 200) 110 (47 - 212) 177 (78 - 297) <.0001 
HIV RNA <400copies/ml 2155 (60.3) 81 (48.2) 228 (44.4) 1846 (63.9) <.0001 
Liver fibrosis F0/F1 2624 (65.4) 38 (21.1) 275 (45.3) 2311 (71.7) <.0001 
 F2/F3 225 (5.6) 21 (11.7) 31 (5.1) 173 (5.4)  
 F4 328 (8.2) 56 (31.1) 48 (7.9) 224 (6.9)  
 Unknown 834 (20.8) 65 (36.1) 253 (41.7) 516 (16.0)  
 
*P-value from Kruskal-Wallis or Chi-square test comparing the different study endpoints 
LRD: Liver-related death; MSM: Men who have sex with men; IDU: Injecting drug users; HBsAg: Hepatitis B surface antigen 
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At baseline 61.3% of those included in the study population were positive for HCV RNA, 
6.3% were negative while 32.4% had no data available on HCV RNA. The median 
minimum duration of HCV infection was 2.4 (IQR 0.4 – 5.4) years. The most frequent HCV 
genotype was G1 (24.9%), followed by G3 (14.4%), G4 (7.0%) and G2 (1.3%); for 52.4% 
HCV genotype was not known at baseline. The majority of participants in this study were 
negative for HBsAg at baseline (79.8%), 6.9% were positive, while 13.4% had no data 
available for HBsAg. 
 
At baseline data on liver fibrosis were available for 79.2% of the study population. Overall 
65.4% had F0/F1 fibrosis while 5.6% and 8.2% had F2/F3 and F4 fibrosis, respectively. 
Interestingly, among those who died of LRD 31.1% had F4 fibrosis at baseline and 21.1% 
had F0/F1 fibrosis. In comparison, 45.3% those who died from non-LRD had F0/F1 fibrosis 
at baseline and 7.9% had F4 fibrosis (P<0.0001). 
 
The overall median baseline CD4 cell count of those included in the study was 385 
cells/mm
3
 (IQR 240 - 569), however, there were large discrepancies between those who 
were censored at the end of follow-up (411 (272 - 589)) and those who died of LRD (232 
(120 - 430)) or non-LRD (270 (140 - 465)) (P<0.0001). Similarly, those who were censored 
at the end of follow-up also had higher nadir CD4 cell counts (177 (78 - 297)) compared 
with those who died of LRD (103 (37 - 200)) or non-LRD (110 (47 - 212)) (P<0.0001). 
Further, the proportion of those included in the analysis who had baseline HIV viral load 
<400 copies/ml was higher in those censored at the end of follow-up (63.9%) compared to 
those who died of LRD (48.2%) or non-LRD (44.4%) (P<0.0001). 
 
8.4.2 Derivation of the LRD score 
The stepwise variable selection process used in the Fine and Gray competing risks Cox 
proportional hazards model selected the covariates shown in Table 8.4. Similar to the 
analysis shown in Chapter 7, age, CD4 cell count, liver fibrosis levels, HBV coinfection, 
minimum duration of HCV infection and whether taking cART or not at baseline were all 
significantly associated with progression to LRD. As expected the largest contributing 
factors to the LRD score were low CD4 cell counts (<50cells/mm
3
 scores 3.5, while 50-
100cells/mm
3
 scores 3) and significant levels of liver fibrosis (F2/F3 fibrosis scores 3, while 
F4 fibrosis scores 4.5).  
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Table 8.4 Factors associated with progression to LRD and their contributions to the 
LRD score 
Covariate β P-Value Scaled 
β 
Score 
contribution 
Age >35 Vs. ≤35 0.93 <0.0001 2.50 2.5 
CD4 <50 Vs. ≥500cells/mm
3 
1.24 0.0003 3.34 3.5 
50≤ CD4 <100 1.18 0.0002 3.19 3 
100≤ CD4 <300 0.41 0.074 1.09 1 
300≤ CD4 <500 0.03 0.89 0.09 0 
F2/F3 Vs. F0/F1 Fibrosis 1.06 <0.0001 2.84 3 
F4 1.71 <0.0001 4.58 4.5 
HBsAg Positive Vs. HBsAg Negative 0.66 0.0052 1.76 2 
2≤ HCV Dur* <10 Vs. HCV Dur* <2 0.60 0.0014 1.60 1.5 
10≤ HCV Dur*  0.87 0.0009 2.32 2.5 
Off cART Vs. Taking cART 0.37 0.020 1 1 
 
β: Estimated coefficient from the model; *HCV Dur: Minimum HCV infection duration 
 
Table 8.5 LRD score calculation sheet 
Variable Criteria Score 
contribution 
Score 
Age < 35 
≥ 35 
0 
2.5 
 
2.5 
CD4 cell count 0 ≤ cells/mm
3
 < 50 
50 ≤ cells/mm
3
 < 100 
3.5 
3 
 
 100 ≤ cells/mm
3
 < 300 1 1 
 300 ≤ cells/mm
3
 < 500 0  
 500 ≤ cells/mm
3
 0  
Taking antiretroviral therapy Yes 0  
 No 1 1 
HBV status HBsAg positive 2  
 HBsAg negative 0 0 
Duration of HCV infection < 2 years 0  
 2 ≤ years < 10 1.5 1.5 
 10 ≤ years 2.5  
Fibrosis staging F0/F1 0  
 F2/F3 3 3 
 F4 4.5  
Total = 9 
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An illustration of a LRD score calculation is shown in Table 8.5 for a 45-year-old individual 
with a CD4 cell count of 250cells/mm
3
, not currently taking cART, with no evidence of HBV 
coinfection, a minimum duration of HCV infection of 4 years, and F2 liver fibrosis. Summing 
all the component parts of the LRD score this individual has a LRD score of 9. 
 
8.4.3 LRD score summary statistics and distribution in EuroSIDA 
The overall mean LRD score for the whole study population was 4.3 (95% CI 4.2 – 4.3), 
while the median was 4 (IQR 2.5 – 5.5). As the mean and median LRD scores for the whole 
study population are close together it indicates that the score is not skewed in this 
population. Figure 8.2 shows the distribution of LRD scores among those who progressed 
to LRD and those who did not. Both distributions appear to be approximately normally 
distributed, however, LRD scores among those who progressed to LRD were higher than 
those for individuals that did not progress to LRD. The mean LRD score was significantly 
higher among those who progressed to LRD (7.3 (95% CI 6.9 – 7.8) vs. 4.1 (4.0 – 4.2); 
P<0.0001) compared to those that did not progress to LRD. The median LRD score was 
also significantly higher among those who progressed to LRD (7.25 (4.75 – 9.5) vs. 4 (IQR 
4.0 – 5.5); P<0.0001) and in each distribution the mean and median were approximately 
the same. 
 
In a univariable Fine and Gray model including the LRD score as the only covariate, a 1-
unit increase in the LRD score was associated with 1.4-fold increased risk of LRD (sub-
distribution hazard ratio (sHR): 1.44 (95% CI 1.37 – 1.51; P<0.0001). The LRD score 
achieved a c-statistic of 0.81 (95% CI 0.77 – 0.85), which indicates strong differentiation 
between those who progress to LRD and those that do not (Figure 8.3). The LRD score 
performed substantially better than an alternative score which only included liver fibrosis 
staging, which achieved a c-statistic of 0.72 (95% CI 0.68 – 0.76). In formal comparison the 
difference between the performance of the two scores was highly statistically significant 
(P<0.0001).  
 
A LRD score cut-off of 5.5 provided the highest combination of sensitivity and specificity 
over 5-years of follow-up. Using a cut-off of 5.5 the LRD score achieved a 5-year sensitivity 
of 68.0% and a specificity of 77.5%, which means that 68% of those with scores above 5.5 
experience LRD, while 77.5% of those with scores below 5.5 do not experience LRD. 
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Figure 8.2 LRD score distribution among those who did and did not progress to LRD 
 
 
Figure 8.3 LRD score ROC curve 
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The quartiles of the distribution of LRD scores among those who progressed to LRD were 
used to categorise individuals into low, medium-low, medium-high and high risk of 
progression to LRD, shown in Table 8.6. Therefore, the individual in the example given in 
Table 8.5 would be considered to have medium-high risk of progression to LRD. 
 
Table 8.6 LRD score risk categories 
 
LRD score risk category LRD score range 
Low LRD score <4.75 
Medium-low 4.75≤ LRD score <7.25 
Medium-high 7.25≤ LRD score <9.5 
High LRD score ≥9.5 
 
 
8.4.4 Incidence and cumulative incidence of LRD by LRD score risk category 
The overall incidence of LRD and the NNTT to prevent one LRD are shown in Table 8.7, 
stratified by LRD score risk category. The incidence of LRD was low among those in the 
low risk category (0.44 per 100 PYFU (95% CI 0.31 – 0.58)), but increased steadily in those 
at medium-low, medium-high and high risk (1.01 (0.71 – 1.31), 3.05 (2.05 – 4.04) and 8.33 
(6.14 – 10.52) per 100 PYFU, respectively). 
 
Assuming that treatment with DAA therapy will lead to a 50% reduction in the overall 
incidence of LRD, then 102 (95% C.I. 74 – 144) coinfected individuals in the low LRD score 
risk category would need to be treated to prevent one LRD over a period of 5-years. 
However, the NNTT falls to 45 (33 - 64), 18 (13 - 27) and 8 (6 - 10) for those in the 
medium-low, medium-high and high risk categories, respectively. Assuming a more 
optimistic outcome of DAA therapy, that treatment will lead to an 80% reduction in the 
overall incidence of LRD, then 58 (42 - 82) coinfected individuals in the low LRD score risk 
category would need to be treated to prevent one LRD over a period of 5-years, falling to 
26 (19 - 36), 10 (8 - 15) and just 4 (4 - 6) for those in the medium-low, medium-high and 
high risk categories, respectively. 
 
Cumulative incidence functions for progression to LRD are shown in Figure 8.4, stratified 
by LRD score risk category. The LRD score risk categories were able to accurately identify 
those at the highest and lowest risk of progression to LRD, with highly significant 
separation between strata (P<0.0001). The 5-year probability of LRD  
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Table 8.7 Incidence of LRD and number needed to treat to prevent one LRD by LRD 
score risk category 
 
LRD score category Incidence of  
LRD/100 PYFU (95% CI) 
NNTT 50% 
(95% CI) 
NNTT 80% 
(95% CI) 
Low 0.44 (0.31 – 0.58) 102 (74 – 144) 58 (42 - 82) 
Medium-low 1.01 (0.71 – 1.31) 45 (33 - 64) 26 (19 - 36) 
Medium-high 3.05 (2.05 – 4.04) 18 (13 - 27) 10 (8 - 15) 
High 8.33 (6.14 – 10.52) 8 (6 - 10) 4 (4 - 6) 
 
NNTT: Calculated based on the 5-year incidence of LRD 
NNTT 50%: Number needed to treat to prevent one LRD assuming that treatment with DAAs 
leads to an average 50% reduction in LRD. 
 
 
varied widely across the score groups illustrating the good discriminatory properties of the 
score. The 5-year probability of LRD was 2.0% (95% CI 1.4 – 2.7) among those in the low 
risk category, increasing to 4.4% (3.1 – 6.0) in those at medium-low risk, 11.0% (7.6 – 15.2) 
in those at medium-high risk, and as high as 25.9% (19.6 – 32.7) among those in the high 
risk category. 
 
Figure 8.4 Cumulative incidence of LRD by LRD score risk category 
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Interestingly, differentiation between the low (0.51% (95% CI 0.27 – 0.89)), medium-low 
(0.95% (0.47 – 1.75)) and medium-high (2.36% (1.05 – 4.60)) risk categories was less 
pronounced for the 1-year probability of LRD. However, those in the high risk category had 
a substantially higher 1-year probability of LRD (10.9% (6.9 – 16.0)), indicating the high risk 
of LRD these individuals face in the short and medium term. 
 
8.4.5 Validation of the LRD in the Swiss HIV Cohort Study 
In the SHCS population of 1,303 HIV/HCV coinfected individuals there were 157 deaths 
from any cause recorded in a total of 7,742 PYFU to June 2014. The overall incidence of 
all-cause mortality was 20.3 per 1,000 PYFU (95% CI 17.1 – 23.4). LRD accounted for 
38/157 (24.2%) of all recorded deaths, giving an incidence of LRD of 4.9 per 1,000 PYFU 
(3.4 – 6.5). A brief description of the data provided by the SHCS is given in Table 8.8, with 
EuroSIDA data given for comparison.  
 
Similar to the EuroSIDA population, the SHCS population was mostly male (66.5%) with a 
median age of 42 (IQR 37 - 46). The most common mode of HIV transmission was IDU 
(47.0%) followed by heterosexual contact (16.6%) and MSM (12.5%). Although IDU was 
the most common mode of HIV transmission the proportion of IDUs in the whole study 
population was substantially lower than in EuroSIDA (47.0% vs. 69.2%; P<0.0001). HBsAg 
was detected among 6.8% of the SHCS population and the median minimum duration of 
HCV infection was 7.1 years, substantially higher than in EuroSIDA (7.1 (IQR 4.0 – 10.3) 
vs. 2.4 (0.4 – 5.4); P<0.0001).  
 
The median baseline CD4 cell count of the SHCS population was 402 (IQR 365 - 588), 
while the median baseline nadir CD4 cell count was almost identical to that of EuroSIDA 
(165 (70 - 282) vs. 163 (67 - 285)). Data on liver fibrosis levels were complete at baseline in 
the SHCS. The proportion of individuals reporting F2/F3 fibrosis or F4 fibrosis was 
comparable between the SHCS and EuroSIDA (6.3% vs. 5.6% and 10.4% vs. 8.2%, 
respectively). 
 
The distribution of LRD scores in the SHCS is shown in Figure 8.5. The distribution of LRD 
scores appears to be approximately normal, as evidenced by the mean (5.2 (95% CI 5.1 – 
5.3)) and median (5 (IQR 4 - 6)) being approximately the same. The mean LRD score was 
significantly higher among those who progressed to LRD (7.5 (95% CI 6.5 – 8.4) vs. 5.1 
(5.0 – 5.2); P<0.0001) compared with those that did not progress to LRD, and very similar 
to the mean LRD score in EuroSIDA among those who progressed to LRD (7.3 (6.9 – 7.8)). 
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Table 8.8 Baseline characteristics of HIV/HCV coinfected individuals from the Swiss HIV Cohort study 
 
Variable 
 
SHCS EuroSIDA 
HCV RNA positive coinfected individuals (Total PYFU) 1303 (7,742) 4011 (17,389) 
Liver-related deaths (Total deaths)  38 (157) 180 (787) 
Baseline Median (IQR) Dec 05 (Dec 05 – Jul 07) Nov 05 (Sep 01 – Nov 08) 
Age Median (IQR) 42 (37 – 46)  37 (31 - 43) 
Male N (%) 866 (66.5)  2734 (68.2) 
Injecting drug user N (%) 612 (47.0)  2774 (69.2) 
MSM N (%) 163 (12.5) 372 (9.3) 
Heterosexual N (%) 216 (16.6) 612 (15.3) 
HBsAg positive N (%)  89 (6.8) 276 (6.9) 
Minimum duration HCV positive (Years) Median (IQR)  7.1 (4.0 – 10.3) 2.4 (0.4 – 5.4) 
Taking cART N (%)  925 (71.0) 2640 (65.8) 
CD4 cell count (cells/mm
3
) Median (IQR)  402 (365 – 588) 385 (240 - 569) 
Nadir CD4 cell count (cells/mm
3
) Median (IQR)  165 (70 – 282) 163 (67 – 285) 
Fibrosis staging (N (%)) F0/F1  1086 (83.4) 2624 (65.4) 
  F2/F3  82 (6.3) 225 (5.6) 
  F4  135 (10.4) 328 (8.2) 
 Unknown 0 834 (20.8) 
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Figure 8.5 Distribution of LRD scores in the Swiss HIV Cohort study 
 
 
 
The LRD score achieved a c-statistic of 0.79 (95% CI 0.70 – 0.88) in the SHCS (Figure 
8.6), which is very similar to the c-statistic of 0.81 (95% CI 0.77 – 0.85) seen in the 
EuroSIDA study population. A c-statistic of 0.79 indicates reasonable to strong 
differentiation between those that do and do not progress to LRD. More importantly, the 
LRD score appears to have a similar prognostic capability for progression to LRD in the 
SHCS as it displayed in EuroSIDA. 
 
Cumulative incidence functions for progression to LRD in the SHCS stratified by the LRD 
risk categories are shown in Figure 8.7. The LRD score risk categories were able to 
accurately identify those at the highest and lowest risk of progression to LRD, with highly 
significant separation between strata (P<0.0001). The 5-year probability of LRD was 0.5% 
(95% CI 0.1 – 1.6) among those in the low risk category, but increased to 2.4% (1.3 – 4.2), 
8.1% (3.2 – 15.8) and 11.6% (5.6 – 19.9) among those at medium-low, medium-high and 
high risk of progression to LRD, respectively. 
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Figure 8.6 LRD score ROC curve in the Swiss HIV Cohort study 
 
 
Figure 8.7 Cumulative incidence of LRD by LRD score risk category in the Swiss HIV 
Cohort study 
 
259 
 
8.5 Discussion 
 
Performance of the LRD score 
This chapter builds on the analysis presented in the previous chapter, describing factors 
associated with progression to LRD, to construct a single, easily applicable prognostic 
score for progression to LRD among HIV/HCV coinfected individuals. The LRD score was 
developed using data from the EuroSIDA study and validated on external SHCS data. To 
my knowledge, this is the first prognostic score developed with the specific intention of 
identifying HIV/HCV coinfected individuals at greatest risk of progression to LRD in the 
presence of HIV-related competing risks. Used in the clinical setting the LRD score may 
help health care providers make difficult decisions about who should be prioritised for 
treatment with new expensive DAA therapy for treatment of HCV. Coinfected individuals in 
the high and medium-high should be prioritised for treatment as they are at the greatest risk 
of LRD. 
 
The LRD score was able to accurately differentiate between those at high and low risk of 
LRD in the EuroSIDA derivation cohort and showed excellent repeatability in the SHCS 
validation cohort. Although no direct comparison is available, as this is the first score 
developed among HIV/HCV coinfected individuals with respect to LRD, the LRD score 
performs well in comparison to other commonly used scores. The well-known Framingham 
risk score commonly used in clinical practise to predict cardiovascular disease achieved c-
statistics of 0.73 and 0.71 in men and women, respectively
686
. The VACS Index, which 
predicts all-cause mortality after 1-year of cART for HIV-positive individuals, was 
considered to achieve strong differentiation in its derivation cohort (c-statistic: 0.78) and 
validation cohort (c-statistic: 0.82) and the LRD score achieves almost identical levels of 
differentiation in this study
688
. 
 
Interestingly, the VACS Index study showed that using information on multiple organ 
systems significantly improved prediction of 1-year all-cause mortality, specifically 
mentioning the addition the liver fibrosis marker FIB-4
688
. The LRD score includes the APRI 
liver fibrosis marker, which is one of the main contributors to the score calculation. It is 
possible that the additional benefit of including FIB-4 in the VACS Index was attributable to 
a better prediction of progression to LRD, although it is not possible to say definitively as 
the VACS study differentiates deaths as HIV-related and non-HIV-related rather than liver-
related and non-liver-related
688
. 
 
Fibrosis staging, as measured by the APRI score, was the largest contributor to the LRD 
score calculation. However, other HIV-related factors such as CD4 cell count were also 
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heavily weighted. Comparing the LRD score to an alternative score, which only included 
the liver fibrosis component, showed that prediction based solely on fibrosis staging was 
highly significantly inferior to the full LRD score.  
 
The Child-Pugh and MELD scores, developed to predict mortality among cirrhotic patients, 
attempt to describe the function of the liver through a number of continuous and 
quantitative measures
692;700
. The LRD score was developed with these scores in mind. The 
Child-Pugh score is often criticised because the components were chosen empirically and 
all weighted equally while the MELD score is not considered to be applicable in the clinical 
setting as the equation is not easily interpreted
693
. The LRD score was developed by 
selecting a large number of variables known to be associated with LRD from previous 
EuroSIDA work and empirical knowledge. The most important of these variables were then 
selected by the model so that each component has a weighted and independent effect on 
LRD. Further, with the use of the calculation sheet the score can be easily calculated in 
everyday practice to determine an individual’s risk category. 
 
The LRD score also performs well in comparison to these historically useful scores. The 
Child-Pugh and MELD scores have traditionally been associated with reasonable to strong 
differentiation between patients with respect to survival following TIPS, development of 
cirrhosis, and development of liver disease (c-statistics ranging between 0.65 and 0.85)
702-
705
. In comparison, the LRD score shows strong differentiation among HIV/HCV-coinfected 
individuals with respect to progression to LRD (c-statistics: 0.81 and 0.79 in the derivation 
and validations cohorts), highlighting the potential usefulness of the LRD score in the 
clinical setting. 
 
This analysis aimed to determine whether the factors identified in Chapter 7 could be 
combined into a prognostic score to predict progression to LRD. The results presented here 
clearly demonstrate that the LRD score has a strong ability to differentiate between those at 
the highest and lowest risk of LRD. This analysis was also specifically designed to make 
the LRD score easy to calculate and interpret. Therefore, individual risk profiles are 
collected into risk categories. While this strategy may be useful in the clinical setting to 
determine those at the greatest risk of LRD, the optimal use of the LRD score would allow 
for an individualised 5-year risk of LRD. However, this would require individual 
characteristics to be input into the underlying formula from the statistical model and may 
not be easily interpretable in the clinical setting.  
 
With this in mind, the logical next step is to make an individualised version of the LRD 
score widely available, while maintaining the ease of use and interpretation. One potential 
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way to achieve this aim would be to develop a mobile phone application or link to the 
EuroSIDA webpage, where individuals could input their characteristics and receive an 
individualised 5-year risk of LRD. These ideas are already being discussed and I foresee 
work progressing on whichever method is easier to administer progressing in the near 
future. 
 
Mortality rates in EuroSIDA and the SHCS 
While life expectancy in HIV-monoinfected individuals with high CD4 cell counts has started 
to approach that of the general population
8;716
, mortality rates among HIV/HCV coinfected 
individuals remain stubbornly high. In 2007 Lohse et al reported that between 1995 and 
2005 in Denmark the mean survival time after age 25 for HIV-monoinfected individuals was 
double that of HIV/HCV-coinfected individuals (39 vs. 20 years)
656
. Differences between 
individual characteristics of these two groups are often cited as reasons for the higher 
mortality seen for coinfected individuals. Coinfected individuals are typically more likely to 
be part of difficult to treat groups participating in active IDU and alcohol abuse. In this study 
69% of the coinfected individuals included reported IDU as the route of HIV transmission. 
However, interplay between the HIV and HCV viruses is also a contributing factor to 
increased mortality in coinfected individuals. Liver fibrosis progression is known to be 
accelerated in the presence of low CD4 cell counts and the LRD score shows that these 
two factors should be considered the most important determinants of progression to 
LRD
414;671
. 
 
A cut-off point of 5.5 provided the optimal combination of sensitivity and specificity for the 
LRD score. However, the strength of the LRD score appears to come from the excellent 
differentiation of risk categories for progression to LRD. In the EuroSIDA cohort those in the 
low risk category had a negligible 5-year probability of LRD, whereas those in the medium-
high and high risk categories had a significant 5-year probability of progression to LRD, as 
high as 26% for the high risk group. Similar patterns were observed in the SHCS cohort 
with negligible risk for those in the low risk category and substantial risk of progression to 
LRD in those with the high risk categories.  
 
Although the risk categories continued to show excellent differentiation in the SHCS it is 
important to note that those in the high risk category were approximately half as likely to 
progress to LRD in 5-years as those in EuroSIDA (12% vs. 26%). The lower probability of 
progression to LRD in the SHCS reflects the lower overall incidence of LRD reported in the 
study. In EuroSIDA the incidence of LRD was approximately double that of the SHCS (10.4 
vs. 4.9 per 1,000 PYFU) over the study period. However, this shows that the LRD score 
can perform well in different risk settings, although the overall incidence of the LRD was 
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lower in the SHCS the risk score categories were still able to accurately identify those at 
the highest and lowest risk of progression to LRD. 
 
Competing risks and the influence of individual factors on who to treat 
The LRD score was developed specifically to predict progression to LRD among HIV/HCV-
coinfected individuals in the presence of HIV-related competing risks. Therefore, the LRD 
score is ideally placed to help clinicians with difficult decisions regarding which HIV/HCV-
coinfected individuals should be prioritised for new expensive DAA treatments for HCV. In 
the resource-limited setting studies of HCV-monoinfection have shown that the most cost 
effective strategies involve restricting treatment to those with higher levels of liver 
fibrosis
709;710
. In HIV/HCV-coinfection decisions on who to treat become somewhat more 
complicated by interplay between HIV- and HCV-related risk factors.  
 
The LRD score can identify those at the greatest risk of progression to LRD but decisions 
about who to treat must then recognise the leading contributors to a high LRD score. For 
example, an individual with a high risk LRD score driven by a high degree of liver fibrosis, 
concurrent HBV infection and a long duration of HCV infection, but not a low CD4 cell 
count, would be a leading candidate for DAA therapy. In this instance DAA therapy if 
successful, along with a cART regimen containing drugs active against HBV, could remove 
the driving force behind progression of liver fibrosis and lower the risk of progression to 
LRD. 
 
An individual with a high risk LRD score driven by a low CD4 cell count, concurrent HBV 
infection and a high degree of liver fibrosis should also be a leading candidate for DAA 
therapy
416
. However, the low CD4 cell count should also be addressed by ensuring they are 
taking appropriate cART, including drugs active against HBV. In this instance it may be 
preferable to delay treatment with DAAs until the CD4 cell count has increased as the low 
CD4 cell count is a possible contributor to fibrosis progression as well as a strong risk 
factor for progression to AIDS-related death
416
. 
 
Number needed to treat 
Treating individuals that fall within the high LRD score risk category with DAA treatment is 
further supported by the NNTT to prevent one LRD in this category. Clinical trials data have 
shown cure rates of >90% for the majority of new DAAs coming to market, regardless of 
HCV genotype, liver fibrosis staging or HIV-coinfection
446;465;658
. Therefore, in instances 
where HCV is the main driver of liver fibrosis progression, treatment with DAA therapy is 
likely to have a major effect on the rate of LRD by removing the underlying cause. 
Assuming that DAA therapy results in an overall 80% reduction in the rate of LRD the 
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NNTT to prevent one LRD in a 5-year period in the high LRD score risk category is four. 
This means that for every four high risk individuals treated with DAA therapy one LRD 
would be prevented, or postponed during the next 5-year period.  
 
The NNTT is also low for those in the medium-high risk category where ten patents would 
need to be treated to prevent one LRD. However, by considering that treatment with DAAs 
will likely be restricted by cost and supply issues, it is easy to see why the two high risk 
groups would be selected for treatment above the low risk groups. Assuming an 80% 
reduction in LRD as a result of DAA therapy, 58 and 26 coinfected individuals in the low 
and medium-low risk categories would have to be treated before one LRD was prevented, 
respectively. 
 
Taking a more pessimistic view of the overall effect of DAAs, it is likely that many HIV/HCV-
coinfected individuals will have many factors contributing to progression of liver disease, 
such as on-going HBV infection or alcohol abuse as well as HCV. In this case successful 
treatment with DAAs will remove the contribution from HCV but the other elements may 
remain. Therefore, DAA treatments may reduce the rate of LRD but not by as much as 
anticipated given treatment success rates seen in clinical trials
446;465;658
. Assuming that 
DAA therapy results in an overall 50% reduction in the rate of LRD, the NNTT to prevent 
one LRD in the high LRD score risk category is still as low as eight. However, the NNTT 
rises to 102 and 45 for those in the low and medium-low risk categories, respectively.  
 
These findings are in agreement with simulation studies of HCV-monoinfection in the 
resource-limited setting which show that, where the number of treatments per year is 
restricted, life years added by HCV treatment are maximised by treating those with F3 and 
F4 fibrosis only
709;710
. The distinction here in HIV/HCV-coinfection is that fibrosis staging is 
not the only factor required when identifying who would see the most benefit from 
treatment. 
 
8.5.1 Limitations 
The main limitation of this study is that as data on alcohol abuse were only added to the 
EuroSIDA data collection form in 2010, alcohol abuse was not included as a variable in the 
LRD score derivation model. Alcohol abuse is known to be a key contributor to the 
progression of liver disease and is known to act synergistically with HCV
673
. However, data 
on alcohol abuse is notoriously difficult to gather from patients in the clinical setting which is 
why the alcohol abuse data recently added to EuroSIDA is of a qualitative nature (see 
Chapter 7 Section 7.5.1)
672;674
. The number of units of alcohol consumed per week is not 
collected in EuroSIDA, just whether an individual is considered to be an alcohol abuser or 
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not. Further, the follow-up form is not filled in by the individual themselves but the clinical 
practitioner, which may incorporate some level of observer level variation. 
 
However, an earlier version of the MELD score contained a component linked to alcohol 
consumption. The cause of cirrhosis, alcoholic or cholestatic, was originally included as a 
quantitative term in the MELD score but was dropped after studies determined that its 
exclusion had only a minimal impact on the accuracy of the model
693;701
. Therefore, 
although not a directly comparable score designed for use in HIV/HCV-coinfected individual 
specifically, the MELD score provides some evidence to suggest that adding a component 
on alcohol consumption to the LRD score may not greatly influence the results. 
 
As in the previous chapter, a limitation of this study was that due to limited power it was not 
possible to model the individual stages of liver fibrosis, which instead were grouped as 
F0/F1, F2/F3 and F4 fibrosis. In addition, the fibrosis data in this study are collected from a 
combination of clinical procedures and biomarkers; therefore, consensus on the definitions 
of the stages of fibrosis is difficult to attain. However, cut-off points for low levels of fibrosis 
or cirrhosis, are relatively well-defined
589
. In particular, the APRI score, which is where the 
majority of fibrosis data are taken from in this study, has been validated in a number of 
studies
425;685
. 
 
The minimum duration of HCV infection was found to be an independent predictor of LRD 
and became a contributing component of the LRD score. The minimum duration of infection 
was calculated using the first available positive HCVAb or HCV RNA test result, when in 
reality HCV infection most likely occurred sometime prior, possibly around the time of HIV 
infection. However, this reflects the nature of data collection and clinical care of HIV/HCV-
coinfected individuals. In most cases the true date of HCV infection will not be known. 
Further, the LRD score performed equally well in the SHCS validation cohort where 
estimated minimum HCV infection durations were considerably longer than in EuroSIDA. 
 
Finally, data were not complete at baseline in this study. However, multiple imputations 
were used to impute the missing data, which is a well-known statistical technique which 
reduces bias when data are missing completely at random (MCAR) or missing at random 
(MAR)
522
. The missing data in this analysis were HCV RNA, HCV genotype, HBsAg and 
fibrosis staging. Section 4.4.1 of this thesis showed that missing HCV RNA data was 
associated with Eastern Europe. Eastern Europe is more likely to have missing data than 
Western Europe due to differences in the quality of clinical management. However, this 
does not mean that the underlying distribution of people positive or negative for HCV RNA 
would be different in this region. Therefore, it is reasonable to assume these data are MAR. 
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Similarly, any differences in the underlying distributions of HBsAg, HCV genotype and 
fibrosis staging between Eastern and Western Europe are likely to be explained by the 
observed variable region of EuroSIDA. Consequently, I believe it is reasonable to assume 
these data are MAR. In addition, the proportion of individuals with missing data was low for 
key variables such as liver fibrosis staging (21%) and HBsAg status (13%). 
 
8.5.2 Conclusion 
The costs of new DAA therapies for treatment of HCV mean that the number of treatments 
available will be limited in many settings, including those not traditionally seen as resource-
limited. Therefore, prioritisation of those at the greatest need of therapy will be essential. 
The LRD score is specifically tailored to determine the risk of progression to LRD among 
HIV/HCV-coinfected individuals in the presence of HIV-related competing risks and 
demonstrated the ability to accurately differentiate between those and highest and lowest 
risk of progression to LRD. To my knowledge this is the first externally validated prognostic 
score to specifically predict LRD in HIV/HCV coinfected individuals and will serve as a 
useful tool in the clinical setting when deciding who to prioritise for treatment with new DAA 
treatments for HCV. 
 
The performance of the LRD score in this analysis opens the door for further work on the 
development of an individualised LRD score which can be applied using a mobile phone 
application or website.  
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Chapter 9 
 
Overall significance and conclusions 
 
9.1 Summary of findings 
 
After the introduction of combination antiretroviral therapy (cART) in the mid-1990s AIDS-
related mortality started to decline dramatically in the HIV population
597
. Consequently, 
research focus in the HIV field has shifted towards coinfections and comorbidities. Due to 
shared transmission routes, coinfection between HIV and HCV is common and liver-related 
death (LRD) as a consequence of hepatitis coinfection has assumed increasing importance 
among HIV/HCV coinfected individuals
372;524;564
. The results from the analysis presented in 
each of my chapters is summarised below, followed by a discussion of the implications for 
the management of HIV/HCV coinfected individuals in Europe, along with the limitations of 
conducting these studies in EuroSIDA. 
 
Chapter 4 
The natural history of HCV RNA during chronic HCV infection among HIV/HCV 
coinfected individuals 
The relationship between HCV RNA levels, LRD and other clinical outcomes has been the 
subject of many studies. While some studies have found no meaningful association 
between HCV RNA and progression to liver disease, others have reported that HCV viral 
load may influence the degree of liver damage
546;548
. In addition, high levels of HCV RNA 
have been consistently linked with a poor response to treatment for HCV using pegylated-
interferon and ribavirin
436
. Therefore, factors that affect changes in HCV RNA levels are 
important for the clinical management of HIV/HCV coinfected individuals where interferon-
based treatment remains the only therapeutic option. 
 
This analysis described the natural history of HCV RNA in HIV/HCV coinfected individuals. 
The main findings of this study showed that HCV RNA levels were affected by cART. 
Among coinfected individuals taking cART HCV RNA levels remained stable over time; 
however, for coinfected individuals not taking cART HCV RNA increased by 28% per year. 
This finding is in agreement with other work on the topic which also found minimal 
increases in the region of 2% per year HCV RNA over time in HIV/HCV coinfected 
individuals
526
. One potential explanation how cART may be able to indirectly control HCV 
RNA levels is that immune reconstitution following cART may lead to an increase in 
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immune responses to HCV core peptides
540
. In other words, when HIV is controlled by 
cART the immune system is better equipped to deal with HCV RNA. 
 
HCV genotype 1 was a significant predictor of high levels of HCV RNA at baseline in this 
study. Further, HCV genotype 1 was also associated with HCV RNA reaching a clinically 
important threshold of 800,000IU/ml and rapid increases in HCV RNA over time. An HCV 
viral load above 800,000IU/ml has been reported as a predictor of poor treatment response 
to HCV treatment with pegylated-interferon and ribavirin among HIV/HCV coinfected 
individuals
436
. HCV treatment success rates with pegylated-interferon and ribavirin have 
been shown to be consistently lower among those with HCV genotype 1 and this 
association between genotype 1 and higher HCV RNA levels could be partially 
responsible
434;435
. 
 
The findings of this analysis have potential implications for the clinical management of 
HIV/HCV coinfected individuals. As cART appears to be able to indirectly stabilise HCV 
RNA it would suggest that HIV/HCV coinfected individuals would benefit from early initiation 
of cART during the course of HIV infection. This strategy could prevent HCV RNA levels 
reaching high levels associated with a poor response to treatment with pegylated-interferon 
and ribavirin, which is still adopted as the standard of care in many resource-limited 
countries. 
 
Chapter 5 
Temporal changes and regional differences in the uptake of treatment for HCV 
among HIV/HCV coinfected individuals in EuroSIDA 
In 2012 European AIDS Clinical Society (EACS) guidelines recommended that all HIV/HCV 
coinfected individuals with significant liver fibrosis should be considered for HCV treatment 
due to an increased risk of LRD
1
. Gold standard HCV therapy at the time consisted of 
pegylated-interferon and ribavirin
1
; however, treatment uptake and sustained virologic 
response rates were typically low among HIV/HCV coinfected individuals, mainly due to 
contraindications to treatment and poor adherence as a result of unpleasant side-
effects
624;717
. 
 
This study described the rate of uptake of treatment for HCV with pegylated-interferon plus 
ribavirin among chronically infected HIV/HCV coinfected individuals in Europe between 
1998 and 2010. The main finding of this analysis was that 25% of coinfected individuals in 
Europe were treated for HCV over the study period. Although the incidence of treatment 
uptake increased 27% per year between 1998 and 2007 treatment rates remained low. 
However, the rate of HCV treatment uptake presented here was higher than in other 
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studies of HCV treatment prevalence which have typically included individuals based solely 
on an HCVAb measurement
582;583
. One of the strengths of this analysis is that HIV/HCV 
coinfected individuals were selected for inclusion based on HCVAb and HCV RNA so that 
only chronically infected individuals, who would be considered for treatment, were included. 
 
After the peak of 2007 there was a significant decline in the rate of HCV treatment uptake. 
In the late 2000s drug development for new direct-acting antivirals (DAA) for treatment of 
HCV was advancing rapidly. New DAA drugs were showing a vast improvement in 
treatment success rates compared to pegylated-interferon and ribavirin in clinical 
trials
445;568
. Consequently, it is possible that clinicians may have begun to defer treatment 
for HCV with pegylated-interferon and ribavirin in anticipation of new drugs on the horizon. 
 
Importantly, although coinfected individuals with significant liver fibrosis were 60% more 
likely to be treated for HCV, there remained a significant proportion of the study population 
who had significant liver fibrosis but had not yet been treated for HCV. Therefore, it is 
important to reinforce treatment guidelines and ensure that those in need of HCV treatment 
are considered for therapy. However, these individuals who were indicated for therapy but 
not treated may have had contraindications to treatment with interferon, which highlights 
the need for new potent less toxic treatments for HCV. 
 
Chapter 6 
The incidence of antiretroviral drug discontinuation among HIV/HCV coinfected 
individuals and those with significant liver fibrosis 
As a consequence of effective cART for HIV, life expectancy of HIV-positive individuals 
diagnosed early in the course of infection has begun to approach that of the general 
population
8;716
. As a result, more patients are presenting with hepatic and renal impairment 
requiring treatment, while some antiretroviral (ARV) drugs are known to contribute to the 
development of these conditions during prolonged exposure
645;718
. Therefore, 
pharmacokinetic considerations have become central in determining appropriate ARV 
dosing strategies
601
. As most ARV drugs have a metabolising contribution from the liver it is 
possible that liver damage as a result of HIV/HCV coinfection could result in ARV drug 
toxicity leading to treatment discontinuation
601
. 
 
This study described the incidence of ARV drug discontinuation due to toxicity and patient 
or physician choice, comparing HIV monoinfected individuals with HIV/HCV coinfected 
individuals. HCVAb positivity was associated with an increased risk of ARV drug 
discontinuation consistent with other studies of the topic
536;629;630
. Expanding the research 
to study the effect HCV RNA on ARV drug discontinuation showed that HIV/HCV coinfected 
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individuals who had cleared HCV RNA had a similar risk of ARV drug discontinuation as 
HIV monoinfected individuals. However, chronically infected HIV/HCV coinfected 
individuals had a consistently increased risk of drug discontinuation for the NRTI, NNRTI 
and PI ARV drug classes. 
 
Interestingly, when additionally adjusting for liver fibrosis using the biomarker hyaluronic 
acid (HA), significant liver fibrosis was consistently associated with ARV drug 
discontinuation but the role of HCV RNA became non-significant. This would suggest that 
liver fibrosis, possibly caused by on-going HCV viral replication, drives the association 
between chronic HIV/HCV coinfection and ARV drug discontinuation and not HCV viral 
replication per se. As most ARV drugs have a metabolising contribution from the P450 
enzyme system in the liver these findings suggest that liver damage as a result of HCV 
coinfection may inhibit ARV metabolization
601
. Inefficient drug metabolization may then lead 
to drug overdosing and toxicity which is clinically manifested as drug discontinuation. 
 
These findings have implications for the management for HIV/HCV coinfected individuals. 
As ritonavir is known to be a powerful inhibitor of the P450 enzyme system
601
, the benefits 
and risks of ritonavir-boosted PI-based cART regimens should be assessed in coinfected 
individuals, particularly those with significant liver fibrosis or cirrhosis, to avoid disruptive 
HIV treatment and the need to discontinue or change cART regimens. 
 
Chapter 7 
Liver-related death among HIV/HCV coinfected individuals, what are the implications 
for treatment with direct-acting antivirals? 
Progression of liver disease is common with HCV infection and known to be accelerated in 
the presence of HIV coinfection
413
. However, LRD is often associated with older age as 
complications of HCV-related liver disease can take decades to develop
651
. Therefore, 
HIV/HCV coinfected individuals encounter many competing risks of death such as AIDS-
related mortality, mortality associated with injecting drug use (IDU), violent death, 
malignancies and renal disease
373
. 
 
The recent approval of less toxic, oral, DAA drugs for HCV will see fewer HIV/HCV 
coinfected individuals with contraindications to treatment, while treatment success rates will 
be greatly improved if promising clinical trials data are repeated in the general 
population
446;658
. However, treatment with new DAAs will be prohibitively expensive and 
availability will be restricted on a cost basis in many European settings
2
. Therefore, a better 
understanding of the spectrum of causes of death among HIV/HCV coinfected individuals 
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and factors associated with LRD is essential so that expensive new DAA therapy can be 
prioritised for those at the greatest risk of LRD. 
 
This study described causes of death among HIV/HCV coinfected individuals in Europe 
along with temporal changes in the incidence of LRD and factors associated with 
progression to LRD. The main findings of this analysis show that although the incidence of 
LRD declined between the years 2000 and 2013, LRD along with AIDS-related death 
remains the leading causes of mortality among HIV/HCV coinfected individuals. The 
decline in LRD rates over the study period appears to be partially explained by 
improvements in CD4 cell count and lower levels of liver fibrosis over time. This finding 
suggests that initiating cART early in the course of HIV infection among HIV/HCV 
coinfected individuals may reduce the burden of LRD by preventing time spent with low 
CD4 cell count, which has been strongly associated with rapid progression of liver 
fibrosis
414;671
. 
 
Significant liver fibrosis was found to be the strongest predictor of progression to LRD, 
followed by low CD4 cell count, concurrent HBV infection and duration of HCV infection. 
Coinfected individuals with F4 liver fibrosis had a 14% 5-year probability of LRD compared 
with 2% for those with F0/F1 fibrosis. Consequently, liver fibrosis levels should be 
considered the most important factor for determining who to prioritise for treatment with 
expensive DAA therapy for HCV. This finding is in agreement with another recent study of 
HIV/HCV coinfected individuals which found that the risk of end stage liver disease (ESLD) 
was minimal among those with F0/F1 fibrosis, as measured by the FIB-4 index, but that the 
5-year probability of ESLD increased to 17% for those with F3/F4 fibrosis
665
. 
 
Current EACS guidelines recommend deferring treatment for HCV in those with F0/F1 liver 
fibrosis, whereas treatment is encouraged for those with significant liver fibrosis
416
. Given 
the low risk of progression to LRD seen among those with low levels of liver fibrosis in this 
study and the prohibitive costs of treating HCV with new DAAs
2
, this study strongly 
supports this treatment prioritisation strategy.  
 
Chapter 8 
A validated prognostic score for estimating the risk of liver-related death among 
HIV/HCV coinfected individuals 
As new DAA regimens for treatment HCV cost in the region of €90,000, with the 
expectation that all-oral regimens will be more expensive still
2
, studies have begun to 
evaluate the cost-effectiveness of these new therapies. Studies using Markov chain models 
to simulate the progression of liver disease among HCV monoinfected individuals following 
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DAA therapy have shown the potential for large reductions in the number of individuals 
developing advanced liver disease
684;706
. Consequently, the reduced costs associated with 
treating advanced liver disease mean that most studies suggest that treatment with DAA 
therapy is cost-effective in the long-term
684;706
.  
 
Earlier this year the National Institute for health and Care Excellence (NICE) approved the 
use of sofosbuvir and simeprevir for treatment of HCV in the UK on the basis that they were 
cost-effective interventions
707
. However, for the first time since NICE began making cost-
effectiveness recommendations the NHS postponed approval of these drugs on the basis 
that the upfront costs were too great to bare
708
. Given that the UK NHS considers the costs 
of new DAA therapy to be prohibitive, it is certain that other regions not traditionally 
considered to be resource-limited will also struggle to meet the costs of treatment in the 
short-term. Therefore, prioritisation of those at the greatest risk of LRD will be of utmost 
importance to ensure that the limited DAA treatments that are available are channelled to 
those with the most urgent need of therapy. 
 
This study built on the analysis presented in the previous chapter, describing factors 
associated with progression to LRD, to construct a prognostic score for LRD to aid 
clinicians when making difficult decisions on whom to prioritise for treatment with new DAA 
therapy for HCV. The LRD prognostic score was developed in EuroSIDA and includes 
contributions from CD4 cell count, age, HBV coinfection, liver fibrosis levels and whether 
taking cART. The LRD score has also been validated on external data from the Swiss HIV 
Cohort Study (SHCS). The main findings of this analysis show that a simple, easy to 
calculate prognostic score for LRD can accurately differentiate between HIV/HCV 
coinfected individuals at the highest and lowest risk of LRD. 
 
Calculation of the score allows the categorisation of coinfected individuals into low, 
medium-low, medium-high and high risk categories. The 5-year risk of LRD for those in the 
low risk category was negligible (2%); however, the 5-year risk of LRD was substantial in 
the medium-high and high risk categories (11% and 26%, respectively). Consequently, in 
an era of prioritisation for those at the greatest risk of LRD for treatment with new DAA 
therapies, new expensive HCV treatments should be offered to those in the medium-high 
and high risk categories in the first instance. 
 
The LRD score was developed specifically to predict progression to LRD among HIV/HCV 
coinfected individuals in the presence of HIV-related competing risks. Consequently, it is 
ideally placed to help clinicians decide who to treat with new DAAs. To my knowledge this 
is the first prognostic score developed with the specific intention of informing who to 
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prioritise for treatment with DAAs. The score may prove useful to clinicians and HIV/HCV 
coinfected individuals who wish to assess their risk of progression to LRD. 
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9.2 Implications for the management of HIV/HCV coinfected 
individuals in Europe 
 
The past five years have seen a revolution in treatment options available for treatment of 
HCV. At the onset of this thesis the gold standard treatment for HCV (both HCV-
monoinfected and HIV/HCV-coinfected) consisted of pegylated-interferon and ribavirin
1
. 
Interferon is typically associated with unpleasant side-effects and often meant many 
HIV/HCV coinfected individuals would have contraindications to therapy
443
.  Chapter 5 of 
this thesis showed that treatment rates with pegylated-interferon remain low in Europe and 
that there is a significant proportion of coinfected individuals with significant liver fibrosis 
indicating therapy yet to be treated.  However, the development of potent, less toxic new 
DAAs have heralded a new era of treatment for HCV. The first generation DAAs telaprevir 
and boceprevir demonstrated vastly improved treatment success rates, with sustained 
virologic response (SVR) rates in the region of 60-70% for HCV genotype 1
437;438
. However, 
these first generation DAAs still had to be taken along with pegylated-interferon, so 
eligibility for treatment remained low
193
. 
 
More recently second generation DAAs have come to market which can be taken with or 
without pegylated-interferon
416
. These second generation DAAs, such as sofosbuvir and 
simeprevir, have performed remarkably well in clinical trials where treatment durations as 
short as 8-12 weeks have resulted in more than 90% achieving SVR seemingly regardless 
of HIV coinfection, HCV genotype, previous unsuccessful treatment or advanced liver 
fibrosis
446;658
. With yet more DAAs set to come to market in the coming months and years it 
now seems like appropriate highly efficacious treatment will exist for everyone who has 
HCV infection
446;658
. However, the costs of treatment with new DAAs are such that many 
European regions will not be able to afford them, including regions not traditionally 
considered to be resource-limited
708
. 
 
Consequently, research efforts have been shifting focus to study the cost-effectiveness of 
new DAAs and which patient groups should be prioritised for the treatments that are 
available
684;706
. The work presented here in Chapters 7 and 8 describes factors associated 
with progression to LRD among HIV/HCV coinfected individuals and derived a LRD 
prognostic score. This is the first prognostic score developed specifically to determine the 
risk of LRD among HIV/HCV coinfected individuals in the presence of HIV-related 
competing risks. Therefore, the LRD score is ideally placed to help clinicians decide who to 
prioritise for DAA therapy. This may prove useful in the clinical setting as individuals at the 
greatest need of treatment have not always been channelled for therapy. 
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Although DAA treatments offer the possibility of complete HCV eradication in the long-term, 
costs, access restrictions and reinfection mean that there is still a long way to go
719
. 
Therefore, the earlier work presented in this thesis has value for the management of 
HIV/HCV coinfected individuals, in particular where new DAA treatments are not available 
due to supply or cost issues. Analysis presented in this thesis has shown that treatment 
with cART is able to indirectly control HCV RNA among HIV/HCV coinfected individuals. 
Further, chronic HCV coinfection and significant liver fibrosis have been associated with an 
increased risk of ARV drug discontinuation. These findings reinforce the message that 
starting HIV treatment early during the course of infection in HIV/HCV coinfected individuals 
is essential. The benefits of early treatment initiation in these individuals include the indirect 
control of HCV RNA, prevention of time spent with low CD4 cell count and suppression of 
HBV DNA, where HBV coinfection is present and appropriate cART regimens are used. All 
of these factors should help to slow the progression of liver fibrosis while waiting for HCV 
treatment to become widely available
388;414
. 
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9.3 Limitations and lessons learnt 
 
The analysis presented in this thesis has been carried out to the best of my ability with the 
data that were available in EuroSIDA at the time of analysis. However, there are a number 
of limitations to these studies relating to the quality of data available in EuroSIDA. As 
described in detail in Section 3.1.1, EuroSIDA was originally set up as an HIV observational 
cohort study in 1994. As treatment for HIV developed over time with fewer individuals 
progressing to AIDS, EuroSIDA evolved to include data on comorbidities such as non-AIDS 
defining malignancies and coinfections such as HCV and HBV. Although EuroSIDA has 
been successful in shifting focus as research needs have changed over time, there are 
consequences in data quality that result from studying HIV/HCV coinfection in a cohort that 
was originally set up to study HIV alone. 
 
Key variables in the analysis of HCV such as the level of alcohol abuse, sustained 
virological response (SVR) rates to HCV treatments and social factors such as active 
injecting drug use, quality of life and accommodation status have only recently been added 
to EuroSIDA or remain uncaptured. Further, other important variables in HCV research 
such as HCV RNA, HCV genotyping and liver fibrosis levels were not of the utmost 
importance during the early days of HIV research. Therefore, this information tends to be 
missing regularly in the early course of follow-up in EuroSIDA, with data becoming more 
reliable over time as HCV has assumed increasing importance in the HIV community.  
 
In addition, EuroSIDA includes clinical centres from a wide and diverse cross-section of 
Europe. In particular there are a number of differences in the quality of care provided in 
Eastern European regions compared to Western and Northern Europe. Consequently, data 
quality is often worse in Eastern Europe resulting in a higher proportion of missing data 
from that region. These limitations and their influence on the analyses presented here are 
discussed in detail below. 
 
9.3.1 Study specific limitations of EuroSIDA data in HIV/HCV coinfection 
Chapter 4 
Chapter 4 of this thesis analysed HCV RNA profiles and their association with HIV 
treatment and HCV genotype. In the introduction to this chapter, previous studies of HCV 
RNA are critiqued as being mainly cross-sectional in nature, while the proposed strength of 
my analysis is described as the long term follow-up and multiple HCV RNA measurements 
per person. While this analysis contained a large amount of individuals with multiple HCV 
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RNA measurements in comparison to previous studies, the analysis still contained many 
individuals with only a single HCV RNA measurement. 
 
Out of 1,541 HIV/HCV coinfected individuals included in this study there were only 258 who 
had at least three HCV RNA measurements, the minimum required in order to assess non-
linear trends over time. Consequently, the study lacked sufficient power to be able to 
describe detailed non-linear patterns in the natural history of HCV RNA. Although the linear 
trends described in this analysis were an important contribution to the literature, the number 
of individuals with only one HCV RNA measurement is a major limitation of the study. 
 
Collection of HCV RNA data has been a priority of the data monitoring process in 
EuroSIDA for some time. Monitors have typically found that HCV RNA measurements are 
taken regularly at clinical sites, but that they are often not input to the EuroSIDA follow-up 
forms. This means that traditionally many HCV RNA measurements were missing from the 
EuroSIDA data. However, data monitoring in recent years has focused on clinical sites with 
a large proportion of HIV/HCV coinfected individuals, with the specific intention of 
identifying missing HCV RNA data. Consequently, the quality and quantity of HCV RNA 
data in EuroSIDA has increased over time. Unfortunately these data were not complete at 
the time of this analysis. 
 
Chapter 5 
This chapter looking at the uptake of treatment for HCV and the proportion of individuals 
who complete a full course of treatment suffers from the same issue of incomplete HCV 
RNA data as the previous chapter. The natural extension to this work would be to consider 
the rate of SVR to treatment for HCV and which factors are associated with a successful 
treatment outcome. However, incomplete or unreported HCV RNA measurements meant 
that the majority of individuals treated for HCV did not have an HCV RNA measurement 
available six months after completion of therapy. Therefore, it was not possible to 
accurately determine the rate of SVR to treatment in this population, which is a major 
limitation of this study. 
 
The analysis of completion of a full course of HCV treatment was further limited by the lack 
of data on social factors in EuroSIDA. Completion of a course of therapy is likely to be 
strongly influenced by qualitative factors associated with chaotic lifestyles typically 
attributed to injecting drug use. Assessment of active injecting drug use has only recently 
been added to the EuroSIDA follow-up form and was not available at the time of analysis. 
Consequently, behavioural factors were estimated based on each individual’s HIV 
transmission route, grouping people as those who acquired HIV via injecting drug use, 
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heterosexual contact, MSM, and haemophiliacs. For most people HIV infection will have 
occurred many years prior to accessing care for HCV, so this is likely to be a very poor 
estimation of active injecting drug use and behavioural factors affecting HCV treatment 
completion. Therefore, active injecting drug use is highly likely to be a confounder of this 
analysis and may have led to some bias in the results. In particular the rates of treatment 
completion in each region of EuroSIDA are likely to be affected by unknown levels of active 
injecting drug use. 
 
Chapter 6 
This chapter attempted to describe the association between HCV status, ARV toxicity and 
drug discontinuation. The findings suggest that HIV/HCV coinfected individuals with chronic 
infection and significant liver fibrosis are at an increased risk of ARV drug discontinuation 
for the PI and NRTI drug classes. However, some ARV drugs, particularly older NRTI drugs 
such as stavudine and didanosine, are associated with the development of liver fibrosis. 
The hypothesis of this analysis was that liver damage as a result of HCV infection could 
lead to overdosing of ARV drugs which then leads to drug discontinuation. However, it is 
possible that some ARVs may be causing liver fibrosis themselves which then leads to 
overdosing and drug discontinuation. This form of reverse causation, that essentially omits 
the effect HCV infection on drug discontinuation, cannot be dismissed although the design 
of the study should limit its likelihood. 
 
Prospective studies accumulating follow-up over time are known to be less prone to 
reverse causation than retrospective studies. In this analysis liver fibrosis levels are known 
at the time of starting each ARV, so it is less likely that the current treatment regimen 
caused the liver fibrosis; however, it is possible that previous ARV regimens may have 
contributed to liver fibrosis. Perhaps what is more likely to be influencing the results 
presented here is that HIV/HCV coinfected individuals may be less tolerant to side effects 
associated with PI and NRTI treatments. Unfortunately, social factors such as employment 
and accommodation status which might help to describe this relationship, as mentioned 
above, are not collected in EuroSIDA and this is a limitation of the analysis. 
 
Chapter 7 
This chapter identified factors associated with progression to LRD among HIV/HCV 
coinfected individuals. The main aim of this analysis was to provide guidance to clinicians 
about the strongest predictors of LRD in order to inform their decisions about who to 
prioritise for treatment with new expensive treatments for HCV. Alcohol intake is known to 
be a key contributor to liver damage and is likely to play a major role in the progression to 
LRD in many cases
720
. Unfortunately, data on alcohol abuse was only added to the 
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EuroSIDA follow-up form in 2010 and baseline for most people in this analysis was around 
January 2000. Therefore, it was not possible to include alcohol intake as a covariate in this 
analysis which is a major limitation of this study. 
 
The data EuroSIDA now collect on alcohol intake is qualitative in nature, simply whether 
the clinician filling out the follow-up form deems the individual to be an alcohol abuser or 
not. This method of collecting alcohol data reflects the difficulty in gleaning this information 
from patients. Self-reported alcohol consumption is known to be a poor estimate of true 
alcohol consumption due to recall bias or an unwillingness of an individual to report their 
true alcohol intake
672
. More accurate assessment of alcohol consumption can usually be 
performed using alcohol use questionnaires, such as the AUDIT-C questionnaire
721
, which 
ask a series of questions about the frequency and quantity of alcohol consumption along 
with other questions which touch on the consequences of heavy drinking, such as feeling 
guilty after drinking, being unable to remember events from a drinking session and personal 
injury caused as a consequence of drinking. 
 
This kind of information is not collected in EuroSIDA. However, if I were to start this 
analysis again I would strongly suggest that such a questionnaire be implemented. 
Accurate alcohol intake data would be of great benefit to EuroSIDA when dealing with 
questions of clinical outcomes in HIV/HCV coinfection, particularly because this data is 
typically missing from most observational cohort studies of HIV/HCV coinfection. In 
addition, accurate assessment of the role of alcohol intake on the rate of progression to 
LRD among coinfected individuals would be vital for clinicians when making tough 
decisions on who to treat with expensive new HCV therapies. 
 
Chapter 8 
As a natural extension to the previous chapter, this study aimed to create a prognostic risk 
score for progression to LRD, combining all the relevant risk factors into a single directly 
comparable statistic. Using the score sheet a clinician could add up the relevant score 
contributions to attain each individual’s LRD risk score. This number can then be compared 
with the low, medium-low, medium-high and high risk group categories to see where the 
individual’s risk lies and the corresponding 5-year probability of LRD. In this regard the 
score is designed to be a tool for use by physicians in the clinic to categorise the risk profile 
of their HIV/HCV coinfected individuals. 
 
However, for the score to be used correctly clinicians would require data on age, CD4 cell 
count, HBV status, duration of HCV infection, HIV treatment status, and liver fibrosis 
staging. Fortunately, most of these factors will be collected in routine clinical care. The only 
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elements that may be difficult to obtain are liver fibrosis staging and duration of HCV 
infection. As discussed in Section 2.2.5.3, the gold standard for liver fibrosis staging is liver 
biopsy; however, many new techniques and biomarkers are available to estimate liver 
fibrosis levels. Consequently, even clinicians without with the possibility of performing a 
liver biopsy or Fibroscan® elastography evaluation, would be able to request standard 
blood work including AST and platelet count assessment in order to estimate fibrosis with 
the APRI score
425
. 
 
In this study duration of HCV infection was estimated using the first evidence of HCV 
infection, the first positive HCV antibody or HCV RNA test result, for example. 
Unfortunately, the date of HCV infection is not captured in EuroSIDA and using the first 
available test result is likely to considerably underestimate the duration of HCV infection, 
which is a major limitation of this analysis. However, the date of HCV infection is often 
unknown for many individuals and not well documented in observational research. In 
EuroSIDA and other European cohorts the majority of HIV/HCV coinfected individuals are 
injecting drug users, who are likely to have acquired HCV some time prior to study entry. 
Therefore, the approach taken in this analysis, using known duration of HCV infection, was 
derived so that duration of infection could be estimated easily in the same manor across 
different cohort studies. 
 
9.3.2 Missing data 
As mentioned above, a consequence of studying HIV/HCV coinfection in EuroSIDA, which 
was originally set up to study HIV alone, is that historical HCV data are often missing. In 
particular, although HCV-related data quality and quantity has improved over time in 
EuroSIDA, many of the studies presented here suffered from missing data on HCV RNA 
and liver fibrosis staging during the early stages of follow-up. Various statistical approaches 
have been used to accommodate these missing data, however, no statistical approach can 
fully compensate for an incomplete dataset. 
 
In the first two studies of this thesis dummy missing categories have been used to account 
for missing data, whereby those with missing data are given a separate category in the 
analysis. Although this is traditionally a fairly common and simple approach for handling 
missing data, studies have shown that using dummy missing categories can lead to bias in 
parameter estimates when using statistical models
522
. At the time of analysis I decided to 
use this method to reduce the complexity of the analysis in what were largely descriptive 
studies. The majority of missing data on HCV RNA and liver fibrosis staging tends to be 
from the Eastern region of EuroSIDA. Therefore, the results presented in these studies 
would tend to be less applicable to Eastern Europe. In hindsight I believe it would have 
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been prudent to use multiple imputations to impute the missing data in order to reduce 
potential bias and improve the overall generalisability of the results. 
 
For the final three studies multiple imputations were used to impute missing data on HCV 
RNA, liver fibrosis staging and HCV genotype. These data tend to be missing more often in 
Eastern Europe which could potentially be problematic even when using multiple 
imputations, which assume data are at least missing at random (MAR)
722
. However, the 
proportion of individuals who were positive for HCV RNA was similar in Eastern Europe and 
the other regions or EuroSIDA in the non-missing data, while any differences in HCV 
genotype and liver fibrosis levels are likely to be well explained by other covariates included 
in EuroSIDA such as age, HIV transmission route, liver transaminases and region of 
residence. Therefore, I believe it is reasonable to assume these data are MAR. 
 
In the multiple imputations performed here three sets of imputations were used in chapter 
6, while for chapters 7 and 8 there were four sets of imputation. The literature suggests that 
relatively few sets of imputation are required, typically three to five,  in order to achieve an 
acceptable level of deviation between imputations and therefore an accurate representation 
of the uncertainty surrounding the missing data
722
. However, given the accessibility of these 
methods with modern computing power, it is now common for many more sets of 
imputation to be used. Although the relatively few sets of imputations used here are unlikely 
to have had a large influence on the results, in hindsight if I were to rerun these analyses I 
would now tend to use approximately 10 sets of imputations. 
 
9.3.3 Observational studies 
Observational studies have many benefits in clinical research. EuroSIDA in particular 
includes follow-up on a large number of HIV-positive individuals over a period of many 
years. In addition, new cohorts of individuals are added as and when required to replace 
those lost to follow-up or who have died. Patients are followed in routine clinical care and 
there are few barriers or exclusions to entry into the study. This means the study is well-
placed to track the epidemiology of HIV/HCV coinfection. However, it is important to note 
that there are inherent limitations with all observational studies. 
 
The limitations of each analysis presented in this thesis have been discussed in detail in 
each chapter and above; however, observational studies in general will always contain the 
possibility of bias. Although a large spectrum of variables relating to HIV and HCV are 
collected in EuroSIDA it is inevitable that some influences on the outcome of disease are 
not observed or collected. Multivariable statistical analysis can begin to account for 
confounding but can never account for information that is unmeasured or unknown. 
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In particular, social factors are likely to play a key role in many facets of HIV/HCV 
coinfection. This is a population that is traditionally associated with injecting drug use and 
these individuals are often known to have chaotic lives that will interfere with the application 
of appropriate treatments and clinical care. With this in mind it I cannot rule out the 
possibility that unmeasured confounding by factors such as residential status, employment 
status and active injecting drug use, which are not currently collected in EuroSIDA, will 
have had an effect on the results presented here. 
 
In addition, EuroSIDA and its participating clinical centres are considered to be centres of 
excellence for the care and management of HIV/HCV coinfected individuals. Therefore, the 
inference derived from EuroSIDA data may not be generalizable to the entire population of 
HIV/HCV coinfected individuals in Europe. 
 
9.3.4 EuroSIDA cohort X 
The EuroSIDA study is currently recruiting a new cohort of HIV/HCV coinfected individuals. 
The aim is to recruit 4,500 coinfected individuals to supplement those already under follow-
up in EuroSIDA and at the last count 2,500 new coinfected individuals had been recruited. 
In order to learn the lesson of the work presented in this thesis, a new data collection form 
has been implemented for cohort X which includes many variables not previously collected 
in EuroSIDA (hepatitis-related sections of the follow-up form are included in Appendix VII). 
For example, the date and mode of HCV transmission will now be collected on the data 
collection form. Previously only the mode of HIV transmission has been collected in 
EuroSIDA and this has been used to make assumptions about the mode of HCV 
transmission. In addition, the new data collection form will include a range of data specific 
to new DAA therapies include dosing schedules and HCV RNA measurements to 
determine SVR, along with data on alcohol abuse, active injecting drug use, liver fibrosis 
measurements and hepatic decompensation events. 
 
Cohort X ensures EuroSIDA will be well-placed to continue the HIV/HCV coinfection 
research agenda. 
  
282 
 
9.4 Further research 
 
The natural next step in continuing the research presented here is to enable the LRD score 
to be used widely in the clinical community. For broad ease of use the probability of 
progression to LRD is categorised as low, medium-low, medium-high and high. However, a 
more personalised approach would be preferable whereby an individual could work out 
their specific risk of progression to LRD. This requires reference against the cumulative 
incidence function of LRD to determine an individual risk of LRD and may not be perceived 
as straight forward in the clinical setting. A more user friendly approach would be to 
develop a website or mobile phone application where individual characteristics can be input 
to return a personalised risk of progression to LRD. Work will be on-going to develop these 
tools in the coming months and I hope to be able to make them widely available as soon as 
possible. 
 
With the continuing enrolment of Cohort X EuroSIDA is well-placed to assess the impact of 
DAAs on the HIV/HCV coinfected community. While clinical trials results have shown the 
new therapies to have excellent cure rates there is often a tendency for trials to include 
select groups of patients that tend to perform better than the general population
723
. In 
addition, clinical trials rarely include long-term follow-up and the comparatively low number 
of individuals included mean that rare conditions that take time to develop are unlikely to be 
discovered. Consequently, it will be essential to monitor the uptake of treatment with DAAs 
and how successful treatment is in the long term. Long-term follow-up in a large number of 
individuals will also allow for the description of rare side effects, reinfection rates and long-
term outcomes following treatment.  
 
While DAA therapies remain prohibitively expensive it is important to continue to reaffirm 
the potential benefits of treatment to exert pressure on authorities to increase access. 
Analysis of the potential burden of liver disease among HIV/HCV coinfected individuals in 
Europe would help to describe the number of preventable deaths should DAA treatment 
become widely available. A Markov model could be used to simulate the progression of 
liver disease among HIV/HCV coinfected individuals. EuroSIDA would be well-placed to 
develop such a model as the large amount of data available on HIV/HCV coinfected 
individuals would allow for accurate estimation of the model’s parameters and disease 
pathways. 
 
As access to DAA treatment becomes more widely available research focus will likely shift 
towards early identification of HIV/HCV coinfected individuals. Effective treatment cannot 
be administered until an individual is aware of their infection. Therefore, qualitative 
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research will be important to discover ways of diagnosing HIV/HCV coinfection. Research 
in the HIV field has attempted to find ways of identifying the undiagnosed with studies 
assessing whether other conditions could act as indicator diseases which would trigger an 
HIV test. Similar work could prove to be beneficial among HIV/HCV coinfected individuals 
to diagnose HCV infection. In the United States the cost-effectiveness of testing the whole 
generation of ‘baby boomers’ for HCV infection has been evaluated724. A similar analysis 
could be performed in European coinfected individuals to establish whether it would be 
cost-effective to test everyone of a certain age group. 
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9.5 Concluding remarks 
 
The aims of this thesis were to describe epidemiological characteristics of HIV/HCV 
coinfection and to provide guidance on the optimum management of coinfected individuals. 
Treatment for HCV has undergone a revolution in the past 5 years and the outlook of 
treatment for HCV is now very promising. There is potential for curative treatment for all 
HIV/HCV coinfected individuals but the costs of treatment mean that for the time being 
prioritisation of those at the greatest risk of LRD is essential. The main contribution to the 
field of HIV/HCV research presented in this thesis is the development of a prognostic score 
to aid clinicians when deciding who to prioritise for new HCV treatments.  
 
Data presented here have also shown that while access to new treatments remains 
restricted by costs it is important that coinfected individuals continue to receive optimal 
care, starting HIV treatment early in the course of infection, to avoid the rapid progression 
of liver fibrosis.  
 
EuroSIDA continues to shift focus to HIV/HCV coinfection and the inception of cohort X will 
ensure it is well-placed to conduct important research in the field for years to come. Future 
work will focus on how to ensure the LRD prognostic score is easily applicable in the 
clinical setting and simulation of the HIV/HCV epidemic in Europe to estimate the future 
burden of liver disease. 
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Appendix I 
 
The EuroSIDA Study Group 
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The multi-centre study group, EuroSIDA (national coordinators in parenthesis). 
 
Argentina: (M Losso), M Kundro, Hospital JM Ramos Mejia, Buenos Aires. Austria: (N 
Vetter), Pulmologisches Zentrum der Stadt Wien, Vienna; R Zangerle, Medical University 
Innsbruck, Innsbruck. Belarus: (I Karpov), A Vassilenko, Belarus State Medical University, 
Minsk, VM Mitsura, Gomel State Medical University, Gomel; D Paduto, Regional AIDS 
Centre, Svetlogorsk. Belgium: (N Clumeck), S De Wit, M Delforge, Saint-Pierre Hospital, 
Brussels; E Florence, Institute of Tropical Medicine, Antwerp; L Vandekerckhove, 
University Ziekenhuis Gent, Gent. Bosnia-Herzegovina: (V Hadziosmanovic), Klinicki 
Centar Univerziteta Sarajevo, Sarajevo. Bulgaria: (K Kostov), Infectious Diseases 
Hospital, Sofia.Croatia: (J Begovac), University Hospital of Infectious Diseases, 
Zagreb. Czech Republic: (L Machala), D Jilich, Faculty Hospital Bulovka, Prague; D 
Sedlacek, Charles University Hospital, Plzen. Denmark: G Kronborg,T Benfield, Hvidovre 
Hospital, Copenhagen; J Gerstoft, T Katzenstein, A-B E Hansen, Rigshospitalet, 
Copenhagen; C Pedersen, NF Møller, Odense University Hospital, Odense; L Ostergaard, 
Skejby Hospital, Aarhus, U B Dragsted, Roskilde Hospital, Roskilde; L N Nielsen, Hillerod 
Hospital, Hillerod. Estonia: (K Zilmer), West-Tallinn Central Hospital, Tallinn; Jelena Smidt, 
Nakkusosakond Siseklinik, Kohtla-Järve. Finland: (M Ristola), I Aho, Helsinki University 
Central Hospital, Helsinki. France: (C Katlama), Hôpital de la Pitié-Salpétière, Paris; J-P 
Viard, Hôtel-Dieu, Paris; P-M Girard, Hospital Saint-Antoine, Paris; L Cotte, Hôpital de la 
Croix Rousse, Lyon; C Pradier, E Fontas, Hôpital de l'Archet, Nice; F Dabis, D Neau, Unité 
INSERM, Bordeaux, C Duvivier, Hôpital Necker-Enfants Malades, Paris. Germany: (J 
Rockstroh), Universitäts Klinik Bonn; R Schmidt, Medizinische Hochschule Hannover; J van 
Lunzen, O Degen, University Medical Center Hamburg-Eppendorf, Infectious Diseases 
Unit, Hamburg; HJ Stellbrink, IPM Study Center, Hamburg; C Stefan, JW Goethe University 
Hospital, Frankfurt; J Bogner, Medizinische Poliklinik, Munich; G. Fätkenheuer, Universität 
Köln, Cologne. Georgia: (N Chkhartishvili) Infectious Diseases, AIDS & Clinical 
Immunology Research Center, Tbilisi Greece: (J Kosmidis), P Gargalianos, G Xylomenos, 
P Lourida, Athens General Hospital; H Sambatakou, Ippokration General Hospital, 
Athens.   Hungary: (D Banhegyi), Szent Lásló Hospital, Budapest. Iceland: (M 
Gottfredsson), Landspitali University Hospital, Reykjavik. Ireland: (F Mulcahy), St. James's 
Hospital, Dublin. Israel: (I Yust), D Turner, M Burke, Ichilov Hospital, Tel Aviv; E Shahar, G 
Hassoun, Rambam Medical Center, Haifa; H Elinav, M Haouzi, Hadassah University 
Hospital, Jerusalem; ZM Sthoeger, AIDS Center (Neve Or), Jerusalem. Italy: (A D’Arminio 
Monforte), Istituto Di Clinica Malattie Infettive e Tropicale, Milan; R Esposito, I Mazeu, C 
Mussini, Università Modena, Modena; F Mazzotta, A Gabbuti, Ospedale S Maria 
Annunziata, Firenze; V Vullo, M Lichtner, University di Roma la Sapienza, Rome; M 
Zaccarelli, A Antinori, R Acinapura, G D'Offizi, Istituto Nazionale Malattie Infettive Lazzaro 
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Spallanzani, Rome; A Lazzarin, A Castagna, N Gianotti, Ospedale San Raffaele, Milan; M 
Galli, A Ridolfo, Osp. L. Sacco, Milan. Latvia: (B Rozentale), Infectology Centre of Latvia, 
Riga. Lithuania: (V Uzdaviniene) Vilnius University Hospital Santariskiu Klinikos, Vilnius; R 
Matulionyte, Center of Infectious Diseases, Vilnius University Hospital Santariskiu Klinikos, 
Vilnius. Luxembourg: (T Staub), R Hemmer, Centre Hospitalier, 
Luxembourg. Netherlands: (P Reiss), Academisch Medisch Centrum bij de Universiteit 
van Amsterdam, Amsterdam. Norway: (V Ormaasen), A Maeland, J Bruun, Ullevål 
Hospital, Oslo. Poland: (B Knysz), J Gasiorowski, M Inglot, Medical University, Wroclaw; A 
Horban, E Bakowska, Centrum Diagnostyki i Terapii AIDS, Warsaw; A Grzeszczuk, R 
Flisiak, Medical University, Bialystok; M Parczewski, M Pynka, K Maciejewska, Medical 
Univesity, Szczecin; M Beniowski, E Mularska, Osrodek Diagnostyki i Terapii AIDS, 
Chorzow; T Smiatacz, M Gensing, Medical University, Gdansk; E Jablonowska, E 
Malolepsza, K Wojcik, Wojewodzki Szpital Specjalistyczny, Lodz; I Mozer-
Lisewska, Poznan University of Medical Sciences, Poznan. Portugal: (M Doroana), L 
Caldeira, Hospital Santa Maria, Lisbon; K Mansinho, Hospital de Egas Moniz, Lisbon; F 
Maltez, Hospital Curry Cabral, Lisbon. Romania: (R Radoi), C Oprea, Spitalul de Boli 
Infectioase si Tropicale: Dr. Victor Babes, Bucarest. Russia: (A Rakhmanova), Medical 
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